
<html lang="en"     class="pb-page"  data-request-id="956d917b-0302-4114-b657-025da4183ae1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b00697;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-18"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors" /></meta><meta name="dc.Creator" content="Mark  Zak" /></meta><meta name="dc.Creator" content="Po-wai  Yuen" /></meta><meta name="dc.Creator" content="Xiongcai  Liu" /></meta><meta name="dc.Creator" content="Snahel  Patel" /></meta><meta name="dc.Creator" content="Deepak  Sampath" /></meta><meta name="dc.Creator" content="Jason  Oeh" /></meta><meta name="dc.Creator" content="Bianca M.  Liederer" /></meta><meta name="dc.Creator" content="Weiru  Wang" /></meta><meta name="dc.Creator" content="Thomas  O’Brien" /></meta><meta name="dc.Creator" content="Yang  Xiao" /></meta><meta name="dc.Creator" content="Nicholas  Skelton" /></meta><meta name="dc.Creator" content="Rongbao  Hua" /></meta><meta name="dc.Creator" content="Jasleen  Sodhi" /></meta><meta name="dc.Creator" content="Yunli  Wang" /></meta><meta name="dc.Creator" content="Lei  Zhang" /></meta><meta name="dc.Creator" content="Guiling  Zhao" /></meta><meta name="dc.Creator" content="Xiaozhang  Zheng" /></meta><meta name="dc.Creator" content="Yen-Ching  Ho" /></meta><meta name="dc.Creator" content="Kenneth W.  Bair" /></meta><meta name="dc.Creator" content="Peter S.  Dragovich" /></meta><meta name="dc.Description" content="NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of..." /></meta><meta name="Description" content="NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 30, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00697" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00697" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00697" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00697" /></link>
        
    
    

<title>Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00697" /></meta><meta property="og:title" content="Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0035.jpeg" /></meta><meta property="og:description" content="NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent and potent inhibition of CYP2C9. In an attempt to reduce CYP2C9 inhibition, a parallel synthesis approach was used to identify central benzyl group replacements with increased Fsp3. A spirocyclic central motif was thus discovered that was combined with left-hand pyridines (or pyridine-like systems) to provide cellularly potent NAMPT inhibitors with minimal CYP2C9 inhibition. Further optimization of potency and ADME properties led to the discovery of compound 68, a highly potent NAMPT inhibitor with outstanding efficacy in a mouse tumor xenograft model and lacking measurable CYP2C9 inhibition at the concentrations tested." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00697"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00697">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00697&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00697&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00697&amp;href=/doi/10.1021/acs.jmedchem.6b00697" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 8345-8368</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00636" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00695" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Zak">Mark Zak</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Po-wai++Yuen">Po-wai Yuen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiongcai++Liu">Xiongcai Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Snahel++Patel">Snahel Patel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Sampath">Deepak Sampath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Oeh">Jason Oeh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bianca+M.++Liederer">Bianca M. Liederer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weiru++Wang">Weiru Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++O%E2%80%99Brien">Thomas O’Brien</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Xiao">Yang Xiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas++Skelton">Nicholas Skelton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rongbao++Hua">Rongbao Hua</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jasleen++Sodhi">Jasleen Sodhi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yunli++Wang">Yunli Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhang">Lei Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guiling++Zhao">Guiling Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaozhang++Zheng">Xiaozhang Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yen-Ching++Ho">Yen-Ching Ho</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+W.++Bair">Kenneth W. Bair</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+S.++Dragovich">Peter S. Dragovich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-467-4533. E-mail: <a href="/cdn-cgi/l/email-protection#2845524943684f4d464d064b4745"><span class="__cf_email__" data-cfemail="dab7a0bbb19abdbfb4bff4b9b5b7">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00697&amp;href=/doi/10.1021%2Facs.jmedchem.6b00697" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 8345–8368</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 19, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 May 2016</li><li><span class="item_label"><b>Published</b> online</span>30 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00697" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00697</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8345%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMark%2BZak%252C%2BPo-wai%2BYuen%252C%2BXiongcai%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D18%26contentID%3Dacs.jmedchem.6b00697%26title%3DMinimizing%2BCYP2C9%2BInhibition%2Bof%2BExposed-Pyridine%2BNAMPT%2B%2528Nicotinamide%2BPhosphoribosyltransferase%2529%2BInhibitors%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8368%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00697"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2693</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00697" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Zak&quot;},{&quot;first_name&quot;:&quot;Po-wai&quot;,&quot;last_name&quot;:&quot;Yuen&quot;},{&quot;first_name&quot;:&quot;Xiongcai&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Snahel&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Sampath&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Oeh&quot;},{&quot;first_name&quot;:&quot;Bianca&quot;,&quot;last_name&quot;:&quot;M. Liederer&quot;},{&quot;first_name&quot;:&quot;Weiru&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;O’Brien&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;Skelton&quot;},{&quot;first_name&quot;:&quot;Rongbao&quot;,&quot;last_name&quot;:&quot;Hua&quot;},{&quot;first_name&quot;:&quot;Jasleen&quot;,&quot;last_name&quot;:&quot;Sodhi&quot;},{&quot;first_name&quot;:&quot;Yunli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Guiling&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Xiaozhang&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Yen-Ching&quot;,&quot;last_name&quot;:&quot;Ho&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;W. Bair&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;S. Dragovich&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8345-8368&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00697&quot;},&quot;abstract&quot;:&quot;NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent and potent inhibition of CYP2C9. In an attempt to reduce CYP2C9 inhibition, a parallel synthesis approach was used to identify central benzyl group replacements with increased Fsp3. A spirocyclic central motif was thus discovered that was combined with left-hand pyridines (or pyridine-like systems) to provide cellularly potent NAMPT inhibitors with minimal CYP2C9 inhibition. Further optimization of potency and ADME properties led to the discovery of compound 68, a highly potent NAMPT inhibitor with outstanding efficacy in a mouse tumor xenograft model and lacking measurable CYP2C9 inhibition at the concentrati&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00697&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00697" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00697&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00697" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00697&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00697" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00697&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00697&amp;href=/doi/10.1021/acs.jmedchem.6b00697" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00697" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00697" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00697%26sid%3Dliteratum%253Aachs%26pmid%3D27541271%26genre%3Darticle%26aulast%3DZak%26date%3D2016%26atitle%3DMinimizing%2BCYP2C9%2BInhibition%2Bof%2BExposed-Pyridine%2BNAMPT%2B%2528Nicotinamide%2BPhosphoribosyltransferase%2529%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D18%26spage%3D8345%26epage%3D8368%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/jmcmar.2016.59.issue-18/20160922/jmcmar.2016.59.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent and potent inhibition of CYP2C9. In an attempt to reduce CYP2C9 inhibition, a parallel synthesis approach was used to identify central benzyl group replacements with increased Fsp3. A spirocyclic central motif was thus discovered that was combined with left-hand pyridines (or pyridine-like systems) to provide cellularly potent NAMPT inhibitors with minimal CYP2C9 inhibition. Further optimization of potency and ADME properties led to the discovery of compound <b>68</b>, a highly potent NAMPT inhibitor with outstanding efficacy in a mouse tumor xenograft model and lacking measurable CYP2C9 inhibition at the concentrations tested.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nicotinamide adenine dinucleotide (NAD) is a ubiquitously expressed biomolecule implicated in multiple biological processes including cell metabolism, calcium homeostasis, cell survival, and aging.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> NAD acts as both an electron-carrying cofactor for oxidoreductases and as an ADP-ribose donator in multiple enzymatic reactions.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In two examples of the latter mode of action, NAD participates in reactions catalyzed by PARPs (poly-ADP ribosylation)<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and sirtuins (deacylation and ADP ribosylation).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Such reactions consume NAD while liberating nicotinamide (NAM) as a byproduct (see <a class="ref internalNav" href="#fig1a" aria-label="Figure 1">Figure 1</a>a). The wide ranging biological functions of NAD, coupled with its consumption by enzymes such as the PARPs and sirtuins, requires cells to replenish NAD in order to survive.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Multiple pathways for NAD biosynthesis have been elucidated, including a mechanism that recycles NAM back to NAD (see <a class="ref internalNav" href="#fig1a" aria-label="Figure 1">Figure 1</a>a).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> This pathway relies on nicotinamide phosphoribosyltransferase (NAMPT) to catalyze its rate-determining step, a condensation reaction between NAM and phosphoribosyl pyrophosphate (PRPP) to generate nicotinamide mononucleotide (NMN).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> NMN, the phosphoribosylated adduct of NAM, is then converted to NAD in a reaction catalyzed by an additional enzyme, nicotinate/nicotinamide mononucleotide adenyltransferase (NMNAT). Rapidly proliferating cells such as cancers possess a high metabolic load and a corresponding high demand for NAD. Reduction of intracellular NAD concentrations via blockade of the NAM-NAD recycling may, thus, be an appropriate mechanism to target such cells.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> As such, there is interest in identifying NAMPT inhibitors as potential therapies for oncology indications.<a onclick="showRef(event, 'ref4 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref8">(4, 8)</a></div><figure id="fig1a" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0002.jpeg" id="GRAPHIC-d25e349-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) NAM-NAD recycling pathway. (b) NMN-like phosphoribose adducts generated by coincubating NAMPT inhibitors <b>1</b>, <b>2</b>, <b>3</b>, or <b>7</b> with NAMPT, ATP, and PRPP.<a onclick="showRef(event, 'cit9a cit9c ref20 ref21'); return false;" href="javascript:void(0);" class="ref cit9a cit9c ref20 ref21">(9a, 9c, 20, 21)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig1a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, multiple NAMPT inhibitors have been previously reported by both our own group (compounds <b>1</b>–<b>6</b><a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>) as well as by other organizations (compounds <b>7</b><a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and <b>8</b><a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>). These compounds share similar molecular features and, as exemplified by compound <b>1</b>, can be divided into four general regions. The left-hand side is comprised of a pyridine or pyridine-like heterocycle containing an exposed and nucleophilic nitrogen atom. The linker group is an amide, urea, or cyanoguanidine. The central region is a lipophilic group comprised of a benzyl group, a phenyl, or an aliphatic chain. The right-hand side may encompass a wide array of groups, including aromatic and nonaromatic cycles, with or without polar heteroatoms. One recurring issue with all these molecules is persistent inhibition of CYP2C9. Indeed, as exemplified in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, the majority of the previously reported NAMPT inhibitors exhibited potent CYP2C9 inhibition, with IC<sub>50</sub> values typically less than 1 μM ((<i>S</i>)-warfarin probe). Also notable is the CYP isoform selectivity exhibited by certain classes of NAMPT inhibitors. Compounds containing bicyclic left-hand moieties, exemplified by <b>1</b>, <b>3</b>, <b>5</b>, and <b>6</b>, were typically potent inhibitors of only CYP2C9 and exhibited little or no inhibition of the other CYP isoforms tested. Another notable finding was the importance of the probe used to assess CYP2C9 inhibition. Indeed, as exemplified by compounds <b>1</b> and <b>3</b>, and consistent with what has previously been reported by others,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> much different inhibition profiles were observed depending on whether (<i>S</i>)-warfarin or diclofenac was used. As (<i>S</i>)-warfarin was the more sensitive of the two probes for this class of inhibitors, it was used to assess CYP2C9 inhibition for the remainder of this work.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0003.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of previously reported NAMPT inhibitors.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. NAMPT and CYP2C9 Inhibition Data<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> for Previously Reported NAMPT Inhibitors<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="7" align="center" char=".">CYP Inhibition IC<sub>50</sub><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">NAMPT IC<sub>50</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">A2780 IC<sub>50</sub><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">2C9 ((<i>S</i>)-warfarin)</th><th class="colsep0 rowsep0" align="center" char=".">2C9 (diclofenac)</th><th class="colsep0 rowsep0" align="center" char=".">3A4 (testosterone)</th><th class="colsep0 rowsep0" align="center" char=".">3A4 (midazolam)</th><th class="colsep0 rowsep0" align="center" char=".">2D6 (dextromethorphan)</th><th class="colsep0 rowsep0" align="center" char=".">1A2 (tacrine)</th><th class="colsep0 rowsep0" align="center" char=".">2C19 (mephenytoin)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.032</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.09</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">0.039</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">0.54</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">All assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2). See ref <a onclick="showRef(event, 'cit9d'); return false;" href="javascript:void(0);" class="ref cit9d">9d</a> for experimental details.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">NAMPT biochemical inhibition. The average coefficient of variation (CV) for all compounds reported in this work is 0.48. Individual CV values are reported in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Antiproliferation activity determined in cell culture experiments using A2780 cell line. This inhibition can be reversed by addition of 0.33 μM of NMN, strongly implicating NAMPT inhibition as the causative MOA. The average coefficient of variation (CV) for all compounds reported in this work is 0.23. Individual CV values are reported in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Reversible cytochrome P450 2C9 inhibition. The probe used to assess inhibition is indicated in parentheses.</p></div></div></div><div class="NLM_p">CYP2C9 inhibition is undesirable for a number of reasons.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> CYP2C9 comprises a substantial proportion of human liver microsomal P450 content, second only to CYP3A4 in abundance. Additionally CYP2C9 is implicated in the metabolism of a significant percentage of drugs undergoing phase 1 metabolism, with values of 15–20% reported in the literature.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Included among these are several nonsteroidal anti-inflammatory drugs, oral antidiabetics, and angiotensin II receptor blockers. CYP2C9 is also the primary enzyme responsible for metabolism of the oral anticoagulant (<i>S</i>)-warfarin, a drug with a low therapeutic index. Drugs metabolized by CYP2C9, especially those with low therapeutic indexes, will be susceptible to drug–drug interactions and potential toxicity when coadministered with potent CYP2C9 inhibitors. Finally, the CYP2C9 gene is highly polymorphic, with common variants exhibiting poor metabolism phenotypes. Patients carrying such genetic variants and expressing defective or partially defective forms of CYP2C9 are especially susceptible to CYP2C9 inhibitors. As such, we wished to discover NAMPT inhibitors with reduced CYP2C9 inhibition profiles.</div><div class="NLM_p">Developing strategies to reduce CYP inhibition remains an emerging area of drug discovery research. Although several computational approaches have been proposed,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> it remains challenging to develop a general model to predict CYP2C9 inhibition due to several factors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The active sites of CYPs are generally large and flexible, consistent with their role of accommodating and metabolizing a wide array of xenobiotics and endogenous substrates. Multiple binding modes and a spectrum of binding sites are possible, spanning direct interaction with the heme, to water mediated heme binding, to binding in close proximity to the heme, or binding to allosteric sites distant from the heme. Additionally, multiple ligands may bind simultaneously and covalent attachment is also possible. Despite not yet being routine, examples of structure-based drug design influencing CYP2C9 inhibition are also beginning to emerge in the literature. Indeed, a recent disclosure by scientists at AstraZeneca and the University of Gothenburg has demonstrated the use of X-ray crystal structures of modified forms of CYP2C9 and CYP3A4 in complex with inhibitors.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> While two successful examples were presented, the authors also highlight the technical challenges associated with routine collection of CYP–inhibitor complexed crystal structures and the fact that iterative CYP structural support is not realistic at the present time. Physical chemical properties and shape also play a role in CYP inhibition. Indeed, reducing the number of aromatic rings and increasing the fraction of sp3 centers (Fsp3)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> may improve a number of drug developability parameters, including reduced CYP inhibition.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Additionally, a recent review summarizes common strategies used to circumvent inhibition of CYP2C9 and other CYP isoforms from a medicinal chemist’s perspective.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Although no general solutions are identified, successful examples are presented of modulating properties such as lipophilicity and molecular weight and blocking or replacing common CYP inhibitory pharmacophores including exposed pyridines and related aromatic heterocycles.</div><div class="NLM_p">Conspicuously, all of the compounds depicted in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> contain an archetypal CYP pharmacophore in the left-hand portion of the inhibitors, an exposed pyridine or related heterocycle with an exposed and nucleophilic nitrogen atom. Such heterocycles are typically thought to cause inhibition by binding to the heme center of the CYP enzymes.<a onclick="showRef(event, 'cit15f'); return false;" href="javascript:void(0);" class="ref cit15f">(15f)</a> Unfortunately, these exposed and nucleophilic left-hand groups are also a necessary pharmacophore for potent NAMPT cell-based inhibition. We<a onclick="showRef(event, 'cit9a cit9c ref20'); return false;" href="javascript:void(0);" class="ref cit9a cit9c ref20">(9a, 9c, 20)</a> and others<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> have shown that such compounds mimic NAMPT’s endogenous substrate, nicotinamide, by undergoing enzyme-catalyzed condensation with PRPP as in step 1 of <a class="ref internalNav" href="#fig1a" aria-label="Figure 1">Figure 1</a>. Indeed, as shown in <a class="ref internalNav" href="#fig1a" aria-label="Figure 1">Figure 1</a>b, the NMN-like phosphoribose adducts <b>1′</b>, <b>2′</b>, <b>3′</b>, and <b>7′</b> have been generated and characterized by incubating inhibitors <b>1</b>, <b>2</b>, <b>3</b>, and <b>7</b> with NAMPT, ATP, and PRPP.<a onclick="showRef(event, 'cit9a cit9c ref20 ref21'); return false;" href="javascript:void(0);" class="ref cit9a cit9c ref20 ref21">(9a, 9c, 20, 21)</a> Additionally, it has been demonstrated that the phosphoribose adduct <b>7′</b> generated in HeLa cells was retained within the cell, whereas the parent compound <b>7</b> was readily washed out.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The formation and subsequent retention of highly impermeable phosphoribose adducts within the cellular environment appears to be a critical factor associated with the cell-based potency of NAMPT inhibitors. Thus, the pharmacophores for CYP2C9 inhibition and potent cellular NAMPT inhibition are closely linked.</div><div class="NLM_p">A previous publication by our group has described a partial solution to the CYP2C9 inhibition issue in the urea series of NAMPT inhibitors related to compound <b>2</b>.<a onclick="showRef(event, 'cit9a ref22'); return false;" href="javascript:void(0);" class="ref cit9a ref22">(9a, 22)</a> Indeed, as shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compound <b>9</b>, containing an exposed left-hand pyridine moiety, was both a relatively potent cellular NAMPT inhibitor and an extremely potent inhibitor of CYP2C9. Consistent with the hypothesis that the pyridine motif was the CYP2C9 pharmacophore, blocking the pyridine N with an ortho methyl group eliminated measurable CYP inhibition at the concentrations measured (compound <b>10</b>). However, cellular NAMPT inhibition was also reduced dramatically. Multiple other groups were screened in an attempt to reduce CYP inhibition while maintaining potent cellular NAMPT activity. The only such modification to produce the desired result was an ortho amino group (compound <b>11</b>). The increased steric bulk adjacent to the pyridine center eliminated CYP2C9 inhibition, while the strongly donating amino group presumably allowed the less accessible pyridine to maintain the required nucleophilicity for phosphoribose adduct formation and cell activity. Unfortunately the increased electron richness present in <b>11</b> also led to potent time dependent inhibition (TDI) of CYP3A4, limiting the utility of this group. Interestingly, in the course of this work, it was also found that modification of the right-hand side of the inhibitor, a site distal to the nucleophilic pyridine, could dramatically reduce CYP2C9 inhibition. Regrettably, such modifications were also found to introduce a new liability into the inhibitors. As exemplified by compound <b>12</b>, the highly polar and often basic groups that were effective in reducing CYP2C9 inhibition also led to extremely low MDCK permeability and hampered oral bioavailability. One final improvement to CYP2C9 inhibition was previously noted in the optimization of bicyclic azabenzofuran NAMPT inhibitors, again at a site distal to the nucleophilic pyridine center.<a onclick="showRef(event, 'cit9f'); return false;" href="javascript:void(0);" class="ref cit9f">(9f)</a> In this case, moving from sulfone <b>13</b> to the more polar sulfoxide <b>14</b> led to a minor decrease in CYP2C9 inhibition, but once again, this CYP2C9 improvement was accompanied by an additional negative outcome in the form of reduced metabolic stability and increased in vivo clearance. To summarize our previous findings, certain modifications in the immediate proximity of, as well as distal to, the left-hand nucleophilic aromatic center of NAMPT inhibitors were found to improve CYP2C9 inhibition. This observation implied a cooperative effect between the left-hand pyridine and the central or right-hand portion of the molecule in producing the CYP2C9 inhibition. However, all modifications to both the pyridines and the center/right-hand sides of previously reported molecules led to additional undesired liabilities. Thus, a solution to the CYP2C9 inhibition problem that did not introduce additional liabilities into the inhibitors was still required.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. NAMPT and CYP2C9 Inhibition Data<a class="ref internalNav" href="#t2fn1" aria-label="j">j</a> for Previously Reported NAMPT Inhibitors<a onclick="showRef(event, 'cit9a cit9f ref22'); return false;" href="javascript:void(0);" class="ref cit9a cit9f ref22">(9a, 9f, 22)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0019.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0020.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup>Table a</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t2fn3"><sup>Table b</sup><p class="last">Measured Log <i>D</i> at pH 7.4. Experimental details may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> of this work.</p></div><div class="footnote" id="t2fn4"><sup>Table c</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t2fn5"><sup>Table d</sup><p class="last">Time-dependent inhibition of cytochrome P450 3A4. A >15% AUC shift considered possible TDI risk.</p></div><div class="footnote" id="t2fn6"><sup>Table e</sup><p class="last">Substrate = testosterone.</p></div><div class="footnote" id="t2fn7"><sup>Table f</sup><p class="last">Substrate = midazolam.</p></div><div class="footnote" id="t2fn8"><sup>Table g</sup><p class="last">Apparent permeability in MDCK transwell culture. Permeability categories are as follows (units of 10<sup>–6</sup> cm/s): low < 1, moderate = 1–10, high > 10. A:B, apical-to-basolateral. B:A, basolateral-to-apical.</p></div><div class="footnote" id="t2fn9"><sup>Table h</sup><p class="last">Human hepatic clearance predicted from human liver microsomes (stable, moderate, labile = <6, 6–15, >15 mL/min/kg, respectively).</p></div><div class="footnote" id="t2fn10"><sup>Table i</sup><p class="last">Single determination (<i>n</i> = 1).</p></div><div class="footnote" id="t2fn1"><sup>Table j</sup><p class="last">Unless otherwise indicated, all assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2). Unless otherwise indicated, experimental details for each assay are described in ref <a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">9b</a>.</p></div></div><div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Similar to the urea series (e.g., <b>2</b>, <b>9</b>, and related compounds), our initial efforts at reducing CYP2C9 inhibition in the bicyclic series focused on blocking the nucleophilic left-hand pyridine moieties in previously reported inhibitors <b>15</b>, <b>17</b>, and <b>19</b>.<a onclick="showRef(event, 'cit9b cit9e'); return false;" href="javascript:void(0);" class="ref cit9b cit9e">(9b, 9e)</a> As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, the novel amino substituted pyridines <b>16</b>, <b>18</b>, and <b>20</b> all possessed notably reduced CYP2C9 inhibition compared to the corresponding des-amino molecules, however, all suffered a significant loss in NAMPT potency. Additionally, analogue <b>16</b> was further found to display potent TDI against CYP3A4. Further work in optimizing additional amino-substituted pyridines and related heterocycles was, thus, abandoned.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. NAMPT and CYP2C9 Inhibition Data for Pyridine and Amino Pyridine Matched Pairs<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0021.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">CYP3A4 TDI (%AUC shift)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">scaffold</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">NAMPT IC<sub>50</sub><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">A2780 IC<sub>50</sub><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">CYP2C9 inhibition IC<sub>50</sub><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."><i>m</i><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15</b></td><td class="colsep0 rowsep0" align="center">A</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char="."><15</td><td class="colsep0 rowsep0" align="char" char="."><15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>16</b></td><td class="colsep0 rowsep0" align="center">A</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.064<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">0.058</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>17</b></td><td class="colsep0 rowsep0" align="center">B</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char="."><15</td><td class="colsep0 rowsep0" align="char" char="."><15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>18</b></td><td class="colsep0 rowsep0" align="center">B</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.074</td><td class="colsep0 rowsep0" align="char" char=".">0.378</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>19</b></td><td class="colsep0 rowsep0" align="center">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char="."><15</td><td class="colsep0 rowsep0" align="char" char="."><15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>20</b></td><td class="colsep0 rowsep0" align="center">C</td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.098<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">0.828</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Unless otherwise indicated, all assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for assay descriptions.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Single determination (<i>n</i> = 1).</p></div></div></div><div class="NLM_p">Because modifying the inhibitors adjacent to the nucleophilic pyridine center did not appear to be a viable strategy to reduce CYP2C9 inhibition without introducing additional liabilities, we further explored alternate modifications in distal portions of the molecule. A number of inhibitors containing benzylic central motifs, but truncated right-hand portions were investigated (<b>21</b>–<b>23</b>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). While NAMPT potency was drastically reduced in each case, an important difference in CYP2C9 inhibition was observed. Indeed, sulfone <b>21</b> and sulfonamide <b>22</b> exhibited potent inhibition, whereas the unsubstituted benzyl analogue (<b>23</b>) showed no measurable CYP2C9 inhibition at the concentrations tested. This observation appeared to suggest that the sulfone or sulfonamide played a key role in CYP2C9 inhibition, thus, a number of related analogues containing either sulfone/sulfonamide replacements or reverse sulfonamides were evaluated. Unfortunately, despite surveying a diverse array of right-hand side groups attached to the central benzylic moiety via O, N, or C linkages (exemplified by <b>24</b>–<b>26</b>), it was not possible to restore desired levels of NAMPT potency while still maintaining lack of CYP2C9 inhibition. This suggested that the sulfone or sulfonamide groups were not, themselves, key drivers of the CYP2C9 inhibition and that any type of substitution on the benzylic central motif leading to improved NAMPT potency would also likely lead to CYP2C9 inhibition.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. NAMPT and CYP2C9 Inhibition Data for Analogues <b>21</b>–<b>29</b></div><p class="last"><a class="ref internalNav" href="#t4fn1" aria-label="g">g</a></p></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0022.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0023.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup>Table a</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t4fn3"><sup>Table b</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for assay description.</p></div><div class="footnote" id="t4fn4"><sup>Table c</sup><p class="last">Fraction of sp3 centers. (number of sp3 hybridized carbons/total carbon count).</p></div><div class="footnote" id="t4fn5"><sup>Table d</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t4fn6"><sup>Table e</sup><p class="last">Single determination (<i>n</i> = 1).</p></div><div class="footnote" id="t4fn7"><sup>Table f</sup><p class="last">Not applicable.</p></div><div class="footnote" id="t4fn1"><sup>Table g</sup><p class="last">Unless otherwise indicated, all assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2).</p></div></div><div></div></div><div class="NLM_p">Having concluded that it was likely not feasible to separate the overlapping NAMPT and CYP2C9 pharmacologies when benzylic groups were employed in the central region of the inhibitors, we pursued an alternate strategy of increasing Fsp3.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Although increasing global Fsp3 in a molecule containing a central benzylic group was not an effective strategy (exemplified by <b>29</b>),<a onclick="showRef(event, 'cit9e'); return false;" href="javascript:void(0);" class="ref cit9e">(9e)</a> we were pleased to see that compounds with simple aliphatic groups in their central regions (<b>27</b> and <b>28</b>) exhibited little or no CYP2C9 inhibition. Interestingly, the reduction in CYP2C9 inhibition was not associated with reduced lipophilicity. Indeed, compounds <b>27</b> and <b>28</b> possessed higher Log <i>D</i><sub>7.4</sub> values than the potent CYP2C9 inhibitors <b>21</b>, <b>22</b>, and <b>26</b>. We then investigated whether related molecules with saturated central regions would allow NAMPT potency to be restored while maintaining the lack of CYP2C9 inhibition.</div><div class="NLM_p">To aid further optimization, X-ray crystal structures of compounds <b>1</b>–<b>6</b> (or closely related analogues) and compound <b>8</b> in complex with NAMPT were examined. These structures showed that the central portions of the various molecules were not perfectly coincident and indeed swept out a diverse volume of space (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). This observation suggested the NAMPT protein could be tolerant of inhibitors with different shapes in this region. Additionally the interactions between the central region of the inhibitors and the NAMPT protein were primarily hydrophobic in nature (see <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a> for a discussion of the residues in this region). The lack of specific polar interactions with strict requirements for directionality, coupled with the observation that a variety of shapes could be tolerated in the central portion of the NAMPT inhibitors, led us to focus on a parallel synthesis approach as opposed to rigorous structure-based design. We believed parallel synthesis could allow us to rapidly explore an array of shapes extending into the central portion of the NAMPT protein. The primary goal was to find high Fsp3 central moieties to improve potency relative to <b>27</b> and <b>28</b> while maintaining the favorable lack of CYP2C9 inhibition. Thus, we designed a 119-membered library (see <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> for general structure and selected examples) heavily focused on maintaining a high degree of saturation in the central and right-hand portions of the inhibitors.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0004.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlay of indicated ligands from previously reported X-ray structures in complex with NAMPT. The proteins are omitted for clarity. PDB accession codes are as follows: <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFO">4KFO</a>;<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a><b>2a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR5">4JR5</a>;<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a><b>3</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O13">4O13</a>;<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LVG">4LVG</a>;<a onclick="showRef(event, 'cit9d'); return false;" href="javascript:void(0);" class="ref cit9d">(9d)</a><b>5a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFP">4KFP</a>;<a onclick="showRef(event, 'cit9e'); return false;" href="javascript:void(0);" class="ref cit9e">(9e)</a><b>6a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WQ6">4WQ6</a>;<a onclick="showRef(event, 'cit9f'); return false;" href="javascript:void(0);" class="ref cit9f">(9f)</a><b>8</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GVJ">2GVJ</a>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<sup>1</sup>) X-ray structures of compounds <b>2</b>, <b>5</b>, and <b>6</b> in complex with NAMPT were not available at the time of this work, thus, structures of related analogues <b>2a</b>, <b>5a</b>, and <b>6a</b> were used as surrogates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4a" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0005.jpeg" id="GRAPHIC-d25e1503-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) X-ray crystal structure of <b>41</b> in complex with NAMPT. The ligand <b>41</b> is shown in orange. Protein side chains forming interactions with the ligand are shown in teal. Hydrogen bonding interactions are shown as dashed lines. Crystallographic waters forming H-bonds with the ligand are shown as red spheres. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT">5KIT</a>, resolution = 1.60 Å. (b) Overlay of the small molecule ligand (<b>41</b>, orange) from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT">5KIT</a> (<b>37</b>) with the ligands from previously reported structures <b>1</b> (green) <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFO">4KFO</a>,<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a> and <b>8</b> (white) <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GVJ">2GVJ</a>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The location of the nucleophilic N in the left-hand side of each ligand is circled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig4a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. NAMPT and CYP2C9 Inhibition Data of Selected Compounds From a 119-Membered Parallel Synthesis Library<a class="ref internalNav" href="#t5fn1" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0024.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0025.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn3"><div class="footnote" id="t5fn3"><sup>Table a</sup><p class="last">Biochemical NAMPT inhibition at a single inhibitor concentration of 1 μM.</p></div><div class="footnote" id="t5fn4"><sup>Table b</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t5fn5"><sup>Table c</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> for description.</p></div><div class="footnote" id="t5fn6"><sup>Table d</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t5fn1"><sup>Table e</sup><p class="last">All assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2). All compounds are racemic.</p></div></div><div></div></div><div class="NLM_p">After synthesis, all of the library compounds were initially tested at a single concentration of 1 μM to assess for NAMPT inhibition. Unfortunately, the majority were found to be virtually inactive, with less than 50% inhibition at 1 μM observed for 117 of the 119 analogues prepared. The two noteworthy exceptions were spirocycles (±)-<b>30</b> and (±)-<b>31</b>. These compounds showed significant NAMPT inhibition at the 1 μM screening concentration, which further translated to IC<sub>50</sub> values of 830 nM ((±)-<b>30</b>) and 74 nM ((±)-<b>31</b>). Notably, the spirocyclic system was found to be crucial to NAMPT inhibition, as related open chain analogues such as <b>32</b> and (±)-<b>33</b> were found to be far less potent NAMPT inhibitors. The final significant finding was the greatly reduced CYP2C9 inhibition of the compounds in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. Importantly, the compound with the best NAMPT potency (compound (±)-<b>31</b>) also exhibited negligible CYP2C9 inhibition at the concentrations tested. These results validated the hypothesis that a high degree of saturation in the central portion of the scaffold was a viable approach to separate the overlapping NAMPT and CYP2C9 pharmacologies observed with earlier inhibitors.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, the most promising spirocyclic moiety identified from the parallel synthesis approach was then appended to several additional left-hand groups mimicking nicotinamide.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The 2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine group present in compound (±)-<b>40</b> was found to combine best with the spirocyclic moiety. Indeed, (±)-<b>40</b> was not only 10-fold more potent than (±)-<b>31</b> in the biochemical assay but was also found to be the most cell potent NAMPT inhibitor, with an IC<sub>50</sub> value of 2 nM in the A2780 antiproliferation assay. The outstanding cell potency of (±)-<b>40</b> did not appear to be related to an increase in membrane permeability relative to the other spirocyclic inhibitors tested. Indeed, all of the compounds in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> tested in the MDCK assay were found to be highly permeable, including compound (±)-<b>34</b>, which lacked measurable cell-based NAMPT inhibition. The difference in cell activity is likely related to the positioning of the nucleophilic pyridine or related heterocycle in the left-hand portion of the inhibitor. We believe the pyridine present in (±)-<b>40</b> is most ideally situated to form the phosphoribose adducts similar to NMN (see <a class="ref internalNav" href="#fig1a" aria-label="Figure 1">Figure 1</a>), previously shown to be a necessary prerequisite to NAMPT cell-based potency.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This hypothesis is supported by the X-ray crystal structure of the enantiomerically pure form of compound (±)-<b>40</b> in complex with NAMPT (see <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a> and accompanying discussion).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. NAMPT and CYP2C9 Inhibition Data for Spirocyclic Analogues<a class="ref internalNav" href="#t6fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0026.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0027.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn3"><div class="footnote" id="t6fn3"><sup>Table a</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t6fn4"><sup>Table b</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t6fn5"><sup>Table c</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for assay descriptions.</p></div><div class="footnote" id="t6fn1"><sup>Table d</sup><p class="last">All assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2). All compounds are racemic.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, the individual enantiomers of (±)-<b>40</b> were found to have differing levels of NAMPT potency, with the (<i>S</i>) isomer (<b>41</b>) being more potent than the (<i>R</i>) (<b>42</b>). Both enantiomers were found to maintain the favorable lack of CYP2C9 inhibition observed in the racemate, and both had similar levels of stability in human liver microsomes.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Characterization of Individual Enantiomers of (±)-<b>40</b><a class="ref internalNav" href="#t7fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0028.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0029.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn2"><div class="footnote" id="t7fn2"><sup>Table a</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t7fn3"><sup>Table b</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t7fn4"><sup>Table c</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for assay descriptions.</p></div><div class="footnote" id="t7fn1"><sup>Table d</sup><p class="last">All assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2).</p></div></div><div></div></div><div class="NLM_p"><a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a>a shows the X-ray crystal structure of compound <b>41</b> in complex with NAMPT, and a summary of the notable interactions is as follows. The bicyclic left-hand side of the inhibitor participates in face to face π-stacking interactions with Tyr18′ and Phe193. The pyridine N of <b>41</b> forms a favorable polar interaction with Arg196 and also engages in an H-bond interaction with a crystallographic water molecule. The pyrrolidine portion of the bicyclic ring system participates in a favorable van der Waals interaction with Arg311, while the pyridine ring makes a similar interaction with the side chain methylene of Asp219. The urea carbonyl of the linker forms an H-bond interaction with the side chain OH of Ser275, while the NH portion of the urea linker forms a similar interaction with a tightly bound crystallographic water stabilized by H-bonds with Asp219, Val242, and Ser241. These linker interactions are a key pharmacophore for NAMPT inhibitors and often involve a bridging water molecule between the ligand and Ser275 or Asp219. In the central region of <b>41</b>, additional van der Waals contacts are formed between the methylene group appended to the cyclopropane and the side chain CH<sub>2</sub> of Ser275 while the cyclopropane itself makes further van der Waals contacts with side chains of His191, Val242, and Ile351. The piperidine portion of spirocyclic system makes favorable van der Waals interactions with side chains of Ile351 and Ala379. Finally, the carbamate carbonyl in the right-hand side of the inhibitor forms an H-bond with a crystallographic water, while the <i>tert</i>-butyl group protrudes into a relatively open and solvent-exposed region of the protein.</div><div class="NLM_p">A potential explanation for the potent NAMPT inhibition yet lack of significant CYP2C9 inhibition exhibited by compound <b>41</b> is as follows. Compounds <b>1</b>, <b>8</b>, and <b>41</b> were three of the most cellularly potent NAMPT inhibitors profiled in our assays, each possessing A2780 IC<sub>50</sub> values of 1–2 nM. The ligands from each compound’s X-ray structure in complex with NAMPT are overlaid in <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a>b. It is notable that the nucleophilic N in the left-hand moiety of each inhibitor is placed in virtually the same location within the active site of NAMPT (circled in <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a>b). Thus, the inhibitors are ideally poised to form the corresponding phosphoribose adducts, leading to the outstanding cell-based NAMPT potency observed in each case. Despite possessing similarly potent NAMPT cellular activity, compounds <b>1</b>, <b>8</b>, and <b>41</b> displayed a range of CYP2C9 IC<sub>50</sub>s spanning potent (<b>1</b>, 0.2 μM) to moderate (<b>8</b>, 3.6 μM) to negligible (<b>41</b>, >10 μM) inhibition. As shown in <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a>b, notable differences were observed in the topology of the central and right-hand regions, which may contribute to each compound’s ability to bind to and inhibit CYP2C9. Additionally, the spirocyclic moiety in <b>41</b> (negligible CYP2C9 inhibition: IC<sub>50</sub> > 10 μM) is much more rigid than the saturated yet conformationally unrestrained central regions of compounds such as <b>7</b> and <b>8</b> (significant CYP2C9 inhibition: IC<sub>50</sub>s 0.12 and 3.6 μM, respectively). Thus, the unique shape and rigidity of the spirocyclic central motif within <b>41</b> allow it to bind productively to NAMPT but may preclude it from binding effectively to CYP2C9.</div><div class="NLM_p">As noted in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, one issue associated with compound <b>41</b> is poor liver microsome stability. As shown in <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a>, the <i>tert</i>-butyl carbamate group protrudes into a relatively open region of the protein and was expected to be tolerant of substitution. A strategy of reducing cLogD<sub>7.4</sub> as a potential means of improving metabolic stability was undertaken by modifying this portion of the inhibitor. Additionally, because both enantiomers of (±)-<b>40</b> possessed similar metabolic stability, the optimization work was done with the racemic spirocyclic system, with only key analogues being resolved into their constituent enantiomers.</div><div class="NLM_p">As exemplified by the entries in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>, a number of <i>tert</i>-butyl carbamate replacements were prepared using either a subsequent round of parallel synthesis or by targeted singleton synthesis for more synthetically challenging analogues. Compounds (±)-<b>43</b>–(±)-<b>59</b> summarize the efforts at replacing the <i>tert</i>-butyl carbamate with amides. A wide array of aliphatic and aromatic amides were prepared. Although reasonable to excellent NAMPT potency was maintained, it was very difficult to substantively improve metabolic stability while maintaining high membrane permeability. Multiple analogues such as (±)-<b>47</b>–(±)-<b>49</b>, and (±)-<b>56</b>–(±)-<b>58</b> were found to be metabolically stable yet possessed poor MDCK permeability. By contrast, amides maintaining promising levels of MDCK permeability were found to suffer from poor metabolic stability (analogues (±)-<b>43</b>, (±)-<b>44</b>, and (±)-<b>51</b>). Compound (±)-<b>60</b>, the urea isostere of (±)-<b>40</b>, was found to moderately improve metabolic stability, although cell-based potency was reduced by over 10-fold. Non-carbonyl linked groups such as alkylated analogue (±)-<b>61</b> suffered from a marked decrease in NAMPT inhibition. Having failed to achieve the required balance of potency, metabolic stability, and membrane permeability with carbamate replacements, we then investigated whether substituted carbamates ((±)-<b>62</b>–(±)-<b>66</b>) could provide the desired profile.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> These analogues maintained high levels of MDCK permeability, and gratifyingly, the most polar example ((±)-<b>66</b>) also exhibited significantly improved metabolic stability relative to the starting point (±)-<b>40</b>. Finally, an in vitro metabolite identification study in human liver microsomes (data not shown) indicated the left-hand side bicycle to be a site of metabolism. Thus, the deuterated molecule (±)-<b>67</b> was prepared in an attempt to further improve metabolic stability but was not found to be meaningfully different than the proto parent (±)-<b>66</b>. Compound (±)-<b>66</b> was, therefore, selected as the most promising compound for further characterization and progression.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. SAR of Carbamate Replacements and Substitutions<a class="ref internalNav" href="#t8fn1" aria-label="g">g</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0030.gif" alt="" id="fx12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0031.gif" alt="" id="fx13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn3"><div class="footnote" id="t8fn3"><sup>Table a</sup><p class="last">Calculated Log <i>D</i> at pH 7.4.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div><div class="footnote" id="t8fn4"><sup>Table b</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for assay descriptions.</p></div><div class="footnote" id="t8fn5"><sup>Table c</sup><p class="last">(<i>S</i>)-Warfarin probe used.</p></div><div class="footnote" id="t8fn6"><sup>Table d</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for assay descriptions.</p></div><div class="footnote" id="t8fn7"><sup>Table e</sup><p class="last">Single determination (<i>n</i> = 1).</p></div><div class="footnote" id="t8fn8"><sup>Table f</sup><p class="last">Not applicable.</p></div><div class="footnote" id="t8fn1"><sup>Table g</sup><p class="last">Unless otherwised indicated, all assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2). All compounds are racemic.</p></div></div><div></div></div><div class="NLM_p">One final point to emphasize about the compounds in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a> is the consistent lack of CYP2C9 inhibition. The saturated and rigid spirocyclic central moiety offered a general solution to the CYP2C9 inhibition issue.</div><div class="NLM_p">The racemic compound with the best balance of potency, metabolic stability, and membrane permeability was found to be (±)<b>-66</b>. The enantiopure versions (<b>68</b> and <b>69</b>) were, thus, isolated and profiled. As shown in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>, the in vitro metabolic stability and membrane permeability was virtually identical among each enantiomer (<b>68</b> and <b>69</b>) and the racemate ((±)-<b>66</b>). However, one enantiomer (<b>68</b>) was notably more potent against NAMPT than the other, with a sub-nM IC<sub>50</sub> observed in the A2780 cell-based antiproliferation assay. As a precursor to a tumor xenograft study, the cell potency of the active enantiomer <b>68</b> was further evaluated in a relevant cell line (HT1080), where a potent antiproliferative IC<sub>50</sub> value of 1.5 nM was observed.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Characterization of Single Enantiomers of (±)-<b>66</b><a class="ref internalNav" href="#t9fn1" aria-label="g">g</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0032.gif" alt="" id="fx14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0033.gif" alt="" id="fx15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn2"><div class="footnote" id="t9fn2"><sup>Table a</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> for description.</p></div><div class="footnote" id="t9fn3"><sup>Table b</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> for description.</p></div><div class="footnote" id="t9fn4"><sup>Table c</sup><p class="last">Antiproliferation activity determined in cell culture experiments using HT1080 cell line. This inhibition can be reversed by addition of 0.33 μM of NMN, strongly implicating NAMPT inhibition as the causative MOA. See ref <a onclick="showRef(event, 'cit9d'); return false;" href="javascript:void(0);" class="ref cit9d">9d</a> for experimental details.</p></div><div class="footnote" id="t9fn5"><sup>Table d</sup><p class="last">The coefficient of variation for this value is 0.03 (<i>n</i> = 3).</p></div><div class="footnote" id="t9fn6"><sup>Table e</sup><p class="last">See footnotes from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> for assay descriptions.</p></div><div class="footnote" id="t9fn7"><sup>Table f</sup><p class="last">Single determination (<i>n</i> = 1).</p></div><div class="footnote" id="t9fn1"><sup>Table g</sup><p class="last">All assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2).</p></div></div><div></div></div><div class="NLM_p">The in vitro ADME properties of compound <b>68</b> are shown in <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>. Compound <b>68</b> did not significantly inhibit any CYP isoform tested (including CYP2C9) at the concentrations evaluated. Similarly, no time dependent CYP inhibition was observed against any isoform tested. <b>68</b> was found to have moderate in vitro liver microsome stability in all species except for mouse, where poor stability (high predicted clearance) was observed. Compound <b>68</b> was generally more metabolically stable in in vitro hepatocyte assays, with low clearance predicted in human, rat, and dog and moderate clearance predicted in mouse and cyno. Plasma protein binding was moderate, with values in the 50–60% range observed across species. MDCK permeability was on the border of moderate and high, with no evidence of significant efflux. Finally, pH 7.4 aqueous solubility was high in both kinetic and thermodynamic assay formats.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. ADME Properties of Compound <b>68</b><a class="ref internalNav" href="#t10fn1" aria-label="j">j</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0034.gif" alt="" id="GRAPHIC-d25e2146-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn2"><div class="footnote" id="t10fn2"><sup>Table a</sup><p class="last">Reversible Cytochrome P450 inhibition. Isoforms tested: 3A4 (testosterone probe), 3A4 (midazolam probe), 2D6, 1A2, 2C19, 2C9 ((<i>S</i>)-Warfarin probe).</p></div><div class="footnote" id="t10fn3"><sup>Table b</sup><p class="last">Time-dependent inhibition of cytochrome P450s. Isoforms tested: 3A4 (testosterone probe), 3A4 (midazolam probe), 2D6, 1A2, 2C19, 2C9. > 15% AUC shift considered possible TDI risk.</p></div><div class="footnote" id="t10fn4"><sup>Table c</sup><p class="last">Hepatic clearance predicted from human, rat, mouse, dog, and cyno liver microsomes, respectively. Numerical values represent predicted hepatic clearance (mL/min/kg). Colors represent stability categories: green = stable (Cl<sub>pred</sub> < 30% of liver blood flow), yellow = moderate (CL<sub>pred</sub> = 30–70% of liver blood flow), red = labile (CL<sub>pred</sub> > 70% of liver blood flow).</p></div><div class="footnote" id="t10fn5"><sup>Table d</sup><p class="last">Hepatic clearance predicted from hepatocytes. Species, numerical values, and colors as above.</p></div><div class="footnote" id="t10fn6"><sup>Table e</sup><p class="last">% Plasma protein binding in human, rat, mouse, dog, and cyno, respectively.</p></div><div class="footnote" id="t10fn7"><sup>Table f</sup><p class="last">Apparent permeability in MDCK transwell culture. Permeability categories are as follows (units of 10<sup>–6</sup> cm/s): low <1, moderate =1–10, high >10. A:B, apical-to-basolateral. B:A, basolateral-to-apical.</p></div><div class="footnote" id="t10fn8"><sup>Table g</sup><p class="last">Measured Log <i>D</i> at pH 7.4.</p></div><div class="footnote" id="t10fn9"><sup>Table h</sup><p class="last">10 mM DMSO stock solution diluted to 200 μM with pH 7.4 aqueous buffer. Final DMSO concentration: 2% (v/v). Solubility measured after shaking for 24 h.</p></div><div class="footnote" id="t10fn10"><sup>Table i</sup><p class="last">Thermodynamic solubility of crystalline powder after shaking for 24 h in aqueous pH 7.4 buffer.</p></div><div class="footnote" id="t10fn1"><sup>Table j</sup><p class="last">All assay results are reported as the arithmetic mean of at least two separate runs (<i>n</i> ≥ 2). See ref <a onclick="showRef(event, 'cit9d'); return false;" href="javascript:void(0);" class="ref cit9d">9d</a> for experimental details.</p></div></div><div></div></div><div class="NLM_p">With <b>68</b> exhibiting a promising in vitro ADME profile, in vivo PK experiments were carried out. These results are summarized in <a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>, and <a class="ref internalNav" href="#fig5" aria-label="Figures 5">Figures 5</a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. Despite moderate to low predicted clearance from in vitro liver microsome and hepatocyte stability experiments (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>), high in vivo clearance and relatively low oral bioavailability was observed in the rat. Similarly, compound <b>68</b> was rapidly eliminated from the plasma of mice. However, because of its outstanding cellular potency and relatively low plasma protein binding, a 25 mg/kg BID oral dose of <b>68</b> in mice produced plasma concentrations that remained above the plasma-protein binding corrected cell-based HT1080 IC<sub>50</sub> for ∼20 h (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). This level of oral exposure provided confidence that <b>68</b> would likely provide robust efficacy in a mouse tumor xenograft experiment. Additionally, dog PK of compound <b>68</b> was more promising than in rodents. An improved IVIVC was observed in the dog with in vitro liver microsome and hepatocyte clearance (moderate to low), being in reasonable agreement with in vivo clearance (bordering moderate and low). Finally, consistent with reduced clearance, oral bioavailability was significantly improved in the dog (86%) relative to the rat (29%).</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. In Vivo PK Parameters of Compound <b>68</b><a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t11fn2" aria-label="b">b</a> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t11fn2" aria-label="b">b</a> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a> (μM·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub><a class="ref internalNav" href="#t11fn3" aria-label="c">c</a> (μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t11fn3" aria-label="c">c</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">10.5</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">86</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup>a</sup><p class="last">Compounds were formulated in EtOH/PEG400/H<sub>2</sub>O (10:60:30) prior to dosing.</p></div><div class="footnote" id="t11fn2"><sup>b</sup><p class="last">IV dosing (1 mg/kg for rat, 0.5 mg/kg for dog).</p></div><div class="footnote" id="t11fn3"><sup>c</sup><p class="last">PO dosing (5 mg/kg for rat, 3 mg/kg for dog).</p></div></div></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0006.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma concentration–time profiles of compound <b>68</b> after intravenous and oral administration in male Sprague–Dawley rats and male beagle dogs. Each time point shows the mean plasma concentration (± standard deviation) from three separate animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0007.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plasma concentration–time profile of compound <b>68</b> after oral administration (25 mg/kg BID) in female NCR nude mice (black line). Each time point shows the mean plasma concentration (± standard deviation) from three separate animals. Compound <b>68</b> was formulated in EtOH/PEG400/H<sub>2</sub>O (10:60:30) prior to dosing. The HT1080 cell-based potency is included for reference (blue lines).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, compound <b>68</b> was then advanced to a mouse tumor xenograft efficacy study in an HT1080 human fibrosarcoma model. The inhibitor was dosed twice daily for 5 days at both 25 and 50 mg/kg. Consistent with the plasma exposure relative to unbound cell potency relationship depicted in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, robust tumor growth inhibition and tumor regressions were observed at both dose levels (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). On the basis of body weights of treated animals, the NAMPT inhibitor appeared to be well tolerated. Indeed, body weights of untreated mice tended to decline over the course of the study due to tumor-induced cachexia, which was reversed upon treatment with compound <b>68</b>. However, additional toxicity studies were not undertaken to further characterize the safety of compound <b>68</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0008.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy and body weight change after treatment with vehicle (60% PEG400/30% H<sub>2</sub>O/10% EtOH) or compound <b>68</b> (25 and 50 mg/kg BID, PO) for five consecutive days in the HT-1080 human fibrosarcoma xenograft model. Ten female NCR tumor-bearing mice were used per group. Data reflects the mean tumor volume or % body weight change (± standard error of mean). ***<i>p</i> < 0.001 for compound <b>68</b> treated vs vehicle group based on Student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compound <b>16</b> was prepared according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The aniline of 6-chloropyridin-2-amine <b>70</b> was bis-protected with PMB groups to afford <b>71</b>. Iodination at the 3-position afforded <b>72</b>, which was then formylated to produce intermediate <b>73</b>. An aldol condensation with 2-azidoacetate, followed by water loss, afforded <b>74</b>, which was then heated to promote cyclization with loss of N<sub>2</sub> and produce azaindole <b>75</b>. Ethyl ester hydrolysis, followed by coupling of the resulting acid (<b>76</b>) with amine <b>77</b>,<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a> produced <b>78</b>. Sequential removal of the PMB groups then the aromatic chloro substituent flanking the pyridine produced analogue <b>16</b>.</div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Analogue <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaH, PMBCl, DMA, 0–25 °C, 20 h, 87%; (ii) NIS, CH<sub>3</sub>CN, 30 °C, 20 h, 97%; (iii) (a) <i>n</i>-BuLi, THF, – 78 °C, 5 min, (b) ethyl formate −78 °C, 10 min, 37%; (iv) 2-azidoacetate, NaOEt, EtOH, 0 °C, 2 h, 39%; (v) xylene, 130 °C, 3 h, 42%; (vi) KOH, EtOH, H<sub>2</sub>O, 25 °C, 20 h; (vii) <b>77</b>, EDCI, HOBt, DIPEA, DMF, 50 °C, 1 h, 84% (2 steps); (viii) TFA, DCM, 25 °C, 2 h, 45%; (ix) H<sub>2</sub>, Pd/C (10%), KOAc, MeOH, 25 °C, 20 h, 13%.</p></p></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, analogue <b>18</b> was prepared by first converting 6-chloronicotinic acid <b>80</b> to the corresponding acid chloride <b>81</b>, then reacting with diisopropylamine to afford amide <b>82</b>. Formylation at the 4-position produced aldehyde <b>83</b>, which was then reduced to alcohol <b>84</b> and cyclized to produce lactone <b>85</b>. Reduction of <b>85</b> produced diol <b>86</b>, which was converted to dichloride <b>87</b>. Inter-, then intramolecular displacement of the benzylic chloride atoms by 2,4-dimethoxybenzylamine afforded isoazaindoline compound <b>88</b>. The chloride atom appended to the pyridine ring was then displaced with 2,4-dimethoxybenzylamine to produce <b>89</b>, then removal of both DMB groups yielded <b>90</b>. Amine <b>91</b><a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a> was activated as a <i>para</i>-nitrophenyl carbamate to provide <b>92</b>, which was further condensed with amine <b>90</b> to afford analogue <b>18</b>.</div><figure id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Analogue <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) SOCl<sub>2</sub>, DMF, toluene, 80 °C, 3 h; (ii) HN(<i>i</i>-Pr)<sub>2</sub>, DCM, 0–25 °C, 50 min, 82% (2 steps); (iii) LDA, DMF, Et<sub>2</sub>O, −50 °C, 3.5 h, then 25 °C, 16 h, 89%; (iv) NaBH<sub>4</sub>, EtOH, 30 °C, 50 min, 97%; (v) 6 M HCl<sub>aq</sub>, 100 °C, 30 min, 80%; (vi) NaBH<sub>4</sub>, EtOH, 25 °C, 1 h, 39%; (vii) SOCl<sub>2</sub>, DCM, 25 °C, 1 h; (viii) H<sub>2</sub>NDMB, DIPEA, DCM, 25 °C, 16 h, 52% (2 steps); (ix) Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>, <i>tert</i>-BuONa, BINAP, H<sub>2</sub>NDMB, toluene, 80 °C, 16 h, 70%; (x) (a) TFA, 90 °C, 16 h, (b) Na<sub>2</sub>CO<sub>3aq</sub>; (xi) 4-NPCOCl, toluene, 120 °C, 30 min, 96%; (xii) <b>90</b>, EtOH, 90 °C, 1 h, 44% (2 steps).</p></p></figure><div class="NLM_p">As delineated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, the first step in accessing analogue <b>20</b> was to protect the phenol group in 6-chloropyridin-3-ol <b>93</b> as a MOM ether to provide compound <b>94</b>. Formylation of <b>94</b> at the 4-position provided aldehyde <b>95</b>, then the MOM group was removed (<b>96</b>) and the exposed phenol moiety alkylated with methyl 2-bromoacetate to provide <b>97</b>. Cyclization under basic conditions afforded the azabenzofuran intermediate <b>98</b>, which was subjected to hydrolysis conditions to convert the pendant methyl ester to the corresponding carboxylic acid <b>99</b>. <b>99</b> was coupled with amine <b>91</b><a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a> to yield amide <b>100</b>. The aromatic chloride was then reacted with diphenylmethanimine under Buchwald–Hartwig conditions to afford <b>101</b>, then the diphenyl imine protecting group was removed under acidic conditions to produce analogue <b>20</b>.</div><figure id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Analogue <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) NaH, DMF, 0–25 °C, 1 h, (b) methoxymethyl bromide, 10–25 °C, 2 h, 75%; (ii) <i>tert</i>-BuLi, DMF, THF, −78 °C, 50 min; (iii) 3 M HCl, THF, 60 °C, 1 h, 64% (2 steps); (iv) methyl 2-bromoacetate, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 2 h, 66%; (v) <i>tert</i>-BuOK, THF, 0–25 °C, 2 h; (vi) NaOH<sub>aq</sub>, THF, 60 °C, 1 h; (vii) <b>91</b>, EDCI, HOBt, DIPEA, 25 °C, 16 h, 23% (3 steps); (viii) DPINH, Pd<sub>2</sub>(dba)<sub>3</sub>·dba, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 120 °C, 3 h; (ix) HCl<sub>aq</sub>, THF, 25 °C, 30 min, 47% (2 steps).</p></p></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>, analogues <b>21</b>–<b>28</b>, (±)-<b>30</b>, (±)-<b>31</b>, <b>32</b>, (±)-<b>33</b>, and (±)-<b>35</b>–(±)-<b>39</b> were prepared by coupling the appropriate carboxylic acids<a onclick="showRef(event, 'cit9b cit9c cit9e'); return false;" href="javascript:void(0);" class="ref cit9b cit9c cit9e">(9b, 9c, 9e)</a> and amines under standard conditions.</div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Analogues <b>21</b>–<b>28</b> and (+)-<b>30</b>, (+)-<b>31</b>, <b>32</b>, (+)-<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) RNH<sub>2</sub>, EDCI, HOBt, DIPEA, DMF, 25 °C, 16 h, or RNH<sub>2</sub>, HBTU, TEA, DMF, 25 °C, 16 h, 8–73%.</p></p></figure><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Analogues (±)-<b>35</b>–(±)-<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: EDCI, HOBt, TEA, DMF, 25 °C, 16 h, 30–61%.</p></p></figure><div class="NLM_p">Ureas (±)-<b>34</b> and (±)-<b>40</b> were synthesized by first activating one of the amine coupling partners as the corresponding <i>para</i>-nitrophenyl carbamate then condensing with the other amine (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of Analogues (±)-<b>34</b> and (±)-<b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) For compound (±)-<b>34</b>: (a) RR<sub>1</sub>NH, TEA, 4-NPCOCl, DCM, 0 °C, 30 min, (b) (±)-<b>104</b>, TEA, DCM, 0–25 °C, 2 h, 34%. For compound (±)<b>-40</b>: (a) (±)-<b>104</b>, TEA, 4-NPCOCl, DCM, 0–25 °C, 2 h, (b) RR<sub>1</sub>NH, TEA, DCM, 0–5 °C, 5 min, 54%.</p></p></figure><div class="NLM_p">In anticipation of synthesizing carbamates (±)-<b>64</b>–(±)-<b>66</b>, activated carbonates <b>107</b>, <b>108</b>, and <b>110</b> were prepared as shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Ketones <b>105</b> and <b>106</b> were reacted with methylmagnesium bromide or methyllitihium, then the corresponding metal alkoxides were condensed with 4-nitrophenyl chloroformate to generate activated carbonates <b>107</b> and <b>108</b>. Alcohol <b>109</b> was converted to the corresponding sodium alkoxide and trapped with CO<sub>2</sub>. Self-condensation facilitated by methanesulfonyl chloride then produced anhydride <b>110</b>.</div><figure id="sch7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Preparation of Intermediates <b>107</b>, <b>108</b>, and <b>110</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) For compound <b>107</b>: (a) <b>105</b>, MeMgBr, THF, −20 °C to 25 °C, 16 h, (b) 4-NPOCl, pyridine, DCM, 0–25 °C, 2 h, 37% (2 steps). For compound <b>108</b>: (a) <b>106</b>, MeLi, THF, −40 °C to 0 °C, 2 h, (b) 4-NPOCl, 0–5 °C, 3 h, 22%; (ii) (a) Na, THF, 70 °C, 12 h, (b) CO<sub>2</sub>, hexane, 25 °C, 1.5 h, (c) MsCl, 0–5 °C, 2 h, 12%.</p></p></figure><div class="NLM_p">The majority of analogues in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a> ((±)-<b>43</b>–(±)-<b>66</b>) were prepared as depicted in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. The <i>tert</i>-butyl carbamate group of compound (±)-<b>40</b> was removed under acidic conditions, then the resulting amine (compound (±)-<b>111</b>) was reacted with a number of elecrophiles to generate the final products. Amides (±)-<b>43</b>–(±)-<b>59</b> were prepared by condensing (±)-<b>111</b> with the appropriate carboxylic acid in the presence of a coupling reagent and base, urea (±)-<b>60</b> was produced by combining (±)-<b>111</b> with the indicated isocyanate, and compound (±)-<b>61</b> was accessed by reductive amination of (±)-<b>111</b> with the corresponding aldehyde, while carbamates (±)-<b>62</b>–(±)-<b>66</b> were derived by reacting (±)-<b>111</b> with the relevant chloroformate, 4-nitrophenyl carbonate, or anhydride.</div><figure id="sch8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Preparation of Analogues (±)-<b>43</b>–(±)-<b>66</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) HCl, MeOH, 25 °C, 2 h; (ii) carboxylic acid, EDCI, HOBt, DIPEA, DMF, 25 °C, 16 h, 17–74%; (iii) 2-isocyanato-2-methylpropane, TEA, DCM, 0–25 °C, 3 h, 15%; (iv) 2-phenylacetaldehyde, NaBH(OAc)<sub>3</sub>, acetic acid, DCM, 25 °C, 18 h, 10%; (v) (±)-<b>62</b>, (±)-<b>63</b>, (±)-<b>66</b>, one of isopropyl chloroformate, ethyl chloroformate, or <b>108</b>, and TEA, DCM, 0–25 °C, 2–3 h, 25–44%; (±)-<b>64</b>, <b>107</b>, TEA, EtOH, 80 °C, 3 h, 2%; (±)-<b>65</b>, <b>110</b>, NaOH, THF/H<sub>2</sub>O, 35 °C, 5 h, 32%.</p></p></figure><div class="NLM_p">The enantiopure intermediates (<b>119</b> and <b>122</b>) required to make compounds <b>41</b>, <b>42</b>, <b>68</b>, and <b>69</b> were accessed as summarized in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. (±)-6-(<i>tert</i>-Butoxycarbonyl)-6-azaspiro[2.5]octane-1-carboxylic acid (<b>112</b>) was converted to the corresponding (<i>S</i>)-methyl benzamide and the diastereomers (<b>113</b> and <b>115</b>) separated by preparative chiral SFC. The <i>tert</i>-butyl carbamate of <b>113</b> was removed under acidic conditions to afford <b>114</b>, which was then exposed to borane in THF to reduce the amide to the corresponding amine <b>117</b>. The free piperidine amine was converted back to the corresponding <i>tert</i>-butyl carbamate (<b>118</b>), then the (<i>S</i>)-methyl benzyl auxiliary was cleaved to liberate the corresponding primary amine <b>119</b>. The same sequence of reactions was used to convert the diastereomeric (<i>S</i>)-methyl benzamide <b>115</b> to the enantiomeric primary amine <b>122</b>. The absolute configurations of the chiral cyclopropane intermediates (<b>113</b>–<b>122</b>) and final products (<b>41</b>, <b>42</b>, <b>68</b>, and <b>69</b>) were assigned as follows. The absolute configuration of the cyclopropane stereocenter present in <b>41</b> was directly established by its X-ray structure in complex with NAMPT as depicted in <a class="ref internalNav" href="#fig4a" aria-label="Figure 4">Figure 4</a>a. The following compounds were either precursors to (<b>113</b>, <b>114</b>, and <b>117</b>–<b>119</b>), or a product of (<b>68</b>) compound <b>41</b>, thus, all were assigned the same cyclopropane configuration. By extension, compound <b>69</b> and its precursors <b>42</b>, <b>115</b>, <b>116</b>, and <b>120</b>–<b>122</b> were assigned the opposite cyclopropane configuration.</div><figure id="sch9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0017.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Preparation of Intermediates <b>119</b> and <b>122</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) (<i>S</i>)-(−)-1-phenylethanamine, HATU, DIPEA, DMF, 0–25 °C, 16 h, 46%, (b) diastereomers separated by chiral SFC; (ii) (a) HCl, MeOH (saturated solution), 0–25 °C, 16 h, (b) 2 M NaOH<sub>aq</sub>; (iii) (a) BH<sub>3</sub>·THF, THF, 25 °C to reflux, 16 h, (b) 5% HCl<sub>aq</sub>, reflux, 4 h, (c) 10% NaOH<sub>aq</sub>; (iv) Boc<sub>2</sub>O, 10% NaOH<sub>aq</sub>, THF, 0–25 °C, 16 h, 29% (3 steps); (v) H<sub>2</sub> (5 atm), Pd(OH)<sub>2</sub> (20% on C), MeOH, 25 °C, 16 h, 82%.</p></p></figure><div class="NLM_p">The deuterated core (<b>127</b>) used to make analogue (±)-<b>67</b> was accessed as shown in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>. Pyridine-3,4-dicarboxylic acid (<b>123</b>) was converted to the corresponding bis-methyl ester <b>124</b>, then reduced by the action of NaBD<sub>4</sub> in the presence of EtOD to provide the tetradeuterated diol <b>125</b>. Subsequent bis-mesylation, followed by displacement, and intramolecular cyclization by 2,4-dimethoxybenzylamine afforded tetradeuterated isoindoline <b>126</b>. Final deprotection of the 2,4-dimethoxybenzyl group, followed by conversion to the HCl salt for ease of isolation, afforded intermediate <b>127</b>.</div><figure id="sch10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0018.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Preparation of Intermediate <b>127</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MeOH, H<sub>2</sub>SO<sub>4</sub>, 25 °C to reflux, 16 h, 73%; (ii) (a) NaBD<sub>4</sub>, EtOD, CaCl<sub>2</sub>, 0–10 °C, 3 h, (b) HCl, EtOH (saturated solution), 0–10 °C, 2 h, 79%; (iii) (a) CH<sub>3</sub>SO<sub>2</sub>Cl, TEA, DCM, 0 °C, 1 h, (b) H<sub>2</sub>NDMB, DIPEA, 0–25 °C, 8 h, 24%; (iv) (a) CF<sub>3</sub>COOD, 80 °C, 10 h, (b) DCM, HCl (saturated solution), 0 °C, 30 min, quant.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40121" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40121" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Decoupling potent cellular NAMPT activity from profound CYP2C9 inhibition is challenging because an exposed pyridine or pyridine-like system acts as a pharmacophore for both phenomena. In an effort to separate these overlapping pharmacologies, we used parallel synthesis to rapidly access compounds with increased Fsp3. These efforts, followed by subsequent rounds of potency and metabolic stability optimization, culminated in the discovery of a NAMPT inhibitor (<b>68</b>) that exhibited negligible CYP2C9 inhibition while maintaining highly potent cellular NAMPT activity. Although high clearance was observed in rodents, <b>68</b> exhibited outstanding efficacy in a mouse tumor xenograft model of human fibrosarcoma and, furthermore, dog PK was improved relative to rodents.</div><div class="NLM_p last">The current work highlights the fact that increasing Fsp3 may lead to decreased CYP2C9 inhibition even in the presence of a conspicuous heme binding group such as an exposed pyridine. However, the specific location of saturation within the inhibitors was also found to be critical. Notably, saturating the central region of the scaffold was the optimal site to reduce CYP2C9 inhibition. Rigidity may have also played a role in improving the CYP2C9 liability. Indeed, the saturated yet rigid spirocycle disclosed in this work solved the CYP2C9 issue, whereas previously reported NAMPT inhibitors (<b>7</b> and <b>8</b>) with saturated yet flexible central moieties were both found to significantly inhibit CYP2C9. Thus, as a general strategy to reduce CYP inhibition, it may not be sufficient to simply increase global Fsp3. Equally important may be to survey diverse molecular shapes via saturation and rigidification at various sites within the scaffold of interest.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">General: Unless otherwise indicated, all reagents and solvents were purchased from commercial sources and used without further purification. Moisture or oxygen sensitive reactions were conducted under an atmosphere of argon or nitrogen gas. <sup>1</sup>H NMR spectra were recorded using Varian or Bruker instruments operating at the indicated frequencies. Chemical shifts are expressed in ppm relative to an internal standard; tetramethylsilane (ppm = 0.00). The following abbreviations are used: br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. Purification by silica gel chromatography was carried out using either hand-packed glass columns or CombiFlash by Teledyne Isco systems with prepacked cartridges. HRMS data was collected on a Thermo Scientific Ultimate 3000 UHPLC coupled with a Q-Exactive orbitrap MS system using electrospray ionization. IR spectra were collected on a Nicolet 380 FT-IR instrument. IR samples were prepared by mixing solid test sample with KBr in a 1:100 ratio by weight, followed by grinding and pressing into a pellet. Optical rotations were collected on a Rudolph Autopol IV instrument using a sodium lamp and a measurement wavelength of 589 nM. Chemical purities were >95% for all final compounds as assessed by LCMS.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Further details on the analytical conditions used for individual compounds may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 6-Amino-<i>N</i>-(4-((3,5-difluorophenyl)sulfonyl)benzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>16</b>)</h3><div class="NLM_p last">To a mixture of <b>79</b> (60 mg, 0.126 mmol) and potassium acetate (0.50 g, 5.10 mmol) in MeOH (20 mL) was added 10% palladium on carbon (60 mg). The mixture was stirred under 1 atm of H<sub>2</sub> for 20 h at 25 °C. The catalyst was removed by filtration, then the filtrate was concentrated under vacuum and the residue was purified on a silica gel column eluting with DCM/MeOH (5/1). The semipure product was further purified by Prep-HPLC (Column: Gemini 10 μm, 25 mm × 200 mm; mobile phase, 18–38% CH<sub>3</sub>CN:H<sub>2</sub>O with 0.4% NH<sub>4</sub>HCO<sub>3</sub> in 20 min; detector, UV 254 nm) to give 7.4 mg (13%) of <b>16</b> as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.26 (s, 1H), 9.04 (s, 1H), 8.38 (s, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 2H), 7.75–7.55 (m, 5H), 7.08 (s, 1H), 6.37 (s, 1H), 5.64 (br, 2H), 4.55 (d, <i>J</i> = 5.7 Hz, 2H). LCMS (method S, ESI) RT = 1.58 min, <i>m</i>/<i>z</i> = 443.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 6-Amino-<i>N</i>-(4-(phenylsulfonyl)benzyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide (<b>18</b>)</h3><div class="NLM_p last">A mixture of <b>90</b> (60 mg, 0.44 mmol) and <b>92</b> (200 mg, 0.49 mmol) in EtOH (20 mL) was stirred for 1 h at 90 °C. The reaction mixture was cooled to 25 °C and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (10:1) to give 74.1 mg (44%, over two steps) of <b>18</b> as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.95–7.87 (m, 5H), 7.72–7.60 (m, 3H), 7.58–7.46 (m, 2H), 7.02 (t, <i>J =</i> 6.0 Hz, 1H), 6.36 (s, 1H), 5.84 (s, 2H), 4.45 (s, 4H), 4.31 (d, <i>J =</i> 5.7 Hz, 2H). LCMS (method G, ESI) RT = 1.46 min, <i>m</i>/<i>z</i> = 409.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 5-Amino-<i>N</i>-(4-(phenylsulfonyl)benzyl)furo[2,3-<i>c</i>]pyridine-2-carboxamide (<b>20</b>)</h3><div class="NLM_p last">A solution of 18% aqeuous HCl (3 mL) was added to <b>101</b> (300 mg, 0.52 mmol) in THF (5 mL), and the reaction mixture was stirred for 30 min at 25 °C. The pH value was adjusted to 7 with 5% aqueous sodium carbonate solution, then the mixture was extracted with 100 mL of EtOAc. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with DCM/MeOH (100/4) to give 100 mg (47%, over two steps) of <b>20</b> as a light-yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.41 (t, <i>J</i> = 6.0 Hz, 1H), 8.36 (s, 1H), 7.94–7.91 (m, 4H), 7.68–7.53 (m, 5H), 7.32 (s, 1H), 6.64 (d, <i>J</i> = 0.9 Hz, 1H), 5.68 (s, 2H), 4.50 (d, <i>J</i> = 5.7 Hz, 2H). LCMS (method V, ESI) RT = 1.87 min, <i>m</i>/<i>z</i> = 408.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(4-(Methylsulfonyl)benzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>21</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.41 (br, 1H), 9.43 (t, <i>J</i> = 6.1 Hz, 1H), 9.10 (s, 1H), 8.29 (d, <i>J</i> = 6.1 Hz, 1H), 7.91 (d, <i>J</i> = 8.1 Hz, 2H), 7.61 (d, <i>J</i> = 8.1 Hz, 2H), 7.52 (d, <i>J</i> = 6.1 Hz, 1H), 7.45 (s, 1H), 4.63 (d, <i>J</i> = 6.0 Hz, 2H), 3.19 (s, 3H). LCMS (method X, ESI) RT = 2.63 min, <i>m</i>/<i>z</i> = 330.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(4-Sulfamoylbenzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>22</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.68 (br, 1H), 9.49 (t, <i>J</i> = 6.0 Hz, 1H), 9.21 (s, 1H), 8.34 (d, <i>J</i> = 6.3 Hz, 1H), 7.84–7.76 (m, 2H), 7.64 (d, <i>J</i> = 6.2 Hz, 1H), 7.56–7.49 (m, 3H), 7.31 (s, 2H), 4.61 (d, <i>J</i> = 5.9 Hz, 2H). LCMS (method X, ESI) RT = 2.68 min, <i>m</i>/<i>z</i> = 331.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-Benzyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>23</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.01 (br, 1H), 9.19 (t, <i>J</i> = 6.1 Hz, 1H), 8.92 (s, 1H), 8.21 (d, <i>J</i> = 5.8 Hz, 1H), 7.40–7.20 (m, 7H), 4.53 (d, <i>J</i> = 5.9 Hz, 2H). LCMS (method X, ESI) RT = 2.36 min, <i>m</i>/<i>z</i> = 252.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(4-((3-(Dimethylcarbamoyl)benzyl)oxy)benzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>24</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.04 (br, 1H), 9.13 (t, <i>J</i> = 5.7 Hz, 1H), 8.91 (s, 1H), 8.21 (d, <i>J</i> = 5.7 Hz, 1H), 7.53–7.24 (m, 8H), 7.02–6.96 (m, 2H), 5.14 (s, 2H), 4.45 (d, <i>J</i> = 5.7 Hz, 2H), 2.99–2.86 (m, 6H). LCMS (method W, ESI) RT = 1.13 min, <i>m</i>/<i>z</i> = 429.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(4-(Cyclopentanesulfonamido)benzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>25</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.01 (br, 1H), 9.66 (s, 1H), 9.14 (t, <i>J</i> = 5.7 Hz, 1H), 8.92 (s, 1H), 8.22 (d, <i>J</i> = 5.7 Hz, 1H), 7.41–7.12 (m, 6H), 4.47 (d, <i>J</i> = 6.0 Hz, 2H), 3.58–3.41 (m, 1H), 1.92–1.48 (m, 8H). LCMS (method A, ESI) RT = 1.32 min, <i>m</i>/<i>z</i> = 399.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(4-(Pyrrolidine-1-carbonyl)benzyl)-1<i>H</i>-pyrrolo[3,2<i>-c</i>]pyridine-2-carboxamide (<b>26</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.05 (s, 1H), 9.25 (t, <i>J</i> = 6.0 Hz, 1H), 8.94 (s, 1H), 8.23 (d, <i>J</i> = 5.6 Hz, 1H), 7.56–7.31 (m, 6H), 4.57 (d, <i>J</i> = 6.0 Hz, 2H), 3.48–3.32 (m, 4H), 2.89–2.78 (m, 4H). LCMS (method A, ESI) RT = 1.36 min, <i>m</i>/<i>z</i> = 349.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(Cyclohexylmethyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>27</b>)</h3><div class="NLM_p last">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.98 (br, 1H), 8.90 (s, 1H), 8.53 (t, <i>J</i> = 5.6 Hz, 1H), 8.20 (d, <i>J</i> = 5.8 Hz, 1H), 7.35 (d, <i>J</i> = 5.8 Hz, 1H), 7.25 (s, 1H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H), 1.77–1.65 (m, 4H), 1.65–1.49 (m, 2H), 1.28–1.11 (m, 3H), 1.02–0.88 (m, 2H). LCMS (method Y, ESI) RT = 2.35 min, <i>m</i>/<i>z</i> = 258.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-Isobutyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>28</b>)</h3><div class="NLM_p">Prepared by a method similar to that used for (±)-<b>36</b>, substituting the appropriate carboxylic acid and amine coupling partners. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (br, 1H), 8.91 (s, 1H), 8.56 (t, <i>J</i> = 5.9 Hz, 1H), 8.20 (d, <i>J</i> = 5.8 Hz, 1H), 7.35 (d, <i>J</i> = 5.8 Hz, 1H), 7.26 (s, 1H), 3.12 (t, <i>J</i> = 6.4 Hz, 2H), 1.94–1.79 (m, 1H), 0.91 (d, <i>J</i> = 6.7 Hz, 6H). LCMS (method Y, ESI) RT = 1.77 min, <i>m</i>/<i>z</i> = 218.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The parallel synthesis library (including compounds (±)-<b>30</b>, (±)-<b>31</b>, <b>32</b>, and (±)-<b>33</b>) was synthesized by the following general procedure. The amine coupling partners (0.15 mmol) were weighed into individual vials. Stock solutions of carboxylic acid <b>102</b> (2.50 g, 15.3 mmol) and HBTU (9.03 g, 23.7 mmol) in DMF (75 mL each) were then prepared. Then 0.5 mL of the carboxylic acid <b>102</b> stock solution (0.10 mmol), followed by TEA (42 μL, 0.30 mmol), then 0.5 mL of the HBTU stock solution (0.16 mmol), was added to each vial containing amine, and the vials were capped and shaken for 16 h at 25 °C. The crude reaction mixtures were evaporated to dryness using a Genevac evaporator, then rediluted in 1 mL of DMF. The mixtures were transferred to 96-well plates, then purified by a mass-triggered Prep-HPLC instrument to afford the desired products in 8–73% yield.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (±)-<i>tert</i>-Butyl 3-((1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamido)methyl)-2-oxa-9-azaspiro[5.5]undecane-9-carboxylate ((±)-<b>30</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (br, 1H), 8.91 (s, 1H), 8.71–8.63 (m, 1H), 8.20 (d, <i>J</i> = 5.8 Hz, 1H), 7.35 (d, <i>J</i> = 5.8 Hz, 1H), 7.28 (s, 1H), 3.76 (d, <i>J</i> = 11.3 Hz, 1H), 3.47–3.19 (m, 6H), 3.07 (d, <i>J</i> = 11.5 Hz, 1H), 1.77 (d, <i>J</i> = 13.0 Hz, 1H), 1.62–1.33 (m, 5H), 1.38 (s, 9H), 1.32–1.20 (m, 1H), 1.20–1.12 (m, 2H). LCMS (method Y, ESI) RT = 3.25 min, <i>m</i>/<i>z</i> = 429.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (±)-<i>tert</i>-Butyl 1-((1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>31</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.94 (br, 1H), 8.91 (s, 1H), 8.64 (t, <i>J</i> = 5.6 Hz, 1H), 8.20 (d, <i>J</i> = 5.8 Hz, 1H), 7.35 (d, <i>J</i> = 5.8, 1H), 7.26 (s, 1H), 3.52–3.20 (m, 5H), 1.62–1.51 (m, 1H), 1.45–1.31 (m, 3H), 1.38 (s, 9H), 1.22–1.11 (m, 1H), 1.06–0.94 (m, 1H), 0.58–0.50 (m, 1H), 0.31–0.25 (m, 1H). LCMS (method Y, ESI) RT = 3.19 min, <i>m</i>/<i>z</i> = 385.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>tert</i>-Butyl 4-(2-(1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamido)ethyl)piperidine-1-carboxylate (<b>32</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.93 (br, 1H), 8.91 (s, 1H), 8.55 (t, <i>J</i> = 5.4 Hz, 1H), 8.20 (d, <i>J</i> = 5.8 Hz, 1H), 7.35 (d, <i>J</i> = 5.8 Hz, 1H), 7.22 (s, 1H), 3.92 (d, <i>J</i> = 13.1 Hz, 2H), 3.39–3.30 (m, 2H), 2.70–2.65 (m, 2H), 1.69 (d, <i>J</i> = 13.3 Hz, 2H), 1.53–1.45 (m, 3H), 1.39 (s, 9H), 1.07–0.97 (m, 2H). LCMS (method Y, ESI) RT = 2.58 min, <i>m</i>/<i>z</i> = 373.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (±)-<i>tert</i>-Butyl 3-(2-(1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamido)ethyl)piperidine-1-carboxylate ((±)-<b>33</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.92 (br, 1H), 8.90 (s, 1H), 8.56 (t, <i>J</i> = 5.9 Hz, 1H), 8.20 (d, <i>J</i> = 5.7 Hz, 1H), 7.35 (dt, <i>J</i> = 5.8, 1.2 Hz, 1H), 7.23 (s, 1H), 3.87–3.59 (m, 2H), 3.39–3.29 (m, 2H), 2.91–2.78 (m, 1H), 1.87–1.79 (m, 1H), 1.64–1.55 (m, 1H), 1.55–1.39 (m, 3H), 1.37 (s, 9H), 1.38–1.25 (m, 2H), 1.20–1.07 (m, 1H). LCMS (method Y, ESI) RT = 2.62 min, <i>m</i>/<i>z</i> = 373.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (±)-<i>tert</i>-Butyl 1-((3-(Pyridin-3-ylmethyl)ureido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>34</b>)</h3><div class="NLM_p last">TEA (551 μL, 3.96 mmol) was added dropwise to a mixture of 4-nitrophenyl chloroformate (810 mg, 4.02 mmol) and pyridin-3-ylmethanamine (430 mg, 3.98 mmol) in DCM (12 mL) at 0 °C. The reaction mixture was stirred for 30 min, then a solution of (±)<b>-</b><i>tert</i>-butyl 1-(aminomethyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>104</b>) (960 mg, 3.99 mmol) in DCM (5.0 mL) was added, followed by dropwise addition of additional TEA (1.10 mL, 7.92 mmol). The reaction mixture was warmed to 25 °C and stirred for 2 h, then washed with H<sub>2</sub>O (3 × 50 mL) and brine (3 × 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions. Column: XBridge Shield RP18 OBD, 5 μm, 19 mm × 150 mm; mobile phase, H<sub>2</sub>O with 10 mM NH<sub>4</sub>HCO<sub>3</sub> and CH<sub>3</sub>CN (25% CH<sub>3</sub>CN up to 40% in 10 min, up to 95% in 1 min, hold 95% for 1 min, down to 25% in 2 min); detector, UV 254/220 nm. Yield: 0.5 g (34%) of (±)-<b>34</b> was obtained as colorless oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.47–8.43 (m, 2H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.32 (dd, <i>J</i> = 7.6, 4.8 Hz, 1H), 6.39 (t, <i>J</i> = 6.0 Hz, 1H), 5.95 (t, <i>J</i> = 5.0 Hz,1H), 4.22 (d, <i>J</i> = 6.0 Hz, 2H), 3.48–3.40 (m, 2H), 3.20–3.14 (m, 3H), 2.95–2.88 (m, 1H), 1.53–1.48 (m, 1H), 1.40 (s, 9H), 1.33–1.30 (m, 2H), 1.15–1.14 (m, 1H), 0.85–0.78 (m, 1H), 0.48–0.43 (m, 1H), 0.21–0.17 (m, 1H). LCMS (method F, ESI) RT = 2.17 min, <i>m</i>/<i>z</i> = 375.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (±)-<i>tert</i>-Butyl 1-((1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridine-5-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>35</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)<b>-36</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.97 (s, 1H), 8.69 (s, 1H), 8.66 (t, <i>J</i> = 4.0 Hz, 1H), 8.27 (s, 1H), 3.53–3.40 (m, 2H), 3.27–3.16 (m, 2H), 1.64–1.51 (m, 1H), 1.44–1.32 (m, 4H), 1.38 (s, 9H), 1.20–1.09 (m, 1H), 1.07–0.95 (m, 1H), 0.58–0.50 (m, 1H), 0.31–0.21 (m, 1H). LCMS (method X, ESI) RT = 4.25 min, <i>m</i>/<i>z</i> = 286.1 [M - Boc + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (±)-<i>tert</i>-Butyl 1-((Imidazo[1,2-<i>a</i>]pyrimidine-6-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>36</b>)</h3><div class="NLM_p last">EDCI (79.6 mg, 0.415 mmol) was added to a mixure of (±)-<b>104</b> (50.0 mg, 0.208 mmol), imidazo[1,2-<i>a</i>]pyrimidine-6-carboxylic acid (37.4 mg, 0.229 mmol), HOBt (33.7 mg, 0.249 mmol), and TEA (116 μL, 0.834 mmol) in DMF (1.0 mL). The resulting solution was stirred for 16 h at 25 °C. Then 50 mL of H<sub>2</sub>O was added and the mixture was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (3 × 50 mL), then the organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by preparative HPLC with the following conditions. Column: Gemini 10 μm, 25 mm × 200 mm; mobile phase, H<sub>2</sub>O with 0.4% NH<sub>4</sub>HCO<sub>3</sub>, CH<sub>3</sub>CN (12% CH<sub>3</sub>CN up to 39% in 15 min, up to 95% in 17 min); detector, UV 254 nm. Yield: 50 mg (62%) of (±)-<b>36</b> was obtained as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.39 (s, 1H), 9.18 (s, 1H), 7.94 (s, 1H), 7.77–7.62 (m, 2H), 3.60–3.45 (m, 4H), 3.22–3.12 (m, 2H), 1.68–1.64 (m, 1H), 1.58–1.54 (m, 1H), 1.43 (s, 9H), 1.28–1.21 (m, 1H), 1.18–1.05 (m, 2H), 0.65–0.62 (m, 1H), 0.33–0.28 (m, 1H). LCMS (method B, ESI) RT = 3.43 min, <i>m</i>/<i>z</i> = 386.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (±)-<i>tert</i>-Butyl 1-((Imidazo[1,2-<i>a</i>]pyridine-6-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>37</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>36</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.80 (s, 1H), 7.69–7.61 (m, 3H), 7.36 (d, <i>J</i> = 9.3 Hz, 1H), 6.16 (br, 1H), 3.71–3.54 (m, 3H), 3.45–3.41 (m, 1H), 3.27–3.17 (m, 2H), 1.69–1.49 (m, 2H), 1.43 (s, 9H), 1.40–1.37 (m, 1H), 1.21–1.11 (m, 1H), 0.99–0.92 (m, 1H), 0.69–0.56 (m, 1H), 0.34–0.28 (m, 1H). LCMS (method B, ESI) RT = 3.60 min, <i>m</i>/<i>z</i> = 385.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (±)-<i>tert</i>-Butyl 1-((Thieno[2,3-<i>c</i>]pyridine-2-carboxamidgo)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>38</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>36</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 9.18 (s, 1H), 8.53 (d, <i>J</i> = 6.0 Hz, 1H), 7.75 (d, <i>J</i> = 6.0 Hz, 1H), 7.73 (s, 1H), 6.29 (br, 1H), 3.64–3.40 (m, 4H), 3.28–3.17 (m, 2H), 1.66–1.63 (m, 1H), 1.57–1.49 (m, 1H), 1.44 (s, 9H), 1.38–1.22 (m, 1H), 1.17–1.12 (m, 1H), 1.02–0.94 (m, 1H), 0.63–0.58 (m, 1H), 0.33–0.28 (m, 1H). LCMS (method H, ESI) RT = 1.63 min, <i>m</i>/<i>z</i> = 402.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (±)-<i>tert</i>-Butyl 1-((Furo[2,3-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>39</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>36</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.99 (br, 1H), 8.50 (s, 1H), 7.69 (d, <i>J</i> = 4.5 Hz, 1H), 7.50 (s, 1H), 6.72 (br, 1H), 3.65–3.57 (m, 3H), 3.48–3.42 (m, 1H), 3.25–3.19 (m, 2H), 1.71–1.53 (m, 2H), 1.44 (s, 9H), 1.38–1.32 (m, 1H), 1.15–1.11 (m, 1H), 1.00–0.92 (m, 1H), 0.66–0.63 (m, 1H), 0.35–0.30 (m, 1H). LCMS (method H, ESI) RT = 1.60 min, <i>m</i>/<i>z</i> = 386.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (±)-<i>tert</i>-Butyl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>40</b>)</h3><div class="NLM_p">TEA (2.6 mL, 18.3 mmol) was added dropwise to a mixture of (±)-<b>104</b> (4.00 g, 16.6 mmol), 4-nitrophenyl chloroformate (3.35 g, 16.6 mmol) in DCM (80 mL) at 0 °C. The reaction mixture was warmed to 25 °C and stirred for 2 h, monitoring for completion by TLC. The reaction mixture was used in the next step without further purification. TLC: EtOAc/petroleum ether = 1/1, <i>R</i><sub>f</sub> = 0.2.</div><div class="NLM_p last">The solution prepared above was cooled to 0 °C, then 2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine dihydrochloride (3.20 g, 16.6 mmol) was added in portions, followed by dropwise addtion of TEA (4.7 mL, 33.7 mmol). The reaction mixture was stirred for 5 min at 0–5 °C, then 100 mL of DCM was added. The organic layer was washed with brine (3 × 20 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with DCM/MeOH (60/40) to afford 3.5 g (54%) of (±)-<b>40</b> as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.39 (d, <i>J</i> = 5.1 Hz, 1H), 6.42 (t, <i>J</i> = 5.4 Hz, 1H), 4.63 (s, 2H), 4.62 (s, 2H), 3.50–3.38 (m, 2H), 3.26–3.07 (m, 4H), 1.62–1.54 (m, 1H), 1.39 (s, 9H), 1.40–1.30 (m, 2H), 1.18–1.09 (m, 1H), 0.96–0.88 (m, 1H), 0.47 (dd, <i>J</i> = 8.6, 4.5 Hz, 1H), 0.20 (t, <i>J</i> = 4.7 Hz, 1H). LCMS (method N, ESI) RT = 1.40 min, <i>m</i>/<i>z</i> = 387.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>tert</i>-Butyl (<i>S</i>)-1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>41</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>40</b>, substituting enantiopure <b>119</b> in place of racemic (±)-<b>104</b>. Analytical data consistent with (±)-<b>40</b>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>tert</i>-Butyl (<i>R</i>)-1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>42</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>40</b>, substituting enantiopure <b>122</b> in place of racemic (±)-<b>104</b>. Analytical data consistent with (±)-<b>40</b>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (±)-<i>N</i>-((6-(3,3-Dimethylbutanoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)-<b>43</b>)</h3><div class="NLM_p last">EDCI (52.0 mg, 0.271 mmol) was added to a mixture of (±)-<b>111</b> (80.0 mg, 0.179 mmol, based on 81% LCMS purity), 3,3-dimethylbutanoic acid (42.0 mg, 0.362 mmol), HOBt (36.5 mg, 0.270 mmol), and DIPEA (119 μL, 0.721 mmol) in DMF (2.0 mL). The reaction mixture was stirred for 16 h at 25 °C, then 50 mL of water was added and the mixture was extracted with DCM (2 × 50 mL). The combined organic layers were washed with brine (2 × 50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with DCM/MeOH (96/4) to afford 22.2 mg (32%) of (±)-<b>43</b> as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 8.56 (s, 1H), 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.45 (d, <i>J</i> = 5.2 Hz, 1H), 4.76 (s, 4H), 3.89–3.76 (m, 1H), 3.73–3.60 (m, 1H), 3.58–3.45 (m, 2H), 3.29–3.24 (m, 2H), 2.40–2.31 (m, 2H), 1.75–1.70 (m, 1H), 1.58–1.46 (m, 2H), 1.33–1.30 (m, 1H), 1.11–1.06 (m, 1H), 1.05 (s, 9H), 0.65–0.62 (m, 1H), 0.37–0.34 (m, 1H). LCMS (LCMS 19, ESI) RT = 1.35 min, <i>m</i>/<i>z</i> = 385.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (±)-<i>N</i>-((6-(3-Methylbutanoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)<b>-44</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.37 (d, <i>J</i> = 5.1 Hz, 1H), 6.41 (t, <i>J</i> = 5.3 Hz, 1H), 4.61 (s, 4H), 3.62–3.49 (m, 2H), 3.38–3.33 (m, 1H), 3.29–3.25 (m, 1H), 3.15–3.09 (m, 2H), 2.16 (d, <i>J</i> = 7.2 Hz, 2H), 2.00–1.94 (m, 1H), 1.58–1.52 (m, 1H), 1.41–1.15 (m, 3H), 0.94–0.93 (m, 1H), 0.86 (d, <i>J</i> = 6.6 Hz, 6H), 0.50–0.45 (m, 1H), 0.24–0.19 (m, 1H). LCMS (method I, ESI) RT = 1.23 min, <i>m</i>/<i>z</i> = 371.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (±)-<i>N</i>-((6-(2-(4-Methyltetrahydro-2<i>H</i>-pyran-4-yl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)-<b>45</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.38 (d, <i>J</i> = 5.1 Hz, 1H), 6.42 (t, <i>J</i> = 4.9 Hz, 1H), 4.61 (s, 4H), 3.69–3.31 (m, 8H), 3.15–3.08 (m, 2H), 2.31 (s, 2H), 1.62–1.49 (m, 3H), 1.45–1.25 (m, 4H), 1.21–1.05 (m, 1H), 1.04–0.89 (m, 4H), 0.55–0.51 (m, 1H), 0.25–0.15 (m, 1H). LCMS (method I, ESI) RT = 1.19 min, <i>m</i>/<i>z</i> = 428.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (±)-<i>N</i>-((6-(3-(Tetrahydro-2<i>H</i>-pyran-4-yl)propanoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)-<b>46</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz,1H), 7.38 (d, <i>J</i> = 5.4 Hz, 1H), 6.41 (t, <i>J</i> = 4.7 Hz, 1H), 4.63 (s, 4H), 3.83–3.78 (m, 2H), 3.73–3.42 (m, 2H), 3.37–3.23 (m, 4H), 3.20–3.10 (m, 2H), 2.29 (t, <i>J</i> = 6.5 Hz, 2H), 1.59–1.40 (m, 8H), 1.37–1.31 (m, 3H), 1.17–1.14 (m, 1H), 0.55–0.40 (m, 1H), 0.30–0.15 (m, 1H). LCMS (method D, ESI) RT = 1.16 min, <i>m</i>/<i>z</i> = 427.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (±)-<i>N</i>-((6-(2-(Tetrahydro-2<i>H</i>-pyran-4-yl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)-<b>47</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 8.60 (d, <i>J</i> = 4.5 Hz, 1H), 7.50 (s, 1H), 4.85 (s, 4H), 4.44 (s, 1H), 3.97–3.92 (m, 3H), 3.58–3.49 (m, 1H), 3.46–3.26 (m, 5H), 2.26 (d, <i>J</i> = 6.9 Hz, 2H), 2.09–2.07 (m, 1H), 1.70–1.66 (m, 3H), 1.57–1.21 (m, 5H), 1.01–0.99 (m, 1H), 0.71–0.58 (m, 1H), 0.38–0.29 (m, 1H). LCMS (method I, ESI) RT = 1.09 min, <i>m</i>/<i>z</i> = 413.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (±)-<i>N</i>-((6-(2-(3-Hydroxy-3-methylcyclobutyl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)<b>-48</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.47 (d, <i>J</i> = 5.1 Hz, 1H), 7.39 (d, <i>J</i> = 5.1 Hz, 1H), 6.42 (t, <i>J</i> = 4.8 Hz, 1H), 4.75 (s, 1H), 4.62 (s, 4H), 3.68–3.42 (m, 2H), 3.32–3.24 (m, 2H), 3.13–3.11 (m, 2H), 2.41 (d, <i>J</i> = 4.5 Hz, 2H), 2.04–2.02 (m, 3H), 1.68–1.50 (m, 3H), 1.48–1.30 (m, 2H), 1.19 (s, 3H), 1.18–1.10 (m, 1H), 0.99–0.87 (m, 1H), 0.55–0.41 (m, 1H), 0.27–0.19 (m, 1H). LCMS (method P, ESI) RT = 7.80 min, <i>m</i>/<i>z</i> = 413.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (±)-<i>N</i>-((6-(2-(3-Methyloxetan-3-yl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>49</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 7.39 (d, <i>J</i> = 5.2 Hz, 1H), 6.44 (t, <i>J</i> = 4.8 Hz, 1H), 4.64 (s, 2H), 4.63 (s, 2H), 4.41 (d, <i>J</i> = 5.6 Hz, 2H), 4.20 (d, <i>J</i> = 6.0 Hz, 2H), 3.66–3.41 (m, 4H), 3.14–3.12 (m, 2H), 2.71–2.68 (m, 2H), 1.68–1.52 (m, 1H), 1.48–1.34 (m, 2H), 1.32 (s, 3H), 1.26–1.14 (m, 1H), 0.93–0.86 (m, 1H), 0.57–0.45 (m, 1H), 0.29–0.19 (m, 1H). LCMS (method B, ESI): RT = 2.61 min, <i>m</i>/<i>z</i> = 399.1 [M + 1]<sup>+</sup>.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (±)-<i>N</i>-((6-(4,4,4-Trifluorobutanoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>50</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.38 (d, <i>J</i> = 5.1 Hz, 1H), 6.41 (t, <i>J</i> = 4.8 Hz, 1H), 4.62 (s, 4H), 3.68–3.42 (m, 2H), 3.40–3.37 (m, 2H), 3.14–3.12 (m, 2H), 2.59–2.57 (m, 3H), 1.69–1.54 (m, 1H), 1.48–1.32 (m, 2H), 1.28–1.12 (m, 2H), 0.96–0.87 (m, 1H), 0.55–0.45 (m, 1H), 0.28–0.19 (m, 1H). LCMS (method Y, ESI) RT = 0.90 min, <i>m</i>/<i>z</i> = 411.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (±)-<i>N</i>-((6-Benzoyl-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>51</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 8.47 (d, <i>J =</i> 4.8 Hz, 1H), 7.45–7.36 (m, 6H), 6.43 (t, <i>J</i> = 5.1 Hz, 1H), 4.65 (s, 4H), 3.85–3.78 (m, 1H), 3.48–3.32 (m, 3H), 3.13–3.10 (m, 2H), 1.68–1.62 (m, 1H), 1.58–1.42 (m, 2H), 1.38–1.14 (m, 1H), 0.97–0.87 (m, 1H), 0.52–0.50 (m, 1H), 0.26–0.22 (m, 1H). LCMS (method Q, ESI) RT= 1.44 min, <i>m</i>/<i>z</i> = 391.1[M + H]<sup>+</sup>.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (±)-<i>N</i>-[[6-[4-(1-Methyl-4-piperidyl)benzoyl]-6-azaspiro[2.5]octan-2-yl]methyl]-1,3-dihydropyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide ((±)<b>-52</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.46 (d, <i>J</i> = 4.5 Hz, 1H), 7.38 (d, <i>J</i> = 3.6 Hz, 1H), 7.32–7.21 (m, 4H), 6.43 (t, <i>J</i> = 4.8 Hz, 1H), 4.63 (s, 4H), 3.76–3.74 (m, 1H), 3.51–3.33 (m, 3H), 3.20–3.12 (m, 2H), 2.87–2.84 (m, 2H), 2.44–2.39 (m, 1H), 2.18 (s, 3H), 1.98–1.91 (m, 2H), 1.70–1.62 (m, 5H), 1.54–1.24 (m, 3H), 1.01–0.96 (m, 1H), 0.54–0.49 (m, 1H), 0.24–0.21 (m, 1H). LCMS (method R, ESI) RT = 1.25 min, <i>m</i>/<i>z</i> = 488.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (±)-<i>N</i>-((6-(2-(Pyrimidin-2-yl)acetyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>53</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 8.62 (t, <i>J</i> = 4.8 Hz, 2H), 8.45 (s, 1H), 8.35 (dd, <i>J</i> = 5.0, 2.3 Hz, 1H), 7.34 (d, <i>J</i> = 3.9 Hz, 1H), 7.29–7.23 (m, 1H), 4.65 (s, 4H), 4.02 (d, <i>J</i> = 2.7 Hz, 2H), 3.72–3.70 (m, 1H), 3.57–3.53 (m, 1H), 3.47–3.40 (m, 2H), 3.22–3.15 (m, 2H), 1.61–1.58 (m, 1H), 1.45–1.38 (m, 2H), 1.22–1.20 (m, 1H), 0.98–0.88 (m, 1H), 0.51 (dd, <i>J</i> = 8.7, 4.2 Hz, 1H), 0.24 (t, <i>J</i> = 4.8 Hz, 1H). LCMS (method W, ESI) RT = 0.92 min, <i>m</i>/<i>z</i> = 407.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (±)-<i>N</i>-((6-(2,4-Dimethylthiazole-5-carbonyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>54</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.39 (d, <i>J</i> = 4.8 Hz, 1H), 6.44 (t, <i>J</i> = 5.3 Hz, 1H), 4.64 (s, 2H), 4.63 (s, 2H), 3.72–3.60 (m, 2H), 3.59–3.41 (m, 2H), 3.14–3.10 (m, 2H), 2.61 (s, 3H), 2.26 (s, 3H), 1.63–1.60 (m, 1H), 1.45–1.39 (m, 2H), 1.25–1.18 (m, 1H), 0.99–0.95 (m, 1H), 0.52 (dd, <i>J</i> = 8.4, 4.4 Hz, 1H), 0.26 (t, <i>J</i> = 4.4 Hz, 1H). LCMS (method O, ESI): RT = 1.16 min, <i>m</i>/<i>z</i> = 426.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (±)-<i>N</i>-((6-(4-Methylnicotinoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>55</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.47 (s, 1H), 8.45–8.43 (m, 2H), 8.35 (s, 1H), 7.38 (d, <i>J</i> = 4.8 Hz, 1H), 7.29 (d, <i>J</i> = 4.8 Hz, 1H), 6.43 (t, <i>J</i> = 5.1 Hz, 1H), 4.62 (s, 4H), 3.83–3.72 (m, 1H), 3.64–3.55 (m, 1H), 3.09–2.99 (m, 4H), 2.26 (s, 3H), 1.79–1.62 (m, 1H), 1.51–1.32 (m, 2H), 1.15–1.00 (m, 1H), 0.98–0.92 (m, 1H), 0.54–0.45 (m, 1H), 0.27–0.21 (m, 1H). LCMS (method I, ESI) RT = 0.94 min, <i>m</i>/<i>z</i> = 406.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (±)-<i>N</i>-((6-(1,5-Dimethyl-1<i>H</i>-pyrazole-4-carbonyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>56</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.44 (s, 1H), 7.39 (d, <i>J</i> = 4.8 Hz, 1H), 6.43 (t, <i>J</i> = 5.0 Hz, 1H), 4.65 (s, 2H), 4.63 (s, 2H), 3.76 (s, 3H), 3.73–3.55 (m, 2H), 3.45–3.38 (m, 2H), 3.15–3.12 (m, 2H), 2.28 (s, 3H), 1.65–1.61 (m, 1H), 1.44–1.40 (m, 2H), 1.24–1.20 (m, 1H), 1.00–0.93 (m, 1H), 0.52–0.45 (m, 1H), 0.27–0.21 (m, 1H). LCMS (method B, ESI) RT = 2.51 min, <i>m</i>/<i>z</i> = 409.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (±)-<i>N</i>-((6-(1,3,5-Trimethyl-1<i>H</i>-pyrazole-4-carbonyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>57</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.37 (d, <i>J</i> = 4.8 Hz, 1H), 6.42 (t, <i>J</i> = 5.1 Hz, 1H), 4.62 (s, 2H), 4.61 (s, 2H), 3.62 (s, 3H), 3.52–3.13 (m, 4H), 3.11–3.05 (m, 2H), 2.14 (s, 3H), 2.03 (s, 3H), 1.68–1.56 (m, 1H), 1.38–1.35 (m, 2H), 1.19–1.12 (m, 1H), 0.99–0.92 (m, 1H), 0.48 (dd, <i>J</i> = 8.4, 4.2 Hz, 1H), 0.21 (t, <i>J</i> = 4.2 Hz, 1H). LCMS (method I, ESI) RT = 1.06 min, <i>m</i>/<i>z</i> = 423.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (±)-<i>N</i>-((6-(1,3-Dimethyl-1<i>H</i>-pyrazole-4-carbonyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>58</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.79 (s, 1H), 7.38 (d, <i>J</i> = 4.8 Hz, 1H), 6.43 (t, <i>J</i> = 5.1 Hz, 1H), 4.64 (s, 2H), 4.63 (s, 2H), 3.75 (s, 3H), 3.70–3.61 (m, 2H), 3.44–3.38 (m, 2H), 3.13–3.11 (m, 2H), 2.14 (s, 3H), 1.64–1.58 (m, 1H), 1.44–1.38 (m, 2H), 1.23–1.18 (m, 1H), 1.00–0.92 (m, 1H), 0.50 (dd, <i>J</i> = 8.6, 4.5 Hz, 1H), 0.23 (t, <i>J</i> = 4.4 Hz, 1H). LCMS (method C, ESI) RT = 1.62 min, <i>m</i>/<i>z</i> = 409.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (±)-<i>N</i>-((6-(2,4-Dimethyloxazole-5-carbonyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>59</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>43</b>, substituting the appropriate carboxylic acid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.38 (d, <i>J</i> = 4.8 Hz, 1H), 6.44 (t, <i>J</i> = 5.4 Hz, 1H), 4.64 (s, 2H), 4.63 (s, 2H), 3.73–3.64 (m, 2H), 3.49–3.43 (m, 2H), 3.16–3.12 (m, 2H), 2.40 (s, 3H), 2.17 (s, 3H), 1.70–1.63 (m, 1H), 1.47–1.42 (m, 2H), 1.27–1.22 (m, 1H), 1.01–0.92 (m, 1H), 0.52 (dd, <i>J</i> = 8.6, 4.6 Hz, 1H), 0.26 (t, <i>J</i> = 4.5 Hz, 1H). LCMS (method I, ESI) RT = 1.14 min, <i>m</i>/<i>z</i> = 410.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (±)-<i>N</i>-((6-(<i>tert</i>-Butylcarbamoyl)-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>60</b>)</h3><div class="NLM_p last">A solution of (±)-<b>111</b> (80.0 mg, 0.223 mmol) in DCM (10 mL) was cooled to 0 °C, then 2-isocyanato-2-methylpropane (27.0 mg, 0.272 mmol), followed by TEA (62 μL, 0.446 mmol) was added. The resulting solution was allowed to warm to 25 °C, then stirred for 3 h. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column eluting with DCM/MeOH (94/6) to provide 12.5 mg (15%) of (±)-<b>60</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.46 (d, <i>J</i> = 5.1 Hz, 1H), 7.38 (d, <i>J</i> = 4.8 Hz, 1H), 6.41 (t, <i>J</i> = 5.1 Hz, 1H), 5.67 (s, 1H), 4.63 (s, 2H), 4.62 (s, 2H), 3.39–3.32 (m, 2H), 3.17–3.08 (m, 4H), 1.55–1.49 (m, 1H), 1.34–1.30 (m, 2H), 1.23 (s, 9H), 1.13–1.09 (m, 1H), 0.92–0.87 (m, 1H), 0.43 (dd, <i>J</i> = 8.7, 4.2 Hz, 1H), 0.19 (t, <i>J</i> = 4.5 Hz, 1H). LCMS (method J, ESI) RT = 2.04 min, <i>m</i>/<i>z</i> = 386.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (±)-<i>N</i>-((6-Phenethyl-6-azaspiro[2.5]octan-1-yl)methyl)-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2(3<i>H</i>)-carboxamide ((±)-<b>61</b>)</h3><div class="NLM_p last">To a solution of (±)-<b>111</b> (100 mg, 0.279 mmol) in DCM (2.0 mL) was added 2-phenylacetaldehyde (110 mg, 0.917 mmol), followed by acetic acid (100 μL, 1.75 mmol). The mixture was stirred for 2 h at 25 °C. NaBH(OAc)<sub>3</sub> (660 mg, 3.06 mmol) was added in several portions, then the reaction mixture was stirred for 16 h. Ten mL of water was added and the layers separated. The aqueous layer was further extracted with EtOAc (3 × 20 mL), and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions. Column: XBridge Shield RP18 OBD column, 5 μm, 19 mm × 150 mm; mobile phase, H<sub>2</sub>O with 10 mM NH<sub>4</sub>HCO<sub>3</sub> and CH<sub>3</sub>CN (10–50% CH<sub>3</sub>CN in 10 min, up to 95% in 1 min, hold for 1 min, down to 5% in 2 min); detector, UV 254 nm. Yield: 11.4 mg (10%) of (±)-<b>61</b> was obtained as a yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 8.59 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.44 (d, <i>J</i> = 5.1 Hz, 1H), 7.29–7.17 (m, 5H), 4.67 (s, 2H), 4.66 (s, 2H), 3.26–3.08 (m, 2H), 2.86–2.81 (m, 2H), 2.76–2.48 (m, 6H), 1.83–1.78 (m, 1H), 1.69–1.58 (m, 2H), 1.41–1.36 (m, 1H), 1.10–0.99 (m, 1H), 0.57 (dd, <i>J</i> = 8.7, 4.8 Hz, 1H), 0.28 (t, <i>J</i> = 4.8 Hz, 1H). LCMS (method D, ESI) RT = 1.17 min, <i>m</i>/<i>z</i> = 390.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (±)-Isopropyl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>62</b>)</h3><div class="NLM_p last">To a solution of (±)-<b>111</b> (120 mg, 0.334 mmol) in DCM (10 mL) was added TEA (140 μL, 1.01 mmol) at 0 °C. Isopropyl chloroformate (49.5 mg, 0.404 mmol) was then added dropwise at 0–5 °C. The reaction mixture was warmed to 25 °C and stirred for 3 h, then diluted with 80 mL of DCM and washed with brine (3 × 100 mL). The organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions. Column: Sunfire C18 19 mm × 150 mm; mobile phase, H<sub>2</sub>O with 0.2% NH<sub>4</sub>OH and CH<sub>3</sub>CN (25% CH<sub>3</sub>CN up to 95% in 12 min, up to 100% in 15 min); detector, UV 254 nm. 31.6 mg (25%) of (±)-<b>62</b> was obtained as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 8.54 (s, 1H), 8.45 (d, <i>J</i> = 5 0.1 Hz, 1H), 7.44 (d, <i>J</i> = 5.1 Hz, 1H), 4.90–4.80 (m, 1H), 4.76 (s, 4H), 3.68–3.55 (m, 2H), 3.40–3.36 (m, 2H), 3.29–3.20 (m, 2H), 1.72–1.64 (m, 1H), 1.53–1.44 (m, 2H), 1.25–1.23 (m, 7H), 1.10–1.02 (m, 1H), 0.62 (dd, <i>J =</i> 8.8, 4.3 Hz, 1H), 0.31 (t, <i>J =</i> 4.6 Hz, 1H). LCMS (method A, ESI) RT = 1.46 min, <i>m</i>/<i>z</i> = 373.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (±)-Ethyl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>63</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>62</b>, substituting ethyl chloroformate. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (s, 1H), 8.46 (d, <i>J</i> = 4.2 Hz, 1H), 7.38 (d, <i>J</i> = 4.2 Hz, 1H), 6.41 (t, <i>J</i> = 4.5 Hz, 1H), 4.63 (s, 4H), 3.98 (q, <i>J</i> = 6.9 Hz, 2H), 3.49–3.32 (m, 2H), 3.26–3.20 (m, 2H), 3.11–3.06 (m, 2H), 1.62–1.57 (m, 1H), 1.42–1.36 (m, 2H), 1.22–1.15 (m, 1H), 1.14 (t, <i>J</i> = 6.9 Hz, 3H), 0.93–0.86 (m, 1H), 0.52–0.46 (m, 1H), 0.25–0.20 (m, 1H). LCMS (method K, ESI) RT = 1.22 min, <i>m</i>/<i>z</i> = 359.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (±)-1-Methylcyclobutyl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido) methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>64</b>)</h3><div class="NLM_p last">To a solution of (±)-<b>111</b> (430 mg, 1.20 mmol) in EtOH (5 mL) was added TEA (500 μL, 3.56 mmol), followed by 1-methylcyclobutyl 4-nitrophenyl carbonate (<b>107</b>, 300 mg, 1.19 mmol). The reaction mixture was stirred for 3 h at 80 °C, then cooled to room temperature and concentrated under vacuum. Five mL of H<sub>2</sub>O was added and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions. Column: XBridge Shield RP18 OBD, 5 μm, 19 mm × 150 mm; mobile phase, H<sub>2</sub>O with 10 mM NH<sub>4</sub>HCO<sub>3</sub> and CH<sub>3</sub>CN (5% CH<sub>3</sub>CN up to 30.5% in 10 min, up to 100% in 1 min, down to 5% in 2 min); detector, UV 254 nm. Yield: 11.1 mg (2%, over two steps) of (±)-<b>64</b> was obtained as an off-white solid. <sup>1</sup>HNMR (300 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 8.55 (s, 1H), 8.47 (d, <i>J</i> = 5.4 Hz, 1H), 7.45 (d, <i>J</i> = 5.1 Hz, 1H), 4.77 (s, 4H), 3.65–3.58 (m, 2H), 3.34–3.26 (m, 4H), 2.34–2.26 (m, 2H), 2.15–2.08 (m, 2H), 1.81–1.65 (m, 3H), 1.60–1.41 (m, 5H), 1.35–1.15 (m, 1H), 1.15–0.90 (m, 1H), 0.60 (dd, <i>J =</i> 8.7, 4.2 Hz, 1H), 0.32 (t, <i>J =</i> 4.8 Hz, 1H). LCMS (method T, ESI) RT = 1.42 min, <i>m</i>/<i>z</i> = 399.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (±)-1-Methoxy-2-methylpropan-2-yl 1-((2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>65</b>)</h3><div class="NLM_p last">To a solution of (±)-<b>111</b> (60.0 mg, 0.167 mmol) in THF (15 mL) was added bis(1-methoxy-2-methylpropan-2-yl) dicarbonate (<b>110</b>, 93.1 mg, 0.335 mmol) then sodium hydroxide (1.0 mL, 2.0 M aqueous solution). The reaction mixture was warmed to 35 °C and stirred for 5 h at that temperature, then concentrated under vacuum. The residue was dissolved in 50 mL of DCM and washed with H<sub>2</sub>O (1 × 50 mL) and brine (1 × 50 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified with a silica gel column eluting with DCM/MeOH (96/4). The product (60 mg) was further purified by Prep-HPLC with the following conditions. Column: XBridge Shield RP18 OBD column, 5 μm, 19 mm × 150 mm; mobile phase, H<sub>2</sub>O with 10 mM NH<sub>4</sub>HCO<sub>3</sub> and CH<sub>3</sub>CN (18% CH<sub>3</sub>CN up to 43% in 10 min, up to 95% in 1 min, hold 95% for 1 min, down to 18% in 2 min); detector, UV 254/220 nm. Yield: 22.1 mg (32%) of (±)-<b>65</b> was obtained as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.38 (d, <i>J</i> = 4.8 Hz, 1H), 6.41 (t, <i>J</i> = 5.1 Hz, 1H), 4.63 (s, 2H), 4.62 (s, 2H), 3.48–3.40 (m, 4H), 3.33–3.23 (m, 5H), 3.13–3.09 (m, 2H), 1.58–1.52 (m, 1H), 1.35–1.31 (m, 8H), 1.16–1.11 (m, 1H), 0.95–0.90 (m, 1H), 0.49–0.42 (m, 1H), 0.24–0.19 (m, 1H). LCMS (method E, ESI) RT = 2.12 min, <i>m</i>/<i>z</i> = 439.2 [M + Na]<sup>+</sup>.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (±)-3-Methyloxetan-3-yl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido) methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>66</b>)</h3><div class="NLM_p last">A solution of (±)-<b>111</b> (9.50 g, 26.4 mmol) in DCM (400 mL) was cooled to 0 °C. TEA (19.6 mL, 140.3 mmol) was added dropwise, followed by 3-methyloxetan-3-yl 4-nitrophenyl carbonate (<b>108</b>, 7.08 g, 28.0 mmol). The reaction mixture was warmed to 25 °C and stirred for 2 h. Then 200 mL of DCM was then added and the mixture was washed with brine (3 × 100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified with a silica gel column eluting with DCM/MeOH (95/5) to give 4.62 g (44%) of (±)-<b>66</b> as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.56 (d, <i>J =</i> 1.0 Hz, 1H), 8.47 (d, <i>J =</i> 5.0 Hz, 1H), 7.39 (dd, <i>J =</i> 5.1, 1.1 Hz, 1H), 6.41 (t, <i>J =</i> 5.4 Hz, 1H), 4.64 (s, 2H), 4.63 (s, 2H), 4.60 (d, <i>J =</i> 7.5 Hz, 2H), 4.37 (d, <i>J =</i> 7.5 Hz, 2H), 3.58–3.43 (m, 2H), 3.32–3.22 (m, 2H), 3.14–3.10 (m, 2H), 1.62 (s, 3H), 1.62–1.53 (m, 1H), 1.42–1.34 (m, 2H), 1.21–1.17 (m, 1H), 0.95–0.88 (m, 1H), 0.48 (dd, <i>J =</i> 8.6, 4.4 Hz, 1H), 0.22 (t, <i>J =</i> 4.8 Hz, 1H). LCMS (method L, ESI) RT = 2.11 min, <i>m</i>/<i>z</i> = 401.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> (±)-3-Methyloxetan-3-yl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido-1,1,3,3-<i>d</i>4)methyl)-6-azaspiro[2.5]octane-6-carboxylate ((±)-<b>67</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>66</b>, substituting amine <b>127</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.38 (dd, <i>J</i> = 5.1, 0.9 Hz, 1H), 6.42 (t, <i>J</i> = 5.3 Hz, 1H), 4.59 (d, <i>J</i> = 6.9 Hz, 2H), 4.37 (d, <i>J</i> = 7.5 Hz, 2H), 3.50–3.47 (m, 2H), 3.31–3.28 (m, 2H), 3.16–3.06 (m, 2H), 1.62 (s, 3H), 1.64–1.56 (m, 1H), 1.40–1.36 (m, 2H), 1.20–1.17 (m, 1H), 1.00–0.96 (m, 1H), 0.48 (dd, <i>J =</i> 8.5, 4.2 Hz, 1H), 0.22 (t, <i>J =</i> 4.4 Hz, 1H). LCMS (method Q, ESI) RT = 1.39 min, <i>m</i>/<i>z</i> = 405.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (<i>S</i>)-3-Methyloxetan-3-yl 1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>68</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>66</b>, substituting enantiopure <b>119</b> in place of racemic (±)-<b>104</b>. <sup>1</sup>H NMR and LCMS data consistent with (±)-<b>66</b>. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 156.26, 152.84, 147.77, 146.34, 144.31, 133.58, 118.19, 80.88, 76.07, 51.29, 49.62, 43.88, 43.22, 39.71 (overlaps with DMSO-<i>d</i><sub>6</sub>), 35.87, 29.42, 23.60, 21.86, 21.41, 15.79. HRMS (ESI) [M + H]<sup>+</sup> expected = 401.2183, found = 401.2176. Chiral SFC (method SFC1) RT = 1.37 min, >98% ee [α]<sup>20</sup><sub>D</sub> −7.6 (<i>c</i> 0.00340, MeOH). IR (KBr pellet) ν<sub>max</sub> 3480, 2997, 2933, 2878, 1694, 1632, 1542, 1432, 1388, 1245, 1194, 1122, 966, 829, 765, 630 cm<sup>–1</sup>.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 3-Methyloxetan-3-yl (<i>R</i>)-1-((2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamido)methyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>69</b>)</h3><div class="NLM_p last">Prepared as described for compound (±)-<b>66</b>, substituting enantiopure <b>122</b> in place of racemic (±)-<b>104</b>. <sup>1</sup>H NMR and LCMS data consistent with (±)-<b>66</b>. <sup>13</sup>C NMR consistent with <b>68</b>. HRMS (ESI) [M + H]<sup>+</sup> expected = 401.2183, found = 401.2174. Chiral SFC (method SFC1) RT = 1.48 min, >98% ee [α]<sup>20</sup><sub>D</sub> 5.0 (<i>c</i> 0.00343, MeOH). IR (film) consistent with <b>68</b>.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 6-Chloro-<i>N</i>,<i>N</i>-bis(4-methoxybenzyl)pyridin-2-amine (<b>71</b>)</h3><div class="NLM_p last">To a solution of 6-chloropyridin-2-amine (<b>70</b>) (20 g, 156 mmol) in dimethylacetamide (200 mL) was added sodium hydride (33.3 g, 60% dispersion in mineral oil, 833 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 20 min then 1-(chloromethyl)-4-methoxybenzene (48 g, 307 mmol) was added dropwise with stirring at 0 °C. The resulting solution was allowed to warm to 25 °C, and stirring was continued for 20 h. The reaction was quenched by the dropwise addition of H<sub>2</sub>O (100 mL), then 400 mL of EtOAc was added and the layers separated. The organic layer was further washed with H<sub>2</sub>O (2 × 100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under vacuum to give 50.1 g of crude <b>71</b> as a yellow oil. TLC: EtOAc/petroleum ether = 1/2, <i>R</i><sub>f</sub> = 0.5.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 6-Chloro-5-iodo-<i>N</i>,<i>N</i>-bis(4-methoxybenzyl)pyridin-2-amine (<b>72</b>)</h3><div class="NLM_p last"><i>N</i>-Iodosuccinimide (24.0 g, 107 mmol) was added to a solution of <b>71</b> (10.0 g, 27.2 mmol) in CH<sub>3</sub>CN (200 mL), and the reaction mixture was stirred at 25 °C for 20 h. A solution containing K<sub>2</sub>CO<sub>3</sub> (20.0 g) and Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (20.0 g) in H<sub>2</sub>O (30 mL) was then added. After stirring for 5 min, the solids were filtered off, the filtrate was concentrated under vacuum, and the residue was diluted with 400 mL of EtOAc. The organic layer was washed with H<sub>2</sub>O (2 × 50 mL) then dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/5) to give 13.1 g (85%, over two steps) of <b>72</b> as a light-yellow solid. TLC: EtOAc/petroleum ether = 1/2, <i>R</i><sub>f</sub> = 0.6.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 6-(Bis(4-methoxybenzyl)amino)-2-chloronicotinaldehyde (<b>73</b>)</h3><div class="NLM_p last"><i>n</i>-BuLi (8 mL of a 2.5 M solution in hexanes) was added to a solution of <b>72</b> (8.00 g, 16.2 mmol) in THF (100 mL) at −78 °C. The reaction mixture was stirred for 5 min at −78 °C, then ethyl formate (5.0 mL) was added. The reaction mixture was allowed to stir for an additional 10 min at −78 °C before being quenched with 10 mL of H<sub>2</sub>O. The resulting mixture was concentrated under vacuum. The residue was diluted with 100 mL of DCM, then the organic layer was washed with H<sub>2</sub>O (1 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/5) to afford 2.41 g (37%) of <b>73</b> as a white solid. TLC: EtOAc/petroleum ether = 1/2, <i>R</i><sub>f</sub> = 0.5.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Ethyl-2-azido-3-(6-(bis(4-methoxybenzyl)amino)-2-chloropyridin-3-yl)acrylate (<b>74</b>)</h3><div class="NLM_p last">To a solution of <b>73</b> (640 mg, 1.62 mmol) and ethyl 2-azidoacetate (800 mg, 6.20 mmol) in EtOH (100 mL) at 0 °C was added sodium ethoxide (400 mg, 5.88 mmol) in several portions. The reaction mixture was stirred at 0 °C for 2 h, then quenched with 10 mL of H<sub>2</sub>O and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/2) to give 320 mg of crude <b>74</b> as a light-yellow solid. TLC: EtOAc/petroleum ether = 1/2, <i>R</i><sub>f</sub> = 0.3.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Ethyl 6-(Bis(4-methoxybenzyl)amino)-4-chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxylate (<b>75</b>)</h3><div class="NLM_p last">A solution of <b>74</b> (250 mg, 0.49 mmol) in xylene (20 mL) was stirred for 3 h at 130 °C. The reaction mixture was cooled to 25 °C then concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/2) to give 101 mg (17%, over two steps) of <b>75</b> as a yellow oil. TLC: EtOAc/petroleum ether = 1/1, <i>R</i><sub>f</sub> = 0.3.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 6-(Bis(4-methoxybenzyl)amino)-4-chloro-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxylic acid (<b>76</b>)</h3><div class="NLM_p last">To a solution of <b>75</b> (400 mg, 0.833 mmol) in EtOH (10 mL) was added a solution of potassium hydroxide (400 mg, 7.14 mmol) in H<sub>2</sub>O (10 mL). The reaction mixture was stirred for 20 h at 25 °C, then the pH value was adjusted to 6 with 1 M aqueous HCl solution. The mixture was concentrated under vacuum to give 1.01 g of crude <b>76</b> as a yellow solid. TLC: DCM/MeOH = 5/1, <i>R</i><sub>f</sub> = 0.3.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 6-(Bis(4-methoxybenzyl)amino)-4-chloro-<i>N</i>-(4-((3,5-difluorophenyl)sulfonyl)benzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>78</b>)</h3><div class="NLM_p last">A mixture of <b>76</b> (300 mg, 0.664 mmol), (4-((3,5-difluorophenyl)sulfonyl)phenyl)methanamine (<b>77</b>) (400 mg, 1.41 mmol), EDCI (300 mg, 1.57 mmol), HOBt (200 mg, 1.48 mmol), and DIPEA (0.77 mL, 4.6 mmol) in DMF (20 mL) was stirred for 1 h at 50 °C. The resulting mixture was concentrated under vacuum, and the residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/1) to give 401 mg (67%, over two steps) of <b>78</b> as a red oil. TLC: EtOAc/petroleum ether = 1/1, <i>R</i><sub>f</sub> = 0.2.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 6-Amino-4-chloro-<i>N</i>-(4-((3,5-difluorophenyl)sulfonyl)benzyl)-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine-2-carboxamide (<b>79</b>)</h3><div class="NLM_p last">A solution of <b>78</b> (200 mg, 0.279 mmol) and TFA (1.0 mL) in DCM (10 mL) was stirred for 2 h at 25 °C. The resulting mixture was concentrated under vacuum, and the residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/1) followed by EtOAc to give 60.1 mg (45%) of <b>79</b> as a red oil. TLC: DCM/MeOH = 5/1, <i>R</i><sub>f</sub> = 0.6.</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 6-Chloronicotinoyl Chloride (<b>81</b>)</h3><div class="NLM_p last">DMF (1.06 mL, 13.7 mmol) and thionyl chloride (20 mL, 275 mmol) were added to a mixture of 6-chloronicotinic acid (<b>80</b>) (20.0 g, 127 mmol) in toluene (200 mL), and the reaction mixture was stirred under nitrogen for 3 h at 80 °C. The resulting solution was cooled to 25 °C and concentrated under vacuum to give 25 g of crude <b>81</b> as a light-yellow solid.</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 6-Chloro-<i>N</i>,<i>N</i>-diisopropylnicotinamide (<b>82</b>)</h3><div class="NLM_p last">Diisopropylamine (69.3 mL, 495 mmol) was added dropwise to a solution of <b>81</b> (25 g, 142 mmol) in DCM (500 mL) at 0 °C. The reaction mixture was warmed to 25 °C and stirred for 50 min, then quenched with H<sub>2</sub>O (300 mL). The organic layer was collected, and the aqueous layer was extracted with DCM (2 × 300 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum to give 25.1 g (82%, over two steps) of <b>82</b> as a light-yellow solid. TLC: EtOAc/petroleum ether = 1:2, <i>R</i><sub>f</sub> = 0.4. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (s, 1H), 7.65 (dd, <i>J</i> = 8.0, 2.4 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 3.67–3.41 (m, 2H), 1.63–1.29 (m, 12H).</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 6-Chloro-4-formyl-<i>N</i>,<i>N</i>-diisopropylnicotinamide (<b>83</b>)</h3><div class="NLM_p last"><i>n</i>-BuLi (5.0 mL, 2.5 M solution in hexanes) was added dropwse to a solution of diisopropylamine (1.39 mL, 9.90 mmol) in diethyl ether (30 mL) at −50 °C. The reaction mixture was stirred for 30 min at −50 °C, then solid <b>82</b> (500 mg, 2.08 mmol) was added in a single portion. The reaction mixture was stirred for 30 min at −50 °C, then DMF (1.0 mL) was added dropwise. The reaction mixture was stirred at −50 °C for a further 3 h then warmed to 25 °C and stirred for 16 h. The reaction mixture was quenched with 10% aqueous citric acid solution (30 mL) and then extracted with diethyl ether (2 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum to give 501 mg of crude <b>83</b> as a yellow solid. LCMS (method M, ESI) RT = 1.40 min, <i>m</i>/<i>z</i> = 269.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.07 (s, 1H), 8.43 (s, 1H), 7.67 (s, 1H), 3.67–3.54 (m, 2H), 1.64–1.10 (m, 12H).</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 6-Chloro-4-(hydroxymethyl)-<i>N</i>,<i>N</i>-diisopropylnicotinamide (<b>84</b>)</h3><div class="NLM_p last">A mixture of <b>83</b> (500 mg, 1.87 mmol) and NaBH<sub>4</sub> (500 mg, 13.2 mmol) in EtOH (50 mL) was stirred for 50 min at 30 °C. The reaction mixture was then quenched with 1 M aqueous HCl. The solids were removed by filtration, and the filtrate was concentrated to provide 502 mg of crude <b>84</b> as a light-yellow solid. LCMS (method I, ESI) RT = 1.25 min, <i>m</i>/<i>z</i> = 271.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 6-Chlorofuro[3,4-<i>c</i>]pyridin-3(1<i>H</i>)-one (<b>85</b>)</h3><div class="NLM_p last">A mixture of <b>84</b> (2.00 g, 7.41 mmol) in 6 M aqueous HCl (40 mL) was stirred for 30 min at 100 °C. The reaction mixture was cooled to 25 °C, and the pH value of the reaction mixture was adjusted to 8 with a saturated aqueous solution of sodium carbonate. The mixture was extracted with 200 mL of DCM, then the organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 1.01 g of crude <b>85</b> as a light-yellow solid. LCMS (method W, ESI) RT= 1.13 min, <i>m</i>/<i>z</i> = 170.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.93 (s, 1H), 7.49 (s, 1H), 5.31 (s, 2H).</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> (6-Chloropyridine-3,4-diyl)dimethanol (<b>86</b>)</h3><div class="NLM_p last">A mixture of <b>85</b> (1.01 g, 5.94 mmol) and NaBH<sub>4</sub> (500 mg, 13.2 mmol) in EtOH (50 mL) was stirred for 1 h at 25 °C. The pH value of the reaction mixture was adjusted to 1 with 6 M aqueous HCl. The solids were removed by filtration and the filtrate was concentrated under vacuum. The residue was purified on a silica gel column eluting with DCM/MeOH (20/1) to give 402 mg (27%, over four steps) of <b>86</b> as a light-yellow solid. LCMS (method W, ESI) RT = 0.95 min, <i>m</i>/<i>z</i> = 174.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.24 (s, 1H), 7.42 (s, 1H), 5.47 (t, <i>J</i> = 5.6 Hz, 1H), 5.29 (t, <i>J</i> = 5.3 Hz, 1H), 4.56 (d, <i>J</i> = 5.4 Hz, 2H), 4.44 (d, <i>J</i> = 5.1 Hz, 2H).</div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 2-Chloro-4,5-bis(chloromethyl)pyridine hydrochloride (<b>87</b>)</h3><div class="NLM_p last">A mixture of <b>86</b> (100 mg, 0.575 mmol) and thionyl chloride (2.0 mL, 27.5 mmol) in DCM (20 mL) was stirred at 25 °C for 1 h. The resulting mixture was concentrated under vacuum to give 101 mg of crude <b>87</b> as a dark-red solid.</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 6-Chloro-2-(2,4-dimethoxybenzyl)-2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine (<b>88</b>)</h3><div class="NLM_p last">DIPEA (1.28 mL, 7.75 mmol) was added to a mixture of <b>87</b> (1.00 g, 4.05 mmol) and (2,4-dimethoxyphenyl)methanamine (1.00 g, 5.99 mmol) in DCM (60 mL), and the reaction mixture was stirred for 16 h at 25 °C, then concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (2/1) to give 902 mg (52%, over two steps) of <b>88</b> as a light-red oil. LCMS (method W, ESI) RT = 0.94 min, <i>m</i>/<i>z</i> = 305.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> <i>N</i>,2-Bis(2,4-Dimethoxybenzyl)-2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridin-6-amine (<b>89</b>)</h3><div class="NLM_p last">A mixture of <b>88</b> (200 mg, 0.655 mmol), Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub> (100 mg, 0.097 mmol), sodium <i>tert</i>-butoxide (200 mg, 2.08 mmol), BINAP (100 mg, 0.161 mmol), and (2,4-dimethoxyphenyl)methanamine (400 mg, 2.4 mmol) in toluene (20 mL) was stirred under nitrogen for 16 h at 80 °C. The reaction mixture was cooled to 25 °C, then 20 mL of H<sub>2</sub>O was added. The layers were separated, and the organic layer was extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/1) to give 202 mg (70%) of <b>89</b> as a dark-red solid. LCMS (method W, ESI) RT = 0.92 min, <i>m</i>/<i>z</i> = 436.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridin-6-amine (<b>90</b>)</h3><div class="NLM_p last">TFA (20 mL) was added to <b>89</b> (300 mg, 0.689 mmol), and the reaction mixture was stirred under nitrogen for 16 h at 90 °C. The resulting mixture was cooled to 25 °C and concentrated under vacuum to remove most of the TFA. The pH value of the residue was adjusted to 8 with a saturated aqueous solution of sodium carbonate. The mixture was concentrated under vacuum, and the residue was dissolved in hot EtOAc and filtered. The filtrate was concentrated under reduced pressure to provide 151 mg of crude <b>90</b> as a red oil. LCMS (method W, ESI): RT = 0.18 min, <i>m</i>/<i>z</i> = 136.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> 4-Nitrophenyl (4-(Phenylsulfonyl)benzyl)carbamate (<b>92</b>)</h3><div class="NLM_p last">4-Nitrophenyl chloroformate (500 mg, 2.5 mmol) was added to a mixture of 4-(phenylsulfonyl)phenyl)methanamine (<b>91</b>) (500 mg, 2.0 mmol) in toluene (30 mL). The reaction mixture was stirred under nitrogen at 120 °C for 30 min, then cooled to 25 °C. A solid precipitated and was collected by filtration, then washed with toluene (5 mL) and dried under vacuum to give 798 mg (96%) of <b>92</b> as a light-yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67 (t, <i>J</i> = 6.2 Hz, 1H), 8.22 (d, <i>J</i> = 9.0 Hz, 2H), 7.97–7.92 (m, 4H), 7.72–7.56 (m, 5H), 7.43 (d, <i>J</i> = 9.3 Hz, 2H), 4.38 (d, <i>J</i> = 6.0 Hz, 2H).</div></div><div id="sec5_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 2-Chloro-5-(methoxymethoxy)pyridine (<b>94</b>)</h3><div class="NLM_p last">To a solution of 6-chloropyridin-3-ol (<b>93</b>, 10.0 g, 77.5 mmol) in DMF (120 mL) at 0 °C was added NaH (3.8 g, 60% in mineral oil, 95.0 mmol) in small portions. The reaction mixture was warmed to 25 °C and stirred for 1 h, then recooled to 0 °C. MOM-Br (8.5 mL, 104 mmol) was then added dropwise while maintaining the reaction temperature at <10 °C. The reaction mixture was stirred at 25 °C for an additional 2 h. Water (200 mL) was added, and the aqueous layer was extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluting with petroleum ether to give 10.1 g (75%) of <b>94</b> as a colorless oil. TLC: petroleum ether/EtOAc = 5/1, <i>R</i><sub>f</sub> = 0.5. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.17 (d, <i>J</i> = 3.0 Hz, 1H), 7.36 (dd, <i>J</i> = 8.7, 3.0 Hz, 1H), 7.23 (d, <i>J</i> = 8.7 Hz, 1H), 5.18 (s, 2H), 3.48 (s, 3H).</div></div><div id="sec5_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 2-Chloro-5-(methoxymethoxy)isonicotinaldehyde (<b>95</b>)</h3><div class="NLM_p last">To a stirred solution of <b>94</b> (10.0 g, 57.6 mmol) in THF (120 mL) at −78 °C was added <i>tert</i>-BuLi (66 mL, 1.3 M solution in pentane) dropwise. The reaction mixture was stirred at −78 °C for 20 min, then DMF (8.4 mL, 109 mmol) was added dropwise. The resulting solution was stirred for a further 30 min at −78 °C and then poured slowly into a saturated aqueous NH<sub>4</sub>Cl solution. The resulting mixture was extracted with 300 mL of EtOAc, then the organic layer was washed with 200 mL of H<sub>2</sub>O, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 11.9 g of crude <b>95</b> as a brown oil. TLC: petroleum ether/EtOAc = 2/1, <i>R</i><sub>f</sub> = 0.4.</div></div><div id="sec5_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 2-Chloro-5-hydroxyisonicotinaldehyde (<b>96</b>)</h3><div class="NLM_p last">A 3 M aqueous HCl solution (130 mL) was added to a mixture of <b>95</b> (11.9 g, 58.9 mmol) in THF (80 mL), and the reaction mixture was stirred for 1 h at 60 °C. The reaction mixture was cooled to 25 °C, and the pH value was adjusted to 7 with 5% aqueous sodium carbonate solution. The resulting solution was extracted with 2 × 200 mL of EtOAc, then the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/3) to give 6.01 g (64% over two steps) of <b>96</b> as a light-yellow solid. TLC: petroleum ether/EtOAc = 2/1, <i>R</i><sub>f</sub> = 0.3.</div></div><div id="sec5_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Methyl 2-((6-Chloro-4-formylpyridin-3-yl)oxy)acetate (<b>97</b>)</h3><div class="NLM_p last">A mixture of <b>96</b> (5.70 g, 36.2 mmol), methyl 2-bromoacetate (4.8 mL, 50.9 mmol), and potassium carbonate (6.50 g, 47.1 mmol) in DMF (100 mL) was stirred for 2 h at 50 °C. The reaction mixture was cooled to room temperature and diluted with 400 mL of EtOAc and washed with H<sub>2</sub>O (2 × 200 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/3) to yield 5.51 g (66%) of <b>97</b> as a light-yellow solid. TLC: petroleum ether/EtOAc = 2/1, <i>R</i><sub>f</sub> = 0.3.</div></div><div id="sec5_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Methyl 5-Chlorofuro[2,3-<i>c</i>]pyridine-2-carboxylate (<b>98</b>)</h3><div class="NLM_p last">A 1 M solution of potassium <i>tert</i>-butoxide in THF (29 mL) was added dropwise to a solution of <b>97</b> (5.51 g, 24.0 mmol) in THF (120 mL) at 0 °C. After addition was completed, the reaction mixture was warmed to 25 °C and stirred for 2 h then 10 mL of H<sub>2</sub>O was added. The resulting mixture was concentrated under vacuum to give 7.01 g of crude <b>98</b> as a light-yellow solid. The product was used in the next step directly without further purification. TLC: petroleum ether/EtOAc = 2/1, <i>R</i><sub>f</sub> = 0.5.</div></div><div id="sec5_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 5-Chlorofuro[2,3-<i>c</i>]pyridine-2-carboxylic Acid (<b>99</b>)</h3><div class="NLM_p last">A mixture of <b>98</b> (370 mg, 1.75 mmol) and 10% aqueous sodium hydroxide solution (4.0 mL) in THF (5.0 mL) was stirred for 1 h at 60 °C. The reaction mixture was cooled to 25 °C, and 9 mL of 5% aqueous HCl was added. The resulting mixture was concentrated under vacuum to give 800 mg of crude <b>99</b> as a white solid. The product was used in the next step without further purification. LCMS (method W, ESI) RT = 1.47 min, <i>m</i>/<i>z</i> = 198.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> 5-Chloro-<i>N</i>-(4-(phenylsulfonyl)benzyl)furo[2,3-<i>c</i>]pyridine-2-carboxamide (<b>100</b>)</h3><div class="NLM_p last">EDCI (400 mg, 2.09 mmol) was added to a mixture of crude <b>99</b> (1.75 mmol), <b>91</b> (520 mg, 2.11 mmol), HOBt (280 mg, 2.09 mmol), and DIPEA (2.0 mL, 12.1 mmol) in DMF (10 mL). The reaction mixture was stirred at 25 °C for 16 h, then diluted with 200 mL of EtOAc and washed with 100 mL of H<sub>2</sub>O. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (30/100 to 50/100) to give 400 mg (23%, over three steps) of <b>100</b> as a white solid. TLC: DCM:MeOH = 10:1, <i>R</i><sub>f</sub> = 0.6.</div></div><div id="sec5_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 5-((Diphenylmethylene)amino)-<i>N</i>-(4-(phenylsulfonyl)benzyl)furo[2,3-<i>c</i>]pyridine-2-carboxamide (<b>101</b>)</h3><div class="NLM_p last">A mixture of <b>100</b> (200 mg, 0.468 mmol), diphenylmethanimine (850 mg, 4.69 mmol), Pd<sub>2</sub>(dba)<sub>3</sub>·dba<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (50.0 mg, 0.0435 mmol), BINAP (50.0 mg, 0.0803 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (185 mg, 0.568 mmol) in 1,4-dioxane (5.0 mL) was stirred for 3 h at 120 °C in a sealed tube under an atmosphere of nitrogen. The reaction mixture was cooled to 25 °C then diluted with 120 mL of EtOAc and washed with 100 mL of H<sub>2</sub>O. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on an alumina column eluting with petroleum ether/EtOAc (1/1) to give 300 mg of crude <b>101</b> as a yellow solid. LCMS (method U, ESI) RT = 1.80 min, <i>m</i>/<i>z</i> = 572.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Methylcyclobutyl 4-Nitrophenyl Carbonate (<b>107</b>)</h3><div class="NLM_p">To a solution of cyclobutanone (<b>105</b>, 5.00 g, 71.4 mmol) in THF (200 mL) was added MeMgBr (47.6 mL, 3 M in THF, 143 mmol) dropwise with stirring at −20 °C under an atmosphere of nitrogen. The reaction mixture was warmed to 25 °C and stirred for 16 h. Then 20 mL of saturated aqueous NH<sub>4</sub>Cl solution was added and the mixture was extracted with EtOAc (3 × 100 mL). The combined organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to provide 4.41 g of 1-methylcyclobutan-1-ol was as a light-brown solid.</div><div class="NLM_p last">A solution of 1-methylcyclobutan-1-ol (1.00 g, 11.6 mmol) in DCM (5.0 mL) was cooled to 0 °C. Pyridine (1.10 g, 13.9 mmol), followed by 4-nitrophenyl chloroformate (1.41 g, 6.99 mmol) in DCM (5.0 mL), was added dropwise over 10 min. The reaction mixture was warmed to 25 °C and stirred for 2 h. Then 5 mL of 1% aqueous HCl solution was added and the layers separated. The aqueous layer was extracted with DCM (1 × 10 mL), and the combined organic layers were washed with brine (1 × 10 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to provide 1.51 g (37% over two steps) of crude <b>107</b> as a light-yellow solid.</div></div><div id="sec5_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 3-Methyloxetan-3-yl 4-Nitrophenyl Carbonate (<b>108</b>)</h3><div class="NLM_p last">A solution of oxetan-3-one (<b>106</b>, 10.0 g, 138.9 mmol) in THF (300 mL) was cooled to −40 °C under an atmosphere of nitrogen. Methyllithium (173 mL, 1.6 M in THF) was added dropwise, and the reaction mixture was warmed to 0 °C and stirred for 2 h. 4-Nitrophenyl chloroformate (27.9 g, 138.4 mmol) was added, and the reaction mixture was stirred for an additional 3 h while the temperature was maintained at 0–5 °C in an ice bath. Then 500 mL of H<sub>2</sub>O was added and the mixture was extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine (3 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified with a silica gel column eluting with petroleum ether/EtOAc (1/1) to provide 7.81 g (22%) of <b>108</b> as a yellow solid. TLC: EtOAc/petroleum ether = 1/2, <i>R</i><sub>f</sub> = 0.4. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.29 (d, <i>J</i> = 9.3 Hz, 2H), 7.40 (d, <i>J</i> = 9.0 Hz, 2H), 4.89 (d, <i>J</i> = 7.5 Hz, 2H), 4.56 (d, <i>J</i> = 8.1 Hz, 2H), 1.85 (s, 3H).</div></div><div id="sec5_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Bis(1-methoxy-2-methylpropan-2-yl) dicarbonate (<b>110</b>)</h3><div class="NLM_p last">To a solution of 1-methoxy-2-methylpropan-2-ol (<b>109</b>, 2.00 g, 19.2 mmol) in THF (30 mL) was added Na (0.397 g, 17.3 mmol). The reaction mixture was stirred for 12 h at 70 °C, then concentrated under vacuum to give 2.31 g (crude) of sodium 1-methoxy-2-methylpropan-2-olate as a yellow solid, which was suspended in hexane (30 mL). CO<sub>2</sub> gas was bubbled in to the reaction mixture for 10 min, then the mixture was stirred for 1.5 h at 25 °C. The reaction mixture was then cooled to 0 °C and methanesulfonyl chloride (743 μL, 9.60 mmol) was then added dropwise. The reaction mixture was stirred for an additional 2 h at 0–5 °C in an ice bath. Then 30 mL of H<sub>2</sub>O was added and stirring was continued for 20 min. Then 20 mL of hexane was added and the layers were separated. The organic layer was washed with 2 × 50 mL of H<sub>2</sub>O, then concentrated under vacuum to provide 601 mg (12%) of <b>110</b> as a light-yellow liquid.</div></div><div id="sec5_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> (±)-<i>N</i>-((6-Azaspiro[2.5]octan-1-yl)methyl)-1,3-dihydro-2<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-2-carboxamide dihydrochloride ((±)-<b>111</b>)</h3><div class="NLM_p last">HCl in MeOH (4.0 M, 15 mL) was added to (±)-<b>40</b> (2.90 g, 7.50 mmol), and the reaction mixture was stirred for 2 h at 25 °C, at which time LCMS indicated the reaction was complete. The reaction mixture was concentrated under vacuum to afford 2.81 g of (±)-<b>111</b> dihydrochloride as a white solid. LCMS (method O, ESI) RT = 0.86 min, <i>m</i>/<i>z</i> = 287.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> <i>tert</i>-Butyl (1<i>S</i>)-1-[[(1<i>S</i>)-1-Phenylethyl]carbamoyl]-6-azaspiro[2.5]octane-6-carboxylate (<b>113</b>)</h3><div class="NLM_p last">A solution of (±)-<b>112</b> (129 g, 505 mmol) in DMF (2000 mL) was cooled to 0 °C. DIPEA (251 mL, 1.52 mol) and (<i>S</i>)-(−)-1-phenylethanamine (87.1 g, 718 mmol) were added, followed by portionwise addition of HATU (231 g, 608 mmol). The reaction mixture was warmed to 25 °C and stirred for 16 h. Then 4500 mL of ice water was added and the mixture was extracted with EtOAc (3 × 2000 mL). The combined organic layers were washed with brine (2 × 800 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/4) to give 83.2 g (46%) of diastereomers <b>113</b> and <b>115</b> (mixture) as a white solid. LCMS (method O, ESI) RT<sub>1</sub> = 4.63 min, RT<sub>2</sub> = 4.73 min, <i>m</i>/<i>z</i> = 359.1 [M + H]<sup>+</sup>. The resulting mixture of diastereomers was separated by chiral supercritical fluid chromatography (Column: 3 cm × 25 cm, 5 μm Chiralpak AD; mobile phase A, CO<sub>2</sub>; mobile phase B, 0.1% NH<sub>4</sub>OH in MeOH; isocratic conditions, 87:13 A:B; flow rate, 200 mL/min; detection UV, 220 nm; back pressure, 100 bar; column temperature, 40 °C). The first eluting diastereomer was carried forward into the next step. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.37–7.29 (m, 5H), 5.86 (br, 1H), 5.16–5.11 (m, 1H), 3.47–3.23 (m, 4H), 1.73–1.70 (m, 1H), 1.65–1.61 (m, 1H), 1.51–1.45 (m, 12H), 1.40–1.38 (m, 2H), 1.37–1.35 (m, 1H), 1.27–1.22 (m, 1H), 0.84–0.78 (m, 1H).</div></div><div id="sec5_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> (1<i>S</i>)-<i>N</i>-[(1<i>S</i>)-1-Phenylethyl]-6-azaspiro[2.5]octane-1-carboxamide (<b>114</b>)</h3><div class="NLM_p last">Hydrogen chloride gas was bubbled into a solution of <b>113</b> (20.0 g, 55.8 mmol) in MeOH (200 mL) at 0 °C for 30 min. The resulting solution was warmed to 25 °C, stirred for 16 h, then concentrated under vacuum. The residue was diluted with 100 mL of H<sub>2</sub>O, and the pH of the solution was adjusted to 12 with 2 M aqueous sodium hydroxide solution. The resulting mixture was extracted with DCM (3 × 100 mL). The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 15.1 g of crude <b>114</b> as a light-yellow solid. LCMS (method O, ESI) RT = 1.03 min, <i>m</i>/<i>z</i> = 259.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> <i>tert</i>-Butyl (1<i>S</i>)-1-([[(1<i>S</i>)-1-Phenylethyl]amino]methyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>118</b>)</h3><div class="NLM_p last">To a solution of <b>114</b> (8.00 g, 31.0 mmol) in THF (100 mL) under nitrogen at 25 °C was added a 1 M solution of borane in THF (100 mL, 100 mmol) dropwise. The resulting mixture was heated to reflux for 16 h, then cooled to room temperature and concentrated under vacuum. Water (50 mL) was added to the residue, and the pH was adjusted to 1 with 5% aqueous HCl solution. The mixture was heated to reflux and stirred for 4 h, then cooled to room temperature and the pH of the solution was adjusted to 12 with a 10% aqueous sodium hydroxide solution. The mixture was cooled to 0 °C, then a solution of di-<i>tert</i>-butyl dicarbonate (6.70 g, 30.7 mmol) in 20 mL of THF was added dropwise. The reaction mixture was warmed to 25 °C and stirred for 16 h, then extracted with EtOAc (2 × 200 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with EtOAc/petroleum ether (1/3) to give 2.91 g (29%, over three steps) of <b>118</b> as light-brown oil. TLC: DCM/MeOH = 10/1, <i>R</i><sub>f</sub> = 0.3.</div></div><div id="sec5_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> <i>tert</i>-Butyl (1<i>S</i>)-1-(Aminomethyl)-6-azaspiro[2.5]octane-6-carboxylate (<b>119</b>)</h3><div class="NLM_p last">A mixture of <b>118</b> (700 mg, 2.03 mmol) and Pd(OH)<sub>2</sub> (100 mg, 20% on carbon) in MeOH (30 mL) was stirred under 5 atm of H<sub>2</sub> in a 50 mL pressure reactor for 16 h at 25 °C. The catalyst was removed by filtration, then the filtrate was concentrated under vacuum to afford 401 mg (82%) of <b>119</b> as a light-yellow oil. LCMS (method I, ESI) RT = 1.25 min, <i>m</i>/<i>z</i> = 241.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.51–3.45 (m, 2H), 3.20–3.16 (m, 2H), 2.64–2.58 (m, 2H), 1.52–1.49 (m, 1H), 1.48 (s, 9H), 1.43–1.40 (m, 1H), 1.24–1.11 (m, 2H), 0.90–0.82 (m, 1H), 0.54–0.46 (m, 1H), 0.33–0.21 (m, 1H).</div></div><div id="sec5_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 3,4-Dimethylpyridine-3,4-dicarboxylate (<b>124</b>)</h3><div class="NLM_p last">To a solution of pyridine-3,4-dicarboxylic acid (<b>123</b>, 35.0 g, 209.4 mmol) in MeOH (250 mL) at 25 °C was added concentrated sulfuric acid (55 mL) dropwise. The reaction mixture was heated to 100 °C for 16 h, then cooled to room temperature and concentrated under vacuum. The residue was diluted with 500 mL of H<sub>2</sub>O, and the pH of the solution was adjusted to 8 with 2.0 M aqueous sodium carbonate solution. The resulting mixture was extracted with DCM (3 × 300 mL), then the combined organic layers were washed with brine (3 × 500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give 30.1 g (73%) of <b>124</b> as a yellow oil. LCMS (method W, ESI) RT = 1.23 min, <i>m</i>/<i>z</i> = 195.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Pyridine-3,4-diylbis(methan-<i>d</i>2-ol) Hydrochloride (<b>125</b>)</h3><div class="NLM_p last">A solution of <b>124</b> (5.01 g, 25.6 mmol, 1.00 equiv) in EtOD (10 mL) was added dropwise to a stirred solution of NaBD<sub>4</sub> (4.31 g, 102.4 mmol) in EtOD (15 mL) maintained under nitrogen at 0 °C. A solution of CaCl<sub>2</sub> (2.51 g, 22.7 mmol, 0.90 equiv) in EtOD (20 mL) was then added dropwise, maintaining the temperature at 0 °C. The reaction mixture was stirred for 3 h while the reaction temperature was maintained between 0 and 10 °C by an ice bath. The mixture was concentrated under vacuum, and the residue was dissolved in 200 mL of EtOH. The solid material was removed by filtration. The filtrate was cooled to 0 °C, then hydrogen chloride gas was bubbled into the solution while keeping the reaction temperature below 5 °C with an ice bath. The reaction mixture was stirred at 0–10 °C for 2 h, then concentrated under vacuum. The residue was triturated in 100 mL of THF, then the solid was collected by filtration and dried under vacuum to give 2.91 g of crude <b>125</b> as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO<i>-d</i><sub>6</sub>) δ 8.83 (d, <i>J</i> = 6.0 Hz, 1H), 8.70 (s, 1H), 8.07 (d, <i>J</i> = 6.0 Hz, 1H).</div></div><div id="sec5_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> 2-(2,4-Dimethoxybenzyl)-2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-1,1,3,3-<i>d</i>4 (<b>126</b>)</h3><div class="NLM_p last">A solution of <b>125</b> (3.00 g, 16.7 mmol) in DCM (80 mL) maintained under nitrogen was cooled to −5 °C. TEA (10 mL, 71.9 mmol) was added dropwise, followed by methanesulfonyl chloride (4.5 mL, 58.1 mmol). The reaction mixture was stirred at 0 °C for 1 h, then 20 mL of H<sub>2</sub>O was added. The organic layer was collected, and the aqueous layer was extracted with DCM (2 × 50 mL). The combined organic layers were washed with brine (1 × 200 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was cooled to 0 °C, then DIPEA (5.0 mL, 30.3 mmol) followed by (2,4-dimethoxyphenyl)methanamine (3.0 mL, 20.0 mmol) was added dropwise at over the course of 5 min. The reaction mixture was warmed to 25 °C and stirred for 8 h. Then 200 mL of H<sub>2</sub>O was added and the layers were separated. The organic layer was washed with brine (2 × 200 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified on a silica gel column eluting with DCM/MeOH (96/4) to give 1.41 g (21%, over three steps) of <b>126</b> as as a red oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.42 (s, 1H), 8.40 (d, <i>J</i> = 4.8 Hz, 1H), 7.25 (d, <i>J</i> = 4.5 Hz, 1H), 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 6.50–6.41 (m, 2H), 3.88 (s, 2H), 3.83 (s, 3H), 3.82 (s, 3H).</div></div><div id="sec5_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> 2,3-Dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-1,1,3,3-<i>d</i>4 Hydrochloride (<b>127</b>)</h3><div class="NLM_p last">A solution of <b>125</b> (700 mg, 2.04 mmol) in CF<sub>3</sub>COOD (5.0 mL) was stirred at 70 °C for 10 h. The resulting mixture was concentrated under vacuum, and the residue was dissolved in 50 mL of DCM. Hydrogen chloride gas was bubbled into the stirred reaction mixture at 0 °C for 30 min. The precipitate was collected by filtration and dried in vacuum to give 600 mg of crude <b>127</b> as a yellow solid. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.77 (s, 1H), 8.69 (d, <i>J</i> = 6.0 Hz, 1H), 8.00 (d, <i>J</i> = 6.0 Hz, 1H).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00697">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74231" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74231" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00697" class="ext-link">10.1021/acs.jmedchem.6b00697</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical LCMS and SFC methods, details of mouse xenograft studies, details of X-ray crystallography of <b>41</b> in complex with NAMPT, experimental details of measured Log <i>D</i> determinations, coefficients of variation in NAMPT biochemical and cell-based inhibition assays, distribution of Fsp3 values and general description of structures in the 119-membered library (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_001.pdf">jm6b00697_si_001.pdf (247.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_002.csv">jm6b00697_si_002.csv (4.98 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>41</b> in complex with NAMPT is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT">5KIT</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.6b00697" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13184" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13184" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Zak</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#026f7863694265676c672c616d6f"><span class="__cf_email__" data-cfemail="e08d9a818ba087858e85ce838f8d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Po-wai Yuen</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiongcai Liu</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Snahel Patel</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Sampath</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Oeh</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bianca M. Liederer</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weiru Wang</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas O’Brien</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Xiao</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas Skelton</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rongbao Hua</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jasleen Sodhi</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunli Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron Beijing Co. Ltd., 6 Taihe Road, BDA, Beijing 100176, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guiling Zhao</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaozhang Zheng</span> - <span class="hlFld-Affiliation affiliation">FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yen-Ching Ho</span> - <span class="hlFld-Affiliation affiliation">FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth W. Bair</span> - <span class="hlFld-Affiliation affiliation">FORMA Therapeutics Inc., 500 Arsenal Street, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter S. Dragovich</span> - <span class="hlFld-Affiliation affiliation">Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): M.Z., D.S, J.O., B.M.L., S.P., W.W., T.O., Y.X., N.S., J.S., G.Z., and P.SD are employees of Genentech, Inc. X.Z., Y.-C.H., and K.W.B. are employees of FORMA Therapeutics. P.-w.Y., X.L., L.Z, R.H., and Y.W. are employees of Pharmaron.<br /></br></div></li></ul></div><div class="ack" id="ACK-d25e7443-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the Genentech DMPK group, especially Leslie Wang, Emile Plise, and Justin Ly, for generating ADME data, Lauren Goeser for synthesizing parallel libraries, Rashida Garcia-Dancey, and Shohini Ganguly for generating biochemical and cellular assay data.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i120" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i120"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i121" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i121"> Abbreviations Used</h2><tr><td class="NLM_term">4-NP</td><td class="NLM_def"><p class="first last">4-nitrophenyl</p></td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism excretion</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthalene</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl carbamate</p></td></tr><tr><td class="NLM_term">brine</td><td class="NLM_def"><p class="first last">saturated aqueous sodium chloride solution</p></td></tr><tr><td class="NLM_term">Bu</td><td class="NLM_def"><p class="first last">butyl</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">coefficient of variation</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMB</td><td class="NLM_def"><p class="first last">dimethoxybenzyl</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPI</td><td class="NLM_def"><p class="first last">diphenyl imine</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electropsray ionization</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">g</td><td class="NLM_def"><p class="first last">gram</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>-[(dimethylamino)-1<i>H</i>-1,2,3-triazolo-[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methylmethanaminium hexafluorophosphate <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(1<i>H</i>-benzotriazol-1-yl)uronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">IVIVC</td><td class="NLM_def"><p class="first last">in vitro–in vivo correlation</p></td></tr><tr><td class="NLM_term">kg</td><td class="NLM_def"><p class="first last">kilogram</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">molar</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney cells</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">mg</td><td class="NLM_def"><p class="first last">milligram</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">MOM</td><td class="NLM_def"><p class="first last">methoxymethyl</p></td></tr><tr><td class="NLM_term">NAD</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">nicotinamide</p></td></tr><tr><td class="NLM_term">NAMPT</td><td class="NLM_def"><p class="first last">nicotinamide phosphoribosyltransferase</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodo succinimide</p></td></tr><tr><td class="NLM_term">NMN</td><td class="NLM_def"><p class="first last">nicotinamide mononucleotide</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance spectroscopy</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last">4-methoxy benzyl</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">by mouth</p></td></tr><tr><td class="NLM_term">Pr</td><td class="NLM_def"><p class="first last">propyl</p></td></tr><tr><td class="NLM_term">Prep-HPLC</td><td class="NLM_def"><p class="first last">preparative HPCL</p></td></tr><tr><td class="NLM_term">PRPP</td><td class="NLM_def"><p class="first last">phosphoribosyl pyrophosphate</p></td></tr><tr><td class="NLM_term"><i>R</i><sub>f</sub></td><td class="NLM_def"><p class="first last">retention factor</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Di Stefano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vettraino, M.</span><span> </span><span class="NLM_article-title">NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2918</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.2174/15680266113136660207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F15680266113136660207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=24171774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFelur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=2918-2929&author=G.+Di+Stefanoauthor=M.+Manerbaauthor=M.+Vettraino&title=NAD+metabolism+and+functions%3A+a+common+therapeutic+target+for+neoplastic%2C+metabolic+and+neurodegenerative+diseases&doi=10.2174%2F15680266113136660207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases</span></div><div class="casAuthors">Di Stefano, Giuseppina; Manerba, Marcella; Vettraino, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2918-2929</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years the study of NAD (NAD) biochem. has been the focus of attention for many researchers.  Although the role of NAD in cellular metab. and in redox reactions had been recognized for over a century, it was also during these recent studies that the precise identification of all NAD biosynthetic routes was achieved and that the variety of NAD controlled cellular processes began to emerge.  Being vital not only for energy transduction, but also for intracellular signaling pathways, this pyridine nucleotide can be considered the most important link between energetic and regulatory processes.  The control of such important events suggested NAD as a possible therapeutic target for the control of different pathol. states, including metabolic disorders and neoplastic transformation.  This review briefly summarizes the recent advances achieved in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYF7d1FNQy7bVg90H21EOLACvtfcHk0lhBSF-xDOd5hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFelur%252FL&md5=653133f0c34440c26b5d3ca799441e32</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.2174%2F15680266113136660207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113136660207%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DManerba%26aufirst%3DM.%26aulast%3DVettraino%26aufirst%3DM.%26atitle%3DNAD%2520metabolism%2520and%2520functions%253A%2520a%2520common%2520therapeutic%2520target%2520for%2520neoplastic%252C%2520metabolic%2520and%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D2918%26epage%3D2929%26doi%3D10.2174%2F15680266113136660207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dölle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoge, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanlinden, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, M.</span><span> </span><span class="NLM_article-title">NAD biosynthesis in humans - enzymes, metabolites and therapeutic aspects</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2907</span><span class="NLM_x">–</span> <span class="NLM_lpage">2917</span><span class="refDoi"> DOI: 10.2174/15680266113136660206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F15680266113136660206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=24171775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeks77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=2907-2917&author=C.+D%C3%B6lleauthor=R.+H.+Skogeauthor=M.+R.+Vanlindenauthor=M.+Ziegler&title=NAD+biosynthesis+in+humans+-+enzymes%2C+metabolites+and+therapeutic+aspects&doi=10.2174%2F15680266113136660206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects</span></div><div class="casAuthors">Dolle, Christian; Skoge, Renate Hvidsten; Van Linden, Magali R.; Ziegler, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2907-2917</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  NAD plays a major role in all cells as substrate for signal transduction and as cofactor in metabolic redox reactions.  Since NAD-dependent signaling involves degrdn. of the nucleotide, continuous restoration of cellular NAD pools is essential.  Moreover, NAD-dependent signaling reactions, which include ADP-ribosylation, protein deacetylation by sirtuins and calcium messenger synthesis, are regulated by NAD availability.  Consequently, perturbations of NAD supply can have severe consequences and, in fact, have been assocd. with major human diseases such as age- and dietinduced disorders, neurodegenerative diseases and cancer.  Given the increasing awareness of the biol. roles of NAD, the routes, mol. mechanisms and regulation of NAD biosynthesis have been the subject of intense research over the last decade.  Impressive progress has been made regarding the mol. identification, functional and structural characterization as well as regulation of the human NAD biosynthetic enzymes.  Exciting therapeutic concepts have emerged, which aim at modulation of NAD availability by interfering with the biosynthetic network to prevent, reduce or reverse pathol. conditions.  Since there are several entry points into NAD synthesis, including the known vitamin B3 precursors nicotinamide and nicotinic acid, targeted nutritional supplementation is likely to have beneficial effects in various diseases.  On the other hand, inhibition of NAD synthesis promotes cell death and has emerged as a therapeutic concept for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN9ejhz87J57Vg90H21EOLACvtfcHk0ljLKGmvclBGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeks77O&md5=be7e86b35a41ff467da33f6d96b0a0e8</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.2174%2F15680266113136660206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113136660206%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6lle%26aufirst%3DC.%26aulast%3DSkoge%26aufirst%3DR.%2BH.%26aulast%3DVanlinden%26aufirst%3DM.%2BR.%26aulast%3DZiegler%26aufirst%3DM.%26atitle%3DNAD%2520biosynthesis%2520in%2520humans%2520-%2520enzymes%252C%2520metabolites%2520and%2520therapeutic%2520aspects%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D2907%26epage%3D2917%26doi%3D10.2174%2F15680266113136660206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Amé, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlehauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">The PARP superfamily</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">893</span><span class="refDoi"> DOI: 10.1002/bies.20085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1002%2Fbies.20085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=15273990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=882-893&author=J.-C.+Am%C3%A9author=C.+Spenlehauerauthor=G.+de+Murcia&title=The+PARP+superfamily&doi=10.1002%2Fbies.20085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP superfamily</span></div><div class="casAuthors">Ame, Jean-Christophe; Spenlehauer, Catherine; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">882-893</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribosyl)ation is an immediate DNA-damage-dependent post-translational modification of histones and other nuclear proteins that contributes to the survival of injured proliferating cells.  Poly(ADP-ribose) polymerases (PARPs) now constitute a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain in which PARP-1 (113 kDa), the founding member, and PARP-2 (62 kDa) are so far the sole enzymes whose catalytic activity has been shown to be immediately stimulated by DNA strand breaks.  A large repertoire of sequences encoding novel PARPs now extends considerably the field of poly(ADP-ribosyl)ation reactions to various aspects of the cell biol. including cell proliferation and cell death.  Some of these new members interact with each other, share common partners and common subcellular localizations suggesting possible fine tuning in the regulation of this post-translational modification of proteins.  This review summarizes the present knowledge of this emerging superfamily, which might ultimately improve pharmacol. strategies to enhance both antitumor efficacy and the treatment of a no. of inflammatory and neurodegenerative disorders.  A provisional nomenclature is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkP1P6SYh67Vg90H21EOLACvtfcHk0ljLKGmvclBGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D&md5=892151993f54e3c1a03019001a365fbf</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1002%2Fbies.20085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.20085%26sid%3Dliteratum%253Aachs%26aulast%3DAm%25C3%25A9%26aufirst%3DJ.-C.%26aulast%3DSpenlehauer%26aufirst%3DC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DThe%2520PARP%2520superfamily%26jtitle%3DBioEssays%26date%3D2004%26volume%3D26%26spage%3D882%26epage%3D893%26doi%3D10.1002%2Fbies.20085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1967</span><span class="refDoi"> DOI: 10.1101/gad.1331805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1101%2Fgad.1331805" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1951-1967&author=M.+Y.+Kimauthor=T.+Zhangauthor=W.+L.+Kraus&title=Poly%28ADP-ribosyl%29ation+by+PARP-1%3A+%E2%80%98PAR-laying%E2%80%99+NAD%2B+into+a+nuclear+signal&doi=10.1101%2Fgad.1331805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1101%2Fgad.1331805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1331805%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DPoly%2528ADP-ribosyl%2529ation%2520by%2520PARP-1%253A%2520%25E2%2580%2598PAR-laying%25E2%2580%2599%2520NAD%252B%2520into%2520a%2520nuclear%2520signal%26jtitle%3DGenes%2520Dev.%26date%3D2005%26volume%3D19%26spage%3D1951%26epage%3D1967%26doi%3D10.1101%2Fgad.1331805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Houtkooper, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirinen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auwerx, J.</span><span> </span><span class="NLM_article-title">Sirtuins as regulators of metabolism and healthspan</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1038/nrm3293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnrm3293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22395773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=225-238&author=R.+H.+Houtkooperauthor=E.+Pirinenauthor=J.+Auwerx&title=Sirtuins+as+regulators+of+metabolism+and+healthspan&doi=10.1038%2Fnrm3293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sirtuins as regulators of metabolism and healthspan</span></div><div class="casAuthors">Houtkooper, Riekelt H.; Pirinen, Eija; Auwerx, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-238</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the beginning of the century, the mammalian sirtuin protein family (comprising SIRT1-SIRT7) has received much attention for its regulatory role, mainly in metab. and ageing.  Sirtuins act in different cellular compartments: they deacetylate histones and several transcriptional regulators in the nucleus, but also specific proteins in other cellular compartments, such as in the cytoplasm and in mitochondria.  As a consequence, sirtuins regulate fat and glucose metab. in response to physiol. changes in energy levels, thereby acting as crucial regulators of the network that controls energy homeostasis and as such dets. healthspan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGF2VZDiGC9LVg90H21EOLACvtfcHk0ljLKGmvclBGwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOktbw%253D&md5=3e7e0a6b23e8d7d4ad7be32bdce28d96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3293%26sid%3Dliteratum%253Aachs%26aulast%3DHoutkooper%26aufirst%3DR.%2BH.%26aulast%3DPirinen%26aufirst%3DE.%26aulast%3DAuwerx%26aufirst%3DJ.%26atitle%3DSirtuins%2520as%2520regulators%2520of%2520metabolism%2520and%2520healthspan%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26spage%3D225%26epage%3D238%26doi%3D10.1038%2Fnrm3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Galli, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhfouri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6279</span><span class="NLM_x">–</span> <span class="NLM_lpage">6296</span><span class="refDoi"> DOI: 10.1021/jm4001049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6279-6296&author=U.+Galliauthor=C.+Travelliauthor=A.+Massarottiauthor=G.+Fakhfouriauthor=R.+Rahimianauthor=G.+C.+Tronauthor=A.+A.+Genazzani&title=Medicinal+chemistry+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors&doi=10.1021%2Fjm4001049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors</span></div><div class="casAuthors">Galli, Ubaldina; Travelli, Cristina; Massarotti, Alberto; Fakhfouri, Gohar; Rahimian, Reza; Tron, Gian Cesare; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6279-6296</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in the replenishment of the NAD pool in cells.  This in turn makes this enzyme an important player in bioenergetics and in the regulation of NAD-using enzymes, such as PARPs and sirtuins.  Furthermore, there is now ample evidence that NAMPT is secreted and has a role as a cytokine.  An important role of either the intracellular or extracellular form of NAMPT has been shown in cancer, inflammation, and metabolic diseases.  The first NAMPT inhibitors (FK866 and CHS828) have already entered clin. trials, and a surge in interest in the synthesis of novel mols. has occurred.  The present review summarizes the recent progress in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuKFhS6T0zD7Vg90H21EOLACvtfcHk0lhqU9-3SxMuGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGisLk%253D&md5=4022c7632cc0b42d62e0fc334d24fefa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm4001049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001049%26sid%3Dliteratum%253Aachs%26aulast%3DGalli%26aufirst%3DU.%26aulast%3DTravelli%26aufirst%3DC.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DFakhfouri%26aufirst%3DG.%26aulast%3DRahimian%26aufirst%3DR.%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6279%26epage%3D6296%26doi%3D10.1021%2Fjm4001049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bieganowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, C.</span><span> </span><span class="NLM_article-title">Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00416-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2FS0092-8674%2804%2900416-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=15137942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=495-502&author=P.+Bieganowskiauthor=C.+Brenner&title=Discoveries+of+nicotinamide+riboside+as+a+nutrient+and+conserved+NRK+genes+establish+a+Preiss-Handler+independent+route+to+NAD%2B+in+fungi+and+humans&doi=10.1016%2FS0092-8674%2804%2900416-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans</span></div><div class="casAuthors">Bieganowski, Pawel; Brenner, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">NAD+ is essential for life in all organisms, both as a coenzyme for oxidoreductases and as a source of ADPribosyl groups used in various reactions, including those that retard aging in exptl. systems.  Nicotinic acid and nicotinamide were defined as the vitamin precursors of NAD+ in Elvehjem's classic discoveries of the 1930s.  The accepted view of eukaryotic NAD+ biosynthesis, that all anabolism flows through nicotinic acid mononucleotide, was challenged exptl. and revealed that nicotinamide riboside is an unanticipated NAD+ precursor in yeast.  Nicotinamide riboside kinases from yeast and humans essential for this pathway were identified and found to be highly specific for phosphorylation of nicotinamide riboside and the cancer drug tiazofurin.  Nicotinamide riboside was discovered as a nutrient in milk, suggesting that nicotinamide riboside is a useful compd. for elevation of NAD+ levels in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTCsziN61hR7Vg90H21EOLACvtfcHk0lh-R8yCrsrNEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlCqtrY%253D&md5=8a7ba85e29a8729b5ffdf86dbbe9ef79</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900416-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900416-7%26sid%3Dliteratum%253Aachs%26aulast%3DBieganowski%26aufirst%3DP.%26aulast%3DBrenner%26aufirst%3DC.%26atitle%3DDiscoveries%2520of%2520nicotinamide%2520riboside%2520as%2520a%2520nutrient%2520and%2520conserved%2520NRK%2520genes%2520establish%2520a%2520Preiss-Handler%2520independent%2520route%2520to%2520NAD%252B%2520in%2520fungi%2520and%2520humans%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D495%26epage%3D502%26doi%3D10.1016%2FS0092-8674%2804%2900416-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Magni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsomando, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggieri, S.</span><span> </span><span class="NLM_article-title">Enzymology of mammalian NAD metabolism in health and disease</span> <span class="citation_source-journal">Front. Biosci., Landmark Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">6135</span><span class="NLM_x">–</span> <span class="NLM_lpage">6154</span><span class="refDoi"> DOI: 10.2741/3143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2741%2F3143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=18508649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVOisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=6135-6154&author=G.+Magniauthor=G.+Orsomandoauthor=N.+Raffelliauthor=S.+Ruggieri&title=Enzymology+of+mammalian+NAD+metabolism+in+health+and+disease&doi=10.2741%2F3143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymology of mammalian NAD metabolism in health and disease</span></div><div class="casAuthors">Magni, Giulio; Orsomando, Giuseppe; Raffelli, Nadia; Ruggieri, Silverio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6135-6154</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Mounting evidence attests to the paramount importance of the non-redox NAD functions.  Indeed, NAD homeostasis is related to the free radicals-mediated prodn. of reactive oxygen species responsible for irreversible cellular damage in infectious disease, diabetes, inflammatory syndromes, neurodegeneration and cancer.  Because the cellular redox status depends on both the abs. concn. of pyridine dinucleotides and their resp. ratios of oxidized and reduced forms (i.e., NAD/NADH and NADP/NADPH), it is conceivable that an altered regulation of the synthesis and degrdn. of NAD impairs the cell redox state and likely contributes to the mechanisms underlying the pathogenesis of the above mentioned diseases.  Taking into account the recent appearance in the literature of comprehensive reviews covering different aspects of the significance of NAD metab., with particular attention to the enzymes involved in NAD cleavage, this monograph includes the most recent results on NAD biosynthesis in mammals and humans.  Due to recent findings on nicotinamide riboside as a nutrient, its inclusion under "niacins" is proposed.  Here, the enzymes involved in the de novo and reutilization pathways are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvX2dsB8dbbrVg90H21EOLACvtfcHk0lgxmlR73Pt5xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVOisb0%253D&md5=aa02e7cb092b9e7449b5bce49e97fa82</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.2741%2F3143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F3143%26sid%3Dliteratum%253Aachs%26aulast%3DMagni%26aufirst%3DG.%26aulast%3DOrsomando%26aufirst%3DG.%26aulast%3DRaffelli%26aufirst%3DN.%26aulast%3DRuggieri%26aufirst%3DS.%26atitle%3DEnzymology%2520of%2520mammalian%2520NAD%2520metabolism%2520in%2520health%2520and%2520disease%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2008%26volume%3D13%26spage%3D6135%26epage%3D6154%26doi%3D10.2741%2F3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chiarugi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, M.</span><span> </span><span class="NLM_article-title">The NAD metabolome--a key determinant of cancer cell biology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">752</span><span class="refDoi"> DOI: 10.1038/nrc3340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnrc3340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=23018234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWnurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=741-752&author=A.+Chiarugiauthor=C.+Dolleauthor=R.+Feliciauthor=M.+Ziegler&title=The+NAD+metabolome%2D%2Da+key+determinant+of+cancer+cell+biology&doi=10.1038%2Fnrc3340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">The NAD metabolome - a key determinant of cancer cell biology</span></div><div class="casAuthors">Chiarugi, Alberto; Doelle, Christian; Felici, Roberta; Ziegler, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">741-752</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  NAD is a vital mol. in all organisms.  It is a key component of both energy and signal transduction - processes that undergo crucial changes in cancer cells.  NAD+-dependent signalling pathways are many and varied, and they regulate fundamental events such as transcription, DNA repair, cell cycle progression, apoptosis and metab.  Many of these processes have been linked to cancer development.  Given that NAD+-dependent signalling reactions involve the degrdn. of the mol., permanent nucleotide resynthesis through different biosynthetic pathways is crucial for incessant cancer cell proliferation.  This necessity supports the targeting of NAD metab. as a new therapeutic concept for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopGSV9JpM_CLVg90H21EOLACvtfcHk0lgxmlR73Pt5xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWnurvP&md5=5111918068b9362f6932cff3b3ebd824</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fnrc3340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3340%26sid%3Dliteratum%253Aachs%26aulast%3DChiarugi%26aufirst%3DA.%26aulast%3DDolle%26aufirst%3DC.%26aulast%3DFelici%26aufirst%3DR.%26aulast%3DZiegler%26aufirst%3DM.%26atitle%3DThe%2520NAD%2520metabolome--a%2520key%2520determinant%2520of%2520cancer%2520cell%2520biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D741%26epage%3D752%26doi%3D10.1038%2Fnrc3340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span> </span><span class="NLM_article-title">Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6123</span><span class="NLM_x">–</span> <span class="NLM_lpage">6132</span><span class="refDoi"> DOI: 10.2174/138161212803582531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F138161212803582531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22934941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVOisbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=6123-6132&author=J.+Heauthor=C.+Tuauthor=M.+Liauthor=S.+Wangauthor=X.+Guanauthor=J.+Linauthor=Z.+Li&title=Nampt%2FVisfatin%2FPBEF%3A+a+functionally+multi-faceted+protein+with+a+pivotal+role+in+malignant+tumors&doi=10.2174%2F138161212803582531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors</span></div><div class="casAuthors">He, Jieyu; Tu, Chao; Li, Mengjun; Wang, Shalong; Guan, Xiaomei; Lin, Jianfeng; Li, Zhihong</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">6123-6132</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nampt/Visfatin/PBEF is a primary, rate-limiting enzyme involved in NAD+ biosynthesis, which serves as a pivotal substance for proteins, and is required for cell growth, survival, DNA replication and repair and energy metab.  Growing researches have elucidated that it is a pleiotropic protein that functions not only as an enzyme, but also as an adipocytokine, a growth factor, and a cytokine.  Addnl., accumulated evidences indicate that Nampt is correlated to various malignant tumors, and complicated mechanisms are proposed to be involved in the carcinogenesis, progression, invasion and metastasis of it, including regulation of energy metab. and genome instability, promotion of proliferation, angiogenesis, and tumor-promoting inflammation, resistance in cell death and avoidance of immune destruction.  APO866 and CHS-828 are recognized inhibitors of Nampt, known to block the intracellular and extracellular NAD+ synthesis pathway.  Both of them are currently in clin. trials for the treatment of various malignant tumors and have been shown to represent novel promising antitumor chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2dU2EjmyZvLVg90H21EOLACvtfcHk0ljk5shKeEPOPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVOisbnE&md5=abcdf8fb49af69aba41e367824af4eb8</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.2174%2F138161212803582531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212803582531%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DNampt%252FVisfatin%252FPBEF%253A%2520a%2520functionally%2520multi-faceted%2520protein%2520with%2520a%2520pivotal%2520role%2520in%2520malignant%2520tumors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D6123%26epage%3D6132%26doi%3D10.2174%2F138161212803582531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Burgos, E. S.</span><span> </span><span class="NLM_article-title">NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1947</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span><span class="refDoi"> DOI: 10.2174/092986711795590101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F092986711795590101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21517777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFehurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1947-1961&author=E.+S.+Burgos&title=NAMPT+in+regulated+NAD+biosynthesis+and+its+pivotal+role+in+human+metabolism&doi=10.2174%2F092986711795590101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism</span></div><div class="casAuthors">Burgos, E. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1947-1961</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the first reversible step in NAD biosynthesis and nicotinamide (NAM) salvage.  The enzyme is designed for efficient capture of nicotinamide by coupling of ATP hydrolysis to assist in extraordinary NAM binding affinity and formation of NMN (NMN).  NAMPT provides the mechanism to replenish the NAD pool in human metab.  In addn. to its role in redox biochem., NAD fuels the sirtuins (SIRTs) to regulate transcription factors involved in pathways linked to inflammation, diabetes and lifespan.  NAMPT-mediated lifespan expansion has caused a focus on the catalytic mechanism, regulation and inhibition of NAMPT.  Structural, mechanistic and inhibitor design all contribute to a developing but yet incomplete story of NAMPT function.  Although the first generation of NAMPT inhibitors has entered clin. trials, disappointing outcomes suggest more powerful and specific inhibitors will be needed.  Understanding the ATP-linked mechanism of NAMPT and the catalytic site machinery may permit the design of improved NAMPT inhibitors as more efficient drugs against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9tpSE0yYDVbVg90H21EOLACvtfcHk0ljk5shKeEPOPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFehurs%253D&md5=cfbd0c1d081468ef98d43c667714e91d</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2174%2F092986711795590101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795590101%26sid%3Dliteratum%253Aachs%26aulast%3DBurgos%26aufirst%3DE.%2BS.%26atitle%3DNAMPT%2520in%2520regulated%2520NAD%2520biosynthesis%2520and%2520its%2520pivotal%2520role%2520in%2520human%2520metabolism%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D1947%26epage%3D1961%26doi%3D10.2174%2F092986711795590101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bi, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.-M.</span><span> </span><span class="NLM_article-title">Nampt/PBEF/visfatin and cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.4161/cbt.10.2.12581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.4161%2Fcbt.10.2.12581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=20647743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFKntLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=119-125&author=T.-Q.+Biauthor=X.-M.+Che&title=Nampt%2FPBEF%2Fvisfatin+and+cancer&doi=10.4161%2Fcbt.10.2.12581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Nampt/PBEF/visfatin and cancer</span></div><div class="casAuthors">Bi, Tie-qiang; Che, Xiang-ming</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-125</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Nampt/PBEF/visfatin is the rate-limiting enzyme that catalyzes the first step in NAD biosynthesis from nicotinamide and regulates growth, apoptosis and angiogenesis of mammalian cells.  This enzyme was originally cloned as a putative cytokine shown to enhance the B-cell precursor maturation in the presence of IL-7 and stem cell factor.  A no. of cancers have increased expression of Nampt/PBEF/visfatin, which regulates a variety of different signaling pathways such as PI3K/Akt, ERK1/2 and STAT3.  FK866/APO866 and CHS828/GMX1777 are two known inhibitors of Nampt/PBEF/visfatin and have been evaluated as anticancer agents in the clinic.  This review will focus on its role in carcinogenesis and cancer progression and its inhibitors as therapeutic target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUbeWp8OFXWLVg90H21EOLACvtfcHk0liQgybczVn9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFKntLfL&md5=91d97cfed00750cc6edba4ff36e25c84</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.4161%2Fcbt.10.2.12581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.10.2.12581%26sid%3Dliteratum%253Aachs%26aulast%3DBi%26aufirst%3DT.-Q.%26aulast%3DChe%26aufirst%3DX.-M.%26atitle%3DNampt%252FPBEF%252Fvisfatin%2520and%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D119%26epage%3D125%26doi%3D10.4161%2Fcbt.10.2.12581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Garten, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzold, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, S.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiess, W.</span><span> </span><span class="NLM_article-title">Nampt: linking NAD biology, metabolism and cancer</span> <span class="citation_source-journal">Trends Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1016/j.tem.2008.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.tem.2008.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19109034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFanu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=130-138&author=A.+Gartenauthor=S.+Petzoldauthor=A.+K%C3%B6rnerauthor=S.-I.+Imaiauthor=W.+Kiess&title=Nampt%3A+linking+NAD+biology%2C+metabolism+and+cancer&doi=10.1016%2Fj.tem.2008.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Nampt: linking NAD biology, metabolism and cancer</span></div><div class="casAuthors">Garten, Antje; Petzold, Stefanie; Koerner, Antje; Imai, Shin-ichiro; Kiess, Wieland</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nicotinamide phosphoribosyltransferase (Nampt) converts nicotinamide to NMN, a key NAD intermediate.  Previously identified as a cytokine pre-B-cell colony-enhancing factor and controversially claimed as an insulin-mimetic hormone visfatin, Nampt has recently drawn much attention in several fields, including NAD biol., metab. and inflammation.  As a NAD biosynthetic enzyme, Nampt regulates the activity of NAD-consuming enzymes such as sirtuins and influences a variety of metabolic and stress responses.  Nampt also plays an important part in regulating insulin secretion in pancreatic β-cells.  Nampt seems to have another function as an immunomodulatory cytokine and, therefore, has a role in inflammation.  This review summarizes these various functional aspects of Nampt and discusses its potential roles in diseases, including type 2 diabetes and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMtmRWd15knbVg90H21EOLACvtfcHk0liQgybczVn9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFanu7o%253D&md5=2e6fc10db431e1963b0b827747466c53</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2008.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2008.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DGarten%26aufirst%3DA.%26aulast%3DPetzold%26aufirst%3DS.%26aulast%3DK%25C3%25B6rner%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DS.-I.%26aulast%3DKiess%26aufirst%3DW.%26atitle%3DNampt%253A%2520linking%2520NAD%2520biology%252C%2520metabolism%2520and%2520cancer%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2009%26volume%3D20%26spage%3D130%26epage%3D138%26doi%3D10.1016%2Fj.tem.2008.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulthard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6605166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fsj.bjc.6605166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19568233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslOmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=256-262&author=T.+Zarembaauthor=P.+Ketzerauthor=M.+Coleauthor=S.+Coulthardauthor=E.+R.+Plummerauthor=N.+J.+Curtin&title=Poly%28ADP-ribose%29+polymerase-1+polymorphisms%2C+expression+and+activity+in+selected+human+tumour+cell+lines&doi=10.1038%2Fsj.bjc.6605166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines</span></div><div class="casAuthors">Zaremba, T.; Ketzer, P.; Cole, M.; Coulthard, S.; Plummer, E. R.; Curtin, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-262</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding enzyme activated by DNA breaks and involved in DNA repair and other cellular processes.  Poly(ADP-ribose) polymerase activity can be higher in cancer than in adjacent normal tissue, but cancer predisposition is reported to be greater in individuals with a single-nucleotide polymorphism (SNP) V762A (T2444C) in the catalytic domain that reduces PARP-1 activity.  Methods: To resolve these divergent observations, we detd. PARP-1 polymorphisms, PARP-1 protein expression and activity in a panel of 19 solid and haematol., adult and pediatric human cancer cell lines.  Results: There was a wide variation in PARP activity in the cell line panel (coeff. of variation, CV=103%), with the lowest and the highest activity being 2460 pmol PAR/106 (HS-5 cells) and 85 750 pmol PAR/106 (NGP cells).  Lower variation (CV=32%) was obsd. in PARP-1 protein expression with the lowest expression being 2.0 ng μg-1 (HS-5 cells) and the highest being 7.1 ng μg-1 (ML-1 cells).  The mean activity in the cancer cells was 45-fold higher than the mean activity in normal human lymphocytes and the PARP-1 protein levels were 23-fold higher.  Conclusions: Surprisingly, there was no significant correlation between PARP activity and PARP-1 protein level or the investigated polymorphisms, T2444C and CA.  British Journal of Cancer (2009) 101, 256-262; doi:10.1038/sj.bjc.6605166 www.bjcancer.com Published online 30 June 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGiXp9dmBsH7Vg90H21EOLACvtfcHk0liQgybczVn9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslOmurg%253D&md5=2e8cbeef3e92351d2afd5bed60ad77d4</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605166%26sid%3Dliteratum%253Aachs%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DKetzer%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DM.%26aulast%3DCoulthard%26aufirst%3DS.%26aulast%3DPlummer%26aufirst%3DE.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase-1%2520polymorphisms%252C%2520expression%2520and%2520activity%2520in%2520selected%2520human%2520tumour%2520cell%2520lines%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2009%26volume%3D101%26spage%3D256%26epage%3D262%26doi%3D10.1038%2Fsj.bjc.6605166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Khan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forouhar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span> </span><span class="NLM_article-title">Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">705</span><span class="refDoi"> DOI: 10.1517/14728222.11.5.695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1517%2F14728222.11.5.695" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=17465726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=695-705&author=J.+A.+Khanauthor=F.+Forouharauthor=X.+Taoauthor=L.+Tong&title=Nicotinamide+adenine+dinucleotide+metabolism+as+an+attractive+target+for+drug+discovery&doi=10.1517%2F14728222.11.5.695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery</span></div><div class="casAuthors">Khan, Javed A.; Forouhar, Farhad; Tao, Xiao; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-705</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  NAD (NAD+) has crucial roles in many cellular processes, both as a coenzyme for redox reactions and as a substrate to donate ADP-ribose units.  Enzymes involved in NAD+ metab. are attractive targets for drug discovery against a variety of human diseases, including cancer, multiple sclerosis, neurodegeneration and Huntington's disease.  A small-mol. inhibitor of nicotinamide phosphoribosyltransferase, an enzyme in the salvage pathway of NAD+ biosynthesis, is presently in clin. trials against cancer.  An analog of a kynurenine pathway intermediate is efficacious against multiple sclerosis in an animal model.  Indoleamine 2,3-dioxygenase plays an important role in immune evasion by cancer cells and other disease processes.  Inhibitors against kynurenine 3-hydroxylase can reduce the prodn. of neurotoxic metabolites while increasing the prodn. of neuroprotective compds.  This review summarizes the existing knowledge on NAD+ metabolic enzymes, with emphasis on their relevance for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCrpVwpXgPHrVg90H21EOLACvtfcHk0lhPaAaIONZn4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslCltbg%253D&md5=43a4c12a1a780feddd233e1d8209f3f6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1517%2F14728222.11.5.695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.11.5.695%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DForouhar%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DNicotinamide%2520adenine%2520dinucleotide%2520metabolism%2520as%2520an%2520attractive%2520target%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2007%26volume%3D11%26spage%3D695%26epage%3D705%26doi%3D10.1517%2F14728222.11.5.695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Koppenol, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounds, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dang, C. V.</span><span> </span><span class="NLM_article-title">Otto Warburg’s contributions to current concepts of cancer metabolism</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1038/nrc3038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnrc3038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21508971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1ags70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=325-337&author=W.+H.+Koppenolauthor=P.+L.+Boundsauthor=C.+V.+Dang&title=Otto+Warburg%E2%80%99s+contributions+to+current+concepts+of+cancer+metabolism&doi=10.1038%2Fnrc3038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Otto Warburg's contributions to current concepts of cancer metabolism</span></div><div class="casAuthors">Koppenol, Willem H.; Bounds, Patricia L.; Dang, Chi V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Otto Warburg pioneered quant. investigations of cancer cell metab., as well as photosynthesis and respiration.  Warburg and co-workers showed in the 1920s that, under aerobic conditions, tumor tissues metabolize approx. tenfold more glucose to lactate in a given time than normal tissues, a phenomenon known as the Warburg effect.  However, this increase in aerobic glycolysis in cancer cells is often erroneously thought to occur instead of mitochondrial respiration and has been misinterpreted as evidence for damage to respiration instead of damage to the regulation of glycolysis.  In fact, many cancers exhibit the Warburg effect while retaining mitochondrial respiration.  We re-examine Warburg's observations in relation to the current concepts of cancer metab. as being intimately linked to alterations of mitochondrial DNA, oncogenes and tumor suppressors, and thus readily exploitable for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdteDUarw-PbVg90H21EOLACvtfcHk0lhPaAaIONZn4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1ags70%253D&md5=72988f428422daecd23b21d242aec18a</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnrc3038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3038%26sid%3Dliteratum%253Aachs%26aulast%3DKoppenol%26aufirst%3DW.%2BH.%26aulast%3DBounds%26aufirst%3DP.%2BL.%26aulast%3DDang%26aufirst%3DC.%2BV.%26atitle%3DOtto%2520Warburg%25E2%2580%2599s%2520contributions%2520to%2520current%2520concepts%2520of%2520cancer%2520metabolism%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D325%26epage%3D337%26doi%3D10.1038%2Fnrc3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ward, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">Metabolic reprogramming: a cancer hallmark even warburg did not anticipate</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.ccr.2012.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22439925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1ylsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=297-308&author=P.+S.+Wardauthor=C.+B.+Thompson&title=Metabolic+reprogramming%3A+a+cancer+hallmark+even+warburg+did+not+anticipate&doi=10.1016%2Fj.ccr.2012.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate</span></div><div class="casAuthors">Ward, Patrick S.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer metab. has long been equated with aerobic glycolysis, seen by early biochemists as primitive and inefficient.  Despite these early beliefs, the metabolic signatures of cancer cells are not passive responses to damaged mitochondria but result from oncogene-directed metabolic reprogramming required to support anabolic growth.  Recent evidence suggests that metabolites themselves can be oncogenic by altering cell signaling and blocking cellular differentiation.  No longer can cancer-assocd. alterations in metab. be viewed as an indirect response to cell proliferation and survival signals.  We contend that altered metab. has attained the status of a core hallmark of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkFCvg4k-_m7Vg90H21EOLACvtfcHk0ljmfTLketwUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1ylsbc%253D&md5=8e991ba77d1bb0b57c3009b6bc39ee99</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DP.%2BS.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DMetabolic%2520reprogramming%253A%2520a%2520cancer%2520hallmark%2520even%2520warburg%2520did%2520not%2520anticipate%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D297%26epage%3D308%26doi%3D10.1016%2Fj.ccr.2012.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cerna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takebe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, S. S.</span><span> </span><span class="NLM_article-title">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">22408</span><span class="NLM_x">–</span> <span class="NLM_lpage">22417</span><span class="refDoi"> DOI: 10.1074/jbc.M112.357301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1074%2Fjbc.M112.357301" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=22408-22417&author=D.+Cernaauthor=H.+Liauthor=S.+Flahertyauthor=N.+Takebeauthor=C.+N.+Colemanauthor=S.+S.+Yoo&title=Inhibition+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+activity+by+small+molecule+GMX1778+regulates+reactive+oxygen+species+%28ROS%29-mediated+cytotoxicity+in+a+p53-+and+nicotinic+acid+phosphoribosyltransferase1+%28NAPRT1%29-dependent+manner&doi=10.1074%2Fjbc.M112.357301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.357301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.357301%26sid%3Dliteratum%253Aachs%26aulast%3DCerna%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DFlaherty%26aufirst%3DS.%26aulast%3DTakebe%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DC.%2BN.%26aulast%3DYoo%26aufirst%3DS.%2BS.%26atitle%3DInhibition%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520activity%2520by%2520small%2520molecule%2520GMX1778%2520regulates%2520reactive%2520oxygen%2520species%2520%2528ROS%2529-mediated%2520cytotoxicity%2520in%2520a%2520p53-%2520and%2520nicotinic%2520acid%2520phosphoribosyltransferase1%2520%2528NAPRT1%2529-dependent%2520manner%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D22408%26epage%3D22417%26doi%3D10.1074%2Fjbc.M112.357301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Vander Heiden, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">Understanding the Warburg effect: the metabolic requirements of cell proliferation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">324</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1033</span><span class="refDoi"> DOI: 10.1126/science.1160809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1126%2Fscience.1160809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19460998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1029-1033&author=M.+G.+Vander+Heidenauthor=L.+C.+Cantleyauthor=C.+B.+Thompson&title=Understanding+the+Warburg+effect%3A+the+metabolic+requirements+of+cell+proliferation&doi=10.1126%2Fscience.1160809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation</span></div><div class="casAuthors">Vander Heiden, Matthew G.; Cantley, Lewis C.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5930</span>),
    <span class="NLM_cas:pages">1029-1033</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect".  Aerobic glycolysis is an inefficient way to generate ATP, however, and the advantage it confers to cancer cells has been unclear.  Here we propose that the metab. of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell.  Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-assocd. mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP prodn.  A better understanding of the mechanistic links between cellular metab. and growth control may ultimately lead to better treatments for human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGvLHGQ9TX77Vg90H21EOLACvtfcHk0ljmfTLketwUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D&md5=f927402a43cdca471c3f4874dcbeb943</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1126%2Fscience.1160809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1160809%26sid%3Dliteratum%253Aachs%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DUnderstanding%2520the%2520Warburg%2520effect%253A%2520the%2520metabolic%2520requirements%2520of%2520cell%2520proliferation%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1029%26epage%3D1033%26doi%3D10.1126%2Fscience.1160809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.pharmthera.2015.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25709099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1eitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2015&pages=16-31&author=D.+Sampathauthor=T.+S.+Zabkaauthor=D.+L.+Misnerauthor=T.+O%E2%80%99Brienauthor=P.+S.+Dragovich&title=Inhibition+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+as+a+therapeutic+strategy+in+cancer&doi=10.1016%2Fj.pharmthera.2015.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer</span></div><div class="casAuthors">Sampath, Deepak; Zabka, Tanja S.; Misner, Dinah L.; O'Brien, Thomas; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-31</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NAD is a metabolite that is an important cofactor and second messenger for a no. of cellular processes such as genomic stability and metab. that are essential for survival.  NAD is generated de novo from tryptophan or recycled from NAM through the NAMPT-dependent salvage pathway.  Alternatively, cells can convert NA to NAD through the NAPRT1-dependent salvage pathway.  Tumor cells rapidly turn over NAD but do not efficiently utilize the de novo synthesis pathway.  Hence, they are more reliant on the NAMPT salvage pathway for NAD regeneration making this enzyme an attractive therapeutic target for cancer.  NAMPT is over-expressed in a no. of cancer types such as colorectal, ovarian, breast, gastric, prostate, gliomas as well as B-cell lymphomas.  A no. of novel, potent and selective NAMPT small mol. inhibitors have been synthesized to date that have displayed robust anti-tumor activity in tumor models in vitro and in vivo.  These inhibitors efficiently suppress NAD prodn. in a time dependent manner and sustained redn. of NAD levels leads to loss of ATP and ultimately cell death.  This review will summarize the chem. properties of these unique NAMPT inhibitors as well as their mechanism of action, pharmacodynamic activity and efficacy in tumor models in vitro and in vivo.  An overview of biomarkers that predict response to treatment and mechanisms of resistance to NAMPT inhibitors will also be provided.  Addnl., NAMPT inhibitors that have advanced into clin. trials will be reviewed along with exptl. strategies tested to potentially increase the therapeutic index of these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqop3xkHKJxG7Vg90H21EOLACvtfcHk0ljmfTLketwUVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1eitrk%253D&md5=c3b08d2345b784eaa05520eabb1f1173</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DInhibition%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520as%2520a%2520therapeutic%2520strategy%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D151%26spage%3D16%26epage%3D31%26doi%3D10.1016%2Fj.pharmthera.2015.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span> </span><span class="NLM_article-title">Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4921</span><span class="NLM_x">–</span> <span class="NLM_lpage">4937</span><span class="refDoi"> DOI: 10.1021/jm400186h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400186h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1WisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4921-4937&author=X.+Zhengauthor=P.+Bauerauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=J.+Linauthor=D.+J.+Reynoldsauthor=G.+Sharmaauthor=C.+C.+Smithauthor=Z.+Wangauthor=P.+S.+Dragovichauthor=A.+Ohauthor=W.+Wangauthor=M.+Zakauthor=J.+Gunzner-Tosteauthor=G.+Zhaoauthor=P.-w.+Yuenauthor=K.+W.+Bair&title=Structure-based+identification+of+ureas+as+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors&doi=10.1021%2Fjm400186h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors</span></div><div class="casAuthors">Zheng, Xiaozhang; Bauer, Paul; Baumeister, Timm; Buckmelter, Alexandre J.; Caligiuri, Maureen; Clodfelter, Karl H.; Han, Bingsong; Ho, Yen-Ching; Kley, Nikolai; Lin, Jian; Reynolds, Dominic J.; Sharma, Geeta; Smith, Chase C.; Wang, Zhongguo; Dragovich, Peter S.; Oh, Angela; Wang, Weiru; Zak, Mark; Gunzner-Toste, Janet; Zhao, Guiling; Yuen, Po-wai; Bair, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4921-4937</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyridinyl sulfonylphenyl ureas and thioureas such as I and II were prepd. as inhibitors of nicotinamide phosphoribosyltransferase (Nampt) for potential use as antitumor agents.  Replacement of the thiourea of I led to a Nampt inhibitor with similar activity and improved soly.  Optimization of the urea substituents identified the 3-pyridyl group as the optimal substituent at one of the urea nitrogens and the urea moiety as the optimal linking group.  II was found to be a Nampt inhibitor with excellent biochem. and cellular potency (IC50 values with Nampt and in cells of 7 nM and 32 nM, resp.); II was an active oral antitumor agent in an ovarian cancer xenograft model.  The inhibition of Nampt by pyridinyl-substituted ureas was inversely dependent on the concn. of nicotinamide.  The structure of I bound to human Nampt was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpESuPRbmSTMrVg90H21EOLACvtfcHk0lgKl-IycnOQhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1WisrY%253D&md5=43777430938274bf8f510a45d9c6e883</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fjm400186h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400186h%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DBair%26aufirst%3DK.%2BW.%26atitle%3DStructure-based%2520identification%2520of%2520ureas%2520as%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4921%26epage%3D4937%26doi%3D10.1021%2Fjm400186h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span> </span><span class="NLM_article-title">Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6413</span><span class="NLM_x">–</span> <span class="NLM_lpage">6433</span><span class="refDoi"> DOI: 10.1021/jm4008664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFams7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6413-6433&author=X.+Zhengauthor=P.+Bauerauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=J.+Linauthor=D.+J.+Reynoldsauthor=G.+Sharmaauthor=C.+C.+Smithauthor=Z.+Wangauthor=P.+S.+Dragovichauthor=J.+Gunzner-Tosteauthor=B.+Liedererauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=A.+Ohauthor=L.+Wangauthor=W.+Wangauthor=Y.+Xiaoauthor=M.+Zakauthor=G.+Zhaoauthor=P.-w.+Yuenauthor=K.+W.+Bair&title=Structure-based+discovery+of+novel+amide-containing+nicotinamide+phosphoribosyltransferase+%28Nampt%29+inhibitors&doi=10.1021%2Fjm4008664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors</span></div><div class="casAuthors">Zheng, Xiaozhang; Bauer, Paul; Baumeister, Timm; Buckmelter, Alexandre J.; Caligiuri, Maureen; Clodfelter, Karl H.; Han, Bingsong; Ho, Yen-Ching; Kley, Nikolai; Lin, Jian; Reynolds, Dominic J.; Sharma, Geeta; Smith, Chase C.; Wang, Zhongguo; Dragovich, Peter S.; Gunzner-Toste, Janet; Liederer, Bianca M.; Ly, Justin; O'Brien, Thomas; Oh, Angela; Wang, Leslie; Wang, Weiru; Xiao, Yang; Zak, Mark; Zhao, Guiling; Yuen, Po-wai; Bair, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6413-6433</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crystal structures of several urea- and thiourea-derived compds. in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein were utilized to design a potent amide-contg. inhibitor bearing an aza-indole moiety (Nampt BC IC50 = 9.0 nM, A2780 cell proliferation IC50 = 10 nM).  A Nampt cocrystal structure was subsequently obtained and enabled the design of addnl. amide-contg. inhibitors which incorporated various other fused 6,5-heterocyclic moieties and biaryl sulfone or sulfonamide motifs.  Addnl. modifications of these mols. afforded many potent biaryl sulfone-contg. Nampt inhibitors which also exhibited favorable in vitro ADME properties (microsomal and hepatocyte stability, MDCK permeability, plasma protein binding).  An optimized compd. was a potent inhibitor of multiple cancer cell lines (IC50 <10 nM vs U251, HT1080, PC3, MiaPaCa2, and HCT116 lines), displayed acceptable mouse PK properties (F = 41%, CL = 52.4 mL/min/kg), and exhibited robust efficacy in a U251 mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLNlDAdwkCzbVg90H21EOLACvtfcHk0lh9h5BNs5KXFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFams7bJ&md5=968025a577ae829928b3ff8b790c6403</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm4008664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008664%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DLiederer%26aufirst%3DB.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DBair%26aufirst%3DK.%2BW.%26atitle%3DStructure-based%2520discovery%2520of%2520novel%2520amide-containing%2520nicotinamide%2520phosphoribosyltransferase%2520%2528Nampt%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6413%26epage%3D6433%26doi%3D10.1021%2Fjm4008664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremayne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Identification of amides derived from 1H-pyrazolo [3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5488</span><span class="NLM_x">–</span> <span class="NLM_lpage">5497</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2013.08.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5488-5497&author=X.+Zhengauthor=K.+W.+Bairauthor=P.+Bauerauthor=T.+Baumeisterauthor=K.+K.+Bowmanauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=Y.+Fengauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=H.+Liauthor=X.+Liangauthor=B.+M.+Liedererauthor=J.+Linauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=A.+Ohauthor=D.+J.+Reynoldsauthor=D.+Sampathauthor=G.+Sharmaauthor=N.+Skeltonauthor=C.+C.+Smithauthor=J.+Tremayneauthor=L.+Wangauthor=W.+Wangauthor=Z.+Wangauthor=H.+Wuauthor=J.+Wuauthor=Y.+Xiaoauthor=G.+Yangauthor=P.-w.+Yuenauthor=M.+Zakauthor=P.+S.+Dragovich&title=Identification+of+amides+derived+from+1H-pyrazolo+%5B3%2C4-b%5Dpyridine-5-carboxylic+acid+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29&doi=10.1016%2Fj.bmcl.2013.08.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.074%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DTremayne%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520amides%2520derived%2520from%25201H-pyrazolo%2520%255B3%252C4-b%255Dpyridine-5-carboxylic%2520acid%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5488%26epage%3D5497%26doi%3D10.1016%2Fj.bmcl.2013.08.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">770</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1021/jm4015108</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4015108" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=770-792&author=A.+M.+Giannettiauthor=X.+Zhengauthor=N.+J.+Skeltonauthor=W.+Wangauthor=B.+J.+Bravoauthor=K.+W.+Bairauthor=T.+Baumeisterauthor=E.+Chengauthor=L.+Crockerauthor=Y.+Fengauthor=J.+Gunzner-Tosteauthor=Y.-C.+Hoauthor=R.+Huaauthor=B.+M.+Liedererauthor=Y.+Liuauthor=X.+Maauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=D.+Sampathauthor=Y.+Shenauthor=C.+Wangauthor=L.+Wangauthor=H.+Wuauthor=Y.+Xiaoauthor=P.-w+Yuenauthor=M.+Zakauthor=G.+Zhaoauthor=Q.+Zhaoauthor=P.+S.+Dragovich&title=Fragment-based+identification+of+amides+derived+from+trans-2-%28pyridin-3-yl%29cyclopropanecarboxylic+acid+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29&doi=10.1021%2Fjm4015108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span></div><div class="casAuthors">Giannetti, Anthony M.; Zheng, Xiaozhang; Skelton, Nicholas J.; Wang, Weiru; Bravo, Brandon J.; Bair, Kenneth W.; Baumeister, Timm; Cheng, Eric; Crocker, Lisa; Feng, Yezhen; Gunzner-Toste, Janet; Ho, Yen-Ching; Hua, Rongbao; Liederer, Bianca M.; Liu, Yongbo; Ma, Xiaolei; O'Brien, Thomas; Oeh, Jason; Sampath, Deepak; Shen, Youming; Wang, Chengcheng; Wang, Leslie; Wu, Hongxing; Xiao, Yang; Yuen, Po-wai; Zak, Mark; Zhao, Guiling; Zhao, Qiang; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">770-792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent, trans-2-(pyridin-3-yl)-cyclopropane-carboxamide-contg. inhibitors of the human nicotinamide phosphoribosyl-transferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques.  Multiple crystal structures were obtained of initial fragment leads, and this structural information was utilized to improve the biochem. and cell-based potency of the assocd. mols.  Many of the optimized compds. exhibited nanomolar antiproliferative activities against human tumor lines in in vitro cell culture expts.  In a key example, a fragment lead (13, KD = 51 μM) was elaborated into a potent NAMPT inhibitor (39, NAMPT IC50 = 0.0051 μM, A2780 cell culture IC50 = 0.000 49 μM) which demonstrated encouraging in vivo efficacy in an HT-1080 mouse xenograft tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGDYM9bbug1rVg90H21EOLACvtfcHk0lj0ABBzwlmoqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFWitQ%253D%253D&md5=cf1e87e52ef0641e48465a44d5b3347c</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1021%2Fjm4015108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4015108%26sid%3Dliteratum%253Aachs%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DHua%26aufirst%3DR.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DP.-w%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DFragment-based%2520identification%2520of%2520amides%2520derived%2520from%2520trans-2-%2528pyridin-3-yl%2529cyclopropanecarboxylic%2520acid%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D770%26epage%3D792%26doi%3D10.1021%2Fjm4015108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span> </span><span class="NLM_article-title">Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4875</span><span class="NLM_x">–</span> <span class="NLM_lpage">4885</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2013.06.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4875-4885&author=P.+S.+Dragovichauthor=K.+W.+Bairauthor=T.+Baumeisterauthor=Y.-C.+Hoauthor=B.+M.+Liedererauthor=X.+Liuauthor=Y.+Liuauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=D.+Sampathauthor=N.+Skeltonauthor=L.+Wangauthor=W.+Wangauthor=H.+Wuauthor=Y.+Xiaoauthor=P.-w.+Yuenauthor=M.+Zakauthor=L.+Zhangauthor=X.+Zheng&title=Identification+of+2%2C3-dihydro-1H-pyrrolo%5B3%2C4-c%5Dpyridine-derived+ureas+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29&doi=10.1016%2Fj.bmcl.2013.06.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.090%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DIdentification%2520of%25202%252C3-dihydro-1H-pyrrolo%255B3%252C4-c%255Dpyridine-derived%2520ureas%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4875%26epage%3D4885%26doi%3D10.1016%2Fj.bmcl.2013.06.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2014.12.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=529-541&author=M.+Zakauthor=B.+M.+Liedererauthor=D.+Sampathauthor=P.-w.+Yuenauthor=K.+W.+Bairauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=K.+H.+Clodfelterauthor=E.+Chengauthor=L.+Crockerauthor=B.+Fuauthor=B.+Hanauthor=G.+Liauthor=Y.-C.+Hoauthor=J.+Linauthor=X.+Liuauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=D.+J.+Reynoldsauthor=N.+Skeltonauthor=C.+C.+Smithauthor=S.+Tayauthor=W.+Wangauthor=Z.+Wangauthor=Y.+Xiaoauthor=L.+Zhangauthor=G.+Zhaoauthor=X.+Zhengauthor=P.+S.+Dragovich&title=Identification+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors+with+no+evidence+of+CYP3A4+time-dependent+inhibition+and+improved+aqueous+solubility&doi=10.1016%2Fj.bmcl.2014.12.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%2520with%2520no%2520evidence%2520of%2520CYP3A4%2520time-dependent%2520inhibition%2520and%2520improved%2520aqueous%2520solubility%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D529%26epage%3D541%26doi%3D10.1016%2Fj.bmcl.2014.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottosen, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjarnaa, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binderup, L.</span><span> </span><span class="NLM_article-title">Novel cyanoguanidines with potent oral antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3095</span><span class="NLM_x">–</span> <span class="NLM_lpage">3100</span><span class="refDoi"> DOI: 10.1016/S0960-894X(97)10152-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2FS0960-894X%2897%2910152-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=3095-3100&author=C.+Schouauthor=E.+R.+Ottosenauthor=H.+J.+Petersenauthor=F.+Bjorklingauthor=S.+Latiniauthor=P.+V.+Hjarnaaauthor=E.+Brammauthor=L.+Binderup&title=Novel+cyanoguanidines+with+potent+oral+antitumor+activity&doi=10.1016%2FS0960-894X%2897%2910152-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2910152-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252910152-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchou%26aufirst%3DC.%26aulast%3DOttosen%26aufirst%3DE.%2BR.%26aulast%3DPetersen%26aufirst%3DH.%2BJ.%26aulast%3DBjorkling%26aufirst%3DF.%26aulast%3DLatini%26aufirst%3DS.%26aulast%3DHjarnaa%26aufirst%3DP.%2BV.%26aulast%3DBramm%26aufirst%3DE.%26aulast%3DBinderup%26aufirst%3DL.%26atitle%3DNovel%2520cyanoguanidines%2520with%2520potent%2520oral%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D3095%26epage%3D3100%26doi%3D10.1016%2FS0960-894X%2897%2910152-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ravaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Droz, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumoleau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twelves, C.</span><span> </span><span class="NLM_article-title">Phase I study and pharmacokinetics of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">702</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1016/j.ejca.2004.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.ejca.2004.12.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=702-707&author=A.+Ravaudauthor=T.+Cernyauthor=C.+Terretauthor=J.+Wandersauthor=B.+N.+Buiauthor=D.+Hessauthor=J.-P.+Drozauthor=P.+Fumoleauauthor=C.+Twelves&title=Phase+I+study+and+pharmacokinetics+of+CHS-828%2C+a+guanidino-containing+compound%2C+administered+orally+as+a+single+dose+every+3+weeks+in+solid+tumours%3A+An+ECSG%2FEORTC+study&doi=10.1016%2Fj.ejca.2004.12.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2004.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2004.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DRavaud%26aufirst%3DA.%26aulast%3DCerny%26aufirst%3DT.%26aulast%3DTerret%26aufirst%3DC.%26aulast%3DWanders%26aufirst%3DJ.%26aulast%3DBui%26aufirst%3DB.%2BN.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DDroz%26aufirst%3DJ.-P.%26aulast%3DFumoleau%26aufirst%3DP.%26aulast%3DTwelves%26aufirst%3DC.%26atitle%3DPhase%2520I%2520study%2520and%2520pharmacokinetics%2520of%2520CHS-828%252C%2520a%2520guanidino-containing%2520compound%252C%2520administered%2520orally%2520as%2520a%2520single%2520dose%2520every%25203%2520weeks%2520in%2520solid%2520tumours%253A%2520An%2520ECSG%252FEORTC%2520study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D702%26epage%3D707%26doi%3D10.1016%2Fj.ejca.2004.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hovstadius, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skov, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissmeyer, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasilnikoff, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonnebo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlgren, J.</span><span> </span><span class="NLM_article-title">A phase I study of CHS 828 in patients with solid tumor malignancy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2843</span><span class="NLM_x">–</span> <span class="NLM_lpage">2850</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=12231525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvVWisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2843-2850&author=P.+Hovstadiusauthor=R.+Larssonauthor=E.+Jonssonauthor=T.+Skovauthor=A.-M.+Kissmeyerauthor=K.+Krasilnikoffauthor=J.+Berghauthor=M.+O.+Karlssonauthor=A.+Lonneboauthor=J.+Ahlgren&title=A+phase+I+study+of+CHS+828+in+patients+with+solid+tumor+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I study of CHS 828 in patients with solid tumor malignancy</span></div><div class="casAuthors">Hovstadius, Peter; Larsson, Rolf; Jonsson, Elin; Skov, Torsten; Kissmeyer, Anne-Marie; Krasilnikoff, Klaus; Bergh, Jonas; Karlsson, Mats O.; Loennebo, Anna; Ahlgren, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2843-2850</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CHS 828 is a cyanoguanidine, which has demonstrated potent antitumor activity in preclin. tumor models.  The activity of CHS 828 in vitro showed only low to moderate correlation to other antineoplastic agents suggesting a unique mechanism of action.  Ten females and 6 males (median age 58 yr) with solid tumors refractory to std. therapy were included in this Phase I study.  The study drug was administered to fasting patients as a single oral dose on days 1-5 of each treatment cycle.  Patients received one to six cycles of treatment.  The doses ranged from 30 mg to 200 mg (total dose within a cycle).  Hematol. toxicity was generally mild and dominated by transient thrombocytopenia and lymphocytopenia.  Nonhematol. toxicity most frequently consisted of nausea, vomiting, diarrhea, fatigue, and localized genital mucositis.  The dose-limiting toxicities were thrombocytopenia, thrombosis, esophagitis, diarrhea, and constipation.  The recommended Phase II dose of CHS 828 was 20 mg once daily for 5 days in cycles of 28 days duration.  The extent of systemic exposure of CHS 828 across patients was approx. dose proportional.  The time at which the highest drug concn. occurs was 2.2 ± 1.3 h and half-life was 2.1 ± 0.52 h (mean ± SD).  Large intra- and interindividual variation in dose level-adjusted max. plasma concn. and the area under the curve from time 0 h to infinity were obsd.  There was an apparent inverse relationship between systemic exposure of CHS 828, and thrombocyte and lymphocyte nadir levels.  No objective tumor responses were obsd., and 7 patients showed stable disease after two courses of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAV8wQZ2ka27Vg90H21EOLACvtfcHk0ljXH60cS5-EpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvVWisb8%253D&md5=3c3eb4621a968358dcd41f321eab2d87</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHovstadius%26aufirst%3DP.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DJonsson%26aufirst%3DE.%26aulast%3DSkov%26aufirst%3DT.%26aulast%3DKissmeyer%26aufirst%3DA.-M.%26aulast%3DKrasilnikoff%26aufirst%3DK.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DKarlsson%26aufirst%3DM.%2BO.%26aulast%3DLonnebo%26aufirst%3DA.%26aulast%3DAhlgren%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520CHS%2520828%2520in%2520patients%2520with%2520solid%2520tumor%2520malignancy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D2843%26epage%3D2850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Biedermann, E.; Hasmann, M.; Loser, R.; Rattel, B.; Reiter, F.; Schein, B.; Seibel, K.; Vogt, K.</span><span> </span><span class="NLM_article-title">Preparation and formulation of pyridine derivatives as antitumor agents and immunosuppressants</span> WO 199748397,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=E.+Biedermann&author=M.+Hasmann&author=R.+Loser&author=B.+Rattel&author=F.+Reiter&author=B.+Schein&author=K.+Seibel&author=K.+Vogt&title=Preparation+and+formulation+of+pyridine+derivatives+as+antitumor+agents+and+immunosuppressants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiedermann%26aufirst%3DE.%26atitle%3DPreparation%2520and%2520formulation%2520of%2520pyridine%2520derivatives%2520as%2520antitumor%2520agents%2520and%2520immunosuppressants%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Holen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltz, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollywood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanauske, A.-R.</span><span> </span><span class="NLM_article-title">The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1007/s10637-007-9083-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1007%2Fs10637-007-9083-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=45-51&author=K.+Holenauthor=L.+B.+Saltzauthor=E.+Hollywoodauthor=K.+Burkauthor=A.-R.+Hanauske&title=The+pharmacokinetics%2C+toxicities%2C+and+biologic+effects+of+FK866%2C+a+nicotinamide+adenine+dinucleotide+biosynthesis+inhibitor&doi=10.1007%2Fs10637-007-9083-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9083-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9083-2%26sid%3Dliteratum%253Aachs%26aulast%3DHolen%26aufirst%3DK.%26aulast%3DSaltz%26aufirst%3DL.%2BB.%26aulast%3DHollywood%26aufirst%3DE.%26aulast%3DBurk%26aufirst%3DK.%26aulast%3DHanauske%26aufirst%3DA.-R.%26atitle%3DThe%2520pharmacokinetics%252C%2520toxicities%252C%2520and%2520biologic%2520effects%2520of%2520FK866%252C%2520a%2520nicotinamide%2520adenine%2520dinucleotide%2520biosynthesis%2520inhibitor%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D45%26epage%3D51%26doi%3D10.1007%2Fs10637-007-9083-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hasmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schemainda, I.</span><span> </span><span class="NLM_article-title">FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7436</span><span class="NLM_x">–</span> <span class="NLM_lpage">7442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=14612543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7436-7442&author=M.+Hasmannauthor=I.+Schemainda&title=FK866%2C+a+highly+specific+noncompetitive+inhibitor+of+nicotinamide+phosphoribosyltransferase%2C+represents+a+novel+mechanism+for+induction+of+tumor+cell+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis</span></div><div class="casAuthors">Hasmann, Max; Schemainda, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7436-7442</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of apoptosis, the physiol. form of cell death, is closely assocd. with immunol. diseases and cancer.  Apoptosis is activated either by death receptor-driven or mitochondrial pathways, both of which may provide potential targets for novel anticancer drugs.  Although several ligands stimulating death receptors have been described, the actual mol. events triggering the mitochondrial pathway are largely unknown.  Here, we show initiation of apoptosis by gradual depletion of the intracellular coenzyme NAD+.  We identified the first low mol. wt. compd., designated FK866, which induces apoptosis by highly specific, noncompetitive inhibition of nicotinamide phosphoribosyltransferase (NAPRT), a key enzyme in the regulation of NAD+ biosynthesis from the natural precursor nicotinamide.  Interference with this enzyme does not primarily intoxicate cells because the mitochondrial respiratory activity and the NAD+-dependent redox reactions involved remain unaffected as long as NAD+ is not effectively depleted by catabolic reactions.  Certain tissues, however, have a high turnover of NAD+ through its cleavage by enzymes like poly(ADP-ribose) polymerase.  Such cells often rely on the more readily available nicotinamide pathway for NAD+ synthesis and undergo apoptosis after inhibition of NAPRT, whereas cells effectively using the nicotinic acid pathway for NAD+ synthesis remain unaffected.  In support of this concept, FK866 effectively induced delayed cell death by apoptosis in HepG2 human liver carcinoma cells with an IC50 of ∼1 nM, did not directly inhibit mitochondrial respiratory activity, but caused gradual NAD+ depletion through specific inhibition of NAPRT.  This enzyme, when partially purified from K562 human leukemia cells, was noncompetitively inhibited by FK866, and the inhibitor consts. were calcd. to be 0.4 nM for the enzyme/substrate complex (Ki) and 0.3 nM for the free enzyme (Ki'), resp.  Nicotinic acid and nicotinamide were both found to have antidote potential for the cellular effects of FK866.  FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer for immunosuppression or as a sensitizer for genotoxic agents.  Furthermore, it may provide an important tool for investigation of the mol. triggers of the mitochondrial pathway leading to apoptosis through enabling temporal sepn. of NAD+ decrease from ATP breakdown and apoptosis by several days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOS3LOADp6LVg90H21EOLACvtfcHk0lgHI8JeTpe24g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGltb4%253D&md5=c67fd08fdfc233ba86478967b13d19a2</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHasmann%26aufirst%3DM.%26aulast%3DSchemainda%26aufirst%3DI.%26atitle%3DFK866%252C%2520a%2520highly%2520specific%2520noncompetitive%2520inhibitor%2520of%2520nicotinamide%2520phosphoribosyltransferase%252C%2520represents%2520a%2520novel%2520mechanism%2520for%2520induction%2520of%2520tumor%2520cell%2520apoptosis%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7436%26epage%3D7442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlstrom, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorman, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, T. S.</span><span> </span><span class="NLM_article-title">CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1966</span><span class="NLM_x">–</span> <span class="NLM_lpage">1975</span><span class="refDoi"> DOI: 10.1124/dmd.106.010926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1124%2Fdmd.106.010926" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1966-1975&author=V.+Kumarauthor=J.+L.+Wahlstromauthor=D.+A.+Rockauthor=C.+J.+Warrenauthor=L.+A.+Gormanauthor=T.+S.+Tracy&title=CYP2C9+inhibition%3A+impact+of+probe+selection+and+pharmacogenetics+on+in+vitro+inhibition+profiles&doi=10.1124%2Fdmd.106.010926"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.010926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.010926%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DWahlstrom%26aufirst%3DJ.%2BL.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DWarren%26aufirst%3DC.%2BJ.%26aulast%3DGorman%26aufirst%3DL.%2BA.%26aulast%3DTracy%26aufirst%3DT.%2BS.%26atitle%3DCYP2C9%2520inhibition%253A%2520impact%2520of%2520probe%2520selection%2520and%2520pharmacogenetics%2520on%2520in%2520vitro%2520inhibition%2520profiles%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D1966%26epage%3D1975%26doi%3D10.1124%2Fdmd.106.010926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rettie, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. P.</span><span> </span><span class="NLM_article-title">Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.095821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1146%2Fannurev.pharmtox.45.120403.095821" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=477-494&author=A.+E.+Rettieauthor=J.+P.+Jones&title=Clinical+and+toxicological+relevance+of+CYP2C9%3A+drug-drug+interactions+and+pharmacogenetics&doi=10.1146%2Fannurev.pharmtox.45.120403.095821"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.095821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.095821%26sid%3Dliteratum%253Aachs%26aulast%3DRettie%26aufirst%3DA.%2BE.%26aulast%3DJones%26aufirst%3DJ.%2BP.%26atitle%3DClinical%2520and%2520toxicological%2520relevance%2520of%2520CYP2C9%253A%2520drug-drug%2520interactions%2520and%2520pharmacogenetics%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26spage%3D477%26epage%3D494%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.095821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Van Booven, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrillo, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangkuhl, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. B.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C9-CYP2C9</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e3283349e84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1097%2FFPC.0b013e3283349e84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=20150829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1ajtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=277-281&author=D.+Van+Boovenauthor=S.+Marshauthor=H.+McLeodauthor=M.+W.+Carrilloauthor=K.+Sangkuhlauthor=T.+E.+Kleinauthor=R.+B.+Altman&title=Cytochrome+P450+2C9-CYP2C9&doi=10.1097%2FFPC.0b013e3283349e84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2C9-CYP2C9</span></div><div class="casAuthors">Van Booven, Derek; Marsh, Sharon; McLeod, Howard; Carrillo, Michelle Whirl; Sangkuhl, Katrin; Klein, Teri E.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-281</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  CYP2C9 is a phase I drug-metabolizing cytochrome P 450 (CYP450) enzyme isoform that plays a major role in the oxidn. of both xenobiotic and endogenous compds.  The cluster comprises four genes arranged in the order CYP2C8-CYP2C9-CYP2C19-CYP2C18 [1].  Several studies identified a single nucleotide polymorphism (SNP) linkage between the CYP2C8 and CYP2C9 genes (2-4).  CYP2C9 is primarily expressed in the liver, and the expression level is reported to be the second highest among CYP isoforms [5].  Only the CYP enzyme CYP3A4 is quant. more highly expressed in the human liver.  It has been estd. that CYP2C9 is responsible for the metabolic clearance of up to 15-20 % of all drugs undergoing phase I metab. [7,8].  This article reports partial list showing examples of the broad substrate spectrum of drugs that are metabolized by CYP2C9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83s0ih92SYbVg90H21EOLACvtfcHk0lgHI8JeTpe24g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1ajtLg%253D&md5=54e698bcb81e6785f605c054af7faf09</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283349e84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283349e84%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBooven%26aufirst%3DD.%26aulast%3DMarsh%26aufirst%3DS.%26aulast%3DMcLeod%26aufirst%3DH.%26aulast%3DCarrillo%26aufirst%3DM.%2BW.%26aulast%3DSangkuhl%26aufirst%3DK.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DCytochrome%2520P450%25202C9-CYP2C9%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2010%26volume%3D20%26spage%3D277%26epage%3D281%26doi%3D10.1097%2FFPC.0b013e3283349e84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lee, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, J. A.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data</span> <span class="citation_source-journal">Pharmacogenetics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1097/00008571-200204000-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1097%2F00008571-200204000-00010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=11927841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=251-263&author=C.+R.+Leeauthor=J.+A.+Goldsteinauthor=J.+A.+Pieper&title=Cytochrome+P450+2C9+polymorphisms%3A+a+comprehensive+review+of+the+in-vitro+and+human+data&doi=10.1097%2F00008571-200204000-00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data</span></div><div class="casAuthors">Lee, Craig R.; Goldstein, Joyce A.; Pieper, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-263</span>CODEN:
                <span class="NLM_cas:coden">PHMCEE</span>;
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The discovery of six distinct polymorphisms in the genetic sequence encoding for the cytochrome P 450 2C9 (CYP2C9) protein has stimulated numerous investigations in an attempt to characterize their population distribution and metabolic activity.  Since the CYP2C9*1, *2 and *3 alleles were discovered first, they have undergone more thorough investigation than the recently identified *4, *5 and *6 alleles.  Population distribution data suggest that the variant *2 and *3 alleles are present in approx. 35% of Caucasian individuals; however, these alleles are significantly less prevalent in African-American and Asian populations.  In-vitro data have consistently demonstrated that the CYP2C9*2 and *3 alleles are assocd. with significant redns. in intrinsic clearance of a variety of 2C9 substrates compared with CYP2C9*1; however, the degree of these redns. appear to be highly substrate-dependent.  In addn., multiple in-vivo investigations and clin. case reports have assocd. genotypes expressing the CYP2C9*2 and *3 alleles with significant redns. in both the metab. and daily dose requirements of selected CYP2C9 substrates.  Individuals expressing these variant genotypes also appear to be significantly more susceptible to adverse events with the narrow therapeutic index agents warfarin and phenytoin, particularly during the initiation of therapy.  These findings have subsequently raised numerous questions regarding the potential clin. utility of genotyping for CYP2C9 prior to initiation of therapy with these agents.  However, further clin. investigations evaluating the metabolic consequences in individuals expressing the CYP2C9*2, *3, *4, *5, or *6 alleles are required before large-scale clin. genotyping can be recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1eDoaPX_Ry7Vg90H21EOLACvtfcHk0lhLWb7JJOiA0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFKqsLc%253D&md5=77e86d192a3cf3cab9153ceb19a4ad26</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1097%2F00008571-200204000-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-200204000-00010%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BR.%26aulast%3DGoldstein%26aufirst%3DJ.%2BA.%26aulast%3DPieper%26aufirst%3DJ.%2BA.%26atitle%3DCytochrome%2520P450%25202C9%2520polymorphisms%253A%2520a%2520comprehensive%2520review%2520of%2520the%2520in-vitro%2520and%2520human%2520data%26jtitle%3DPharmacogenetics%26date%3D2002%26volume%3D12%26spage%3D251%26epage%3D263%26doi%3D10.1097%2F00008571-200204000-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ali, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ysla, F. M.</span><span> </span><span class="NLM_article-title">CYP2C9 polymorphisms: considerations in NSAID therapy</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=108-114&author=Z.+K.+Aliauthor=R.+J.+Kimauthor=F.+M.+Ysla&title=CYP2C9+polymorphisms%3A+considerations+in+NSAID+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DZ.%2BK.%26aulast%3DKim%26aufirst%3DR.%2BJ.%26aulast%3DYsla%26aufirst%3DF.%2BM.%26atitle%3DCYP2C9%2520polymorphisms%253A%2520considerations%2520in%2520NSAID%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2009%26volume%3D12%26spage%3D108%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Horn, J. R.; Hansten, P. D.</span><span> </span><span class="NLM_article-title">Get to know an enzyme: CYP2C9</span>. <i>Pharmacy Times</i><span class="NLM_x"> </span><span class="NLM_year">2008</span>. <a href="http://www.pharmacytimes.com/publications/issue/2008/2008-03/2008-03-8462" class="extLink">www.pharmacytimes.com/publications/issue/2008/2008-03/2008-03-8462</a> (accessed July 21, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+R.+Horn&author=P.+D.+Hansten&title=Get+to+know+an+enzyme%3A+CYP2C9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DJ.%2BR.%26atitle%3DGet%2520to%2520know%2520an%2520enzyme%253A%2520CYP2C9%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schuster, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steindl, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, T.</span><span> </span><span class="NLM_article-title">Development and validation of an in silico P450 profiler based on pharmacophore models</span> <span class="citation_source-journal">Curr. Drug Discovery Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.2174/157016306776637609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F157016306776637609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=16712462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFSlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=1-48&author=D.+Schusterauthor=C.+Laggnerauthor=T.+M.+Steindlauthor=T.+Langer&title=Development+and+validation+of+an+in+silico+P450+profiler+based+on+pharmacophore+models&doi=10.2174%2F157016306776637609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of an in silico P450 profiler based on pharmacophore models</span></div><div class="casAuthors">Schuster, Daniela; Laggner, Christian; Steindl, Theodora M.; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-48</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In today's drug discovery process, the very early consideration of ADME properties is aimed at a redn. of drug candidate drop out rate in later development stages.  A part from in vitro testing, in silico methods are evaluated as complementary screening tools for compds. with unfavorable ADME attributes.  Esp. members of the cytochrome P 450 (P 450) enzyme superfamily. e.g. P 450 1A2, P 450 2C9, P 450 2C19, P 450 2D6, and P 450 3A4, contribute to xenobiotic metab., and compd. interaction with one of these enzymes is therefore critically evaluated.  Pharmacophore models are widely used to identify common features amongst ligands for any target.  In this study, both structure-based and ligand-based models for prominent drug-metabolizing members of the P 450 family were generated employing the software packages LigandScout and Catalyst.  Essential chem. ligand features for substrate and inhibitor activity for all five P 450 enzymes investigated were detd. and analyzed.  Finally, a collection of 11 pharmacophores for substrates and inhibitors was evaluated as an in silico P 450 profiling tool that could be used for early ADME estn. of new chem. entities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonOo9JPrdQG7Vg90H21EOLACvtfcHk0lj3HEMY3JvXCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFSlt7k%253D&md5=e7b84fb801c5fcdb96d44a57de3487fc</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.2174%2F157016306776637609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157016306776637609%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSteindl%26aufirst%3DT.%2BM.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520an%2520in%2520silico%2520P450%2520profiler%2520based%2520on%2520pharmacophore%2520models%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2006%26volume%3D3%26spage%3D1%26epage%3D48%26doi%3D10.2174%2F157016306776637609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bazeley, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prithivi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Povinelli, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sem, D. S.</span><span> </span><span class="NLM_article-title">Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2698</span><span class="NLM_x">–</span> <span class="NLM_lpage">2708</span><span class="refDoi"> DOI: 10.1021/ci600267k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci600267k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyntLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=2698-2708&author=P.+S.+Bazeleyauthor=S.+Prithiviauthor=C.+A.+Strubleauthor=R.+J.+Povinelliauthor=D.+S.+Sem&title=Synergistic+use+of+compound+properties+and+docking+scores+in+neural+network+modeling+of+CYP2D6+binding%3A+predicting+affinity+and+conformational+sampling&doi=10.1021%2Fci600267k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Use of Compound Properties and Docking Scores in Neural Network Modeling of CYP2D6 Binding: Predicting Affinity and Conformational Sampling</span></div><div class="casAuthors">Bazeley, Peter S.; Prithivi, Sridevi; Struble, Craig A.; Povinelli, Richard J.; Sem, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2698-2708</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytochrome P 450 2D6 (CYP2D6) is used to develop an approach for predicting affinity and relevant binding conformation(s) for highly flexible binding sites.  The approach combines the use of docking scores and compd. properties as attributes in building a neural network (NN) model.  It begins by identifying segments of CYP2D6 that are important for binding specificity, based on structural variability among diverse CYP enzymes.  A family of distinct, low-energy conformations of CYP2D6 are generated using simulated annealing (SA) and a collection of 82 compds. with known CYP2D6 affinities are docked.  Interestingly, docking poses are obsd. on the backside of the heme as well as in the known active site.  Docking scores for the active site binders, along with compd.-specific attributes, are used to train a neural network model to properly bin compds. as strong binders, moderate binders, or nonbinders.  Attribute selection is used to preselect the most important scores and compd.-specific attributes for the model.  A prediction accuracy of 85±6% is achieved.  Dominant attributes include docking scores for three of the 20 conformations in the ensemble as well as the compd.'s formal charge, no. of arom. rings, and AlogP.  Although compd. properties were highly predictive attributes (12% improvement over baseline) in the NN-based prediction of CYP2D6 binders, their combined use with docking score attributes is synergistic (net increase of 23% above baseline).  Beyond prediction of affinity, attribute selection provides a way to identify the most relevant protein conformation(s), in terms of binding competence.  In the case of CYP2D6, three out of the ensemble of 20 SA-generated structures are found to be the most predictive for binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod8cODdvl2VbVg90H21EOLACvtfcHk0lj3HEMY3JvXCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyntLfE&md5=0114183912cc1375352faef0e747b7c0</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fci600267k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600267k%26sid%3Dliteratum%253Aachs%26aulast%3DBazeley%26aufirst%3DP.%2BS.%26aulast%3DPrithivi%26aufirst%3DS.%26aulast%3DStruble%26aufirst%3DC.%2BA.%26aulast%3DPovinelli%26aufirst%3DR.%2BJ.%26aulast%3DSem%26aufirst%3DD.%2BS.%26atitle%3DSynergistic%2520use%2520of%2520compound%2520properties%2520and%2520docking%2520scores%2520in%2520neural%2520network%2520modeling%2520of%2520CYP2D6%2520binding%253A%2520predicting%2520affinity%2520and%2520conformational%2520sampling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D2698%26epage%3D2708%26doi%3D10.1021%2Fci600267k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Yasuo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaotsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujishita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirono, S.</span><span> </span><span class="NLM_article-title">Structure-based CoMFA as a predictive model – CYP2C9 inhibitors as a test case</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">864</span><span class="refDoi"> DOI: 10.1021/ci800313h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800313h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=853-864&author=K.+Yasuoauthor=N.+Yamaotsuauthor=H.+Goudaauthor=H.+Tsujishitaauthor=S.+Hirono&title=Structure-based+CoMFA+as+a+predictive+model+%E2%80%93+CYP2C9+inhibitors+as+a+test+case&doi=10.1021%2Fci800313h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based CoMFA As a Predictive Model - CYP2C9 Inhibitors As a Test Case</span></div><div class="casAuthors">Yasuo, Kazuya; Yamaotsu, Noriyuki; Gouda, Hiroaki; Tsujishita, Hideki; Hirono, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">853-864</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we tried to establish a general scheme to create a model that could predict the affinity of small compds. to their target proteins.  This scheme consists of a search for ligand-binding sites on a protein, a generation of bound conformations (poses) of ligands in each of the sites by docking, identifications of the correct poses of each ligand by consensus scoring and MM-PBSA anal., and a construction of a CoMFA model with the obtained poses to predict the affinity of the ligands.  By using a crystal structure of CYP 2C9 and the twenty known CYP inhibitors as a test case, we obtained a CoMFA model with a good statistics, which suggested that the classification of the binding sites as well as the predicted bound poses of the ligands should be reasonable enough.  The scheme described here would give a method to predict the affinity of small compds. with a reasonable accuracy, which is expected to heighten the value of computational chem. in the drug design process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0JgE3-yVPhbVg90H21EOLACvtfcHk0lgJ63vNI8aS5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSjurg%253D&md5=a6c80422d5dff2c003af2459a882d95b</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fci800313h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800313h%26sid%3Dliteratum%253Aachs%26aulast%3DYasuo%26aufirst%3DK.%26aulast%3DYamaotsu%26aufirst%3DN.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DTsujishita%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26atitle%3DStructure-based%2520CoMFA%2520as%2520a%2520predictive%2520model%2520%25E2%2580%2593%2520CYP2C9%2520inhibitors%2520as%2520a%2520test%2520case%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D853%26epage%3D864%26doi%3D10.1021%2Fci800313h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Stjernschantz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oostenbrink, C.</span><span> </span><span class="NLM_article-title">Improved ligand–protein binding affinity predictions using multiple binding modes</span> <span class="citation_source-journal">Biophys. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span><span class="refDoi"> DOI: 10.1016/j.bpj.2010.02.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bpj.2010.02.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2010&pages=2682-2691&author=E.+Stjernschantzauthor=C.+Oostenbrink&title=Improved+ligand%E2%80%93protein+binding+affinity+predictions+using+multiple+binding+modes&doi=10.1016%2Fj.bpj.2010.02.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2010.02.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2010.02.034%26sid%3Dliteratum%253Aachs%26aulast%3DStjernschantz%26aufirst%3DE.%26aulast%3DOostenbrink%26aufirst%3DC.%26atitle%3DImproved%2520ligand%25E2%2580%2593protein%2520binding%2520affinity%2520predictions%2520using%2520multiple%2520binding%2520modes%26jtitle%3DBiophys.%2520J.%26date%3D2010%26volume%3D98%26spage%3D2682%26epage%3D2691%26doi%3D10.1016%2Fj.bpj.2010.02.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Rossato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiesko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedani, A.</span><span> </span><span class="NLM_article-title">Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2088</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1002/cmdc.201000358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1002%2Fcmdc.201000358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=2088-2101&author=G.+Rossatoauthor=B.+Ernstauthor=M.+Smieskoauthor=M.+Spreaficoauthor=A.+Vedani&title=Probing+small-molecule+binding+to+cytochrome+P450+2D6+and+2C9%3A+an+in+silico+protocol+for+generating+toxicity+alerts&doi=10.1002%2Fcmdc.201000358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15e&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000358%26sid%3Dliteratum%253Aachs%26aulast%3DRossato%26aufirst%3DG.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DSmiesko%26aufirst%3DM.%26aulast%3DSpreafico%26aufirst%3DM.%26aulast%3DVedani%26aufirst%3DA.%26atitle%3DProbing%2520small-molecule%2520binding%2520to%2520cytochrome%2520P450%25202D6%2520and%25202C9%253A%2520an%2520in%2520silico%2520protocol%2520for%2520generating%2520toxicity%2520alerts%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D2088%26epage%3D2101%26doi%3D10.1002%2Fcmdc.201000358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kidley, N. J.</span><span> </span><span class="NLM_article-title">Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span><span class="refDoi"> DOI: 10.1021/ci2000506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2000506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFyktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=1048-1063&author=A.+G.+Leachauthor=N.+J.+Kidley&title=Quantitatively+interpreted+enhanced+inhibition+of+cytochrome+P450s+by+heteroaromatic+rings+containing+nitrogen&doi=10.1021%2Fci2000506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15fR"><div class="casContent"><span class="casTitleNuber">15f</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitatively Interpreted Enhanced Inhibition of Cytochrome P450s by Heteroaromatic Rings Containing Nitrogen</span></div><div class="casAuthors">Leach, Andrew G.; Kidley, Nathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1063</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It has been known for a long time that certain substructures bind to the heme iron in cytochromes P 450.  Detection of spectroscopic changes and crystal structures of protein ligand complexes have provided qual. evidence, including for arom. nitrogen-contg. ligands.  Compds. contg. these same substructures are more likely to inhibit cytochrome P450s than expected due to lipophilicity.  These two sets of observations are not easily linked by expt., because binding to the iron atom alone is not readily measured.  Quantum mech. (d. functional) calcns. of binding energies for a no. of different arom. heterocycles to heme iron in a range of oxidn. and spin states can provide a quant. link between the obsd. structures and the biochem. inhibition that is measured.  The studies reported here for a set of heteroarom. rings contg. nitrogen begin with quantum mech. calcns. which provide geometries and binding energies.  Subsequently, AstraZeneca's database of cytochrome P 450 inhibition assays has been searched to find data that are relevant to the same set of heteroarom. compds.  These data have been analyzed in a no. of fashions to account for both the narrow dynamic range of the assays and the lipophilicity dependence of this kind of inhibition.  Finally, crystal structures have provided exptl. geometric information.  Taken together these different sources suggest that binding to the metal in our inhibition assays is dominated by FeIII in its doublet state, most likely occurring when the iron is pentavalent.  Computed binding energies to this state contrast with the hydrogen-bond acceptor ability and basicity of the compds., neither of which are able to correctly account for the effect of the particular environment in which the iron is found.  This highlights the value of modeling biochem. events as closely as can be computationally afforded.  The computational protocol devised was used to make predictions about a set of as yet unknown heteroarom. compds. suggested by Pitt et al.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBAwZ7AH7k17Vg90H21EOLACvtfcHk0ljG1jGeG8xQyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFyktbc%253D&md5=9b37fed557509c4c40c4521797bea92e</span></div><a href="/servlet/linkout?suffix=cit15f&amp;dbid=16384&amp;doi=10.1021%2Fci2000506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2000506%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DKidley%26aufirst%3DN.%2BJ.%26atitle%3DQuantitatively%2520interpreted%2520enhanced%2520inhibition%2520of%2520cytochrome%2520P450s%2520by%2520heteroaromatic%2520rings%2520containing%2520nitrogen%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D1048%26epage%3D1063%26doi%3D10.1021%2Fci2000506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Shi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span> </span><span class="NLM_article-title">Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1941</span><span class="NLM_x">–</span> <span class="NLM_lpage">1951</span><span class="refDoi"> DOI: 10.1007/s00894-010-0903-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1007%2Fs00894-010-0903-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21120554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1941-1951&author=R.+Shiauthor=J.+Liauthor=X.+Caoauthor=X.+Zhuauthor=X.+Lu&title=Exploration+of+the+binding+of+proton+pump+inhibitors+to+human+P450+2C9+based+on+docking+and+molecular+dynamics+simulation&doi=10.1007%2Fs00894-010-0903-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15gR"><div class="casContent"><span class="casTitleNuber">15g</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the binding of proton pump inhibitors to human P 450 2C9 based on docking and molecular dynamics simulation</span></div><div class="casAuthors">Shi, Rongwei; Li, Jinyu; Cao, Xiaoning; Zhu, Xiaolei; Lu, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1941-1951</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Human cytochrome P 450 isoform 2C9 (CYP2C9) is one of the major drug-metabolizing isoforms, contributing to the oxidn. of 16% of the drugs currently in clin. use.  To examine the interaction mechanisms between CYP2C9 and proton pump inhibitors (PPIs), the authors used mol. docking and mol. dynamics (MD) simulation methods to investigate the conformations and interactions around the binding sites of PPI-CYP2C9 complexes.  The results from mol. docking and MD simulations demonstrated that 9 PPIs adopted 2 different conformations (extended and U-bend structures) at the binding sites and positioned themselves far above the heme moiety of CYP2C9.  The presence of the PPIs changed the secondary structure and residue flexibility of CYP2C9.  Interestingly, at the binding sites of all PPI-CYP2C9 complexes except for the lansoprazole-CYP2C9 complex, there were H--bonding networks formed from PPIs, water mols., and some residues of CYP2C9.  Moreover, there were strong hydrophobic interactions at all binding sites for PPI-CYP2C9 complexes, which indicated that electrostatic interactions and hydrophobic interactions appeared to be important for stabilizing the binding sites of most PPI-CYP2C9 complexes.  However, in the case of the lansoprazole-CYP2C9 complex, the hydrophobic interactions were more important than the electrostatic interactions in stabilizing the binding site.  In addn., an interesting conformational conversion from extended to U-bend structures was obsd. for pantoprazole, which was attributed to an H-bond interaction in the binding pocket, an internal π-π stacking interaction, and an internal electrostatic interaction of pantoprazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwjQhITPuJLVg90H21EOLACvtfcHk0ljG1jGeG8xQyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFejtb0%253D&md5=3c9e7d67cffbdaf26cba3cc209c9872c</span></div><a href="/servlet/linkout?suffix=cit15g&amp;dbid=16384&amp;doi=10.1007%2Fs00894-010-0903-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-010-0903-5%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26atitle%3DExploration%2520of%2520the%2520binding%2520of%2520proton%2520pump%2520inhibitors%2520to%2520human%2520P450%25202C9%2520based%2520on%2520docking%2520and%2520molecular%2520dynamics%2520simulation%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2011%26volume%3D17%26spage%3D1941%26epage%3D1951%26doi%3D10.1007%2Fs00894-010-0903-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Lardy, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebrun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, A.</span><span> </span><span class="NLM_article-title">Building a three-dimensional model of CYP2C9 inhibition using the Autocorrelator: an autonomous model generator</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1328</span><span class="NLM_x">–</span> <span class="NLM_lpage">1336</span><span class="refDoi"> DOI: 10.1021/ci200558e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200558e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Sjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1328-1336&author=M.+A.+Lardyauthor=L.+Lebrunauthor=D.+Bullardauthor=C.+Kissingerauthor=A.+Gobbi&title=Building+a+three-dimensional+model+of+CYP2C9+inhibition+using+the+Autocorrelator%3A+an+autonomous+model+generator&doi=10.1021%2Fci200558e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15hR"><div class="casContent"><span class="casTitleNuber">15h</span><div class="casTitle"><span class="NLM_cas:atitle">Building a Three-Dimensional Model of CYP2C9 Inhibition Using the Autocorrelator: An Autonomous Model Generator</span></div><div class="casAuthors">Lardy, M. A.; LeBrun, L.; Bullard, D.; Kissinger, C.; Gobbi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1328-1336</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In modern day drug discovery campaigns, computational chemists have to be concerned not only about improving the potency of mols. but also reducing any off-target ADMET activity.  There are a plethora of antitargets that computational chemists may have to consider.  Fortunately many antitargets have crystal structures deposited in the PDB.  These structures are immediately useful to our Autocorrelator: an automated model generator that optimizes variables for building computational models.  This paper describes the use of the Autocorrelator to construct high quality docking models for cytochrome P 450 2C9 (CYP2C9) from two publicly available crystal structures.  Both models result in strong correlation coeffs. (R2 > 0.66) between the predicted and exptl. detd. log(IC50) values.  Results from the two models overlap well with each other, converging on the same scoring function, deprotonated charge state, and predicted the binding orientation for our collection of mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqleMG7422K97Vg90H21EOLACvtfcHk0liMuhL9ciYBuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Sjtrg%253D&md5=2eddd2395a7831b3d49c0e0b50344089</span></div><a href="/servlet/linkout?suffix=cit15h&amp;dbid=16384&amp;doi=10.1021%2Fci200558e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200558e%26sid%3Dliteratum%253Aachs%26aulast%3DLardy%26aufirst%3DM.%2BA.%26aulast%3DLebrun%26aufirst%3DL.%26aulast%3DBullard%26aufirst%3DD.%26aulast%3DKissinger%26aufirst%3DC.%26aulast%3DGobbi%26aufirst%3DA.%26atitle%3DBuilding%2520a%2520three-dimensional%2520model%2520of%2520CYP2C9%2520inhibition%2520using%2520the%2520Autocorrelator%253A%2520an%2520autonomous%2520model%2520generator%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D1328%26epage%3D1336%26doi%3D10.1021%2Fci200558e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Sridhar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foroozesh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C. L.</span><span> </span><span class="NLM_article-title">Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">9283</span><span class="NLM_x">–</span> <span class="NLM_lpage">9305</span><span class="refDoi"> DOI: 10.3390/molecules17089283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.3390%2Fmolecules17089283" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=9283-9305&author=J.+Sridharauthor=J.+Liuauthor=M.+Foroozeshauthor=C.+L.+Stevens&title=Insights+on+cytochrome+p450+enzymes+and+inhibitors+obtained+through+QSAR+studies&doi=10.3390%2Fmolecules17089283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15i&amp;dbid=16384&amp;doi=10.3390%2Fmolecules17089283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules17089283%26sid%3Dliteratum%253Aachs%26aulast%3DSridhar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DForoozesh%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DC.%2BL.%26atitle%3DInsights%2520on%2520cytochrome%2520p450%2520enzymes%2520and%2520inhibitors%2520obtained%2520through%2520QSAR%2520studies%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D9283%26epage%3D9305%26doi%3D10.3390%2Fmolecules17089283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brändén, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjögren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnecke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span> </span><span class="NLM_article-title">Structure-based ligand design to overcome CYP inhibition in drug discovery projects</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span><span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.drudis.2014.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=905-911&author=G.+Br%C3%A4nd%C3%A9nauthor=T.+Sj%C3%B6grenauthor=V.+Schneckeauthor=Y.+Xue&title=Structure-based+ligand+design+to+overcome+CYP+inhibition+in+drug+discovery+projects&doi=10.1016%2Fj.drudis.2014.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25A4nd%25C3%25A9n%26aufirst%3DG.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DT.%26aulast%3DSchnecke%26aufirst%3DV.%26aulast%3DXue%26aufirst%3DY.%26atitle%3DStructure-based%2520ligand%2520design%2520to%2520overcome%2520CYP%2520inhibition%2520in%2520drug%2520discovery%2520projects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D905%26epage%3D911%26doi%3D10.1016%2Fj.drudis.2014.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sodhi, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukadam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J. S.</span><span> </span><span class="NLM_article-title">1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1124/dmd.113.055913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1124%2Fdmd.113.055913" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=813-817&author=J.+K.+Sodhiauthor=K.+A.+Fordauthor=S.+Mukadamauthor=S.+Wongauthor=C.+E.+Hopauthor=S.+C.+Khojastehauthor=J.+S.+Halladay&title=1-Aminobenzotriazole+coincubated+with+%28S%29-warfarin+results+in+potent+inactivation+of+CYP2C9&doi=10.1124%2Fdmd.113.055913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.055913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.055913%26sid%3Dliteratum%253Aachs%26aulast%3DSodhi%26aufirst%3DJ.%2BK.%26aulast%3DFord%26aufirst%3DK.%2BA.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26atitle%3D1-Aminobenzotriazole%2520coincubated%2520with%2520%2528S%2529-warfarin%2520results%2520in%2520potent%2520inactivation%2520of%2520CYP2C9%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D813%26epage%3D817%26doi%3D10.1124%2Fdmd.113.055913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgymGdl3nh1-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lovering, F.</span><span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lgymGdl3nh1-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lh69bpcQeZs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roychowdhury, A.</span><span> </span><span class="NLM_article-title">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3605</span><span class="NLM_x">–</span> <span class="NLM_lpage">3621</span><span class="refDoi"> DOI: 10.2174/092986712801323180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F092986712801323180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22680629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3605-3621&author=S.+Kumarauthor=R.+Sharmaauthor=A.+Roychowdhury&title=Modulation+of+cytochrome-P450+inhibition+%28CYP%29+in+drug+discovery%3A+a+medicinal+chemistry+perspective&doi=10.2174%2F092986712801323180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span></div><div class="casAuthors">Kumar, Sanjay; Sharma, Rajiv; Roychowdhury, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3605-3621</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP450) has widely been implicated for drug-drug interactions (DDI) in the pharmaceutical industry.  Inhibition or induction of this enzyme family has led to withdrawal of multiple drugs from the market leading to major time and financial losses for the pharmaceutical industry.  CYP450 plays a prevailing role in the biotransformation of a large no. of structurally diverse drugs.  Few isoenzymes of the CYP enzyme family (CYP3A4, 2D6 and 2C9 family) are mainly involved in metab. of most of the drugs.  To avoid such interactions and potentially minimize DDI, major pharmaceutical organizations prefer to incorporate CYP enzyme screening at an early stage of their discovery program.  While this has been a prevalent practice in the pharmaceutical industry lately, there is very limited literature available reviewing the relationship between chemotypes and CYP isoforms.  This review will collate literature pertaining to CYP-inhibition modulation through physicochem. parameters and chem. modification and thus bring to focus commonly used trends by medicinal chemists world-wide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVIogYUZJywLVg90H21EOLACvtfcHk0lh69bpcQeZs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF&md5=1f675ef0f7cd31a254b82d8b2eaac44b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F092986712801323180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801323180%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DRoychowdhury%26aufirst%3DA.%26atitle%3DModulation%2520of%2520cytochrome-P450%2520inhibition%2520%2528CYP%2529%2520in%2520drug%2520discovery%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3605%26epage%3D3621%26doi%3D10.2174%2F092986712801323180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span> </span><span class="NLM_article-title">Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1002/cbic.201402023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1002%2Fcbic.201402023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1121-1130&author=A.+Ohauthor=Y.-C.+Hoauthor=M.+Zakauthor=Y.+Liuauthor=X.+Chenauthor=P.-w.+Yuenauthor=X.+Zhengauthor=Y.+Liuauthor=P.+S.+Dragovichauthor=W.+Wang&title=Structural+and+biochemical+analyses+of+the+catalysis+and+potency+impact+of+inhibitor+phosphoribosylation+by+human+nicotinamide+phosphoribosyltransferase&doi=10.1002%2Fcbic.201402023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402023%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DWang%26aufirst%3DW.%26atitle%3DStructural%2520and%2520biochemical%2520analyses%2520of%2520the%2520catalysis%2520and%2520potency%2520impact%2520of%2520inhibitor%2520phosphoribosylation%2520by%2520human%2520nicotinamide%2520phosphoribosyltransferase%26jtitle%3DChemBioChem%26date%3D2014%26volume%3D15%26spage%3D1121%26epage%3D1130%26doi%3D10.1002%2Fcbic.201402023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Additional discussion on the relationship between the ability of NAMPT inhibitors to form phosphoribosylated adducts and the cell-based NAMPT potency of such compounds is presented in refs <a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">9a</a> and <a onclick="showRef(event, 'cit9c'); return false;" href="javascript:void(0);" class="ref cit9c">9c</a> and additional citations therein.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Additional+discussion+on+the+relationship+between+the+ability+of+NAMPT+inhibitors+to+form+phosphoribosylated+adducts+and+the+cell-based+NAMPT+potency+of+such+compounds+is+presented+in+refs+9a+and+9c+and+additional+citations+therein."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Watson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roulston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bélec, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billot, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bédard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branchaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratton, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakau, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khadir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawless, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turcotte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shore, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauparlant, P.</span><span> </span><span class="NLM_article-title">The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">5872</span><span class="NLM_x">–</span> <span class="NLM_lpage">5888</span><span class="refDoi"> DOI: 10.1128/MCB.00112-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1128%2FMCB.00112-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19703994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=5872-5888&author=M.+Watsonauthor=A.+Roulstonauthor=L.+B%C3%A9lecauthor=X.+Billotauthor=R.+Marcellusauthor=D.+B%C3%A9dardauthor=C.+Bernierauthor=S.+Branchaudauthor=H.+Chanauthor=K.+Dairiauthor=K.+Gilbertauthor=D.+Gouletauthor=M.+O.+Grattonauthor=H.+Isakauauthor=A.+Jangauthor=A.+Khadirauthor=E.+Kochauthor=M.+Lavoieauthor=M.+Lawlessauthor=M.+Nguyenauthor=D.+Paquetteauthor=E.+Turcotteauthor=A.+Bergerauthor=M.+Mitchellauthor=G.+C.+Shoreauthor=P.+Beauparlant&title=The+small+molecule+GMX1778+is+a+potent+inhibitor+of+NAD%2B+biosynthesis%3A+strategy+for+enhanced+therapy+in+nicotinic+acid+phosphoribosyltransferase+1-deficient+tumors&doi=10.1128%2FMCB.00112-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors</span></div><div class="casAuthors">Watson, Mark; Roulston, Anne; Belec, Laurent; Billot, Xavier; Marcellus, Richard; Bedard, Dominique; Bernier, Cynthia; Branchaud, Stephane; Chan, Helen; Dairi, Kenza; Gilbert, Karine; Goulet, Daniel; Gratton, Michel-Olivier; Isakau, Henady; Jang, Anne; Khadir, Abdelkrim; Koch, Elizabeth; Lavoie, Manon; Lawless, Michael; Nguyen, Mai; Paquette, Denis; Turcotte, Emilie; Berger, Alvin; Mitchell, Matthew; Shore, Gordon C.; Beauparlant, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5872-5888</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GMX1777 is a prodrug of the small mol. GMX1778, currently in phase I clin. trials for the treatment of cancer.  We describe findings indicating that GMX1778 is a potent and specific inhibitor of the NAD+ biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT).  Cancer cells have a very high rate of NAD+ turnover, which makes NAD+ modulation an attractive target for anticancer therapy.  Selective inhibition by GMX1778 of NAMPT blocks the prodn. of NAD+ and results in tumor cell death.  Furthermore, GMX1778 is phosphoribosylated by NAMPT, which increases its cellular retention.  The cytotoxicity of GMX1778 can be bypassed with exogenous nicotinic acid (NA), which permits NAD+ repletion via NA phosphoribosyltransferase 1 (NAPRT1).  The cytotoxicity of GMX1778 in cells with NAPRT1 deficiency, however, cannot be rescued by NA.  Analyses of NAPRT1 mRNA and protein levels in cell lines and primary tumor tissue indicate that high frequencies of glioblastomas, neuroblastomas, and sarcomas are deficient in NAPRT1 and not susceptible to rescue with NA.  As a result, the therapeutic index of GMX1777 can be widended in the treatment animals bearing NAPRT1-deficient tumors by coadministration with NA.  This provides the rationale for a novel therapeutic approach for the use of GMX1777 in the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT7TUeIRTTIrVg90H21EOLACvtfcHk0limtD3CXsFxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbvE&md5=a6157117d7e67368954ff5ae11986879</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FMCB.00112-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00112-09%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DM.%26aulast%3DRoulston%26aufirst%3DA.%26aulast%3DB%25C3%25A9lec%26aufirst%3DL.%26aulast%3DBillot%26aufirst%3DX.%26aulast%3DMarcellus%26aufirst%3DR.%26aulast%3DB%25C3%25A9dard%26aufirst%3DD.%26aulast%3DBernier%26aufirst%3DC.%26aulast%3DBranchaud%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDairi%26aufirst%3DK.%26aulast%3DGilbert%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DD.%26aulast%3DGratton%26aufirst%3DM.%2BO.%26aulast%3DIsakau%26aufirst%3DH.%26aulast%3DJang%26aufirst%3DA.%26aulast%3DKhadir%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DE.%26aulast%3DLavoie%26aufirst%3DM.%26aulast%3DLawless%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DPaquette%26aufirst%3DD.%26aulast%3DTurcotte%26aufirst%3DE.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DM.%26aulast%3DShore%26aufirst%3DG.%2BC.%26aulast%3DBeauparlant%26aufirst%3DP.%26atitle%3DThe%2520small%2520molecule%2520GMX1778%2520is%2520a%2520potent%2520inhibitor%2520of%2520NAD%252B%2520biosynthesis%253A%2520strategy%2520for%2520enhanced%2520therapy%2520in%2520nicotinic%2520acid%2520phosphoribosyltransferase%25201-deficient%2520tumors%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2009%26volume%3D29%26spage%3D5872%26epage%3D5888%26doi%3D10.1128%2FMCB.00112-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukadam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodhi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3531</span><span class="NLM_x">–</span> <span class="NLM_lpage">3538</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2013.04.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=23668988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFGrsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3531-3538&author=J.+Gunzner-Tosteauthor=G.+Zhaoauthor=P.+Bauerauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=B.+Fuauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=X.+Liangauthor=B.+M.+Liedererauthor=J.+Linauthor=S.+Mukadamauthor=T.+O%E2%80%99Brienauthor=A.+Ohauthor=D.+J.+Reynoldsauthor=G.+Sharmaauthor=N.+Skeltonauthor=C.+C.+Smithauthor=J.+Sodhiauthor=W.+Wangauthor=Z.+Wangauthor=Y.+Xiaoauthor=P.-w.+Yuenauthor=M.+Zakauthor=L.+Zhangauthor=X.+Zhengauthor=K.+W.+Bairauthor=P.+S.+Dragovich&title=Discovery+of+potent+and+efficacious+urea-containing+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors+with+reduced+CYP2C9+inhibition+properties&doi=10.1016%2Fj.bmcl.2013.04.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties</span></div><div class="casAuthors">Gunzner-Toste, Janet; Zhao, Guiling; Bauer, Paul; Baumeister, Timm; Buckmelter, Alexandre J.; Caligiuri, Maureen; Clodfelter, Karl H.; Fu, Bang; Han, Bingsong; Ho, Yen-Ching; Kley, Nikolai; Liang, Xiaorong; Liederer, Bianca M.; Lin, Jian; Mukadam, Sophie; O'Brien, Thomas; Oh, Angela; Reynolds, Dominic J.; Sharma, Geeta; Skelton, Nicholas; Smith, Chase C.; Sodhi, Jasleen; Wang, Weiru; Wang, Zhongguo; Xiao, Yang; Yuen, Po-wai; Zak, Mark; Zhang, Lei; Zheng, Xiaozhang; Bair, Kenneth W.; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3531-3538</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Potent, reversible inhibition of the cytochrome P 450 CYP2C9 isoform was obsd. in a series of urea-contg. nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.  This unwanted property was successfully removed from the described inhibitors through a combination of structure-based design and medicinal chem. activities.  An optimized compd., I, which did not inhibit CYP2C9 exhibited potent anti-NAMPT activity (BC NAMPT IC50 = 3 nM; A2780 antiproliferative IC50 = 70 nM), good mouse PK properties, and was efficacious in an A2780 mouse xenograft model.  The crystal structure of this compd. in complex with the NAMPT protein is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvravlmt8_mbVg90H21EOLACvtfcHk0lhiDbBlIGZ6Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFGrsrk%253D&md5=6db1abf81339d6ce9d3d51e85cdfc1e6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.040%26sid%3Dliteratum%253Aachs%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DSodhi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520efficacious%2520urea-containing%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%2520with%2520reduced%2520CYP2C9%2520inhibition%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3531%26epage%3D3538%26doi%3D10.1016%2Fj.bmcl.2013.04.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">See Supporting Information, <a class="ref internalNav" href="#notes-1" aria-label="Figure S1">Figure S1</a>, for the Fsp3 distribution of the 119-membered library.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brillantes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmont, L. D.</span><span> </span><span class="NLM_article-title">Structural basis for resistance to diverse classes of NAMPT inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e109366</span><span class="refDoi"> DOI: 10.1371/journal.pone.0109366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1371%2Fjournal.pone.0109366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25285661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKiur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e109366&author=W.+Wangauthor=K.+Elkinsauthor=A.+Ohauthor=Y.+C.+Hoauthor=J.+Wuauthor=H.+Liauthor=Y.+Xiaoauthor=M.+Kwongauthor=M.+Coonsauthor=B.+Brillantesauthor=E.+Chengauthor=L.+Crockerauthor=P.+S.+Dragovichauthor=D.+Sampathauthor=X.+Zhengauthor=K.+W.+Bairauthor=T.+O%E2%80%99Brienauthor=L.+D.+Belmont&title=Structural+basis+for+resistance+to+diverse+classes+of+NAMPT+inhibitors&doi=10.1371%2Fjournal.pone.0109366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for resistance to diverse classes of NAMPT inhibitors</span></div><div class="casAuthors">Wang, Weiru; Elkins, Kristi; Oh, Angela; Ho, Yen-Ching; Wu, Jiansheng; Li, Hong; Xiao, Yang; Kwong, Mandy; Coons, Mary; Brillantes, Bobby; Cheng, Eric; Crocker, Lisa; Dragovich, Peter S.; Sampath, Deepak; Zheng, Xiaozhang; Bair, Kenneth W.; O'Brien, Thomas; Belmont, Lisa D.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e109366/1-e109366/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metab.  However, the development of drug resistance commonly limits the efficacy of cancer therapeutics.  This study identifies mutations in NAMPT that confer resistance to a novel NAMPT inhibitor, GNE-618, in cell culture and in vivo, thus demonstrating that the cytotoxicity of GNE-618 is on target.  We det. the crystal structures of six NAMPT mutants in the apo form and in complex with various inhibitors and use cellular, biochem. and structural data to elucidate two resistance mechanisms.  One is the surprising finding of allosteric modulation by mutation of residue Ser165, resulting in unwinding of an a-helix that binds the NAMPT substrate 5-phosphoribosyl-1-pyrophosphate (PRPP).  The other mechanism is orthosteric blocking of inhibitor binding by mutations of Gly217.  Furthermore, by evaluating a panel of diverse small mol. inhibitors, we unravel inhibitor structure activity relationships on the mutant enzymes.  These results provide valuable insights into the design of next generation NAMPT inhibitors that offer improved therapeutic potential by evading certain mechanisms of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP5iFUmBeJC7Vg90H21EOLACvtfcHk0lgPgmKJNrV0EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKiur%252FI&md5=cdae9fb4ad44c429e24aaf0f297fcfb8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0109366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0109366%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DElkins%26aufirst%3DK.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DY.%2BC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKwong%26aufirst%3DM.%26aulast%3DCoons%26aufirst%3DM.%26aulast%3DBrillantes%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26atitle%3DStructural%2520basis%2520for%2520resistance%2520to%2520diverse%2520classes%2520of%2520NAMPT%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De109366%26doi%3D10.1371%2Fjournal.pone.0109366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Khan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span> </span><span class="NLM_article-title">Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">582</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span><span class="refDoi"> DOI: 10.1038/nsmb1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnsmb1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=16783377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1elt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=582-588&author=J.+A.+Khanauthor=X.+Taoauthor=L.+Tong&title=Molecular+basis+for+the+inhibition+of+human+NMPRTase%2C+a+novel+target+for+anticancer+agents&doi=10.1038%2Fnsmb1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents</span></div><div class="casAuthors">Khan, Javed A.; Tao, Xiao; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">582-588</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors.  The authors have detd. the crystal structures at up to 2.1-Å resoln. of human and murine NMPRTase, alone and in complex with the reaction product NMN or the inhibitor FK866.  The structures suggest that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies.  FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866.  Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate.  Our structural and biochem. studies provide a starting point for the development of new anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1s-XY1uB70LVg90H21EOLACvtfcHk0lgPgmKJNrV0EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1elt7k%253D&md5=debef567dbcf629422472ef1b63dc396</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1105%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DMolecular%2520basis%2520for%2520the%2520inhibition%2520of%2520human%2520NMPRTase%252C%2520a%2520novel%2520target%2520for%2520anticancer%2520agents%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D582%26epage%3D588%26doi%3D10.1038%2Fnsmb1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">The discovery of these left-hand side moieties was previously disclosed in refs <a onclick="showRef(event, 'cit9a cit9b cit9c cit9e'); return false;" href="javascript:void(0);" class="ref cit9a cit9b cit9c cit9e">9a−9c, 9e</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><div class="note"><p class="first last">A review on the use of carbamates in Medicinal Chemistry was recently published</p></div><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindisi, M.</span><span> </span><span class="NLM_article-title">Organic carbamates in drug design and medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2895</span><span class="NLM_x">–</span> <span class="NLM_lpage">2940</span><span class="refDoi"> DOI: 10.1021/jm501371s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501371s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2895-2940&author=A.+K.+Ghoshauthor=M.+Brindisi&title=Organic+carbamates+in+drug+design+and+medicinal+chemistry&doi=10.1021%2Fjm501371s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Organic Carbamates in Drug Design and Medicinal Chemistry</span></div><div class="casAuthors">Ghosh, Arun K.; Brindisi, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2895-2940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The carbamate group is a key structural motif in many approved drugs and prodrugs.  There is an increasing use of carbamates in medicinal chem. and many derivs. are specifically designed to make drug-target interactions through their carbamate moiety.  In this Perspective, we present properties and stabilities of carbamates, reagents and chem. methodologies for the synthesis of carbamates, and recent applications of carbamates in drug design and medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGollKFyXYJJHLVg90H21EOLACvtfcHk0lgM44GeJPhsPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D&md5=e3548247931b74b60e299ada1e27dda5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm501371s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501371s%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DOrganic%2520carbamates%2520in%2520drug%2520design%2520and%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2895%26epage%3D2940%26doi%3D10.1021%2Fjm501371s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">cLogD<sub>pH7.4</sub> values were calculated using the Mo Kα sofware (<a href="http://www.moldiscovery.com" class="extLink">www.moldiscovery.com</a> (ref <a onclick="showRef(event, 'cit28a'); return false;" href="javascript:void(0);" class="ref cit28a">28a</a>)) and a custom p<i>K</i><sub>a</sub> model (ref <a onclick="showRef(event, 'cit28b'); return false;" href="javascript:void(0);" class="ref cit28b">28b</a>).</p></div><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sforna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">New and original pKa prediction method using grid molecular interaction fields</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2172</span><span class="NLM_x">–</span> <span class="NLM_lpage">2181</span><span class="refDoi"> DOI: 10.1021/ci700018y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci700018y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2172-2181&author=F.+Millettiauthor=L.+Storchiauthor=G.+Sfornaauthor=G.+Cruciani&title=New+and+original+pKa+prediction+method+using+grid+molecular+interaction+fields&doi=10.1021%2Fci700018y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">New and Original pKa Prediction Method Using Grid Molecular Interaction Fields</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Sforna, Gianluca; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2172-2181</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most important physicochem. properties of a mol. is pKa.  It is known that two parameters imperative in ADME profiling, soly., and lipophilicity are governed by pKa, and receptor binding can be influenced by pKa.  Because most drugs are ionized in physiol. conditions, pKa is particularly relevant to medicinal chem.  Despite the numerous advances in high-throughput measurements, in silico detn. is still the fastest and cheapest way of obtaining pKa.  This paper presents a new original computational method for pKa prediction of org. compds.  Descriptors were generated using the program GRID, and these descriptors are based on mol. interaction fields precomputed on a set of mol. fragments.  The new method was developed, trained, and cross-validated by using a large and diverse data set of 24 617 pKa values.  This paper presents the results for a class of 421 acidic nitrogen compds. (RMSE = 0.41, r2 = 0.97, q2 = 0.87) and for a class of 947 six-membered N-heterocyclic bases (RMSE = 0.60, r2 = 0.93, q2 = 0.85).  For external validation 28 novel compds. were selected that covered nine different ionizable groups, and 39 pKa values could be exptl. detd. by spectral gradient anal. (SGA).  Comparison of exptl. pKa with calcd. pKa demonstrated that the predictive ability of the method is good (external set, r2 = 0.85, RMSE = 0.90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEk0uiS1E6rVg90H21EOLACvtfcHk0lgM44GeJPhsPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF&md5=f2b1dec853ccb0ef1a40540d234232fb</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fci700018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700018y%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DSforna%26aufirst%3DG.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DNew%2520and%2520original%2520pKa%2520prediction%2520method%2520using%2520grid%2520molecular%2520interaction%2520fields%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2172%26epage%3D2181%26doi%3D10.1021%2Fci700018y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goracci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4270</span><span class="NLM_x">–</span> <span class="NLM_lpage">4279</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2010.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series&doi=10.1016%2Fj.ejmech.2010.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKα, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKα, such as hydrazide derivs.  These findings helped us to enhance MoKα, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0lhhOhf-G4EAAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D4270%26epage%3D4279%26doi%3D10.1016%2Fj.ejmech.2010.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="note"><p class="first last">We have characterized and reported on aspects of the in vitro and in vivo toxicity profiles of previously reported NAMPT inhibitors.</p></div><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uppal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span> </span><span class="NLM_article-title">Retinal toxicity, in vivo and in vitro, associated with inhibition of Nicotinamide Phosphoribosyltransferase</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1093/toxsci/kfu268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1093%2Ftoxsci%2Fkfu268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25505128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2015&pages=163-172&author=T.+S.+Zabkaauthor=J.+Singhauthor=P.+Dhawanauthor=B.+M.+Liedererauthor=J.+Oehauthor=M.+A.+Kaussauthor=Y.+Xiaoauthor=M.+Zakauthor=T.+Linauthor=B.+McCrayauthor=N.+Laauthor=T.+Nguyenauthor=J.+Beyerauthor=C.+Farmanauthor=H.+Uppalauthor=P.+S.+Dragovichauthor=T.+O%E2%80%99Brienauthor=D.+Sampathauthor=D.+L.+Misner&title=Retinal+toxicity%2C+in+vivo+and+in+vitro%2C+associated+with+inhibition+of+Nicotinamide+Phosphoribosyltransferase&doi=10.1093%2Ftoxsci%2Fkfu268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase</span></div><div class="casAuthors">Zabka, Tanja S.; Singh, Jatinder; Dhawan, Preeti; Liederer, Bianca M.; Oeh, Jason; Kauss, Mara A.; Xiao, Yang; Zak, Mark; Lin, Tori; McCray, Bobbi; La, Nghi; Nguyen, Trung; Beyer, Joseph; Farman, Cynthia; Uppal, Hirdesh; Dragovich, Peter S.; O'Brien, Thomas; Sampath, Deepak; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Nicotinamide phosphoribosyltransferase (NAMPT) is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone.  NAMPT is of interest for oncol., because it catalyzes the rate-limiting step in the salvage pathway to generate NAD, which is considered a universal energy- and signal-carrying mol. involved in cellular energy metab. and many homeostatic functions.  This manuscript describes NAMPT inhibitor-induced retinal toxicity that was identified in rodent safety studies.  This toxicity had a rapid onset and progression and initially targeted the photoreceptor and outer nuclear layers.  Using in vivo safety and efficacy rodent studies, human and mouse cell line potency data, human and rat retinal pigmented epithelial cell in vitro systems, and rat mRNA expression data of NAMPT, nicotinic acid phosphoribosyltransferase, and NMN adenylyltransferease (NMNAT) in several tissues from rat including retina, we demonstrate that the retinal toxicity is on-target and likely human relevant.  We demonstrate that this toxicity is not mitigated by coadministration of nicotinic acid (NA), which can enable NAD prodn. through the NAMPT-independent pathway.  Further, modifying the physiochem. properties of NAMPT inhibitors could not sufficiently reduce retinal exposure.  Our work highlights opportunities to leverage appropriately designed efficacy studies to identify known and measurable safety findings to screen compds. more rapidly and reduce animal use.  It also demonstrates that in vitro systems with the appropriate cell compn. and relevant biol. and toxicity endpoints can provide tools to investigate mechanism of toxicity and the human translation of nonclin. safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83daf3aktlLVg90H21EOLACvtfcHk0lhMEAAkYD7U0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbrI&md5=2db52370c9372badbcf31c7800acc94f</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfu268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfu268%26sid%3Dliteratum%253Aachs%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DDhawan%26aufirst%3DP.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DKauss%26aufirst%3DM.%2BA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DMcCray%26aufirst%3DB.%26aulast%3DLa%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DFarman%26aufirst%3DC.%26aulast%3DUppal%26aufirst%3DH.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DRetinal%2520toxicity%252C%2520in%2520vivo%2520and%2520in%2520vitro%252C%2520associated%2520with%2520inhibition%2520of%2520Nicotinamide%2520Phosphoribosyltransferase%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D144%26spage%3D163%26epage%3D172%26doi%3D10.1093%2Ftoxsci%2Fkfu268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tarrant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DosSantos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uppal, H.</span><span> </span><span class="NLM_article-title">Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid</span> <span class="citation_source-journal">Toxicol. Mech. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.3109/15376516.2015.1014080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.3109%2F15376516.2015.1014080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25894564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVSjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=201-211&author=J.+M.+Tarrantauthor=P.+Dhawanauthor=J.+Singhauthor=T.+S.+Zabkaauthor=E.+Clarkeauthor=G.+DosSantosauthor=P.+S.+Dragovichauthor=D.+Sampathauthor=T.+Linauthor=B.+McCrayauthor=N.+Laauthor=T.+Nguyenauthor=A.+Kaussauthor=D.+Dambachauthor=D.+L.+Misnerauthor=D.+Diazauthor=H.+Uppal&title=Preclinical+models+of+nicotinamide+phosphoribosyltransferase+inhibitor-mediated+hematotoxicity+and+mitigation+by+co-treatment+with+nicotinic+acid&doi=10.3109%2F15376516.2015.1014080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid</span></div><div class="casAuthors">Tarrant, Jacqueline M.; Dhawan, Preeti; Singh, Jatinder; Zabka, Tanja S.; Clarke, Emer; DosSantos, Garry; Dragovich, Peter S.; Sampath, Deepak; Lin, Tori; McCray, Bobbi; La, Nghi; Nguyen, Trung; Kauss, Ariel; Dambach, Donna; Misner, Dinah L.; Diaz, Dolores; Uppal, Hirdesh</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Mechanisms and Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-211</span>CODEN:
                <span class="NLM_cas:coden">TMMOCP</span>;
        ISSN:<span class="NLM_cas:issn">1537-6516</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">NAD (NAD) is an essential co-factor in glycolysis and is a key mol. involved in maintaining cellular energy metab.  Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of an important salvage pathway in which nicotinamide is recycled into NAD.  NAMPT is up-regulated in many types of cancer and NAMPT inhibitors (NAMPTi) have potential therapeutic benefit in cancer by impairing tumor metab.  Clin. trials with NAMPTi APO-866 and GMX-1778, however, failed to reach projected efficacious exposures due to dose-limiting thrombocytopenia.  We evaluated preclin. models for thrombocytopenia that could be used in candidate drug selection and risk mitigation strategies for NAMPTi-related toxicity.  Rats treated with a suite of structurally diverse and potent NAMPTi at max. tolerated doses had decreased reticulocyte and lymphocyte counts, but no thrombocytopenia.  We therefore evaluated and qualified a human colony forming unit-megakaryocyte (CFU-MK) as in vitro predictive model of NAMPTi-induced MK toxicity and thrombocytopenia.  We further demonstrate that the MK toxicity is on-target based on the evidence that nicotinic acid (NA), which is converted to NAD via a NAMPT-independent pathway, can mitigate NAMPTi toxicity to human CFU-MK in vitro and was also protective for the hematotoxicity in rats in vivo.  Finally, assessment of CFU-MK and human platelet bioenergetics and function show that NAMPTi was toxic to MK and not platelets, which is consistent with the clin. obsd. time-course of thrombocytopenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVoRVrRU14ubVg90H21EOLACvtfcHk0lhMEAAkYD7U0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVSjt7k%253D&md5=536137fdb1961f4dbf5807d9655e6549</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.3109%2F15376516.2015.1014080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15376516.2015.1014080%26sid%3Dliteratum%253Aachs%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DDhawan%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DClarke%26aufirst%3DE.%26aulast%3DDosSantos%26aufirst%3DG.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DMcCray%26aufirst%3DB.%26aulast%3DLa%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DKauss%26aufirst%3DA.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DUppal%26aufirst%3DH.%26atitle%3DPreclinical%2520models%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520inhibitor-mediated%2520hematotoxicity%2520and%2520mitigation%2520by%2520co-treatment%2520with%2520nicotinic%2520acid%26jtitle%3DToxicol.%2520Mech.%2520Methods%26date%3D2015%26volume%3D25%26spage%3D201%26epage%3D211%26doi%3D10.3109%2F15376516.2015.1014080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">The chemical purities of all final compounds described in this work were >95% at the time of their biological assessments as determined by LCMS analysis with UV detection at 220 and/or 254 nm. We also noted, however, that some molecules containing the 2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-derived urea moiety experienced oxidation upon prolonged storage (detected via LCMS analysis of stored materials). No attempts were made to study or suppress this process and the oxidized compounds were neither isolated nor biologically characterized. LCMS fragmentation patterns suggested the oxidation products depicted below, but no additional analyses were conducted to confirm these assignments.<span class="NLM_inline-graphic"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0036.tif.gif" alt="" /></img></span></p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Djakovitch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, K.</span><span> </span><span class="NLM_article-title">Pd-catalyzed Heck arylation of cycloalkenes—studies on selectivity comparing homogeneous and heterogeneous catalysts</span> <span class="citation_source-journal">J. Mol. Catal. A: Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">219</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1016/j.molcata.2004.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.molcata.2004.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Wrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2004&pages=121-130&author=L.+Djakovitchauthor=M.+Wagnerauthor=C.+G.+Hartungauthor=M.+Bellerauthor=K.+Koehler&title=Pd-catalyzed+Heck+arylation+of+cycloalkenes%E2%80%94studies+on+selectivity+comparing+homogeneous+and+heterogeneous+catalysts&doi=10.1016%2Fj.molcata.2004.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-catalyzed Heck arylation of cycloalkenes: studies on selectivity comparing homogeneous and heterogeneous catalysts</span></div><div class="casAuthors">Djakovitch, L.; Wagner, M.; Hartung, C. G.; Beller, M.; Koehler, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Catalysis A: Chemical</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-130</span>CODEN:
                <span class="NLM_cas:coden">JMCCF2</span>;
        ISSN:<span class="NLM_cas:issn">1381-1169</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Heck reactions of aryl bromides with cyclohexene and cyclopentene catalyzed by typical homogeneous as well as heterogeneous Pd catalysts (Pd/C, Pd/SiO2, Pd/MgO, Pd/Al2O3, and Pd(0), Pd(II) and [Pd(NH3)4]2+ in zeolites Y or ZSM-5) have been studied in order to get detailed information on the reaction mechanism with regard to the catalyst.  The focus of the present investigation was on correlations between selectivity (Heck products: double bond isomers of arylcycloalkenes, dehalogenation and double arylation products) and nature of the catalyst or active Pd species.  The results indicate that dissolved mol. Pd species are responsible for the Heck coupling for both homogeneous and heterogeneous (solid) catalysts, whereas dehalogenation is due to a mechanism involving the surface of solid Pd metal particles and radical processes.  The selectivity of the reactions can be controlled by the choice of catalyst and reaction conditions (base, solvent, temp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNUgJ1tdMRbVg90H21EOLACvtfcHk0lhCbmnPWX4MBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Wrur0%253D&md5=b20ee85dc88c8ee3e0617f7b766b366d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.molcata.2004.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcata.2004.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DDjakovitch%26aufirst%3DL.%26aulast%3DWagner%26aufirst%3DM.%26aulast%3DHartung%26aufirst%3DC.%2BG.%26aulast%3DBeller%26aufirst%3DM.%26aulast%3DKoehler%26aufirst%3DK.%26atitle%3DPd-catalyzed%2520Heck%2520arylation%2520of%2520cycloalkenes%25E2%2580%2594studies%2520on%2520selectivity%2520comparing%2520homogeneous%2520and%2520heterogeneous%2520catalysts%26jtitle%3DJ.%2520Mol.%2520Catal.%2520A%253A%2520Chem.%26date%3D2004%26volume%3D219%26spage%3D121%26epage%3D130%26doi%3D10.1016%2Fj.molcata.2004.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b','cit7c','cit7d','cit7e','cit7f'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d','cit9e','cit9f'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11a','cit11b','cit11c'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15a','cit15b','cit15c','cit15d','cit15e','cit15f','cit15g','cit15h','cit15i'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21'],'ref22':['cit22'],'ref23':[],'ref24':['cit24'],'ref25':['cit25'],'ref26':[],'ref27':['cit27'],'ref28':['cit28a','cit28b'],'ref29':['cit29a','cit29b'],'ref30':[],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Travelli</span>, <span class="hlFld-ContribAuthor ">Silvio  Aprile</span>, <span class="hlFld-ContribAuthor ">Reza  Rahimian</span>, <span class="hlFld-ContribAuthor ">Ambra A.  Grolla</span>, <span class="hlFld-ContribAuthor ">Federica  Rogati</span>, <span class="hlFld-ContribAuthor ">Mattia  Bertolotti</span>, <span class="hlFld-ContribAuthor ">Floriana  Malagnino</span>, <span class="hlFld-ContribAuthor ">Rosanna  di Paola</span>, <span class="hlFld-ContribAuthor ">Daniela  Impellizzeri</span>, <span class="hlFld-ContribAuthor ">Roberta  Fusco</span>, <span class="hlFld-ContribAuthor ">Valentina  Mercalli</span>, <span class="hlFld-ContribAuthor ">Alberto  Massarotti</span>, <span class="hlFld-ContribAuthor ">Giorgio  Stortini</span>, <span class="hlFld-ContribAuthor ">Salvatore  Terrazzino</span>, <span class="hlFld-ContribAuthor ">Erika  Del Grosso</span>, <span class="hlFld-ContribAuthor ">Gohar  Fakhfouri</span>, <span class="hlFld-ContribAuthor ">Maria Pia  Troiani</span>, <span class="hlFld-ContribAuthor ">Maria Alessandra  Alisi</span>, <span class="hlFld-ContribAuthor ">Giorgio  Grosa</span>, <span class="hlFld-ContribAuthor ">Giovanni  Sorba</span>, <span class="hlFld-ContribAuthor ">Pier Luigi  Canonico</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Orsomando</span>, <span class="hlFld-ContribAuthor ">Salvatore  Cuzzocrea</span>, <span class="hlFld-ContribAuthor ">Armando A.  Genazzani</span>, <span class="hlFld-ContribAuthor ">Ubaldina  Galli</span>, and <span class="hlFld-ContribAuthor ">Gian Cesare  Tron</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1768-1792. <a href="https://doi.org/10.1021/acs.jmedchem.6b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BNovel%252BTriazole-Based%252BNicotinamide%252BPhosphoribosyltransferase%252B%252528NAMPT%252529%252BInhibitors%252BEndowed%252Bwith%252BAntiproliferative%252Band%252BAntiinflammatory%252BActivity%26aulast%3DTravelli%26aufirst%3DCristina%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D22092016%26date%3D22022017%26date%3D09032017%26date%3D06022017%26volume%3D60%26issue%3D5%26spage%3D1768%26epage%3D1792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mayuko  Akiu</span>, <span class="hlFld-ContribAuthor ">Takashi  Tsuji</span>, <span class="hlFld-ContribAuthor ">Yoshitaka  Sogawa</span>, <span class="hlFld-ContribAuthor ">Koji  Terayama</span>, <span class="hlFld-ContribAuthor ">Mika  Yokoyama</span>, <span class="hlFld-ContribAuthor ">Jun  Tanaka</span>, <span class="hlFld-ContribAuthor ">Daigo  Asano</span>, <span class="hlFld-ContribAuthor ">Ken  Sakurai</span>, <span class="hlFld-ContribAuthor ">Eduard  Sergienko</span>, <span class="hlFld-ContribAuthor ">E. Hampton  Sessions</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Gardell</span>, <span class="hlFld-ContribAuthor ">Anthony B.  Pinkerton</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>43 </em>, 128048. <a href="https://doi.org/10.1016/j.bmcl.2021.128048" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B1-%25255B2-%2525281-methyl-1H-pyrazol-5-yl%252529-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B1%25252C5-a%25255Dpyridin-6-yl%25255D-3-%252528pyridin-4-ylmethyl%252529urea%252Bas%252Ba%252Bpotent%252BNAMPT%252B%252528nicotinamide%252Bphosphoribosyltransferase%252529%252Bactivator%252Bwith%252Battenuated%252BCYP%252Binhibition%26aulast%3DAkiu%26aufirst%3DMayuko%26date%3D2021%26volume%3D43%26spage%3D128048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony B.  Pinkerton</span>, <span class="hlFld-ContribAuthor ">E.  Hampton Sessions</span>, <span class="hlFld-ContribAuthor ">Paul  Hershberger</span>, <span class="hlFld-ContribAuthor ">Patrick R.  Maloney</span>, <span class="hlFld-ContribAuthor ">Satyamaheshwar  Peddibhotla</span>, <span class="hlFld-ContribAuthor ">Meghan  Hopf</span>, <span class="hlFld-ContribAuthor ">Eduard  Sergienko</span>, <span class="hlFld-ContribAuthor ">Chen-Ting  Ma</span>, <span class="hlFld-ContribAuthor ">Layton H.  Smith</span>, <span class="hlFld-ContribAuthor ">Michael R.  Jackson</span>, <span class="hlFld-ContribAuthor ">Jun  Tanaka</span>, <span class="hlFld-ContribAuthor ">Takashi  Tsuji</span>, <span class="hlFld-ContribAuthor ">Mayuko  Akiu</span>, <span class="hlFld-ContribAuthor ">Steven E.  Cohen</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Nakamura</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Gardell</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of a Urea-containing Series of Nicotinamide Phosphoribosyltransferase (NAMPT) Activators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em> </em>, 128007. <a href="https://doi.org/10.1016/j.bmcl.2021.128007" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOptimization%252Bof%252Ba%252BUrea-containing%252BSeries%252Bof%252BNicotinamide%252BPhosphoribosyltransferase%252B%252528NAMPT%252529%252BActivators%26aulast%3DPinkerton%26aufirst%3DAnthony%2BB.%26date%3D2021%26spage%3D128007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nady  Braidy</span>, <span class="hlFld-ContribAuthor ">Maria  Villalva</span>. </span><span class="cited-content_cbyCitation_article-title">NAD+: a crucial regulator of sirtuin activity in aging. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 23-35. <a href="https://doi.org/10.1016/B978-0-12-814118-2.00008-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-814118-2.00008-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-814118-2.00008-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-814118-2.00008-2%26sid%3Dliteratum%253Aachs%26atitle%3DNAD%25252B%25253A%252Ba%252Bcrucial%252Bregulator%252Bof%252Bsirtuin%252Bactivity%252Bin%252Baging%26aulast%3DBraidy%26aufirst%3DNady%26date%3D2021%26spage%3D23%26epage%3D35%26pub%3DElsevier%26atitle%3DSirtuin%252BBiology%252Bin%252BMedicine%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. V.  Fedoseev</span>, <span class="hlFld-ContribAuthor ">M. Yu.  Belikov</span>, <span class="hlFld-ContribAuthor ">O. V.  Ershov</span>, <span class="hlFld-ContribAuthor ">V. A.  Tafeenko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4-Halofuro[3,4-c]pyridin-3(1H)-ones from 2-Halopyridine-3,4-dicarbonitriles. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>56 </em>
                                    (9)
                                     , 1540-1544. <a href="https://doi.org/10.1134/S1070428020090067" title="DOI URL">https://doi.org/10.1134/S1070428020090067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428020090067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428020090067%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B4-Halofuro%25255B3%25252C4-c%25255Dpyridin-3%2525281H%252529-ones%252Bfrom%252B2-Halopyridine-3%25252C4-dicarbonitriles%26aulast%3DFedoseev%26aufirst%3DS.%2BV.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D9%26spage%3D1540%26epage%3D1544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ubaldina  Galli</span>, <span class="hlFld-ContribAuthor ">Giorgia  Colombo</span>, <span class="hlFld-ContribAuthor ">Cristina  Travelli</span>, <span class="hlFld-ContribAuthor ">Gian Cesare  Tron</span>, <span class="hlFld-ContribAuthor ">Armando A.  Genazzani</span>, <span class="hlFld-ContribAuthor ">Ambra A.  Grolla</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00656" title="DOI URL">https://doi.org/10.3389/fphar.2020.00656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00656%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DRecent%252BAdvances%252Bin%252BNAMPT%252BInhibitors%25253A%252BA%252BNovel%252BImmunotherapic%252BStrategy%26aulast%3DGalli%26aufirst%3DUbaldina%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fikriye  Ozgencil</span>, <span class="hlFld-ContribAuthor ">Gokcen  Eren</span>, <span class="hlFld-ContribAuthor ">Yesim  Ozkan</span>, <span class="hlFld-ContribAuthor ">Sezen  Guntekin-Ergun</span>, <span class="hlFld-ContribAuthor ">Rengul  Cetin-Atalay</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (1)
                                     , 115217. <a href="https://doi.org/10.1016/j.bmc.2019.115217" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115217%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bsmall-molecule%252Burea%252Bderivatives%252Bas%252Bnovel%252BNAMPT%252Binhibitors%252Bvia%252Bpharmacophore-based%252Bvirtual%252Bscreening%26aulast%3DOzgencil%26aufirst%3DFikriye%26date%3D2020%26volume%3D28%26issue%3D1%26spage%3D115217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Travelli</span>, <span class="hlFld-ContribAuthor ">Silvio  Aprile</span>, <span class="hlFld-ContribAuthor ">Daiana  Mattoteia</span>, <span class="hlFld-ContribAuthor ">Giorgia  Colombo</span>, <span class="hlFld-ContribAuthor ">Nausicaa  Clemente</span>, <span class="hlFld-ContribAuthor ">Eugenio  Scanziani</span>, <span class="hlFld-ContribAuthor ">Salvatore  Terrazzino</span>, <span class="hlFld-ContribAuthor ">Maria Alessandra  Alisi</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Polenzani</span>, <span class="hlFld-ContribAuthor ">Giorgio  Grosa</span>, <span class="hlFld-ContribAuthor ">Armando A.  Genazzani</span>, <span class="hlFld-ContribAuthor ">Gian Cesare  Tron</span>, <span class="hlFld-ContribAuthor ">Ubaldina  Galli</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111576. <a href="https://doi.org/10.1016/j.ejmech.2019.111576" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111576%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bpotent%252Btriazolylpyridine%252Bnicotinamide%252Bphosphoribosyltransferase%252B%252528NAMPT%252529%252Binhibitors%252Bbearing%252Ba%252B1%25252C2%25252C3-triazole%252Btail%252Bgroup%26aulast%3DTravelli%26aufirst%3DCristina%26date%3D2019%26volume%3D181%26spage%3D111576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhito  Harada</span>, <span class="hlFld-ContribAuthor ">Jun  Mizukami</span>, <span class="hlFld-ContribAuthor ">Sho  Kadowaki</span>, <span class="hlFld-ContribAuthor ">Isamu  Matsuda</span>, <span class="hlFld-ContribAuthor ">Takashi  Watanabe</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Oe</span>, <span class="hlFld-ContribAuthor ">Yoshitoshi  Kodama</span>, <span class="hlFld-ContribAuthor ">Kenta  Aoki</span>, <span class="hlFld-ContribAuthor ">Katsunori  Suwa</span>, <span class="hlFld-ContribAuthor ">Sumiaki  Fukuda</span>, <span class="hlFld-ContribAuthor ">Shinji  Yata</span>, <span class="hlFld-ContribAuthor ">Takashi  Inaba</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel and potent GPR119 agonists with a spirocyclic structure. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (7)
                                     , 1228-1233. <a href="https://doi.org/10.1016/j.bmcl.2018.02.044" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.02.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.02.044%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Band%252Bpotent%252BGPR119%252Bagonists%252Bwith%252Ba%252Bspirocyclic%252Bstructure%26aulast%3DHarada%26aufirst%3DKazuhito%26date%3D2018%26volume%3D28%26issue%3D7%26spage%3D1228%26epage%3D1233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tara L.S.  Kishbaugh</span>, <span class="hlFld-ContribAuthor ">Katherine  Lehman</span>. </span><span class="cited-content_cbyCitation_article-title">Six-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 383-439. <a href="https://doi.org/10.1016/B978-0-08-102310-5.00012-6" title="DOI URL">https://doi.org/10.1016/B978-0-08-102310-5.00012-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102310-5.00012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102310-5.00012-6%26sid%3Dliteratum%253Aachs%26atitle%3DSix-Membered%252BRing%252BSystems%26aulast%3DKishbaugh%26aufirst%3DTara%2BL.S.%26date%3D2017%26spage%3D383%26epage%3D439%26pub%3DElsevier%26date%3D2017%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1a" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0002.jpeg" id="rightTab-GRAPHIC-d25e349-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) NAM-NAD recycling pathway. (b) NMN-like phosphoribose adducts generated by coincubating NAMPT inhibitors <b>1</b>, <b>2</b>, <b>3</b>, or <b>7</b> with NAMPT, ATP, and PRPP.<a onclick="showRef(event, 'cit9a cit9c ref20 ref21'); return false;" href="javascript:void(0);" class="ref cit9a cit9c ref20 ref21">(9a, 9c, 20, 21)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig1a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0003.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of previously reported NAMPT inhibitors.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0004.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlay of indicated ligands from previously reported X-ray structures in complex with NAMPT. The proteins are omitted for clarity. PDB accession codes are as follows: <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFO">4KFO</a>;<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a><b>2a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR5">4JR5</a>;<a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">(9a)</a><b>3</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O13">4O13</a>;<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>4</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LVG">4LVG</a>;<a onclick="showRef(event, 'cit9d'); return false;" href="javascript:void(0);" class="ref cit9d">(9d)</a><b>5a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFP">4KFP</a>;<a onclick="showRef(event, 'cit9e'); return false;" href="javascript:void(0);" class="ref cit9e">(9e)</a><b>6a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WQ6">4WQ6</a>;<a onclick="showRef(event, 'cit9f'); return false;" href="javascript:void(0);" class="ref cit9f">(9f)</a><b>8</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GVJ">2GVJ</a>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<sup>1</sup>) X-ray structures of compounds <b>2</b>, <b>5</b>, and <b>6</b> in complex with NAMPT were not available at the time of this work, thus, structures of related analogues <b>2a</b>, <b>5a</b>, and <b>6a</b> were used as surrogates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4a" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0005.jpeg" id="rightTab-GRAPHIC-d25e1503-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) X-ray crystal structure of <b>41</b> in complex with NAMPT. The ligand <b>41</b> is shown in orange. Protein side chains forming interactions with the ligand are shown in teal. Hydrogen bonding interactions are shown as dashed lines. Crystallographic waters forming H-bonds with the ligand are shown as red spheres. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT">5KIT</a>, resolution = 1.60 Å. (b) Overlay of the small molecule ligand (<b>41</b>, orange) from PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT">5KIT</a> (<b>37</b>) with the ligands from previously reported structures <b>1</b> (green) <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFO">4KFO</a>,<a onclick="showRef(event, 'cit9b'); return false;" href="javascript:void(0);" class="ref cit9b">(9b)</a> and <b>8</b> (white) <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GVJ">2GVJ</a>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The location of the nucleophilic N in the left-hand side of each ligand is circled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig4a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0006.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Plasma concentration–time profiles of compound <b>68</b> after intravenous and oral administration in male Sprague–Dawley rats and male beagle dogs. Each time point shows the mean plasma concentration (± standard deviation) from three separate animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0007.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plasma concentration–time profile of compound <b>68</b> after oral administration (25 mg/kg BID) in female NCR nude mice (black line). Each time point shows the mean plasma concentration (± standard deviation) from three separate animals. Compound <b>68</b> was formulated in EtOH/PEG400/H<sub>2</sub>O (10:60:30) prior to dosing. The HT1080 cell-based potency is included for reference (blue lines).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0008.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy and body weight change after treatment with vehicle (60% PEG400/30% H<sub>2</sub>O/10% EtOH) or compound <b>68</b> (25 and 50 mg/kg BID, PO) for five consecutive days in the HT-1080 human fibrosarcoma xenograft model. Ten female NCR tumor-bearing mice were used per group. Data reflects the mean tumor volume or % body weight change (± standard error of mean). ***<i>p</i> < 0.001 for compound <b>68</b> treated vs vehicle group based on Student’s <i>t</i> test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Analogue <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaH, PMBCl, DMA, 0–25 °C, 20 h, 87%; (ii) NIS, CH<sub>3</sub>CN, 30 °C, 20 h, 97%; (iii) (a) <i>n</i>-BuLi, THF, – 78 °C, 5 min, (b) ethyl formate −78 °C, 10 min, 37%; (iv) 2-azidoacetate, NaOEt, EtOH, 0 °C, 2 h, 39%; (v) xylene, 130 °C, 3 h, 42%; (vi) KOH, EtOH, H<sub>2</sub>O, 25 °C, 20 h; (vii) <b>77</b>, EDCI, HOBt, DIPEA, DMF, 50 °C, 1 h, 84% (2 steps); (viii) TFA, DCM, 25 °C, 2 h, 45%; (ix) H<sub>2</sub>, Pd/C (10%), KOAc, MeOH, 25 °C, 20 h, 13%.</p></p></figure><figure data-id="sch2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Analogue <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) SOCl<sub>2</sub>, DMF, toluene, 80 °C, 3 h; (ii) HN(<i>i</i>-Pr)<sub>2</sub>, DCM, 0–25 °C, 50 min, 82% (2 steps); (iii) LDA, DMF, Et<sub>2</sub>O, −50 °C, 3.5 h, then 25 °C, 16 h, 89%; (iv) NaBH<sub>4</sub>, EtOH, 30 °C, 50 min, 97%; (v) 6 M HCl<sub>aq</sub>, 100 °C, 30 min, 80%; (vi) NaBH<sub>4</sub>, EtOH, 25 °C, 1 h, 39%; (vii) SOCl<sub>2</sub>, DCM, 25 °C, 1 h; (viii) H<sub>2</sub>NDMB, DIPEA, DCM, 25 °C, 16 h, 52% (2 steps); (ix) Pd<sub>2</sub>(dba)<sub>3</sub>·CHCl<sub>3</sub>, <i>tert</i>-BuONa, BINAP, H<sub>2</sub>NDMB, toluene, 80 °C, 16 h, 70%; (x) (a) TFA, 90 °C, 16 h, (b) Na<sub>2</sub>CO<sub>3aq</sub>; (xi) 4-NPCOCl, toluene, 120 °C, 30 min, 96%; (xii) <b>90</b>, EtOH, 90 °C, 1 h, 44% (2 steps).</p></p></figure><figure data-id="sch3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Analogue <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) NaH, DMF, 0–25 °C, 1 h, (b) methoxymethyl bromide, 10–25 °C, 2 h, 75%; (ii) <i>tert</i>-BuLi, DMF, THF, −78 °C, 50 min; (iii) 3 M HCl, THF, 60 °C, 1 h, 64% (2 steps); (iv) methyl 2-bromoacetate, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 2 h, 66%; (v) <i>tert</i>-BuOK, THF, 0–25 °C, 2 h; (vi) NaOH<sub>aq</sub>, THF, 60 °C, 1 h; (vii) <b>91</b>, EDCI, HOBt, DIPEA, 25 °C, 16 h, 23% (3 steps); (viii) DPINH, Pd<sub>2</sub>(dba)<sub>3</sub>·dba, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 120 °C, 3 h; (ix) HCl<sub>aq</sub>, THF, 25 °C, 30 min, 47% (2 steps).</p></p></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Analogues <b>21</b>–<b>28</b> and (+)-<b>30</b>, (+)-<b>31</b>, <b>32</b>, (+)-<b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) RNH<sub>2</sub>, EDCI, HOBt, DIPEA, DMF, 25 °C, 16 h, or RNH<sub>2</sub>, HBTU, TEA, DMF, 25 °C, 16 h, 8–73%.</p></p></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Analogues (±)-<b>35</b>–(±)-<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: EDCI, HOBt, TEA, DMF, 25 °C, 16 h, 30–61%.</p></p></figure><figure data-id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Preparation of Analogues (±)-<b>34</b> and (±)-<b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) For compound (±)-<b>34</b>: (a) RR<sub>1</sub>NH, TEA, 4-NPCOCl, DCM, 0 °C, 30 min, (b) (±)-<b>104</b>, TEA, DCM, 0–25 °C, 2 h, 34%. For compound (±)<b>-40</b>: (a) (±)-<b>104</b>, TEA, 4-NPCOCl, DCM, 0–25 °C, 2 h, (b) RR<sub>1</sub>NH, TEA, DCM, 0–5 °C, 5 min, 54%.</p></p></figure><figure data-id="sch7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Preparation of Intermediates <b>107</b>, <b>108</b>, and <b>110</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) For compound <b>107</b>: (a) <b>105</b>, MeMgBr, THF, −20 °C to 25 °C, 16 h, (b) 4-NPOCl, pyridine, DCM, 0–25 °C, 2 h, 37% (2 steps). For compound <b>108</b>: (a) <b>106</b>, MeLi, THF, −40 °C to 0 °C, 2 h, (b) 4-NPOCl, 0–5 °C, 3 h, 22%; (ii) (a) Na, THF, 70 °C, 12 h, (b) CO<sub>2</sub>, hexane, 25 °C, 1.5 h, (c) MsCl, 0–5 °C, 2 h, 12%.</p></p></figure><figure data-id="sch8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Preparation of Analogues (±)-<b>43</b>–(±)-<b>66</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) HCl, MeOH, 25 °C, 2 h; (ii) carboxylic acid, EDCI, HOBt, DIPEA, DMF, 25 °C, 16 h, 17–74%; (iii) 2-isocyanato-2-methylpropane, TEA, DCM, 0–25 °C, 3 h, 15%; (iv) 2-phenylacetaldehyde, NaBH(OAc)<sub>3</sub>, acetic acid, DCM, 25 °C, 18 h, 10%; (v) (±)-<b>62</b>, (±)-<b>63</b>, (±)-<b>66</b>, one of isopropyl chloroformate, ethyl chloroformate, or <b>108</b>, and TEA, DCM, 0–25 °C, 2–3 h, 25–44%; (±)-<b>64</b>, <b>107</b>, TEA, EtOH, 80 °C, 3 h, 2%; (±)-<b>65</b>, <b>110</b>, NaOH, THF/H<sub>2</sub>O, 35 °C, 5 h, 32%.</p></p></figure><figure data-id="sch9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0017.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Preparation of Intermediates <b>119</b> and <b>122</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (a) (<i>S</i>)-(−)-1-phenylethanamine, HATU, DIPEA, DMF, 0–25 °C, 16 h, 46%, (b) diastereomers separated by chiral SFC; (ii) (a) HCl, MeOH (saturated solution), 0–25 °C, 16 h, (b) 2 M NaOH<sub>aq</sub>; (iii) (a) BH<sub>3</sub>·THF, THF, 25 °C to reflux, 16 h, (b) 5% HCl<sub>aq</sub>, reflux, 4 h, (c) 10% NaOH<sub>aq</sub>; (iv) Boc<sub>2</sub>O, 10% NaOH<sub>aq</sub>, THF, 0–25 °C, 16 h, 29% (3 steps); (v) H<sub>2</sub> (5 atm), Pd(OH)<sub>2</sub> (20% on C), MeOH, 25 °C, 16 h, 82%.</p></p></figure><figure data-id="sch10" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0018.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Preparation of Intermediate <b>127</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/large/jm-2016-00697p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00697&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) MeOH, H<sub>2</sub>SO<sub>4</sub>, 25 °C to reflux, 16 h, 73%; (ii) (a) NaBD<sub>4</sub>, EtOD, CaCl<sub>2</sub>, 0–10 °C, 3 h, (b) HCl, EtOH (saturated solution), 0–10 °C, 2 h, 79%; (iii) (a) CH<sub>3</sub>SO<sub>2</sub>Cl, TEA, DCM, 0 °C, 1 h, (b) H<sub>2</sub>NDMB, DIPEA, 0–25 °C, 8 h, 24%; (iv) (a) CF<sub>3</sub>COOD, 80 °C, 10 h, (b) DCM, HCl (saturated solution), 0 °C, 30 min, quant.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i122">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Di Stefano, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manerba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vettraino, M.</span><span> </span><span class="NLM_article-title">NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2918</span><span class="NLM_x">–</span> <span class="NLM_lpage">2929</span><span class="refDoi"> DOI: 10.2174/15680266113136660207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F15680266113136660207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=24171774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFelur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=2918-2929&author=G.+Di+Stefanoauthor=M.+Manerbaauthor=M.+Vettraino&title=NAD+metabolism+and+functions%3A+a+common+therapeutic+target+for+neoplastic%2C+metabolic+and+neurodegenerative+diseases&doi=10.2174%2F15680266113136660207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases</span></div><div class="casAuthors">Di Stefano, Giuseppina; Manerba, Marcella; Vettraino, Marina</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2918-2929</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years the study of NAD (NAD) biochem. has been the focus of attention for many researchers.  Although the role of NAD in cellular metab. and in redox reactions had been recognized for over a century, it was also during these recent studies that the precise identification of all NAD biosynthetic routes was achieved and that the variety of NAD controlled cellular processes began to emerge.  Being vital not only for energy transduction, but also for intracellular signaling pathways, this pyridine nucleotide can be considered the most important link between energetic and regulatory processes.  The control of such important events suggested NAD as a possible therapeutic target for the control of different pathol. states, including metabolic disorders and neoplastic transformation.  This review briefly summarizes the recent advances achieved in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYF7d1FNQy7bVg90H21EOLACvtfcHk0lhB3pqvF_mtHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFelur%252FL&md5=653133f0c34440c26b5d3ca799441e32</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.2174%2F15680266113136660207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113136660207%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BStefano%26aufirst%3DG.%26aulast%3DManerba%26aufirst%3DM.%26aulast%3DVettraino%26aufirst%3DM.%26atitle%3DNAD%2520metabolism%2520and%2520functions%253A%2520a%2520common%2520therapeutic%2520target%2520for%2520neoplastic%252C%2520metabolic%2520and%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D2918%26epage%3D2929%26doi%3D10.2174%2F15680266113136660207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dölle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skoge, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanlinden, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, M.</span><span> </span><span class="NLM_article-title">NAD biosynthesis in humans - enzymes, metabolites and therapeutic aspects</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2907</span><span class="NLM_x">–</span> <span class="NLM_lpage">2917</span><span class="refDoi"> DOI: 10.2174/15680266113136660206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F15680266113136660206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=24171775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFeks77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=2907-2917&author=C.+D%C3%B6lleauthor=R.+H.+Skogeauthor=M.+R.+Vanlindenauthor=M.+Ziegler&title=NAD+biosynthesis+in+humans+-+enzymes%2C+metabolites+and+therapeutic+aspects&doi=10.2174%2F15680266113136660206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects</span></div><div class="casAuthors">Dolle, Christian; Skoge, Renate Hvidsten; Van Linden, Magali R.; Ziegler, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2907-2917</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  NAD plays a major role in all cells as substrate for signal transduction and as cofactor in metabolic redox reactions.  Since NAD-dependent signaling involves degrdn. of the nucleotide, continuous restoration of cellular NAD pools is essential.  Moreover, NAD-dependent signaling reactions, which include ADP-ribosylation, protein deacetylation by sirtuins and calcium messenger synthesis, are regulated by NAD availability.  Consequently, perturbations of NAD supply can have severe consequences and, in fact, have been assocd. with major human diseases such as age- and dietinduced disorders, neurodegenerative diseases and cancer.  Given the increasing awareness of the biol. roles of NAD, the routes, mol. mechanisms and regulation of NAD biosynthesis have been the subject of intense research over the last decade.  Impressive progress has been made regarding the mol. identification, functional and structural characterization as well as regulation of the human NAD biosynthetic enzymes.  Exciting therapeutic concepts have emerged, which aim at modulation of NAD availability by interfering with the biosynthetic network to prevent, reduce or reverse pathol. conditions.  Since there are several entry points into NAD synthesis, including the known vitamin B3 precursors nicotinamide and nicotinic acid, targeted nutritional supplementation is likely to have beneficial effects in various diseases.  On the other hand, inhibition of NAD synthesis promotes cell death and has emerged as a therapeutic concept for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN9ejhz87J57Vg90H21EOLACvtfcHk0lhB3pqvF_mtHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFeks77O&md5=be7e86b35a41ff467da33f6d96b0a0e8</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.2174%2F15680266113136660206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266113136660206%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6lle%26aufirst%3DC.%26aulast%3DSkoge%26aufirst%3DR.%2BH.%26aulast%3DVanlinden%26aufirst%3DM.%2BR.%26aulast%3DZiegler%26aufirst%3DM.%26atitle%3DNAD%2520biosynthesis%2520in%2520humans%2520-%2520enzymes%252C%2520metabolites%2520and%2520therapeutic%2520aspects%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D2907%26epage%3D2917%26doi%3D10.2174%2F15680266113136660206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Amé, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlehauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Murcia, G.</span><span> </span><span class="NLM_article-title">The PARP superfamily</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">893</span><span class="refDoi"> DOI: 10.1002/bies.20085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1002%2Fbies.20085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=15273990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2004&pages=882-893&author=J.-C.+Am%C3%A9author=C.+Spenlehauerauthor=G.+de+Murcia&title=The+PARP+superfamily&doi=10.1002%2Fbies.20085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP superfamily</span></div><div class="casAuthors">Ame, Jean-Christophe; Spenlehauer, Catherine; de Murcia, Gilbert</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">882-893</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribosyl)ation is an immediate DNA-damage-dependent post-translational modification of histones and other nuclear proteins that contributes to the survival of injured proliferating cells.  Poly(ADP-ribose) polymerases (PARPs) now constitute a large family of 18 proteins, encoded by different genes and displaying a conserved catalytic domain in which PARP-1 (113 kDa), the founding member, and PARP-2 (62 kDa) are so far the sole enzymes whose catalytic activity has been shown to be immediately stimulated by DNA strand breaks.  A large repertoire of sequences encoding novel PARPs now extends considerably the field of poly(ADP-ribosyl)ation reactions to various aspects of the cell biol. including cell proliferation and cell death.  Some of these new members interact with each other, share common partners and common subcellular localizations suggesting possible fine tuning in the regulation of this post-translational modification of proteins.  This review summarizes the present knowledge of this emerging superfamily, which might ultimately improve pharmacol. strategies to enhance both antitumor efficacy and the treatment of a no. of inflammatory and neurodegenerative disorders.  A provisional nomenclature is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkP1P6SYh67Vg90H21EOLACvtfcHk0li_Khx_dko6Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1CqtLk%253D&md5=892151993f54e3c1a03019001a365fbf</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1002%2Fbies.20085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.20085%26sid%3Dliteratum%253Aachs%26aulast%3DAm%25C3%25A9%26aufirst%3DJ.-C.%26aulast%3DSpenlehauer%26aufirst%3DC.%26aulast%3Dde%2BMurcia%26aufirst%3DG.%26atitle%3DThe%2520PARP%2520superfamily%26jtitle%3DBioEssays%26date%3D2004%26volume%3D26%26spage%3D882%26epage%3D893%26doi%3D10.1002%2Fbies.20085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kim, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1951</span><span class="NLM_x">–</span> <span class="NLM_lpage">1967</span><span class="refDoi"> DOI: 10.1101/gad.1331805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1101%2Fgad.1331805" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=1951-1967&author=M.+Y.+Kimauthor=T.+Zhangauthor=W.+L.+Kraus&title=Poly%28ADP-ribosyl%29ation+by+PARP-1%3A+%E2%80%98PAR-laying%E2%80%99+NAD%2B+into+a+nuclear+signal&doi=10.1101%2Fgad.1331805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1101%2Fgad.1331805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1331805%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DPoly%2528ADP-ribosyl%2529ation%2520by%2520PARP-1%253A%2520%25E2%2580%2598PAR-laying%25E2%2580%2599%2520NAD%252B%2520into%2520a%2520nuclear%2520signal%26jtitle%3DGenes%2520Dev.%26date%3D2005%26volume%3D19%26spage%3D1951%26epage%3D1967%26doi%3D10.1101%2Fgad.1331805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Houtkooper, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirinen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auwerx, J.</span><span> </span><span class="NLM_article-title">Sirtuins as regulators of metabolism and healthspan</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">–</span> <span class="NLM_lpage">238</span><span class="refDoi"> DOI: 10.1038/nrm3293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnrm3293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22395773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=225-238&author=R.+H.+Houtkooperauthor=E.+Pirinenauthor=J.+Auwerx&title=Sirtuins+as+regulators+of+metabolism+and+healthspan&doi=10.1038%2Fnrm3293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Sirtuins as regulators of metabolism and healthspan</span></div><div class="casAuthors">Houtkooper, Riekelt H.; Pirinen, Eija; Auwerx, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">225-238</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the beginning of the century, the mammalian sirtuin protein family (comprising SIRT1-SIRT7) has received much attention for its regulatory role, mainly in metab. and ageing.  Sirtuins act in different cellular compartments: they deacetylate histones and several transcriptional regulators in the nucleus, but also specific proteins in other cellular compartments, such as in the cytoplasm and in mitochondria.  As a consequence, sirtuins regulate fat and glucose metab. in response to physiol. changes in energy levels, thereby acting as crucial regulators of the network that controls energy homeostasis and as such dets. healthspan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGF2VZDiGC9LVg90H21EOLACvtfcHk0liA_ymS1r_T0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOktbw%253D&md5=3e7e0a6b23e8d7d4ad7be32bdce28d96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3293%26sid%3Dliteratum%253Aachs%26aulast%3DHoutkooper%26aufirst%3DR.%2BH.%26aulast%3DPirinen%26aufirst%3DE.%26aulast%3DAuwerx%26aufirst%3DJ.%26atitle%3DSirtuins%2520as%2520regulators%2520of%2520metabolism%2520and%2520healthspan%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26spage%3D225%26epage%3D238%26doi%3D10.1038%2Fnrm3293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Galli, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massarotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhfouri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahimian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tron, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genazzani, A. A.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6279</span><span class="NLM_x">–</span> <span class="NLM_lpage">6296</span><span class="refDoi"> DOI: 10.1021/jm4001049</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001049" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6279-6296&author=U.+Galliauthor=C.+Travelliauthor=A.+Massarottiauthor=G.+Fakhfouriauthor=R.+Rahimianauthor=G.+C.+Tronauthor=A.+A.+Genazzani&title=Medicinal+chemistry+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors&doi=10.1021%2Fjm4001049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors</span></div><div class="casAuthors">Galli, Ubaldina; Travelli, Cristina; Massarotti, Alberto; Fakhfouri, Gohar; Rahimian, Reza; Tron, Gian Cesare; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6279-6296</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in the replenishment of the NAD pool in cells.  This in turn makes this enzyme an important player in bioenergetics and in the regulation of NAD-using enzymes, such as PARPs and sirtuins.  Furthermore, there is now ample evidence that NAMPT is secreted and has a role as a cytokine.  An important role of either the intracellular or extracellular form of NAMPT has been shown in cancer, inflammation, and metabolic diseases.  The first NAMPT inhibitors (FK866 and CHS828) have already entered clin. trials, and a surge in interest in the synthesis of novel mols. has occurred.  The present review summarizes the recent progress in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuKFhS6T0zD7Vg90H21EOLACvtfcHk0liA_ymS1r_T0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGisLk%253D&md5=4022c7632cc0b42d62e0fc334d24fefa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm4001049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001049%26sid%3Dliteratum%253Aachs%26aulast%3DGalli%26aufirst%3DU.%26aulast%3DTravelli%26aufirst%3DC.%26aulast%3DMassarotti%26aufirst%3DA.%26aulast%3DFakhfouri%26aufirst%3DG.%26aulast%3DRahimian%26aufirst%3DR.%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DMedicinal%2520chemistry%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6279%26epage%3D6296%26doi%3D10.1021%2Fjm4001049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bieganowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, C.</span><span> </span><span class="NLM_article-title">Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1016/S0092-8674(04)00416-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2FS0092-8674%2804%2900416-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=15137942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlCqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=495-502&author=P.+Bieganowskiauthor=C.+Brenner&title=Discoveries+of+nicotinamide+riboside+as+a+nutrient+and+conserved+NRK+genes+establish+a+Preiss-Handler+independent+route+to+NAD%2B+in+fungi+and+humans&doi=10.1016%2FS0092-8674%2804%2900416-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans</span></div><div class="casAuthors">Bieganowski, Pawel; Brenner, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">495-502</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">NAD+ is essential for life in all organisms, both as a coenzyme for oxidoreductases and as a source of ADPribosyl groups used in various reactions, including those that retard aging in exptl. systems.  Nicotinic acid and nicotinamide were defined as the vitamin precursors of NAD+ in Elvehjem's classic discoveries of the 1930s.  The accepted view of eukaryotic NAD+ biosynthesis, that all anabolism flows through nicotinic acid mononucleotide, was challenged exptl. and revealed that nicotinamide riboside is an unanticipated NAD+ precursor in yeast.  Nicotinamide riboside kinases from yeast and humans essential for this pathway were identified and found to be highly specific for phosphorylation of nicotinamide riboside and the cancer drug tiazofurin.  Nicotinamide riboside was discovered as a nutrient in milk, suggesting that nicotinamide riboside is a useful compd. for elevation of NAD+ levels in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTCsziN61hR7Vg90H21EOLACvtfcHk0li0hssZAKEF0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlCqtrY%253D&md5=8a7ba85e29a8729b5ffdf86dbbe9ef79</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900416-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900416-7%26sid%3Dliteratum%253Aachs%26aulast%3DBieganowski%26aufirst%3DP.%26aulast%3DBrenner%26aufirst%3DC.%26atitle%3DDiscoveries%2520of%2520nicotinamide%2520riboside%2520as%2520a%2520nutrient%2520and%2520conserved%2520NRK%2520genes%2520establish%2520a%2520Preiss-Handler%2520independent%2520route%2520to%2520NAD%252B%2520in%2520fungi%2520and%2520humans%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D495%26epage%3D502%26doi%3D10.1016%2FS0092-8674%2804%2900416-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Magni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsomando, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffelli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggieri, S.</span><span> </span><span class="NLM_article-title">Enzymology of mammalian NAD metabolism in health and disease</span> <span class="citation_source-journal">Front. Biosci., Landmark Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">6135</span><span class="NLM_x">–</span> <span class="NLM_lpage">6154</span><span class="refDoi"> DOI: 10.2741/3143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2741%2F3143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=18508649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVOisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=6135-6154&author=G.+Magniauthor=G.+Orsomandoauthor=N.+Raffelliauthor=S.+Ruggieri&title=Enzymology+of+mammalian+NAD+metabolism+in+health+and+disease&doi=10.2741%2F3143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymology of mammalian NAD metabolism in health and disease</span></div><div class="casAuthors">Magni, Giulio; Orsomando, Giuseppe; Raffelli, Nadia; Ruggieri, Silverio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Bioscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6135-6154</span>CODEN:
                <span class="NLM_cas:coden">FRBIF6</span>;
        ISSN:<span class="NLM_cas:issn">1093-4715</span>.
    
            (<span class="NLM_cas:orgname">Frontiers in Bioscience</span>)
        </div><div class="casAbstract">A review.  Mounting evidence attests to the paramount importance of the non-redox NAD functions.  Indeed, NAD homeostasis is related to the free radicals-mediated prodn. of reactive oxygen species responsible for irreversible cellular damage in infectious disease, diabetes, inflammatory syndromes, neurodegeneration and cancer.  Because the cellular redox status depends on both the abs. concn. of pyridine dinucleotides and their resp. ratios of oxidized and reduced forms (i.e., NAD/NADH and NADP/NADPH), it is conceivable that an altered regulation of the synthesis and degrdn. of NAD impairs the cell redox state and likely contributes to the mechanisms underlying the pathogenesis of the above mentioned diseases.  Taking into account the recent appearance in the literature of comprehensive reviews covering different aspects of the significance of NAD metab., with particular attention to the enzymes involved in NAD cleavage, this monograph includes the most recent results on NAD biosynthesis in mammals and humans.  Due to recent findings on nicotinamide riboside as a nutrient, its inclusion under "niacins" is proposed.  Here, the enzymes involved in the de novo and reutilization pathways are overviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvX2dsB8dbbrVg90H21EOLACvtfcHk0li0hssZAKEF0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVOisb0%253D&md5=aa02e7cb092b9e7449b5bce49e97fa82</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.2741%2F3143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2741%252F3143%26sid%3Dliteratum%253Aachs%26aulast%3DMagni%26aufirst%3DG.%26aulast%3DOrsomando%26aufirst%3DG.%26aulast%3DRaffelli%26aufirst%3DN.%26aulast%3DRuggieri%26aufirst%3DS.%26atitle%3DEnzymology%2520of%2520mammalian%2520NAD%2520metabolism%2520in%2520health%2520and%2520disease%26jtitle%3DFront.%2520Biosci.%252C%2520Landmark%2520Ed.%26date%3D2008%26volume%3D13%26spage%3D6135%26epage%3D6154%26doi%3D10.2741%2F3143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chiarugi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, M.</span><span> </span><span class="NLM_article-title">The NAD metabolome--a key determinant of cancer cell biology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">752</span><span class="refDoi"> DOI: 10.1038/nrc3340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnrc3340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=23018234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWnurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=741-752&author=A.+Chiarugiauthor=C.+Dolleauthor=R.+Feliciauthor=M.+Ziegler&title=The+NAD+metabolome%2D%2Da+key+determinant+of+cancer+cell+biology&doi=10.1038%2Fnrc3340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">The NAD metabolome - a key determinant of cancer cell biology</span></div><div class="casAuthors">Chiarugi, Alberto; Doelle, Christian; Felici, Roberta; Ziegler, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">741-752</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  NAD is a vital mol. in all organisms.  It is a key component of both energy and signal transduction - processes that undergo crucial changes in cancer cells.  NAD+-dependent signalling pathways are many and varied, and they regulate fundamental events such as transcription, DNA repair, cell cycle progression, apoptosis and metab.  Many of these processes have been linked to cancer development.  Given that NAD+-dependent signalling reactions involve the degrdn. of the mol., permanent nucleotide resynthesis through different biosynthetic pathways is crucial for incessant cancer cell proliferation.  This necessity supports the targeting of NAD metab. as a new therapeutic concept for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopGSV9JpM_CLVg90H21EOLACvtfcHk0li0hssZAKEF0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWnurvP&md5=5111918068b9362f6932cff3b3ebd824</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1038%2Fnrc3340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3340%26sid%3Dliteratum%253Aachs%26aulast%3DChiarugi%26aufirst%3DA.%26aulast%3DDolle%26aufirst%3DC.%26aulast%3DFelici%26aufirst%3DR.%26aulast%3DZiegler%26aufirst%3DM.%26atitle%3DThe%2520NAD%2520metabolome--a%2520key%2520determinant%2520of%2520cancer%2520cell%2520biology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D741%26epage%3D752%26doi%3D10.1038%2Fnrc3340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span> </span><span class="NLM_article-title">Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6123</span><span class="NLM_x">–</span> <span class="NLM_lpage">6132</span><span class="refDoi"> DOI: 10.2174/138161212803582531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F138161212803582531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22934941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVOisbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=6123-6132&author=J.+Heauthor=C.+Tuauthor=M.+Liauthor=S.+Wangauthor=X.+Guanauthor=J.+Linauthor=Z.+Li&title=Nampt%2FVisfatin%2FPBEF%3A+a+functionally+multi-faceted+protein+with+a+pivotal+role+in+malignant+tumors&doi=10.2174%2F138161212803582531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Nampt/Visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors</span></div><div class="casAuthors">He, Jieyu; Tu, Chao; Li, Mengjun; Wang, Shalong; Guan, Xiaomei; Lin, Jianfeng; Li, Zhihong</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">6123-6132</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nampt/Visfatin/PBEF is a primary, rate-limiting enzyme involved in NAD+ biosynthesis, which serves as a pivotal substance for proteins, and is required for cell growth, survival, DNA replication and repair and energy metab.  Growing researches have elucidated that it is a pleiotropic protein that functions not only as an enzyme, but also as an adipocytokine, a growth factor, and a cytokine.  Addnl., accumulated evidences indicate that Nampt is correlated to various malignant tumors, and complicated mechanisms are proposed to be involved in the carcinogenesis, progression, invasion and metastasis of it, including regulation of energy metab. and genome instability, promotion of proliferation, angiogenesis, and tumor-promoting inflammation, resistance in cell death and avoidance of immune destruction.  APO866 and CHS-828 are recognized inhibitors of Nampt, known to block the intracellular and extracellular NAD+ synthesis pathway.  Both of them are currently in clin. trials for the treatment of various malignant tumors and have been shown to represent novel promising antitumor chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2dU2EjmyZvLVg90H21EOLACvtfcHk0ljYwXA9_4OjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVOisbnE&md5=abcdf8fb49af69aba41e367824af4eb8</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.2174%2F138161212803582531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212803582531%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DNampt%252FVisfatin%252FPBEF%253A%2520a%2520functionally%2520multi-faceted%2520protein%2520with%2520a%2520pivotal%2520role%2520in%2520malignant%2520tumors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D6123%26epage%3D6132%26doi%3D10.2174%2F138161212803582531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Burgos, E. S.</span><span> </span><span class="NLM_article-title">NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1947</span><span class="NLM_x">–</span> <span class="NLM_lpage">1961</span><span class="refDoi"> DOI: 10.2174/092986711795590101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F092986711795590101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21517777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFehurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=1947-1961&author=E.+S.+Burgos&title=NAMPT+in+regulated+NAD+biosynthesis+and+its+pivotal+role+in+human+metabolism&doi=10.2174%2F092986711795590101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism</span></div><div class="casAuthors">Burgos, E. S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1947-1961</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the first reversible step in NAD biosynthesis and nicotinamide (NAM) salvage.  The enzyme is designed for efficient capture of nicotinamide by coupling of ATP hydrolysis to assist in extraordinary NAM binding affinity and formation of NMN (NMN).  NAMPT provides the mechanism to replenish the NAD pool in human metab.  In addn. to its role in redox biochem., NAD fuels the sirtuins (SIRTs) to regulate transcription factors involved in pathways linked to inflammation, diabetes and lifespan.  NAMPT-mediated lifespan expansion has caused a focus on the catalytic mechanism, regulation and inhibition of NAMPT.  Structural, mechanistic and inhibitor design all contribute to a developing but yet incomplete story of NAMPT function.  Although the first generation of NAMPT inhibitors has entered clin. trials, disappointing outcomes suggest more powerful and specific inhibitors will be needed.  Understanding the ATP-linked mechanism of NAMPT and the catalytic site machinery may permit the design of improved NAMPT inhibitors as more efficient drugs against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9tpSE0yYDVbVg90H21EOLACvtfcHk0ljYwXA9_4OjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFehurs%253D&md5=cfbd0c1d081468ef98d43c667714e91d</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2174%2F092986711795590101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795590101%26sid%3Dliteratum%253Aachs%26aulast%3DBurgos%26aufirst%3DE.%2BS.%26atitle%3DNAMPT%2520in%2520regulated%2520NAD%2520biosynthesis%2520and%2520its%2520pivotal%2520role%2520in%2520human%2520metabolism%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D1947%26epage%3D1961%26doi%3D10.2174%2F092986711795590101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bi, T.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.-M.</span><span> </span><span class="NLM_article-title">Nampt/PBEF/visfatin and cancer</span> <span class="citation_source-journal">Cancer Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.4161/cbt.10.2.12581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.4161%2Fcbt.10.2.12581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=20647743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFKntLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=119-125&author=T.-Q.+Biauthor=X.-M.+Che&title=Nampt%2FPBEF%2Fvisfatin+and+cancer&doi=10.4161%2Fcbt.10.2.12581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Nampt/PBEF/visfatin and cancer</span></div><div class="casAuthors">Bi, Tie-qiang; Che, Xiang-ming</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-125</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Nampt/PBEF/visfatin is the rate-limiting enzyme that catalyzes the first step in NAD biosynthesis from nicotinamide and regulates growth, apoptosis and angiogenesis of mammalian cells.  This enzyme was originally cloned as a putative cytokine shown to enhance the B-cell precursor maturation in the presence of IL-7 and stem cell factor.  A no. of cancers have increased expression of Nampt/PBEF/visfatin, which regulates a variety of different signaling pathways such as PI3K/Akt, ERK1/2 and STAT3.  FK866/APO866 and CHS828/GMX1777 are two known inhibitors of Nampt/PBEF/visfatin and have been evaluated as anticancer agents in the clinic.  This review will focus on its role in carcinogenesis and cancer progression and its inhibitors as therapeutic target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUbeWp8OFXWLVg90H21EOLACvtfcHk0lgg5klCBxwZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFKntLfL&md5=91d97cfed00750cc6edba4ff36e25c84</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.4161%2Fcbt.10.2.12581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.10.2.12581%26sid%3Dliteratum%253Aachs%26aulast%3DBi%26aufirst%3DT.-Q.%26aulast%3DChe%26aufirst%3DX.-M.%26atitle%3DNampt%252FPBEF%252Fvisfatin%2520and%2520cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D119%26epage%3D125%26doi%3D10.4161%2Fcbt.10.2.12581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Garten, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzold, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Körner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, S.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiess, W.</span><span> </span><span class="NLM_article-title">Nampt: linking NAD biology, metabolism and cancer</span> <span class="citation_source-journal">Trends Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1016/j.tem.2008.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.tem.2008.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19109034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsFanu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2009&pages=130-138&author=A.+Gartenauthor=S.+Petzoldauthor=A.+K%C3%B6rnerauthor=S.-I.+Imaiauthor=W.+Kiess&title=Nampt%3A+linking+NAD+biology%2C+metabolism+and+cancer&doi=10.1016%2Fj.tem.2008.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Nampt: linking NAD biology, metabolism and cancer</span></div><div class="casAuthors">Garten, Antje; Petzold, Stefanie; Koerner, Antje; Imai, Shin-ichiro; Kiess, Wieland</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nicotinamide phosphoribosyltransferase (Nampt) converts nicotinamide to NMN, a key NAD intermediate.  Previously identified as a cytokine pre-B-cell colony-enhancing factor and controversially claimed as an insulin-mimetic hormone visfatin, Nampt has recently drawn much attention in several fields, including NAD biol., metab. and inflammation.  As a NAD biosynthetic enzyme, Nampt regulates the activity of NAD-consuming enzymes such as sirtuins and influences a variety of metabolic and stress responses.  Nampt also plays an important part in regulating insulin secretion in pancreatic β-cells.  Nampt seems to have another function as an immunomodulatory cytokine and, therefore, has a role in inflammation.  This review summarizes these various functional aspects of Nampt and discusses its potential roles in diseases, including type 2 diabetes and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMtmRWd15knbVg90H21EOLACvtfcHk0lgg5klCBxwZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsFanu7o%253D&md5=2e6fc10db431e1963b0b827747466c53</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2008.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2008.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DGarten%26aufirst%3DA.%26aulast%3DPetzold%26aufirst%3DS.%26aulast%3DK%25C3%25B6rner%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DS.-I.%26aulast%3DKiess%26aufirst%3DW.%26atitle%3DNampt%253A%2520linking%2520NAD%2520biology%252C%2520metabolism%2520and%2520cancer%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2009%26volume%3D20%26spage%3D130%26epage%3D138%26doi%3D10.1016%2Fj.tem.2008.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulthard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plummer, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6605166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fsj.bjc.6605166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19568233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslOmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=256-262&author=T.+Zarembaauthor=P.+Ketzerauthor=M.+Coleauthor=S.+Coulthardauthor=E.+R.+Plummerauthor=N.+J.+Curtin&title=Poly%28ADP-ribose%29+polymerase-1+polymorphisms%2C+expression+and+activity+in+selected+human+tumour+cell+lines&doi=10.1038%2Fsj.bjc.6605166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines</span></div><div class="casAuthors">Zaremba, T.; Ketzer, P.; Cole, M.; Coulthard, S.; Plummer, E. R.; Curtin, N. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-262</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA-binding enzyme activated by DNA breaks and involved in DNA repair and other cellular processes.  Poly(ADP-ribose) polymerase activity can be higher in cancer than in adjacent normal tissue, but cancer predisposition is reported to be greater in individuals with a single-nucleotide polymorphism (SNP) V762A (T2444C) in the catalytic domain that reduces PARP-1 activity.  Methods: To resolve these divergent observations, we detd. PARP-1 polymorphisms, PARP-1 protein expression and activity in a panel of 19 solid and haematol., adult and pediatric human cancer cell lines.  Results: There was a wide variation in PARP activity in the cell line panel (coeff. of variation, CV=103%), with the lowest and the highest activity being 2460 pmol PAR/106 (HS-5 cells) and 85 750 pmol PAR/106 (NGP cells).  Lower variation (CV=32%) was obsd. in PARP-1 protein expression with the lowest expression being 2.0 ng μg-1 (HS-5 cells) and the highest being 7.1 ng μg-1 (ML-1 cells).  The mean activity in the cancer cells was 45-fold higher than the mean activity in normal human lymphocytes and the PARP-1 protein levels were 23-fold higher.  Conclusions: Surprisingly, there was no significant correlation between PARP activity and PARP-1 protein level or the investigated polymorphisms, T2444C and CA.  British Journal of Cancer (2009) 101, 256-262; doi:10.1038/sj.bjc.6605166 www.bjcancer.com Published online 30 June 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGiXp9dmBsH7Vg90H21EOLACvtfcHk0lhC3KFcTV0n1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslOmurg%253D&md5=2e8cbeef3e92351d2afd5bed60ad77d4</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605166%26sid%3Dliteratum%253Aachs%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DKetzer%26aufirst%3DP.%26aulast%3DCole%26aufirst%3DM.%26aulast%3DCoulthard%26aufirst%3DS.%26aulast%3DPlummer%26aufirst%3DE.%2BR.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase-1%2520polymorphisms%252C%2520expression%2520and%2520activity%2520in%2520selected%2520human%2520tumour%2520cell%2520lines%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2009%26volume%3D101%26spage%3D256%26epage%3D262%26doi%3D10.1038%2Fsj.bjc.6605166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Khan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forouhar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span> </span><span class="NLM_article-title">Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery</span> <span class="citation_source-journal">Expert Opin. Ther. Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">705</span><span class="refDoi"> DOI: 10.1517/14728222.11.5.695</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1517%2F14728222.11.5.695" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=17465726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=695-705&author=J.+A.+Khanauthor=F.+Forouharauthor=X.+Taoauthor=L.+Tong&title=Nicotinamide+adenine+dinucleotide+metabolism+as+an+attractive+target+for+drug+discovery&doi=10.1517%2F14728222.11.5.695"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery</span></div><div class="casAuthors">Khan, Javed A.; Forouhar, Farhad; Tao, Xiao; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-705</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  NAD (NAD+) has crucial roles in many cellular processes, both as a coenzyme for redox reactions and as a substrate to donate ADP-ribose units.  Enzymes involved in NAD+ metab. are attractive targets for drug discovery against a variety of human diseases, including cancer, multiple sclerosis, neurodegeneration and Huntington's disease.  A small-mol. inhibitor of nicotinamide phosphoribosyltransferase, an enzyme in the salvage pathway of NAD+ biosynthesis, is presently in clin. trials against cancer.  An analog of a kynurenine pathway intermediate is efficacious against multiple sclerosis in an animal model.  Indoleamine 2,3-dioxygenase plays an important role in immune evasion by cancer cells and other disease processes.  Inhibitors against kynurenine 3-hydroxylase can reduce the prodn. of neurotoxic metabolites while increasing the prodn. of neuroprotective compds.  This review summarizes the existing knowledge on NAD+ metabolic enzymes, with emphasis on their relevance for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCrpVwpXgPHrVg90H21EOLACvtfcHk0lhC3KFcTV0n1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslCltbg%253D&md5=43a4c12a1a780feddd233e1d8209f3f6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1517%2F14728222.11.5.695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.11.5.695%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DForouhar%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DNicotinamide%2520adenine%2520dinucleotide%2520metabolism%2520as%2520an%2520attractive%2520target%2520for%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2007%26volume%3D11%26spage%3D695%26epage%3D705%26doi%3D10.1517%2F14728222.11.5.695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Koppenol, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounds, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dang, C. V.</span><span> </span><span class="NLM_article-title">Otto Warburg’s contributions to current concepts of cancer metabolism</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1038/nrc3038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnrc3038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21508971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1ags70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=325-337&author=W.+H.+Koppenolauthor=P.+L.+Boundsauthor=C.+V.+Dang&title=Otto+Warburg%E2%80%99s+contributions+to+current+concepts+of+cancer+metabolism&doi=10.1038%2Fnrc3038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Otto Warburg's contributions to current concepts of cancer metabolism</span></div><div class="casAuthors">Koppenol, Willem H.; Bounds, Patricia L.; Dang, Chi V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Otto Warburg pioneered quant. investigations of cancer cell metab., as well as photosynthesis and respiration.  Warburg and co-workers showed in the 1920s that, under aerobic conditions, tumor tissues metabolize approx. tenfold more glucose to lactate in a given time than normal tissues, a phenomenon known as the Warburg effect.  However, this increase in aerobic glycolysis in cancer cells is often erroneously thought to occur instead of mitochondrial respiration and has been misinterpreted as evidence for damage to respiration instead of damage to the regulation of glycolysis.  In fact, many cancers exhibit the Warburg effect while retaining mitochondrial respiration.  We re-examine Warburg's observations in relation to the current concepts of cancer metab. as being intimately linked to alterations of mitochondrial DNA, oncogenes and tumor suppressors, and thus readily exploitable for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdteDUarw-PbVg90H21EOLACvtfcHk0lhwzKIw201-2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1ags70%253D&md5=72988f428422daecd23b21d242aec18a</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnrc3038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3038%26sid%3Dliteratum%253Aachs%26aulast%3DKoppenol%26aufirst%3DW.%2BH.%26aulast%3DBounds%26aufirst%3DP.%2BL.%26aulast%3DDang%26aufirst%3DC.%2BV.%26atitle%3DOtto%2520Warburg%25E2%2580%2599s%2520contributions%2520to%2520current%2520concepts%2520of%2520cancer%2520metabolism%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D325%26epage%3D337%26doi%3D10.1038%2Fnrc3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ward, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">Metabolic reprogramming: a cancer hallmark even warburg did not anticipate</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1016/j.ccr.2012.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.ccr.2012.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22439925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkt1ylsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=297-308&author=P.+S.+Wardauthor=C.+B.+Thompson&title=Metabolic+reprogramming%3A+a+cancer+hallmark+even+warburg+did+not+anticipate&doi=10.1016%2Fj.ccr.2012.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate</span></div><div class="casAuthors">Ward, Patrick S.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-308</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer metab. has long been equated with aerobic glycolysis, seen by early biochemists as primitive and inefficient.  Despite these early beliefs, the metabolic signatures of cancer cells are not passive responses to damaged mitochondria but result from oncogene-directed metabolic reprogramming required to support anabolic growth.  Recent evidence suggests that metabolites themselves can be oncogenic by altering cell signaling and blocking cellular differentiation.  No longer can cancer-assocd. alterations in metab. be viewed as an indirect response to cell proliferation and survival signals.  We contend that altered metab. has attained the status of a core hallmark of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkFCvg4k-_m7Vg90H21EOLACvtfcHk0lhwzKIw201-2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkt1ylsbc%253D&md5=8e991ba77d1bb0b57c3009b6bc39ee99</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DP.%2BS.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DMetabolic%2520reprogramming%253A%2520a%2520cancer%2520hallmark%2520even%2520warburg%2520did%2520not%2520anticipate%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D21%26spage%3D297%26epage%3D308%26doi%3D10.1016%2Fj.ccr.2012.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cerna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takebe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, S. S.</span><span> </span><span class="NLM_article-title">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">22408</span><span class="NLM_x">–</span> <span class="NLM_lpage">22417</span><span class="refDoi"> DOI: 10.1074/jbc.M112.357301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1074%2Fjbc.M112.357301" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=22408-22417&author=D.+Cernaauthor=H.+Liauthor=S.+Flahertyauthor=N.+Takebeauthor=C.+N.+Colemanauthor=S.+S.+Yoo&title=Inhibition+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+activity+by+small+molecule+GMX1778+regulates+reactive+oxygen+species+%28ROS%29-mediated+cytotoxicity+in+a+p53-+and+nicotinic+acid+phosphoribosyltransferase1+%28NAPRT1%29-dependent+manner&doi=10.1074%2Fjbc.M112.357301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.357301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.357301%26sid%3Dliteratum%253Aachs%26aulast%3DCerna%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DFlaherty%26aufirst%3DS.%26aulast%3DTakebe%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DC.%2BN.%26aulast%3DYoo%26aufirst%3DS.%2BS.%26atitle%3DInhibition%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520activity%2520by%2520small%2520molecule%2520GMX1778%2520regulates%2520reactive%2520oxygen%2520species%2520%2528ROS%2529-mediated%2520cytotoxicity%2520in%2520a%2520p53-%2520and%2520nicotinic%2520acid%2520phosphoribosyltransferase1%2520%2528NAPRT1%2529-dependent%2520manner%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D22408%26epage%3D22417%26doi%3D10.1074%2Fjbc.M112.357301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Vander Heiden, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, C. B.</span><span> </span><span class="NLM_article-title">Understanding the Warburg effect: the metabolic requirements of cell proliferation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">324</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1033</span><span class="refDoi"> DOI: 10.1126/science.1160809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1126%2Fscience.1160809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19460998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2009&pages=1029-1033&author=M.+G.+Vander+Heidenauthor=L.+C.+Cantleyauthor=C.+B.+Thompson&title=Understanding+the+Warburg+effect%3A+the+metabolic+requirements+of+cell+proliferation&doi=10.1126%2Fscience.1160809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7fR"><div class="casContent"><span class="casTitleNuber">7f</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation</span></div><div class="casAuthors">Vander Heiden, Matthew G.; Cantley, Lewis C.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">5930</span>),
    <span class="NLM_cas:pages">1029-1033</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect".  Aerobic glycolysis is an inefficient way to generate ATP, however, and the advantage it confers to cancer cells has been unclear.  Here we propose that the metab. of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell.  Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-assocd. mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP prodn.  A better understanding of the mechanistic links between cellular metab. and growth control may ultimately lead to better treatments for human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGvLHGQ9TX77Vg90H21EOLACvtfcHk0lhUSKO0mIDCoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKlsbg%253D&md5=f927402a43cdca471c3f4874dcbeb943</span></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1126%2Fscience.1160809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1160809%26sid%3Dliteratum%253Aachs%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DUnderstanding%2520the%2520Warburg%2520effect%253A%2520the%2520metabolic%2520requirements%2520of%2520cell%2520proliferation%26jtitle%3DScience%26date%3D2009%26volume%3D324%26spage%3D1029%26epage%3D1033%26doi%3D10.1126%2Fscience.1160809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">151</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.pharmthera.2015.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25709099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1eitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2015&pages=16-31&author=D.+Sampathauthor=T.+S.+Zabkaauthor=D.+L.+Misnerauthor=T.+O%E2%80%99Brienauthor=P.+S.+Dragovich&title=Inhibition+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+as+a+therapeutic+strategy+in+cancer&doi=10.1016%2Fj.pharmthera.2015.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer</span></div><div class="casAuthors">Sampath, Deepak; Zabka, Tanja S.; Misner, Dinah L.; O'Brien, Thomas; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-31</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">NAD is a metabolite that is an important cofactor and second messenger for a no. of cellular processes such as genomic stability and metab. that are essential for survival.  NAD is generated de novo from tryptophan or recycled from NAM through the NAMPT-dependent salvage pathway.  Alternatively, cells can convert NA to NAD through the NAPRT1-dependent salvage pathway.  Tumor cells rapidly turn over NAD but do not efficiently utilize the de novo synthesis pathway.  Hence, they are more reliant on the NAMPT salvage pathway for NAD regeneration making this enzyme an attractive therapeutic target for cancer.  NAMPT is over-expressed in a no. of cancer types such as colorectal, ovarian, breast, gastric, prostate, gliomas as well as B-cell lymphomas.  A no. of novel, potent and selective NAMPT small mol. inhibitors have been synthesized to date that have displayed robust anti-tumor activity in tumor models in vitro and in vivo.  These inhibitors efficiently suppress NAD prodn. in a time dependent manner and sustained redn. of NAD levels leads to loss of ATP and ultimately cell death.  This review will summarize the chem. properties of these unique NAMPT inhibitors as well as their mechanism of action, pharmacodynamic activity and efficacy in tumor models in vitro and in vivo.  An overview of biomarkers that predict response to treatment and mechanisms of resistance to NAMPT inhibitors will also be provided.  Addnl., NAMPT inhibitors that have advanced into clin. trials will be reviewed along with exptl. strategies tested to potentially increase the therapeutic index of these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqop3xkHKJxG7Vg90H21EOLACvtfcHk0lhUSKO0mIDCoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1eitrk%253D&md5=c3b08d2345b784eaa05520eabb1f1173</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DInhibition%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520as%2520a%2520therapeutic%2520strategy%2520in%2520cancer%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D151%26spage%3D16%26epage%3D31%26doi%3D10.1016%2Fj.pharmthera.2015.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span> </span><span class="NLM_article-title">Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4921</span><span class="NLM_x">–</span> <span class="NLM_lpage">4937</span><span class="refDoi"> DOI: 10.1021/jm400186h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400186h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1WisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4921-4937&author=X.+Zhengauthor=P.+Bauerauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=J.+Linauthor=D.+J.+Reynoldsauthor=G.+Sharmaauthor=C.+C.+Smithauthor=Z.+Wangauthor=P.+S.+Dragovichauthor=A.+Ohauthor=W.+Wangauthor=M.+Zakauthor=J.+Gunzner-Tosteauthor=G.+Zhaoauthor=P.-w.+Yuenauthor=K.+W.+Bair&title=Structure-based+identification+of+ureas+as+novel+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors&doi=10.1021%2Fjm400186h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors</span></div><div class="casAuthors">Zheng, Xiaozhang; Bauer, Paul; Baumeister, Timm; Buckmelter, Alexandre J.; Caligiuri, Maureen; Clodfelter, Karl H.; Han, Bingsong; Ho, Yen-Ching; Kley, Nikolai; Lin, Jian; Reynolds, Dominic J.; Sharma, Geeta; Smith, Chase C.; Wang, Zhongguo; Dragovich, Peter S.; Oh, Angela; Wang, Weiru; Zak, Mark; Gunzner-Toste, Janet; Zhao, Guiling; Yuen, Po-wai; Bair, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4921-4937</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyridinyl sulfonylphenyl ureas and thioureas such as I and II were prepd. as inhibitors of nicotinamide phosphoribosyltransferase (Nampt) for potential use as antitumor agents.  Replacement of the thiourea of I led to a Nampt inhibitor with similar activity and improved soly.  Optimization of the urea substituents identified the 3-pyridyl group as the optimal substituent at one of the urea nitrogens and the urea moiety as the optimal linking group.  II was found to be a Nampt inhibitor with excellent biochem. and cellular potency (IC50 values with Nampt and in cells of 7 nM and 32 nM, resp.); II was an active oral antitumor agent in an ovarian cancer xenograft model.  The inhibition of Nampt by pyridinyl-substituted ureas was inversely dependent on the concn. of nicotinamide.  The structure of I bound to human Nampt was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpESuPRbmSTMrVg90H21EOLACvtfcHk0ljruQfO78Fixw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1WisrY%253D&md5=43777430938274bf8f510a45d9c6e883</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1021%2Fjm400186h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400186h%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DBair%26aufirst%3DK.%2BW.%26atitle%3DStructure-based%2520identification%2520of%2520ureas%2520as%2520novel%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4921%26epage%3D4937%26doi%3D10.1021%2Fjm400186h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span> </span><span class="NLM_article-title">Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6413</span><span class="NLM_x">–</span> <span class="NLM_lpage">6433</span><span class="refDoi"> DOI: 10.1021/jm4008664</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008664" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFams7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6413-6433&author=X.+Zhengauthor=P.+Bauerauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=J.+Linauthor=D.+J.+Reynoldsauthor=G.+Sharmaauthor=C.+C.+Smithauthor=Z.+Wangauthor=P.+S.+Dragovichauthor=J.+Gunzner-Tosteauthor=B.+Liedererauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=A.+Ohauthor=L.+Wangauthor=W.+Wangauthor=Y.+Xiaoauthor=M.+Zakauthor=G.+Zhaoauthor=P.-w.+Yuenauthor=K.+W.+Bair&title=Structure-based+discovery+of+novel+amide-containing+nicotinamide+phosphoribosyltransferase+%28Nampt%29+inhibitors&doi=10.1021%2Fjm4008664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors</span></div><div class="casAuthors">Zheng, Xiaozhang; Bauer, Paul; Baumeister, Timm; Buckmelter, Alexandre J.; Caligiuri, Maureen; Clodfelter, Karl H.; Han, Bingsong; Ho, Yen-Ching; Kley, Nikolai; Lin, Jian; Reynolds, Dominic J.; Sharma, Geeta; Smith, Chase C.; Wang, Zhongguo; Dragovich, Peter S.; Gunzner-Toste, Janet; Liederer, Bianca M.; Ly, Justin; O'Brien, Thomas; Oh, Angela; Wang, Leslie; Wang, Weiru; Xiao, Yang; Zak, Mark; Zhao, Guiling; Yuen, Po-wai; Bair, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6413-6433</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Crystal structures of several urea- and thiourea-derived compds. in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein were utilized to design a potent amide-contg. inhibitor bearing an aza-indole moiety (Nampt BC IC50 = 9.0 nM, A2780 cell proliferation IC50 = 10 nM).  A Nampt cocrystal structure was subsequently obtained and enabled the design of addnl. amide-contg. inhibitors which incorporated various other fused 6,5-heterocyclic moieties and biaryl sulfone or sulfonamide motifs.  Addnl. modifications of these mols. afforded many potent biaryl sulfone-contg. Nampt inhibitors which also exhibited favorable in vitro ADME properties (microsomal and hepatocyte stability, MDCK permeability, plasma protein binding).  An optimized compd. was a potent inhibitor of multiple cancer cell lines (IC50 <10 nM vs U251, HT1080, PC3, MiaPaCa2, and HCT116 lines), displayed acceptable mouse PK properties (F = 41%, CL = 52.4 mL/min/kg), and exhibited robust efficacy in a U251 mouse xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLNlDAdwkCzbVg90H21EOLACvtfcHk0lgiLJ16ztPnlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFams7bJ&md5=968025a577ae829928b3ff8b790c6403</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm4008664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008664%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DLiederer%26aufirst%3DB.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DBair%26aufirst%3DK.%2BW.%26atitle%3DStructure-based%2520discovery%2520of%2520novel%2520amide-containing%2520nicotinamide%2520phosphoribosyltransferase%2520%2528Nampt%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6413%26epage%3D6433%26doi%3D10.1021%2Fjm4008664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tremayne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Identification of amides derived from 1H-pyrazolo [3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5488</span><span class="NLM_x">–</span> <span class="NLM_lpage">5497</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2013.08.074" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5488-5497&author=X.+Zhengauthor=K.+W.+Bairauthor=P.+Bauerauthor=T.+Baumeisterauthor=K.+K.+Bowmanauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=Y.+Fengauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=H.+Liauthor=X.+Liangauthor=B.+M.+Liedererauthor=J.+Linauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=A.+Ohauthor=D.+J.+Reynoldsauthor=D.+Sampathauthor=G.+Sharmaauthor=N.+Skeltonauthor=C.+C.+Smithauthor=J.+Tremayneauthor=L.+Wangauthor=W.+Wangauthor=Z.+Wangauthor=H.+Wuauthor=J.+Wuauthor=Y.+Xiaoauthor=G.+Yangauthor=P.-w.+Yuenauthor=M.+Zakauthor=P.+S.+Dragovich&title=Identification+of+amides+derived+from+1H-pyrazolo+%5B3%2C4-b%5Dpyridine-5-carboxylic+acid+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29&doi=10.1016%2Fj.bmcl.2013.08.074"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.074%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DTremayne%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520amides%2520derived%2520from%25201H-pyrazolo%2520%255B3%252C4-b%255Dpyridine-5-carboxylic%2520acid%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5488%26epage%3D5497%26doi%3D10.1016%2Fj.bmcl.2013.08.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">770</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1021/jm4015108</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4015108" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvFWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=770-792&author=A.+M.+Giannettiauthor=X.+Zhengauthor=N.+J.+Skeltonauthor=W.+Wangauthor=B.+J.+Bravoauthor=K.+W.+Bairauthor=T.+Baumeisterauthor=E.+Chengauthor=L.+Crockerauthor=Y.+Fengauthor=J.+Gunzner-Tosteauthor=Y.-C.+Hoauthor=R.+Huaauthor=B.+M.+Liedererauthor=Y.+Liuauthor=X.+Maauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=D.+Sampathauthor=Y.+Shenauthor=C.+Wangauthor=L.+Wangauthor=H.+Wuauthor=Y.+Xiaoauthor=P.-w+Yuenauthor=M.+Zakauthor=G.+Zhaoauthor=Q.+Zhaoauthor=P.+S.+Dragovich&title=Fragment-based+identification+of+amides+derived+from+trans-2-%28pyridin-3-yl%29cyclopropanecarboxylic+acid+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29&doi=10.1021%2Fjm4015108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9dR"><div class="casContent"><span class="casTitleNuber">9d</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span></div><div class="casAuthors">Giannetti, Anthony M.; Zheng, Xiaozhang; Skelton, Nicholas J.; Wang, Weiru; Bravo, Brandon J.; Bair, Kenneth W.; Baumeister, Timm; Cheng, Eric; Crocker, Lisa; Feng, Yezhen; Gunzner-Toste, Janet; Ho, Yen-Ching; Hua, Rongbao; Liederer, Bianca M.; Liu, Yongbo; Ma, Xiaolei; O'Brien, Thomas; Oeh, Jason; Sampath, Deepak; Shen, Youming; Wang, Chengcheng; Wang, Leslie; Wu, Hongxing; Xiao, Yang; Yuen, Po-wai; Zak, Mark; Zhao, Guiling; Zhao, Qiang; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">770-792</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent, trans-2-(pyridin-3-yl)-cyclopropane-carboxamide-contg. inhibitors of the human nicotinamide phosphoribosyl-transferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques.  Multiple crystal structures were obtained of initial fragment leads, and this structural information was utilized to improve the biochem. and cell-based potency of the assocd. mols.  Many of the optimized compds. exhibited nanomolar antiproliferative activities against human tumor lines in in vitro cell culture expts.  In a key example, a fragment lead (13, KD = 51 μM) was elaborated into a potent NAMPT inhibitor (39, NAMPT IC50 = 0.0051 μM, A2780 cell culture IC50 = 0.000 49 μM) which demonstrated encouraging in vivo efficacy in an HT-1080 mouse xenograft tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGDYM9bbug1rVg90H21EOLACvtfcHk0lgmgioW5EkK4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvFWitQ%253D%253D&md5=cf1e87e52ef0641e48465a44d5b3347c</span></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=10.1021%2Fjm4015108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4015108%26sid%3Dliteratum%253Aachs%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DHua%26aufirst%3DR.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DP.-w%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DFragment-based%2520identification%2520of%2520amides%2520derived%2520from%2520trans-2-%2528pyridin-3-yl%2529cyclopropanecarboxylic%2520acid%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D770%26epage%3D792%26doi%3D10.1021%2Fjm4015108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span> </span><span class="NLM_article-title">Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">4875</span><span class="NLM_x">–</span> <span class="NLM_lpage">4885</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2013.06.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4875-4885&author=P.+S.+Dragovichauthor=K.+W.+Bairauthor=T.+Baumeisterauthor=Y.-C.+Hoauthor=B.+M.+Liedererauthor=X.+Liuauthor=Y.+Liuauthor=T.+O%E2%80%99Brienauthor=J.+Oehauthor=D.+Sampathauthor=N.+Skeltonauthor=L.+Wangauthor=W.+Wangauthor=H.+Wuauthor=Y.+Xiaoauthor=P.-w.+Yuenauthor=M.+Zakauthor=L.+Zhangauthor=X.+Zheng&title=Identification+of+2%2C3-dihydro-1H-pyrrolo%5B3%2C4-c%5Dpyridine-derived+ureas+as+potent+inhibitors+of+human+nicotinamide+phosphoribosyltransferase+%28NAMPT%29&doi=10.1016%2Fj.bmcl.2013.06.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.090%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DIdentification%2520of%25202%252C3-dihydro-1H-pyrrolo%255B3%252C4-c%255Dpyridine-derived%2520ureas%2520as%2520potent%2520inhibitors%2520of%2520human%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4875%26epage%3D4885%26doi%3D10.1016%2Fj.bmcl.2013.06.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">541</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2014.12.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=529-541&author=M.+Zakauthor=B.+M.+Liedererauthor=D.+Sampathauthor=P.-w.+Yuenauthor=K.+W.+Bairauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=K.+H.+Clodfelterauthor=E.+Chengauthor=L.+Crockerauthor=B.+Fuauthor=B.+Hanauthor=G.+Liauthor=Y.-C.+Hoauthor=J.+Linauthor=X.+Liuauthor=J.+Lyauthor=T.+O%E2%80%99Brienauthor=D.+J.+Reynoldsauthor=N.+Skeltonauthor=C.+C.+Smithauthor=S.+Tayauthor=W.+Wangauthor=Z.+Wangauthor=Y.+Xiaoauthor=L.+Zhangauthor=G.+Zhaoauthor=X.+Zhengauthor=P.+S.+Dragovich&title=Identification+of+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors+with+no+evidence+of+CYP3A4+time-dependent+inhibition+and+improved+aqueous+solubility&doi=10.1016%2Fj.bmcl.2014.12.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.026%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DIdentification%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%2520with%2520no%2520evidence%2520of%2520CYP3A4%2520time-dependent%2520inhibition%2520and%2520improved%2520aqueous%2520solubility%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D529%26epage%3D541%26doi%3D10.1016%2Fj.bmcl.2014.12.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottosen, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hjarnaa, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bramm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binderup, L.</span><span> </span><span class="NLM_article-title">Novel cyanoguanidines with potent oral antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3095</span><span class="NLM_x">–</span> <span class="NLM_lpage">3100</span><span class="refDoi"> DOI: 10.1016/S0960-894X(97)10152-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2FS0960-894X%2897%2910152-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=3095-3100&author=C.+Schouauthor=E.+R.+Ottosenauthor=H.+J.+Petersenauthor=F.+Bjorklingauthor=S.+Latiniauthor=P.+V.+Hjarnaaauthor=E.+Brammauthor=L.+Binderup&title=Novel+cyanoguanidines+with+potent+oral+antitumor+activity&doi=10.1016%2FS0960-894X%2897%2910152-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2910152-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252910152-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchou%26aufirst%3DC.%26aulast%3DOttosen%26aufirst%3DE.%2BR.%26aulast%3DPetersen%26aufirst%3DH.%2BJ.%26aulast%3DBjorkling%26aufirst%3DF.%26aulast%3DLatini%26aufirst%3DS.%26aulast%3DHjarnaa%26aufirst%3DP.%2BV.%26aulast%3DBramm%26aufirst%3DE.%26aulast%3DBinderup%26aufirst%3DL.%26atitle%3DNovel%2520cyanoguanidines%2520with%2520potent%2520oral%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D3095%26epage%3D3100%26doi%3D10.1016%2FS0960-894X%2897%2910152-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ravaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerny, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terret, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanders, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Droz, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumoleau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twelves, C.</span><span> </span><span class="NLM_article-title">Phase I study and pharmacokinetics of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">702</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1016/j.ejca.2004.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.ejca.2004.12.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=702-707&author=A.+Ravaudauthor=T.+Cernyauthor=C.+Terretauthor=J.+Wandersauthor=B.+N.+Buiauthor=D.+Hessauthor=J.-P.+Drozauthor=P.+Fumoleauauthor=C.+Twelves&title=Phase+I+study+and+pharmacokinetics+of+CHS-828%2C+a+guanidino-containing+compound%2C+administered+orally+as+a+single+dose+every+3+weeks+in+solid+tumours%3A+An+ECSG%2FEORTC+study&doi=10.1016%2Fj.ejca.2004.12.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2004.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2004.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DRavaud%26aufirst%3DA.%26aulast%3DCerny%26aufirst%3DT.%26aulast%3DTerret%26aufirst%3DC.%26aulast%3DWanders%26aufirst%3DJ.%26aulast%3DBui%26aufirst%3DB.%2BN.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DDroz%26aufirst%3DJ.-P.%26aulast%3DFumoleau%26aufirst%3DP.%26aulast%3DTwelves%26aufirst%3DC.%26atitle%3DPhase%2520I%2520study%2520and%2520pharmacokinetics%2520of%2520CHS-828%252C%2520a%2520guanidino-containing%2520compound%252C%2520administered%2520orally%2520as%2520a%2520single%2520dose%2520every%25203%2520weeks%2520in%2520solid%2520tumours%253A%2520An%2520ECSG%252FEORTC%2520study%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D702%26epage%3D707%26doi%3D10.1016%2Fj.ejca.2004.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hovstadius, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skov, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissmeyer, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krasilnikoff, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonnebo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahlgren, J.</span><span> </span><span class="NLM_article-title">A phase I study of CHS 828 in patients with solid tumor malignancy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">2843</span><span class="NLM_x">–</span> <span class="NLM_lpage">2850</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=12231525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvVWisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2843-2850&author=P.+Hovstadiusauthor=R.+Larssonauthor=E.+Jonssonauthor=T.+Skovauthor=A.-M.+Kissmeyerauthor=K.+Krasilnikoffauthor=J.+Berghauthor=M.+O.+Karlssonauthor=A.+Lonneboauthor=J.+Ahlgren&title=A+phase+I+study+of+CHS+828+in+patients+with+solid+tumor+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I study of CHS 828 in patients with solid tumor malignancy</span></div><div class="casAuthors">Hovstadius, Peter; Larsson, Rolf; Jonsson, Elin; Skov, Torsten; Kissmeyer, Anne-Marie; Krasilnikoff, Klaus; Bergh, Jonas; Karlsson, Mats O.; Loennebo, Anna; Ahlgren, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2843-2850</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CHS 828 is a cyanoguanidine, which has demonstrated potent antitumor activity in preclin. tumor models.  The activity of CHS 828 in vitro showed only low to moderate correlation to other antineoplastic agents suggesting a unique mechanism of action.  Ten females and 6 males (median age 58 yr) with solid tumors refractory to std. therapy were included in this Phase I study.  The study drug was administered to fasting patients as a single oral dose on days 1-5 of each treatment cycle.  Patients received one to six cycles of treatment.  The doses ranged from 30 mg to 200 mg (total dose within a cycle).  Hematol. toxicity was generally mild and dominated by transient thrombocytopenia and lymphocytopenia.  Nonhematol. toxicity most frequently consisted of nausea, vomiting, diarrhea, fatigue, and localized genital mucositis.  The dose-limiting toxicities were thrombocytopenia, thrombosis, esophagitis, diarrhea, and constipation.  The recommended Phase II dose of CHS 828 was 20 mg once daily for 5 days in cycles of 28 days duration.  The extent of systemic exposure of CHS 828 across patients was approx. dose proportional.  The time at which the highest drug concn. occurs was 2.2 ± 1.3 h and half-life was 2.1 ± 0.52 h (mean ± SD).  Large intra- and interindividual variation in dose level-adjusted max. plasma concn. and the area under the curve from time 0 h to infinity were obsd.  There was an apparent inverse relationship between systemic exposure of CHS 828, and thrombocyte and lymphocyte nadir levels.  No objective tumor responses were obsd., and 7 patients showed stable disease after two courses of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAV8wQZ2ka27Vg90H21EOLACvtfcHk0ljXcy2nSEwwjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvVWisb8%253D&md5=3c3eb4621a968358dcd41f321eab2d87</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHovstadius%26aufirst%3DP.%26aulast%3DLarsson%26aufirst%3DR.%26aulast%3DJonsson%26aufirst%3DE.%26aulast%3DSkov%26aufirst%3DT.%26aulast%3DKissmeyer%26aufirst%3DA.-M.%26aulast%3DKrasilnikoff%26aufirst%3DK.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DKarlsson%26aufirst%3DM.%2BO.%26aulast%3DLonnebo%26aufirst%3DA.%26aulast%3DAhlgren%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520CHS%2520828%2520in%2520patients%2520with%2520solid%2520tumor%2520malignancy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D2843%26epage%3D2850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Biedermann, E.; Hasmann, M.; Loser, R.; Rattel, B.; Reiter, F.; Schein, B.; Seibel, K.; Vogt, K.</span><span> </span><span class="NLM_article-title">Preparation and formulation of pyridine derivatives as antitumor agents and immunosuppressants</span> WO 199748397,<span class="NLM_x"> </span><span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=E.+Biedermann&author=M.+Hasmann&author=R.+Loser&author=B.+Rattel&author=F.+Reiter&author=B.+Schein&author=K.+Seibel&author=K.+Vogt&title=Preparation+and+formulation+of+pyridine+derivatives+as+antitumor+agents+and+immunosuppressants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiedermann%26aufirst%3DE.%26atitle%3DPreparation%2520and%2520formulation%2520of%2520pyridine%2520derivatives%2520as%2520antitumor%2520agents%2520and%2520immunosuppressants%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Holen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltz, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollywood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanauske, A.-R.</span><span> </span><span class="NLM_article-title">The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1007/s10637-007-9083-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1007%2Fs10637-007-9083-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=45-51&author=K.+Holenauthor=L.+B.+Saltzauthor=E.+Hollywoodauthor=K.+Burkauthor=A.-R.+Hanauske&title=The+pharmacokinetics%2C+toxicities%2C+and+biologic+effects+of+FK866%2C+a+nicotinamide+adenine+dinucleotide+biosynthesis+inhibitor&doi=10.1007%2Fs10637-007-9083-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1007%2Fs10637-007-9083-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-007-9083-2%26sid%3Dliteratum%253Aachs%26aulast%3DHolen%26aufirst%3DK.%26aulast%3DSaltz%26aufirst%3DL.%2BB.%26aulast%3DHollywood%26aufirst%3DE.%26aulast%3DBurk%26aufirst%3DK.%26aulast%3DHanauske%26aufirst%3DA.-R.%26atitle%3DThe%2520pharmacokinetics%252C%2520toxicities%252C%2520and%2520biologic%2520effects%2520of%2520FK866%252C%2520a%2520nicotinamide%2520adenine%2520dinucleotide%2520biosynthesis%2520inhibitor%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2008%26volume%3D26%26spage%3D45%26epage%3D51%26doi%3D10.1007%2Fs10637-007-9083-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hasmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schemainda, I.</span><span> </span><span class="NLM_article-title">FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">7436</span><span class="NLM_x">–</span> <span class="NLM_lpage">7442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=14612543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7436-7442&author=M.+Hasmannauthor=I.+Schemainda&title=FK866%2C+a+highly+specific+noncompetitive+inhibitor+of+nicotinamide+phosphoribosyltransferase%2C+represents+a+novel+mechanism+for+induction+of+tumor+cell+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis</span></div><div class="casAuthors">Hasmann, Max; Schemainda, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7436-7442</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deregulation of apoptosis, the physiol. form of cell death, is closely assocd. with immunol. diseases and cancer.  Apoptosis is activated either by death receptor-driven or mitochondrial pathways, both of which may provide potential targets for novel anticancer drugs.  Although several ligands stimulating death receptors have been described, the actual mol. events triggering the mitochondrial pathway are largely unknown.  Here, we show initiation of apoptosis by gradual depletion of the intracellular coenzyme NAD+.  We identified the first low mol. wt. compd., designated FK866, which induces apoptosis by highly specific, noncompetitive inhibition of nicotinamide phosphoribosyltransferase (NAPRT), a key enzyme in the regulation of NAD+ biosynthesis from the natural precursor nicotinamide.  Interference with this enzyme does not primarily intoxicate cells because the mitochondrial respiratory activity and the NAD+-dependent redox reactions involved remain unaffected as long as NAD+ is not effectively depleted by catabolic reactions.  Certain tissues, however, have a high turnover of NAD+ through its cleavage by enzymes like poly(ADP-ribose) polymerase.  Such cells often rely on the more readily available nicotinamide pathway for NAD+ synthesis and undergo apoptosis after inhibition of NAPRT, whereas cells effectively using the nicotinic acid pathway for NAD+ synthesis remain unaffected.  In support of this concept, FK866 effectively induced delayed cell death by apoptosis in HepG2 human liver carcinoma cells with an IC50 of ∼1 nM, did not directly inhibit mitochondrial respiratory activity, but caused gradual NAD+ depletion through specific inhibition of NAPRT.  This enzyme, when partially purified from K562 human leukemia cells, was noncompetitively inhibited by FK866, and the inhibitor consts. were calcd. to be 0.4 nM for the enzyme/substrate complex (Ki) and 0.3 nM for the free enzyme (Ki'), resp.  Nicotinic acid and nicotinamide were both found to have antidote potential for the cellular effects of FK866.  FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer for immunosuppression or as a sensitizer for genotoxic agents.  Furthermore, it may provide an important tool for investigation of the mol. triggers of the mitochondrial pathway leading to apoptosis through enabling temporal sepn. of NAD+ decrease from ATP breakdown and apoptosis by several days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOS3LOADp6LVg90H21EOLACvtfcHk0liwcUmEnq7jtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGltb4%253D&md5=c67fd08fdfc233ba86478967b13d19a2</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHasmann%26aufirst%3DM.%26aulast%3DSchemainda%26aufirst%3DI.%26atitle%3DFK866%252C%2520a%2520highly%2520specific%2520noncompetitive%2520inhibitor%2520of%2520nicotinamide%2520phosphoribosyltransferase%252C%2520represents%2520a%2520novel%2520mechanism%2520for%2520induction%2520of%2520tumor%2520cell%2520apoptosis%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7436%26epage%3D7442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kumar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlstrom, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rock, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorman, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, T. S.</span><span> </span><span class="NLM_article-title">CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1966</span><span class="NLM_x">–</span> <span class="NLM_lpage">1975</span><span class="refDoi"> DOI: 10.1124/dmd.106.010926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1124%2Fdmd.106.010926" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1966-1975&author=V.+Kumarauthor=J.+L.+Wahlstromauthor=D.+A.+Rockauthor=C.+J.+Warrenauthor=L.+A.+Gormanauthor=T.+S.+Tracy&title=CYP2C9+inhibition%3A+impact+of+probe+selection+and+pharmacogenetics+on+in+vitro+inhibition+profiles&doi=10.1124%2Fdmd.106.010926"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.010926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.010926%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DWahlstrom%26aufirst%3DJ.%2BL.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DWarren%26aufirst%3DC.%2BJ.%26aulast%3DGorman%26aufirst%3DL.%2BA.%26aulast%3DTracy%26aufirst%3DT.%2BS.%26atitle%3DCYP2C9%2520inhibition%253A%2520impact%2520of%2520probe%2520selection%2520and%2520pharmacogenetics%2520on%2520in%2520vitro%2520inhibition%2520profiles%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D1966%26epage%3D1975%26doi%3D10.1124%2Fdmd.106.010926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rettie, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J. P.</span><span> </span><span class="NLM_article-title">Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.095821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1146%2Fannurev.pharmtox.45.120403.095821" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=477-494&author=A.+E.+Rettieauthor=J.+P.+Jones&title=Clinical+and+toxicological+relevance+of+CYP2C9%3A+drug-drug+interactions+and+pharmacogenetics&doi=10.1146%2Fannurev.pharmtox.45.120403.095821"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.095821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.095821%26sid%3Dliteratum%253Aachs%26aulast%3DRettie%26aufirst%3DA.%2BE.%26aulast%3DJones%26aufirst%3DJ.%2BP.%26atitle%3DClinical%2520and%2520toxicological%2520relevance%2520of%2520CYP2C9%253A%2520drug-drug%2520interactions%2520and%2520pharmacogenetics%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26spage%3D477%26epage%3D494%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.095821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Van Booven, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrillo, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangkuhl, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. B.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C9-CYP2C9</span> <span class="citation_source-journal">Pharmacogenet. Genomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span><span class="refDoi"> DOI: 10.1097/FPC.0b013e3283349e84</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1097%2FFPC.0b013e3283349e84" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=20150829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1ajtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=277-281&author=D.+Van+Boovenauthor=S.+Marshauthor=H.+McLeodauthor=M.+W.+Carrilloauthor=K.+Sangkuhlauthor=T.+E.+Kleinauthor=R.+B.+Altman&title=Cytochrome+P450+2C9-CYP2C9&doi=10.1097%2FFPC.0b013e3283349e84"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2C9-CYP2C9</span></div><div class="casAuthors">Van Booven, Derek; Marsh, Sharon; McLeod, Howard; Carrillo, Michelle Whirl; Sangkuhl, Katrin; Klein, Teri E.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics and Genomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">277-281</span>CODEN:
                <span class="NLM_cas:coden">PGHEAI</span>;
        ISSN:<span class="NLM_cas:issn">1744-6872</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  CYP2C9 is a phase I drug-metabolizing cytochrome P 450 (CYP450) enzyme isoform that plays a major role in the oxidn. of both xenobiotic and endogenous compds.  The cluster comprises four genes arranged in the order CYP2C8-CYP2C9-CYP2C19-CYP2C18 [1].  Several studies identified a single nucleotide polymorphism (SNP) linkage between the CYP2C8 and CYP2C9 genes (2-4).  CYP2C9 is primarily expressed in the liver, and the expression level is reported to be the second highest among CYP isoforms [5].  Only the CYP enzyme CYP3A4 is quant. more highly expressed in the human liver.  It has been estd. that CYP2C9 is responsible for the metabolic clearance of up to 15-20 % of all drugs undergoing phase I metab. [7,8].  This article reports partial list showing examples of the broad substrate spectrum of drugs that are metabolized by CYP2C9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83s0ih92SYbVg90H21EOLACvtfcHk0lhCy5IK-VnaPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1ajtLg%253D&md5=54e698bcb81e6785f605c054af7faf09</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1097%2FFPC.0b013e3283349e84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFPC.0b013e3283349e84%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBooven%26aufirst%3DD.%26aulast%3DMarsh%26aufirst%3DS.%26aulast%3DMcLeod%26aufirst%3DH.%26aulast%3DCarrillo%26aufirst%3DM.%2BW.%26aulast%3DSangkuhl%26aufirst%3DK.%26aulast%3DKlein%26aufirst%3DT.%2BE.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DCytochrome%2520P450%25202C9-CYP2C9%26jtitle%3DPharmacogenet.%2520Genomics%26date%3D2010%26volume%3D20%26spage%3D277%26epage%3D281%26doi%3D10.1097%2FFPC.0b013e3283349e84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lee, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pieper, J. A.</span><span> </span><span class="NLM_article-title">Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data</span> <span class="citation_source-journal">Pharmacogenetics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1097/00008571-200204000-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1097%2F00008571-200204000-00010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=11927841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFKqsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=251-263&author=C.+R.+Leeauthor=J.+A.+Goldsteinauthor=J.+A.+Pieper&title=Cytochrome+P450+2C9+polymorphisms%3A+a+comprehensive+review+of+the+in-vitro+and+human+data&doi=10.1097%2F00008571-200204000-00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data</span></div><div class="casAuthors">Lee, Craig R.; Goldstein, Joyce A.; Pieper, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-263</span>CODEN:
                <span class="NLM_cas:coden">PHMCEE</span>;
        ISSN:<span class="NLM_cas:issn">0960-314X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The discovery of six distinct polymorphisms in the genetic sequence encoding for the cytochrome P 450 2C9 (CYP2C9) protein has stimulated numerous investigations in an attempt to characterize their population distribution and metabolic activity.  Since the CYP2C9*1, *2 and *3 alleles were discovered first, they have undergone more thorough investigation than the recently identified *4, *5 and *6 alleles.  Population distribution data suggest that the variant *2 and *3 alleles are present in approx. 35% of Caucasian individuals; however, these alleles are significantly less prevalent in African-American and Asian populations.  In-vitro data have consistently demonstrated that the CYP2C9*2 and *3 alleles are assocd. with significant redns. in intrinsic clearance of a variety of 2C9 substrates compared with CYP2C9*1; however, the degree of these redns. appear to be highly substrate-dependent.  In addn., multiple in-vivo investigations and clin. case reports have assocd. genotypes expressing the CYP2C9*2 and *3 alleles with significant redns. in both the metab. and daily dose requirements of selected CYP2C9 substrates.  Individuals expressing these variant genotypes also appear to be significantly more susceptible to adverse events with the narrow therapeutic index agents warfarin and phenytoin, particularly during the initiation of therapy.  These findings have subsequently raised numerous questions regarding the potential clin. utility of genotyping for CYP2C9 prior to initiation of therapy with these agents.  However, further clin. investigations evaluating the metabolic consequences in individuals expressing the CYP2C9*2, *3, *4, *5, or *6 alleles are required before large-scale clin. genotyping can be recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1eDoaPX_Ry7Vg90H21EOLACvtfcHk0lhCy5IK-VnaPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFKqsLc%253D&md5=77e86d192a3cf3cab9153ceb19a4ad26</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1097%2F00008571-200204000-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00008571-200204000-00010%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BR.%26aulast%3DGoldstein%26aufirst%3DJ.%2BA.%26aulast%3DPieper%26aufirst%3DJ.%2BA.%26atitle%3DCytochrome%2520P450%25202C9%2520polymorphisms%253A%2520a%2520comprehensive%2520review%2520of%2520the%2520in-vitro%2520and%2520human%2520data%26jtitle%3DPharmacogenetics%26date%3D2002%26volume%3D12%26spage%3D251%26epage%3D263%26doi%3D10.1097%2F00008571-200204000-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ali, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ysla, F. M.</span><span> </span><span class="NLM_article-title">CYP2C9 polymorphisms: considerations in NSAID therapy</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2009&pages=108-114&author=Z.+K.+Aliauthor=R.+J.+Kimauthor=F.+M.+Ysla&title=CYP2C9+polymorphisms%3A+considerations+in+NSAID+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DZ.%2BK.%26aulast%3DKim%26aufirst%3DR.%2BJ.%26aulast%3DYsla%26aufirst%3DF.%2BM.%26atitle%3DCYP2C9%2520polymorphisms%253A%2520considerations%2520in%2520NSAID%2520therapy%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2009%26volume%3D12%26spage%3D108%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Horn, J. R.; Hansten, P. D.</span><span> </span><span class="NLM_article-title">Get to know an enzyme: CYP2C9</span>. <i>Pharmacy Times</i><span class="NLM_x"> </span><span class="NLM_year">2008</span>. <a href="http://www.pharmacytimes.com/publications/issue/2008/2008-03/2008-03-8462" class="extLink">www.pharmacytimes.com/publications/issue/2008/2008-03/2008-03-8462</a> (accessed July 21, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=J.+R.+Horn&author=P.+D.+Hansten&title=Get+to+know+an+enzyme%3A+CYP2C9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DJ.%2BR.%26atitle%3DGet%2520to%2520know%2520an%2520enzyme%253A%2520CYP2C9%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schuster, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steindl, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, T.</span><span> </span><span class="NLM_article-title">Development and validation of an in silico P450 profiler based on pharmacophore models</span> <span class="citation_source-journal">Curr. Drug Discovery Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">48</span><span class="refDoi"> DOI: 10.2174/157016306776637609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F157016306776637609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=16712462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtFSlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=1-48&author=D.+Schusterauthor=C.+Laggnerauthor=T.+M.+Steindlauthor=T.+Langer&title=Development+and+validation+of+an+in+silico+P450+profiler+based+on+pharmacophore+models&doi=10.2174%2F157016306776637609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of an in silico P450 profiler based on pharmacophore models</span></div><div class="casAuthors">Schuster, Daniela; Laggner, Christian; Steindl, Theodora M.; Langer, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Discovery Technologies</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-48</span>CODEN:
                <span class="NLM_cas:coden">CDDTAF</span>;
        ISSN:<span class="NLM_cas:issn">1570-1638</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">In today's drug discovery process, the very early consideration of ADME properties is aimed at a redn. of drug candidate drop out rate in later development stages.  A part from in vitro testing, in silico methods are evaluated as complementary screening tools for compds. with unfavorable ADME attributes.  Esp. members of the cytochrome P 450 (P 450) enzyme superfamily. e.g. P 450 1A2, P 450 2C9, P 450 2C19, P 450 2D6, and P 450 3A4, contribute to xenobiotic metab., and compd. interaction with one of these enzymes is therefore critically evaluated.  Pharmacophore models are widely used to identify common features amongst ligands for any target.  In this study, both structure-based and ligand-based models for prominent drug-metabolizing members of the P 450 family were generated employing the software packages LigandScout and Catalyst.  Essential chem. ligand features for substrate and inhibitor activity for all five P 450 enzymes investigated were detd. and analyzed.  Finally, a collection of 11 pharmacophores for substrates and inhibitors was evaluated as an in silico P 450 profiling tool that could be used for early ADME estn. of new chem. entities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonOo9JPrdQG7Vg90H21EOLACvtfcHk0lj-VsncHILb8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtFSlt7k%253D&md5=e7b84fb801c5fcdb96d44a57de3487fc</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.2174%2F157016306776637609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157016306776637609%26sid%3Dliteratum%253Aachs%26aulast%3DSchuster%26aufirst%3DD.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DSteindl%26aufirst%3DT.%2BM.%26aulast%3DLanger%26aufirst%3DT.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520an%2520in%2520silico%2520P450%2520profiler%2520based%2520on%2520pharmacophore%2520models%26jtitle%3DCurr.%2520Drug%2520Discovery%2520Technol.%26date%3D2006%26volume%3D3%26spage%3D1%26epage%3D48%26doi%3D10.2174%2F157016306776637609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bazeley, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prithivi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struble, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Povinelli, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sem, D. S.</span><span> </span><span class="NLM_article-title">Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2698</span><span class="NLM_x">–</span> <span class="NLM_lpage">2708</span><span class="refDoi"> DOI: 10.1021/ci600267k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci600267k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyntLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=2698-2708&author=P.+S.+Bazeleyauthor=S.+Prithiviauthor=C.+A.+Strubleauthor=R.+J.+Povinelliauthor=D.+S.+Sem&title=Synergistic+use+of+compound+properties+and+docking+scores+in+neural+network+modeling+of+CYP2D6+binding%3A+predicting+affinity+and+conformational+sampling&doi=10.1021%2Fci600267k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Use of Compound Properties and Docking Scores in Neural Network Modeling of CYP2D6 Binding: Predicting Affinity and Conformational Sampling</span></div><div class="casAuthors">Bazeley, Peter S.; Prithivi, Sridevi; Struble, Craig A.; Povinelli, Richard J.; Sem, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2698-2708</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytochrome P 450 2D6 (CYP2D6) is used to develop an approach for predicting affinity and relevant binding conformation(s) for highly flexible binding sites.  The approach combines the use of docking scores and compd. properties as attributes in building a neural network (NN) model.  It begins by identifying segments of CYP2D6 that are important for binding specificity, based on structural variability among diverse CYP enzymes.  A family of distinct, low-energy conformations of CYP2D6 are generated using simulated annealing (SA) and a collection of 82 compds. with known CYP2D6 affinities are docked.  Interestingly, docking poses are obsd. on the backside of the heme as well as in the known active site.  Docking scores for the active site binders, along with compd.-specific attributes, are used to train a neural network model to properly bin compds. as strong binders, moderate binders, or nonbinders.  Attribute selection is used to preselect the most important scores and compd.-specific attributes for the model.  A prediction accuracy of 85±6% is achieved.  Dominant attributes include docking scores for three of the 20 conformations in the ensemble as well as the compd.'s formal charge, no. of arom. rings, and AlogP.  Although compd. properties were highly predictive attributes (12% improvement over baseline) in the NN-based prediction of CYP2D6 binders, their combined use with docking score attributes is synergistic (net increase of 23% above baseline).  Beyond prediction of affinity, attribute selection provides a way to identify the most relevant protein conformation(s), in terms of binding competence.  In the case of CYP2D6, three out of the ensemble of 20 SA-generated structures are found to be the most predictive for binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod8cODdvl2VbVg90H21EOLACvtfcHk0lj-VsncHILb8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyntLfE&md5=0114183912cc1375352faef0e747b7c0</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fci600267k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci600267k%26sid%3Dliteratum%253Aachs%26aulast%3DBazeley%26aufirst%3DP.%2BS.%26aulast%3DPrithivi%26aufirst%3DS.%26aulast%3DStruble%26aufirst%3DC.%2BA.%26aulast%3DPovinelli%26aufirst%3DR.%2BJ.%26aulast%3DSem%26aufirst%3DD.%2BS.%26atitle%3DSynergistic%2520use%2520of%2520compound%2520properties%2520and%2520docking%2520scores%2520in%2520neural%2520network%2520modeling%2520of%2520CYP2D6%2520binding%253A%2520predicting%2520affinity%2520and%2520conformational%2520sampling%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D2698%26epage%3D2708%26doi%3D10.1021%2Fci600267k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Yasuo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaotsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujishita, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirono, S.</span><span> </span><span class="NLM_article-title">Structure-based CoMFA as a predictive model – CYP2C9 inhibitors as a test case</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">864</span><span class="refDoi"> DOI: 10.1021/ci800313h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800313h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=853-864&author=K.+Yasuoauthor=N.+Yamaotsuauthor=H.+Goudaauthor=H.+Tsujishitaauthor=S.+Hirono&title=Structure-based+CoMFA+as+a+predictive+model+%E2%80%93+CYP2C9+inhibitors+as+a+test+case&doi=10.1021%2Fci800313h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based CoMFA As a Predictive Model - CYP2C9 Inhibitors As a Test Case</span></div><div class="casAuthors">Yasuo, Kazuya; Yamaotsu, Noriyuki; Gouda, Hiroaki; Tsujishita, Hideki; Hirono, Shuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">853-864</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we tried to establish a general scheme to create a model that could predict the affinity of small compds. to their target proteins.  This scheme consists of a search for ligand-binding sites on a protein, a generation of bound conformations (poses) of ligands in each of the sites by docking, identifications of the correct poses of each ligand by consensus scoring and MM-PBSA anal., and a construction of a CoMFA model with the obtained poses to predict the affinity of the ligands.  By using a crystal structure of CYP 2C9 and the twenty known CYP inhibitors as a test case, we obtained a CoMFA model with a good statistics, which suggested that the classification of the binding sites as well as the predicted bound poses of the ligands should be reasonable enough.  The scheme described here would give a method to predict the affinity of small compds. with a reasonable accuracy, which is expected to heighten the value of computational chem. in the drug design process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0JgE3-yVPhbVg90H21EOLACvtfcHk0ljbKu3Z47YVZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSjurg%253D&md5=a6c80422d5dff2c003af2459a882d95b</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fci800313h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800313h%26sid%3Dliteratum%253Aachs%26aulast%3DYasuo%26aufirst%3DK.%26aulast%3DYamaotsu%26aufirst%3DN.%26aulast%3DGouda%26aufirst%3DH.%26aulast%3DTsujishita%26aufirst%3DH.%26aulast%3DHirono%26aufirst%3DS.%26atitle%3DStructure-based%2520CoMFA%2520as%2520a%2520predictive%2520model%2520%25E2%2580%2593%2520CYP2C9%2520inhibitors%2520as%2520a%2520test%2520case%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D853%26epage%3D864%26doi%3D10.1021%2Fci800313h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Stjernschantz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oostenbrink, C.</span><span> </span><span class="NLM_article-title">Improved ligand–protein binding affinity predictions using multiple binding modes</span> <span class="citation_source-journal">Biophys. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span><span class="refDoi"> DOI: 10.1016/j.bpj.2010.02.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bpj.2010.02.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2010&pages=2682-2691&author=E.+Stjernschantzauthor=C.+Oostenbrink&title=Improved+ligand%E2%80%93protein+binding+affinity+predictions+using+multiple+binding+modes&doi=10.1016%2Fj.bpj.2010.02.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2010.02.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2010.02.034%26sid%3Dliteratum%253Aachs%26aulast%3DStjernschantz%26aufirst%3DE.%26aulast%3DOostenbrink%26aufirst%3DC.%26atitle%3DImproved%2520ligand%25E2%2580%2593protein%2520binding%2520affinity%2520predictions%2520using%2520multiple%2520binding%2520modes%26jtitle%3DBiophys.%2520J.%26date%3D2010%26volume%3D98%26spage%3D2682%26epage%3D2691%26doi%3D10.1016%2Fj.bpj.2010.02.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Rossato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smiesko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spreafico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedani, A.</span><span> </span><span class="NLM_article-title">Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2088</span><span class="NLM_x">–</span> <span class="NLM_lpage">2101</span><span class="refDoi"> DOI: 10.1002/cmdc.201000358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1002%2Fcmdc.201000358" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=2088-2101&author=G.+Rossatoauthor=B.+Ernstauthor=M.+Smieskoauthor=M.+Spreaficoauthor=A.+Vedani&title=Probing+small-molecule+binding+to+cytochrome+P450+2D6+and+2C9%3A+an+in+silico+protocol+for+generating+toxicity+alerts&doi=10.1002%2Fcmdc.201000358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15e&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000358%26sid%3Dliteratum%253Aachs%26aulast%3DRossato%26aufirst%3DG.%26aulast%3DErnst%26aufirst%3DB.%26aulast%3DSmiesko%26aufirst%3DM.%26aulast%3DSpreafico%26aufirst%3DM.%26aulast%3DVedani%26aufirst%3DA.%26atitle%3DProbing%2520small-molecule%2520binding%2520to%2520cytochrome%2520P450%25202D6%2520and%25202C9%253A%2520an%2520in%2520silico%2520protocol%2520for%2520generating%2520toxicity%2520alerts%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D2088%26epage%3D2101%26doi%3D10.1002%2Fcmdc.201000358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kidley, N. J.</span><span> </span><span class="NLM_article-title">Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span><span class="refDoi"> DOI: 10.1021/ci2000506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci2000506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFyktbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=1048-1063&author=A.+G.+Leachauthor=N.+J.+Kidley&title=Quantitatively+interpreted+enhanced+inhibition+of+cytochrome+P450s+by+heteroaromatic+rings+containing+nitrogen&doi=10.1021%2Fci2000506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15fR"><div class="casContent"><span class="casTitleNuber">15f</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitatively Interpreted Enhanced Inhibition of Cytochrome P450s by Heteroaromatic Rings Containing Nitrogen</span></div><div class="casAuthors">Leach, Andrew G.; Kidley, Nathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1063</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It has been known for a long time that certain substructures bind to the heme iron in cytochromes P 450.  Detection of spectroscopic changes and crystal structures of protein ligand complexes have provided qual. evidence, including for arom. nitrogen-contg. ligands.  Compds. contg. these same substructures are more likely to inhibit cytochrome P450s than expected due to lipophilicity.  These two sets of observations are not easily linked by expt., because binding to the iron atom alone is not readily measured.  Quantum mech. (d. functional) calcns. of binding energies for a no. of different arom. heterocycles to heme iron in a range of oxidn. and spin states can provide a quant. link between the obsd. structures and the biochem. inhibition that is measured.  The studies reported here for a set of heteroarom. rings contg. nitrogen begin with quantum mech. calcns. which provide geometries and binding energies.  Subsequently, AstraZeneca's database of cytochrome P 450 inhibition assays has been searched to find data that are relevant to the same set of heteroarom. compds.  These data have been analyzed in a no. of fashions to account for both the narrow dynamic range of the assays and the lipophilicity dependence of this kind of inhibition.  Finally, crystal structures have provided exptl. geometric information.  Taken together these different sources suggest that binding to the metal in our inhibition assays is dominated by FeIII in its doublet state, most likely occurring when the iron is pentavalent.  Computed binding energies to this state contrast with the hydrogen-bond acceptor ability and basicity of the compds., neither of which are able to correctly account for the effect of the particular environment in which the iron is found.  This highlights the value of modeling biochem. events as closely as can be computationally afforded.  The computational protocol devised was used to make predictions about a set of as yet unknown heteroarom. compds. suggested by Pitt et al.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBAwZ7AH7k17Vg90H21EOLACvtfcHk0lhlzjx2j4U2zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFyktbc%253D&md5=9b37fed557509c4c40c4521797bea92e</span></div><a href="/servlet/linkout?suffix=cit15f&amp;dbid=16384&amp;doi=10.1021%2Fci2000506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci2000506%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DKidley%26aufirst%3DN.%2BJ.%26atitle%3DQuantitatively%2520interpreted%2520enhanced%2520inhibition%2520of%2520cytochrome%2520P450s%2520by%2520heteroaromatic%2520rings%2520containing%2520nitrogen%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D1048%26epage%3D1063%26doi%3D10.1021%2Fci2000506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Shi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span> </span><span class="NLM_article-title">Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1941</span><span class="NLM_x">–</span> <span class="NLM_lpage">1951</span><span class="refDoi"> DOI: 10.1007/s00894-010-0903-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1007%2Fs00894-010-0903-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21120554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFejtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=1941-1951&author=R.+Shiauthor=J.+Liauthor=X.+Caoauthor=X.+Zhuauthor=X.+Lu&title=Exploration+of+the+binding+of+proton+pump+inhibitors+to+human+P450+2C9+based+on+docking+and+molecular+dynamics+simulation&doi=10.1007%2Fs00894-010-0903-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15gR"><div class="casContent"><span class="casTitleNuber">15g</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the binding of proton pump inhibitors to human P 450 2C9 based on docking and molecular dynamics simulation</span></div><div class="casAuthors">Shi, Rongwei; Li, Jinyu; Cao, Xiaoning; Zhu, Xiaolei; Lu, Xiaohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1941-1951</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Human cytochrome P 450 isoform 2C9 (CYP2C9) is one of the major drug-metabolizing isoforms, contributing to the oxidn. of 16% of the drugs currently in clin. use.  To examine the interaction mechanisms between CYP2C9 and proton pump inhibitors (PPIs), the authors used mol. docking and mol. dynamics (MD) simulation methods to investigate the conformations and interactions around the binding sites of PPI-CYP2C9 complexes.  The results from mol. docking and MD simulations demonstrated that 9 PPIs adopted 2 different conformations (extended and U-bend structures) at the binding sites and positioned themselves far above the heme moiety of CYP2C9.  The presence of the PPIs changed the secondary structure and residue flexibility of CYP2C9.  Interestingly, at the binding sites of all PPI-CYP2C9 complexes except for the lansoprazole-CYP2C9 complex, there were H--bonding networks formed from PPIs, water mols., and some residues of CYP2C9.  Moreover, there were strong hydrophobic interactions at all binding sites for PPI-CYP2C9 complexes, which indicated that electrostatic interactions and hydrophobic interactions appeared to be important for stabilizing the binding sites of most PPI-CYP2C9 complexes.  However, in the case of the lansoprazole-CYP2C9 complex, the hydrophobic interactions were more important than the electrostatic interactions in stabilizing the binding site.  In addn., an interesting conformational conversion from extended to U-bend structures was obsd. for pantoprazole, which was attributed to an H-bond interaction in the binding pocket, an internal π-π stacking interaction, and an internal electrostatic interaction of pantoprazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwjQhITPuJLVg90H21EOLACvtfcHk0lhlzjx2j4U2zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFejtb0%253D&md5=3c9e7d67cffbdaf26cba3cc209c9872c</span></div><a href="/servlet/linkout?suffix=cit15g&amp;dbid=16384&amp;doi=10.1007%2Fs00894-010-0903-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-010-0903-5%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26atitle%3DExploration%2520of%2520the%2520binding%2520of%2520proton%2520pump%2520inhibitors%2520to%2520human%2520P450%25202C9%2520based%2520on%2520docking%2520and%2520molecular%2520dynamics%2520simulation%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2011%26volume%3D17%26spage%3D1941%26epage%3D1951%26doi%3D10.1007%2Fs00894-010-0903-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Lardy, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebrun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, A.</span><span> </span><span class="NLM_article-title">Building a three-dimensional model of CYP2C9 inhibition using the Autocorrelator: an autonomous model generator</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1328</span><span class="NLM_x">–</span> <span class="NLM_lpage">1336</span><span class="refDoi"> DOI: 10.1021/ci200558e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200558e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1Sjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1328-1336&author=M.+A.+Lardyauthor=L.+Lebrunauthor=D.+Bullardauthor=C.+Kissingerauthor=A.+Gobbi&title=Building+a+three-dimensional+model+of+CYP2C9+inhibition+using+the+Autocorrelator%3A+an+autonomous+model+generator&doi=10.1021%2Fci200558e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15hR"><div class="casContent"><span class="casTitleNuber">15h</span><div class="casTitle"><span class="NLM_cas:atitle">Building a Three-Dimensional Model of CYP2C9 Inhibition Using the Autocorrelator: An Autonomous Model Generator</span></div><div class="casAuthors">Lardy, M. A.; LeBrun, L.; Bullard, D.; Kissinger, C.; Gobbi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1328-1336</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In modern day drug discovery campaigns, computational chemists have to be concerned not only about improving the potency of mols. but also reducing any off-target ADMET activity.  There are a plethora of antitargets that computational chemists may have to consider.  Fortunately many antitargets have crystal structures deposited in the PDB.  These structures are immediately useful to our Autocorrelator: an automated model generator that optimizes variables for building computational models.  This paper describes the use of the Autocorrelator to construct high quality docking models for cytochrome P 450 2C9 (CYP2C9) from two publicly available crystal structures.  Both models result in strong correlation coeffs. (R2 > 0.66) between the predicted and exptl. detd. log(IC50) values.  Results from the two models overlap well with each other, converging on the same scoring function, deprotonated charge state, and predicted the binding orientation for our collection of mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqleMG7422K97Vg90H21EOLACvtfcHk0lhzH421fS4-yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1Sjtrg%253D&md5=2eddd2395a7831b3d49c0e0b50344089</span></div><a href="/servlet/linkout?suffix=cit15h&amp;dbid=16384&amp;doi=10.1021%2Fci200558e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200558e%26sid%3Dliteratum%253Aachs%26aulast%3DLardy%26aufirst%3DM.%2BA.%26aulast%3DLebrun%26aufirst%3DL.%26aulast%3DBullard%26aufirst%3DD.%26aulast%3DKissinger%26aufirst%3DC.%26aulast%3DGobbi%26aufirst%3DA.%26atitle%3DBuilding%2520a%2520three-dimensional%2520model%2520of%2520CYP2C9%2520inhibition%2520using%2520the%2520Autocorrelator%253A%2520an%2520autonomous%2520model%2520generator%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D1328%26epage%3D1336%26doi%3D10.1021%2Fci200558e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Sridhar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foroozesh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C. L.</span><span> </span><span class="NLM_article-title">Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">9283</span><span class="NLM_x">–</span> <span class="NLM_lpage">9305</span><span class="refDoi"> DOI: 10.3390/molecules17089283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.3390%2Fmolecules17089283" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=9283-9305&author=J.+Sridharauthor=J.+Liuauthor=M.+Foroozeshauthor=C.+L.+Stevens&title=Insights+on+cytochrome+p450+enzymes+and+inhibitors+obtained+through+QSAR+studies&doi=10.3390%2Fmolecules17089283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15i&amp;dbid=16384&amp;doi=10.3390%2Fmolecules17089283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules17089283%26sid%3Dliteratum%253Aachs%26aulast%3DSridhar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DForoozesh%26aufirst%3DM.%26aulast%3DStevens%26aufirst%3DC.%2BL.%26atitle%3DInsights%2520on%2520cytochrome%2520p450%2520enzymes%2520and%2520inhibitors%2520obtained%2520through%2520QSAR%2520studies%26jtitle%3DMolecules%26date%3D2012%26volume%3D17%26spage%3D9283%26epage%3D9305%26doi%3D10.3390%2Fmolecules17089283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Brändén, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjögren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnecke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Y.</span><span> </span><span class="NLM_article-title">Structure-based ligand design to overcome CYP inhibition in drug discovery projects</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">911</span><span class="refDoi"> DOI: 10.1016/j.drudis.2014.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.drudis.2014.03.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=905-911&author=G.+Br%C3%A4nd%C3%A9nauthor=T.+Sj%C3%B6grenauthor=V.+Schneckeauthor=Y.+Xue&title=Structure-based+ligand+design+to+overcome+CYP+inhibition+in+drug+discovery+projects&doi=10.1016%2Fj.drudis.2014.03.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DBr%25C3%25A4nd%25C3%25A9n%26aufirst%3DG.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DT.%26aulast%3DSchnecke%26aufirst%3DV.%26aulast%3DXue%26aufirst%3DY.%26atitle%3DStructure-based%2520ligand%2520design%2520to%2520overcome%2520CYP%2520inhibition%2520in%2520drug%2520discovery%2520projects%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D905%26epage%3D911%26doi%3D10.1016%2Fj.drudis.2014.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sodhi, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukadam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J. S.</span><span> </span><span class="NLM_article-title">1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1124/dmd.113.055913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1124%2Fdmd.113.055913" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=813-817&author=J.+K.+Sodhiauthor=K.+A.+Fordauthor=S.+Mukadamauthor=S.+Wongauthor=C.+E.+Hopauthor=S.+C.+Khojastehauthor=J.+S.+Halladay&title=1-Aminobenzotriazole+coincubated+with+%28S%29-warfarin+results+in+potent+inactivation+of+CYP2C9&doi=10.1124%2Fdmd.113.055913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.055913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.055913%26sid%3Dliteratum%253Aachs%26aulast%3DSodhi%26aufirst%3DJ.%2BK.%26aulast%3DFord%26aufirst%3DK.%2BA.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26atitle%3D1-Aminobenzotriazole%2520coincubated%2520with%2520%2528S%2529-warfarin%2520results%2520in%2520potent%2520inactivation%2520of%2520CYP2C9%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D813%26epage%3D817%26doi%3D10.1124%2Fdmd.113.055913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgFd0dsD8wFnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lovering, F.</span><span> </span><span class="NLM_article-title">Escape from Flatland 2: complexity and promiscuity</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">515</span><span class="NLM_x">–</span> <span class="NLM_lpage">519</span><span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+Flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lgFd0dsD8wFnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520Flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lhKegn7F33sfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roychowdhury, A.</span><span> </span><span class="NLM_article-title">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3605</span><span class="NLM_x">–</span> <span class="NLM_lpage">3621</span><span class="refDoi"> DOI: 10.2174/092986712801323180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.2174%2F092986712801323180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=22680629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3605-3621&author=S.+Kumarauthor=R.+Sharmaauthor=A.+Roychowdhury&title=Modulation+of+cytochrome-P450+inhibition+%28CYP%29+in+drug+discovery%3A+a+medicinal+chemistry+perspective&doi=10.2174%2F092986712801323180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span></div><div class="casAuthors">Kumar, Sanjay; Sharma, Rajiv; Roychowdhury, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3605-3621</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP450) has widely been implicated for drug-drug interactions (DDI) in the pharmaceutical industry.  Inhibition or induction of this enzyme family has led to withdrawal of multiple drugs from the market leading to major time and financial losses for the pharmaceutical industry.  CYP450 plays a prevailing role in the biotransformation of a large no. of structurally diverse drugs.  Few isoenzymes of the CYP enzyme family (CYP3A4, 2D6 and 2C9 family) are mainly involved in metab. of most of the drugs.  To avoid such interactions and potentially minimize DDI, major pharmaceutical organizations prefer to incorporate CYP enzyme screening at an early stage of their discovery program.  While this has been a prevalent practice in the pharmaceutical industry lately, there is very limited literature available reviewing the relationship between chemotypes and CYP isoforms.  This review will collate literature pertaining to CYP-inhibition modulation through physicochem. parameters and chem. modification and thus bring to focus commonly used trends by medicinal chemists world-wide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVIogYUZJywLVg90H21EOLACvtfcHk0lhKegn7F33sfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF&md5=1f675ef0f7cd31a254b82d8b2eaac44b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F092986712801323180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801323180%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DRoychowdhury%26aufirst%3DA.%26atitle%3DModulation%2520of%2520cytochrome-P450%2520inhibition%2520%2528CYP%2529%2520in%2520drug%2520discovery%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3605%26epage%3D3621%26doi%3D10.2174%2F092986712801323180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span> </span><span class="NLM_article-title">Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1121</span><span class="NLM_x">–</span> <span class="NLM_lpage">1130</span><span class="refDoi"> DOI: 10.1002/cbic.201402023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1002%2Fcbic.201402023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1121-1130&author=A.+Ohauthor=Y.-C.+Hoauthor=M.+Zakauthor=Y.+Liuauthor=X.+Chenauthor=P.-w.+Yuenauthor=X.+Zhengauthor=Y.+Liuauthor=P.+S.+Dragovichauthor=W.+Wang&title=Structural+and+biochemical+analyses+of+the+catalysis+and+potency+impact+of+inhibitor+phosphoribosylation+by+human+nicotinamide+phosphoribosyltransferase&doi=10.1002%2Fcbic.201402023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402023%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DWang%26aufirst%3DW.%26atitle%3DStructural%2520and%2520biochemical%2520analyses%2520of%2520the%2520catalysis%2520and%2520potency%2520impact%2520of%2520inhibitor%2520phosphoribosylation%2520by%2520human%2520nicotinamide%2520phosphoribosyltransferase%26jtitle%3DChemBioChem%26date%3D2014%26volume%3D15%26spage%3D1121%26epage%3D1130%26doi%3D10.1002%2Fcbic.201402023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Additional discussion on the relationship between the ability of NAMPT inhibitors to form phosphoribosylated adducts and the cell-based NAMPT potency of such compounds is presented in refs <a onclick="showRef(event, 'cit9a'); return false;" href="javascript:void(0);" class="ref cit9a">9a</a> and <a onclick="showRef(event, 'cit9c'); return false;" href="javascript:void(0);" class="ref cit9c">9c</a> and additional citations therein.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Additional+discussion+on+the+relationship+between+the+ability+of+NAMPT+inhibitors+to+form+phosphoribosylated+adducts+and+the+cell-based+NAMPT+potency+of+such+compounds+is+presented+in+refs+9a+and+9c+and+additional+citations+therein."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Watson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roulston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bélec, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billot, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcellus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bédard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branchaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dairi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gratton, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakau, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khadir, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavoie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawless, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turcotte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shore, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauparlant, P.</span><span> </span><span class="NLM_article-title">The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">5872</span><span class="NLM_x">–</span> <span class="NLM_lpage">5888</span><span class="refDoi"> DOI: 10.1128/MCB.00112-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1128%2FMCB.00112-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=19703994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=5872-5888&author=M.+Watsonauthor=A.+Roulstonauthor=L.+B%C3%A9lecauthor=X.+Billotauthor=R.+Marcellusauthor=D.+B%C3%A9dardauthor=C.+Bernierauthor=S.+Branchaudauthor=H.+Chanauthor=K.+Dairiauthor=K.+Gilbertauthor=D.+Gouletauthor=M.+O.+Grattonauthor=H.+Isakauauthor=A.+Jangauthor=A.+Khadirauthor=E.+Kochauthor=M.+Lavoieauthor=M.+Lawlessauthor=M.+Nguyenauthor=D.+Paquetteauthor=E.+Turcotteauthor=A.+Bergerauthor=M.+Mitchellauthor=G.+C.+Shoreauthor=P.+Beauparlant&title=The+small+molecule+GMX1778+is+a+potent+inhibitor+of+NAD%2B+biosynthesis%3A+strategy+for+enhanced+therapy+in+nicotinic+acid+phosphoribosyltransferase+1-deficient+tumors&doi=10.1128%2FMCB.00112-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors</span></div><div class="casAuthors">Watson, Mark; Roulston, Anne; Belec, Laurent; Billot, Xavier; Marcellus, Richard; Bedard, Dominique; Bernier, Cynthia; Branchaud, Stephane; Chan, Helen; Dairi, Kenza; Gilbert, Karine; Goulet, Daniel; Gratton, Michel-Olivier; Isakau, Henady; Jang, Anne; Khadir, Abdelkrim; Koch, Elizabeth; Lavoie, Manon; Lawless, Michael; Nguyen, Mai; Paquette, Denis; Turcotte, Emilie; Berger, Alvin; Mitchell, Matthew; Shore, Gordon C.; Beauparlant, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5872-5888</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GMX1777 is a prodrug of the small mol. GMX1778, currently in phase I clin. trials for the treatment of cancer.  We describe findings indicating that GMX1778 is a potent and specific inhibitor of the NAD+ biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT).  Cancer cells have a very high rate of NAD+ turnover, which makes NAD+ modulation an attractive target for anticancer therapy.  Selective inhibition by GMX1778 of NAMPT blocks the prodn. of NAD+ and results in tumor cell death.  Furthermore, GMX1778 is phosphoribosylated by NAMPT, which increases its cellular retention.  The cytotoxicity of GMX1778 can be bypassed with exogenous nicotinic acid (NA), which permits NAD+ repletion via NA phosphoribosyltransferase 1 (NAPRT1).  The cytotoxicity of GMX1778 in cells with NAPRT1 deficiency, however, cannot be rescued by NA.  Analyses of NAPRT1 mRNA and protein levels in cell lines and primary tumor tissue indicate that high frequencies of glioblastomas, neuroblastomas, and sarcomas are deficient in NAPRT1 and not susceptible to rescue with NA.  As a result, the therapeutic index of GMX1777 can be widended in the treatment animals bearing NAPRT1-deficient tumors by coadministration with NA.  This provides the rationale for a novel therapeutic approach for the use of GMX1777 in the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT7TUeIRTTIrVg90H21EOLACvtfcHk0lhz48QRdAOYbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKntbvE&md5=a6157117d7e67368954ff5ae11986879</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1128%2FMCB.00112-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00112-09%26sid%3Dliteratum%253Aachs%26aulast%3DWatson%26aufirst%3DM.%26aulast%3DRoulston%26aufirst%3DA.%26aulast%3DB%25C3%25A9lec%26aufirst%3DL.%26aulast%3DBillot%26aufirst%3DX.%26aulast%3DMarcellus%26aufirst%3DR.%26aulast%3DB%25C3%25A9dard%26aufirst%3DD.%26aulast%3DBernier%26aufirst%3DC.%26aulast%3DBranchaud%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DH.%26aulast%3DDairi%26aufirst%3DK.%26aulast%3DGilbert%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DD.%26aulast%3DGratton%26aufirst%3DM.%2BO.%26aulast%3DIsakau%26aufirst%3DH.%26aulast%3DJang%26aufirst%3DA.%26aulast%3DKhadir%26aufirst%3DA.%26aulast%3DKoch%26aufirst%3DE.%26aulast%3DLavoie%26aufirst%3DM.%26aulast%3DLawless%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DPaquette%26aufirst%3DD.%26aulast%3DTurcotte%26aufirst%3DE.%26aulast%3DBerger%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DM.%26aulast%3DShore%26aufirst%3DG.%2BC.%26aulast%3DBeauparlant%26aufirst%3DP.%26atitle%3DThe%2520small%2520molecule%2520GMX1778%2520is%2520a%2520potent%2520inhibitor%2520of%2520NAD%252B%2520biosynthesis%253A%2520strategy%2520for%2520enhanced%2520therapy%2520in%2520nicotinic%2520acid%2520phosphoribosyltransferase%25201-deficient%2520tumors%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2009%26volume%3D29%26spage%3D5872%26epage%3D5888%26doi%3D10.1128%2FMCB.00112-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Gunzner-Toste, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckmelter, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clodfelter, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukadam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodhi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, P.-w.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3531</span><span class="NLM_x">–</span> <span class="NLM_lpage">3538</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.bmcl.2013.04.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=23668988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsFGrsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3531-3538&author=J.+Gunzner-Tosteauthor=G.+Zhaoauthor=P.+Bauerauthor=T.+Baumeisterauthor=A.+J.+Buckmelterauthor=M.+Caligiuriauthor=K.+H.+Clodfelterauthor=B.+Fuauthor=B.+Hanauthor=Y.-C.+Hoauthor=N.+Kleyauthor=X.+Liangauthor=B.+M.+Liedererauthor=J.+Linauthor=S.+Mukadamauthor=T.+O%E2%80%99Brienauthor=A.+Ohauthor=D.+J.+Reynoldsauthor=G.+Sharmaauthor=N.+Skeltonauthor=C.+C.+Smithauthor=J.+Sodhiauthor=W.+Wangauthor=Z.+Wangauthor=Y.+Xiaoauthor=P.-w.+Yuenauthor=M.+Zakauthor=L.+Zhangauthor=X.+Zhengauthor=K.+W.+Bairauthor=P.+S.+Dragovich&title=Discovery+of+potent+and+efficacious+urea-containing+nicotinamide+phosphoribosyltransferase+%28NAMPT%29+inhibitors+with+reduced+CYP2C9+inhibition+properties&doi=10.1016%2Fj.bmcl.2013.04.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties</span></div><div class="casAuthors">Gunzner-Toste, Janet; Zhao, Guiling; Bauer, Paul; Baumeister, Timm; Buckmelter, Alexandre J.; Caligiuri, Maureen; Clodfelter, Karl H.; Fu, Bang; Han, Bingsong; Ho, Yen-Ching; Kley, Nikolai; Liang, Xiaorong; Liederer, Bianca M.; Lin, Jian; Mukadam, Sophie; O'Brien, Thomas; Oh, Angela; Reynolds, Dominic J.; Sharma, Geeta; Skelton, Nicholas; Smith, Chase C.; Sodhi, Jasleen; Wang, Weiru; Wang, Zhongguo; Xiao, Yang; Yuen, Po-wai; Zak, Mark; Zhang, Lei; Zheng, Xiaozhang; Bair, Kenneth W.; Dragovich, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3531-3538</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Potent, reversible inhibition of the cytochrome P 450 CYP2C9 isoform was obsd. in a series of urea-contg. nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.  This unwanted property was successfully removed from the described inhibitors through a combination of structure-based design and medicinal chem. activities.  An optimized compd., I, which did not inhibit CYP2C9 exhibited potent anti-NAMPT activity (BC NAMPT IC50 = 3 nM; A2780 antiproliferative IC50 = 70 nM), good mouse PK properties, and was efficacious in an A2780 mouse xenograft model.  The crystal structure of this compd. in complex with the NAMPT protein is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvravlmt8_mbVg90H21EOLACvtfcHk0lhz48QRdAOYbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsFGrsrk%253D&md5=6db1abf81339d6ce9d3d51e85cdfc1e6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.040%26sid%3Dliteratum%253Aachs%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DP.%26aulast%3DBaumeister%26aufirst%3DT.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DCaligiuri%26aufirst%3DM.%26aulast%3DClodfelter%26aufirst%3DK.%2BH.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DHo%26aufirst%3DY.-C.%26aulast%3DKley%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DSodhi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DP.-w.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520efficacious%2520urea-containing%2520nicotinamide%2520phosphoribosyltransferase%2520%2528NAMPT%2529%2520inhibitors%2520with%2520reduced%2520CYP2C9%2520inhibition%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3531%26epage%3D3538%26doi%3D10.1016%2Fj.bmcl.2013.04.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">See Supporting Information, <a class="ref internalNav" href="#notes-1" aria-label="Figure S1">Figure S1</a>, for the Fsp3 distribution of the 119-membered library.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coons, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brillantes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bair, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmont, L. D.</span><span> </span><span class="NLM_article-title">Structural basis for resistance to diverse classes of NAMPT inhibitors</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e109366</span><span class="refDoi"> DOI: 10.1371/journal.pone.0109366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1371%2Fjournal.pone.0109366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25285661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKiur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e109366&author=W.+Wangauthor=K.+Elkinsauthor=A.+Ohauthor=Y.+C.+Hoauthor=J.+Wuauthor=H.+Liauthor=Y.+Xiaoauthor=M.+Kwongauthor=M.+Coonsauthor=B.+Brillantesauthor=E.+Chengauthor=L.+Crockerauthor=P.+S.+Dragovichauthor=D.+Sampathauthor=X.+Zhengauthor=K.+W.+Bairauthor=T.+O%E2%80%99Brienauthor=L.+D.+Belmont&title=Structural+basis+for+resistance+to+diverse+classes+of+NAMPT+inhibitors&doi=10.1371%2Fjournal.pone.0109366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for resistance to diverse classes of NAMPT inhibitors</span></div><div class="casAuthors">Wang, Weiru; Elkins, Kristi; Oh, Angela; Ho, Yen-Ching; Wu, Jiansheng; Li, Hong; Xiao, Yang; Kwong, Mandy; Coons, Mary; Brillantes, Bobby; Cheng, Eric; Crocker, Lisa; Dragovich, Peter S.; Sampath, Deepak; Zheng, Xiaozhang; Bair, Kenneth W.; O'Brien, Thomas; Belmont, Lisa D.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e109366/1-e109366/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metab.  However, the development of drug resistance commonly limits the efficacy of cancer therapeutics.  This study identifies mutations in NAMPT that confer resistance to a novel NAMPT inhibitor, GNE-618, in cell culture and in vivo, thus demonstrating that the cytotoxicity of GNE-618 is on target.  We det. the crystal structures of six NAMPT mutants in the apo form and in complex with various inhibitors and use cellular, biochem. and structural data to elucidate two resistance mechanisms.  One is the surprising finding of allosteric modulation by mutation of residue Ser165, resulting in unwinding of an a-helix that binds the NAMPT substrate 5-phosphoribosyl-1-pyrophosphate (PRPP).  The other mechanism is orthosteric blocking of inhibitor binding by mutations of Gly217.  Furthermore, by evaluating a panel of diverse small mol. inhibitors, we unravel inhibitor structure activity relationships on the mutant enzymes.  These results provide valuable insights into the design of next generation NAMPT inhibitors that offer improved therapeutic potential by evading certain mechanisms of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP5iFUmBeJC7Vg90H21EOLACvtfcHk0lgWgf4eZKCl_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKiur%252FI&md5=cdae9fb4ad44c429e24aaf0f297fcfb8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0109366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0109366%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DElkins%26aufirst%3DK.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DY.%2BC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DKwong%26aufirst%3DM.%26aulast%3DCoons%26aufirst%3DM.%26aulast%3DBrillantes%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DE.%26aulast%3DCrocker%26aufirst%3DL.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DBair%26aufirst%3DK.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26atitle%3DStructural%2520basis%2520for%2520resistance%2520to%2520diverse%2520classes%2520of%2520NAMPT%2520inhibitors%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De109366%26doi%3D10.1371%2Fjournal.pone.0109366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Khan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span> </span><span class="NLM_article-title">Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">582</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span><span class="refDoi"> DOI: 10.1038/nsmb1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1038%2Fnsmb1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=16783377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD28Xms1elt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=582-588&author=J.+A.+Khanauthor=X.+Taoauthor=L.+Tong&title=Molecular+basis+for+the+inhibition+of+human+NMPRTase%2C+a+novel+target+for+anticancer+agents&doi=10.1038%2Fnsmb1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents</span></div><div class="casAuthors">Khan, Javed A.; Tao, Xiao; Tong, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">582-588</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors.  The authors have detd. the crystal structures at up to 2.1-Å resoln. of human and murine NMPRTase, alone and in complex with the reaction product NMN or the inhibitor FK866.  The structures suggest that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies.  FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866.  Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate.  Our structural and biochem. studies provide a starting point for the development of new anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1s-XY1uB70LVg90H21EOLACvtfcHk0lgLtD1SotcMIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xms1elt7k%253D&md5=debef567dbcf629422472ef1b63dc396</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnsmb1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb1105%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BA.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DTong%26aufirst%3DL.%26atitle%3DMolecular%2520basis%2520for%2520the%2520inhibition%2520of%2520human%2520NMPRTase%252C%2520a%2520novel%2520target%2520for%2520anticancer%2520agents%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D582%26epage%3D588%26doi%3D10.1038%2Fnsmb1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">The discovery of these left-hand side moieties was previously disclosed in refs <a onclick="showRef(event, 'cit9a cit9b cit9c cit9e'); return false;" href="javascript:void(0);" class="ref cit9a cit9b cit9c cit9e">9a−9c, 9e</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><div class="note"><p class="first last">A review on the use of carbamates in Medicinal Chemistry was recently published</p></div><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brindisi, M.</span><span> </span><span class="NLM_article-title">Organic carbamates in drug design and medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2895</span><span class="NLM_x">–</span> <span class="NLM_lpage">2940</span><span class="refDoi"> DOI: 10.1021/jm501371s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501371s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2895-2940&author=A.+K.+Ghoshauthor=M.+Brindisi&title=Organic+carbamates+in+drug+design+and+medicinal+chemistry&doi=10.1021%2Fjm501371s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Organic Carbamates in Drug Design and Medicinal Chemistry</span></div><div class="casAuthors">Ghosh, Arun K.; Brindisi, Margherita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2895-2940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The carbamate group is a key structural motif in many approved drugs and prodrugs.  There is an increasing use of carbamates in medicinal chem. and many derivs. are specifically designed to make drug-target interactions through their carbamate moiety.  In this Perspective, we present properties and stabilities of carbamates, reagents and chem. methodologies for the synthesis of carbamates, and recent applications of carbamates in drug design and medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGollKFyXYJJHLVg90H21EOLACvtfcHk0lgLtD1SotcMIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWkuw%253D%253D&md5=e3548247931b74b60e299ada1e27dda5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm501371s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501371s%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DBrindisi%26aufirst%3DM.%26atitle%3DOrganic%2520carbamates%2520in%2520drug%2520design%2520and%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2895%26epage%3D2940%26doi%3D10.1021%2Fjm501371s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">cLogD<sub>pH7.4</sub> values were calculated using the Mo Kα sofware (<a href="http://www.moldiscovery.com" class="extLink">www.moldiscovery.com</a> (ref <a onclick="showRef(event, 'cit28a'); return false;" href="javascript:void(0);" class="ref cit28a">28a</a>)) and a custom p<i>K</i><sub>a</sub> model (ref <a onclick="showRef(event, 'cit28b'); return false;" href="javascript:void(0);" class="ref cit28b">28b</a>).</p></div><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sforna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">New and original pKa prediction method using grid molecular interaction fields</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2172</span><span class="NLM_x">–</span> <span class="NLM_lpage">2181</span><span class="refDoi"> DOI: 10.1021/ci700018y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci700018y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2172-2181&author=F.+Millettiauthor=L.+Storchiauthor=G.+Sfornaauthor=G.+Cruciani&title=New+and+original+pKa+prediction+method+using+grid+molecular+interaction+fields&doi=10.1021%2Fci700018y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">New and Original pKa Prediction Method Using Grid Molecular Interaction Fields</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Sforna, Gianluca; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2172-2181</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most important physicochem. properties of a mol. is pKa.  It is known that two parameters imperative in ADME profiling, soly., and lipophilicity are governed by pKa, and receptor binding can be influenced by pKa.  Because most drugs are ionized in physiol. conditions, pKa is particularly relevant to medicinal chem.  Despite the numerous advances in high-throughput measurements, in silico detn. is still the fastest and cheapest way of obtaining pKa.  This paper presents a new original computational method for pKa prediction of org. compds.  Descriptors were generated using the program GRID, and these descriptors are based on mol. interaction fields precomputed on a set of mol. fragments.  The new method was developed, trained, and cross-validated by using a large and diverse data set of 24 617 pKa values.  This paper presents the results for a class of 421 acidic nitrogen compds. (RMSE = 0.41, r2 = 0.97, q2 = 0.87) and for a class of 947 six-membered N-heterocyclic bases (RMSE = 0.60, r2 = 0.93, q2 = 0.85).  For external validation 28 novel compds. were selected that covered nine different ionizable groups, and 39 pKa values could be exptl. detd. by spectral gradient anal. (SGA).  Comparison of exptl. pKa with calcd. pKa demonstrated that the predictive ability of the method is good (external set, r2 = 0.85, RMSE = 0.90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEk0uiS1E6rVg90H21EOLACvtfcHk0lgLtD1SotcMIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF&md5=f2b1dec853ccb0ef1a40540d234232fb</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fci700018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700018y%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DSforna%26aufirst%3DG.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DNew%2520and%2520original%2520pKa%2520prediction%2520method%2520using%2520grid%2520molecular%2520interaction%2520fields%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2172%26epage%3D2181%26doi%3D10.1021%2Fci700018y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goracci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4270</span><span class="NLM_x">–</span> <span class="NLM_lpage">4279</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2010.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series&doi=10.1016%2Fj.ejmech.2010.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKα, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKα, such as hydrazide derivs.  These findings helped us to enhance MoKα, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0liyS8FF1yVrMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D4270%26epage%3D4279%26doi%3D10.1016%2Fj.ejmech.2010.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="note"><p class="first last">We have characterized and reported on aspects of the in vitro and in vivo toxicity profiles of previously reported NAMPT inhibitors.</p></div><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liederer, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uppal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span> </span><span class="NLM_article-title">Retinal toxicity, in vivo and in vitro, associated with inhibition of Nicotinamide Phosphoribosyltransferase</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">144</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1093/toxsci/kfu268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1093%2Ftoxsci%2Fkfu268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25505128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2015&pages=163-172&author=T.+S.+Zabkaauthor=J.+Singhauthor=P.+Dhawanauthor=B.+M.+Liedererauthor=J.+Oehauthor=M.+A.+Kaussauthor=Y.+Xiaoauthor=M.+Zakauthor=T.+Linauthor=B.+McCrayauthor=N.+Laauthor=T.+Nguyenauthor=J.+Beyerauthor=C.+Farmanauthor=H.+Uppalauthor=P.+S.+Dragovichauthor=T.+O%E2%80%99Brienauthor=D.+Sampathauthor=D.+L.+Misner&title=Retinal+toxicity%2C+in+vivo+and+in+vitro%2C+associated+with+inhibition+of+Nicotinamide+Phosphoribosyltransferase&doi=10.1093%2Ftoxsci%2Fkfu268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase</span></div><div class="casAuthors">Zabka, Tanja S.; Singh, Jatinder; Dhawan, Preeti; Liederer, Bianca M.; Oeh, Jason; Kauss, Mara A.; Xiao, Yang; Zak, Mark; Lin, Tori; McCray, Bobbi; La, Nghi; Nguyen, Trung; Beyer, Joseph; Farman, Cynthia; Uppal, Hirdesh; Dragovich, Peter S.; O'Brien, Thomas; Sampath, Deepak; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">163-172</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Nicotinamide phosphoribosyltransferase (NAMPT) is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone.  NAMPT is of interest for oncol., because it catalyzes the rate-limiting step in the salvage pathway to generate NAD, which is considered a universal energy- and signal-carrying mol. involved in cellular energy metab. and many homeostatic functions.  This manuscript describes NAMPT inhibitor-induced retinal toxicity that was identified in rodent safety studies.  This toxicity had a rapid onset and progression and initially targeted the photoreceptor and outer nuclear layers.  Using in vivo safety and efficacy rodent studies, human and mouse cell line potency data, human and rat retinal pigmented epithelial cell in vitro systems, and rat mRNA expression data of NAMPT, nicotinic acid phosphoribosyltransferase, and NMN adenylyltransferease (NMNAT) in several tissues from rat including retina, we demonstrate that the retinal toxicity is on-target and likely human relevant.  We demonstrate that this toxicity is not mitigated by coadministration of nicotinic acid (NA), which can enable NAD prodn. through the NAMPT-independent pathway.  Further, modifying the physiochem. properties of NAMPT inhibitors could not sufficiently reduce retinal exposure.  Our work highlights opportunities to leverage appropriately designed efficacy studies to identify known and measurable safety findings to screen compds. more rapidly and reduce animal use.  It also demonstrates that in vitro systems with the appropriate cell compn. and relevant biol. and toxicity endpoints can provide tools to investigate mechanism of toxicity and the human translation of nonclin. safety concerns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp83daf3aktlLVg90H21EOLACvtfcHk0liyS8FF1yVrMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2rsbrI&md5=2db52370c9372badbcf31c7800acc94f</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfu268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfu268%26sid%3Dliteratum%253Aachs%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DDhawan%26aufirst%3DP.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DKauss%26aufirst%3DM.%2BA.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DMcCray%26aufirst%3DB.%26aulast%3DLa%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DBeyer%26aufirst%3DJ.%26aulast%3DFarman%26aufirst%3DC.%26aulast%3DUppal%26aufirst%3DH.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DRetinal%2520toxicity%252C%2520in%2520vivo%2520and%2520in%2520vitro%252C%2520associated%2520with%2520inhibition%2520of%2520Nicotinamide%2520Phosphoribosyltransferase%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D144%26spage%3D163%26epage%3D172%26doi%3D10.1093%2Ftoxsci%2Fkfu268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tarrant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhawan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DosSantos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dambach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uppal, H.</span><span> </span><span class="NLM_article-title">Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid</span> <span class="citation_source-journal">Toxicol. Mech. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.3109/15376516.2015.1014080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.3109%2F15376516.2015.1014080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=25894564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptVSjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=201-211&author=J.+M.+Tarrantauthor=P.+Dhawanauthor=J.+Singhauthor=T.+S.+Zabkaauthor=E.+Clarkeauthor=G.+DosSantosauthor=P.+S.+Dragovichauthor=D.+Sampathauthor=T.+Linauthor=B.+McCrayauthor=N.+Laauthor=T.+Nguyenauthor=A.+Kaussauthor=D.+Dambachauthor=D.+L.+Misnerauthor=D.+Diazauthor=H.+Uppal&title=Preclinical+models+of+nicotinamide+phosphoribosyltransferase+inhibitor-mediated+hematotoxicity+and+mitigation+by+co-treatment+with+nicotinic+acid&doi=10.3109%2F15376516.2015.1014080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid</span></div><div class="casAuthors">Tarrant, Jacqueline M.; Dhawan, Preeti; Singh, Jatinder; Zabka, Tanja S.; Clarke, Emer; DosSantos, Garry; Dragovich, Peter S.; Sampath, Deepak; Lin, Tori; McCray, Bobbi; La, Nghi; Nguyen, Trung; Kauss, Ariel; Dambach, Donna; Misner, Dinah L.; Diaz, Dolores; Uppal, Hirdesh</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Mechanisms and Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-211</span>CODEN:
                <span class="NLM_cas:coden">TMMOCP</span>;
        ISSN:<span class="NLM_cas:issn">1537-6516</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">NAD (NAD) is an essential co-factor in glycolysis and is a key mol. involved in maintaining cellular energy metab.  Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step of an important salvage pathway in which nicotinamide is recycled into NAD.  NAMPT is up-regulated in many types of cancer and NAMPT inhibitors (NAMPTi) have potential therapeutic benefit in cancer by impairing tumor metab.  Clin. trials with NAMPTi APO-866 and GMX-1778, however, failed to reach projected efficacious exposures due to dose-limiting thrombocytopenia.  We evaluated preclin. models for thrombocytopenia that could be used in candidate drug selection and risk mitigation strategies for NAMPTi-related toxicity.  Rats treated with a suite of structurally diverse and potent NAMPTi at max. tolerated doses had decreased reticulocyte and lymphocyte counts, but no thrombocytopenia.  We therefore evaluated and qualified a human colony forming unit-megakaryocyte (CFU-MK) as in vitro predictive model of NAMPTi-induced MK toxicity and thrombocytopenia.  We further demonstrate that the MK toxicity is on-target based on the evidence that nicotinic acid (NA), which is converted to NAD via a NAMPT-independent pathway, can mitigate NAMPTi toxicity to human CFU-MK in vitro and was also protective for the hematotoxicity in rats in vivo.  Finally, assessment of CFU-MK and human platelet bioenergetics and function show that NAMPTi was toxic to MK and not platelets, which is consistent with the clin. obsd. time-course of thrombocytopenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVoRVrRU14ubVg90H21EOLACvtfcHk0lj-xOo0bLOMBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptVSjt7k%253D&md5=536137fdb1961f4dbf5807d9655e6549</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.3109%2F15376516.2015.1014080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15376516.2015.1014080%26sid%3Dliteratum%253Aachs%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DDhawan%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DClarke%26aufirst%3DE.%26aulast%3DDosSantos%26aufirst%3DG.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DMcCray%26aufirst%3DB.%26aulast%3DLa%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DKauss%26aufirst%3DA.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DUppal%26aufirst%3DH.%26atitle%3DPreclinical%2520models%2520of%2520nicotinamide%2520phosphoribosyltransferase%2520inhibitor-mediated%2520hematotoxicity%2520and%2520mitigation%2520by%2520co-treatment%2520with%2520nicotinic%2520acid%26jtitle%3DToxicol.%2520Mech.%2520Methods%26date%3D2015%26volume%3D25%26spage%3D201%26epage%3D211%26doi%3D10.3109%2F15376516.2015.1014080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">The chemical purities of all final compounds described in this work were >95% at the time of their biological assessments as determined by LCMS analysis with UV detection at 220 and/or 254 nm. We also noted, however, that some molecules containing the 2,3-dihydro-1<i>H</i>-pyrrolo[3,4-<i>c</i>]pyridine-derived urea moiety experienced oxidation upon prolonged storage (detected via LCMS analysis of stored materials). No attempts were made to study or suppress this process and the oxidized compounds were neither isolated nor biologically characterized. LCMS fragmentation patterns suggested the oxidation products depicted below, but no additional analyses were conducted to confirm these assignments.<span class="NLM_inline-graphic"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-18/acs.jmedchem.6b00697/20160916/images/medium/jm-2016-00697p_0036.tif.gif" alt="" /></img></span></p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Djakovitch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, K.</span><span> </span><span class="NLM_article-title">Pd-catalyzed Heck arylation of cycloalkenes—studies on selectivity comparing homogeneous and heterogeneous catalysts</span> <span class="citation_source-journal">J. Mol. Catal. A: Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">219</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1016/j.molcata.2004.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=10.1016%2Fj.molcata.2004.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Wrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=219&publication_year=2004&pages=121-130&author=L.+Djakovitchauthor=M.+Wagnerauthor=C.+G.+Hartungauthor=M.+Bellerauthor=K.+Koehler&title=Pd-catalyzed+Heck+arylation+of+cycloalkenes%E2%80%94studies+on+selectivity+comparing+homogeneous+and+heterogeneous+catalysts&doi=10.1016%2Fj.molcata.2004.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-catalyzed Heck arylation of cycloalkenes: studies on selectivity comparing homogeneous and heterogeneous catalysts</span></div><div class="casAuthors">Djakovitch, L.; Wagner, M.; Hartung, C. G.; Beller, M.; Koehler, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Catalysis A: Chemical</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">219</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-130</span>CODEN:
                <span class="NLM_cas:coden">JMCCF2</span>;
        ISSN:<span class="NLM_cas:issn">1381-1169</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Heck reactions of aryl bromides with cyclohexene and cyclopentene catalyzed by typical homogeneous as well as heterogeneous Pd catalysts (Pd/C, Pd/SiO2, Pd/MgO, Pd/Al2O3, and Pd(0), Pd(II) and [Pd(NH3)4]2+ in zeolites Y or ZSM-5) have been studied in order to get detailed information on the reaction mechanism with regard to the catalyst.  The focus of the present investigation was on correlations between selectivity (Heck products: double bond isomers of arylcycloalkenes, dehalogenation and double arylation products) and nature of the catalyst or active Pd species.  The results indicate that dissolved mol. Pd species are responsible for the Heck coupling for both homogeneous and heterogeneous (solid) catalysts, whereas dehalogenation is due to a mechanism involving the surface of solid Pd metal particles and radical processes.  The selectivity of the reactions can be controlled by the choice of catalyst and reaction conditions (base, solvent, temp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNUgJ1tdMRbVg90H21EOLACvtfcHk0lj86jqv6GWDxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Wrur0%253D&md5=b20ee85dc88c8ee3e0617f7b766b366d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.molcata.2004.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcata.2004.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DDjakovitch%26aufirst%3DL.%26aulast%3DWagner%26aufirst%3DM.%26aulast%3DHartung%26aufirst%3DC.%2BG.%26aulast%3DBeller%26aufirst%3DM.%26aulast%3DKoehler%26aufirst%3DK.%26atitle%3DPd-catalyzed%2520Heck%2520arylation%2520of%2520cycloalkenes%25E2%2580%2594studies%2520on%2520selectivity%2520comparing%2520homogeneous%2520and%2520heterogeneous%2520catalysts%26jtitle%3DJ.%2520Mol.%2520Catal.%2520A%253A%2520Chem.%26date%3D2004%26volume%3D219%26spage%3D121%26epage%3D130%26doi%3D10.1016%2Fj.molcata.2004.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFO','PDB','4KFO'); return false;">PDB: 4KFO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JR5','PDB','4JR5'); return false;">PDB: 4JR5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O13" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4O13','PDB','4O13'); return false;">PDB: 4O13</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LVG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LVG','PDB','4LVG'); return false;">PDB: 4LVG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4KFP','PDB','4KFP'); return false;">PDB: 4KFP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WQ6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4WQ6','PDB','4WQ6'); return false;">PDB: 4WQ6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GVJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GVJ','PDB','2GVJ'); return false;">PDB: 2GVJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT','PDB','5KIT'); return false;">PDB: 5KIT</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i117"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00697">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_63182"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00697">10.1021/acs.jmedchem.6b00697</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical LCMS and SFC methods, details of mouse xenograft studies, details of X-ray crystallography of <b>41</b> in complex with NAMPT, experimental details of measured Log <i>D</i> determinations, coefficients of variation in NAMPT biochemical and cell-based inhibition assays, distribution of Fsp3 values and general description of structures in the 119-membered library (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_001.pdf">jm6b00697_si_001.pdf (247.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00697/suppl_file/jm6b00697_si_002.csv">jm6b00697_si_002.csv (4.98 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>41</b> in complex with NAMPT is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5KIT">5KIT</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00697&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00697%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-18" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00697" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992788fd54234a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
